"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management.",38,"Ladies and gentlemen, thank you for standing by, and welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Good morning, and welcome to Anthem's Fourth Quarter 2015 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and Wayne DeVeydt, our CFO. Joe will offer an overview",182,"Good morning, and welcome to Anthem's Fourth Quarter 2015 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and Wayne DeVeydt, our CFO. Joe will offer an overview of our fourth quarter 2015 financial results and will walk through the financials and provide the details of our initial 2016 outlook. We are then available for Q&A. 
During the call, we will reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website at antheminc.com. We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Anthem. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in today's press release and in our quarterly and annual filings with the SEC. 
I will now turn the call over to Joe."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Doug, and good morning. We're pleased to announced fourth quarter 2015 adjusted earnings per share of $1.14. On a GAAP basis, we reported earnings per share of $0.68. For the full year 2015, adjusted earnings per share was $10.16, representing",2105,"Thank you, Doug, and good morning. We're pleased to announced fourth quarter 2015 adjusted earnings per share of $1.14. On a GAAP basis, we reported earnings per share of $0.68. For the full year 2015, adjusted earnings per share was $10.16, representing year-over-year growth of 8.7%, and GAAP earnings per share of $9.38. It's important to note that our results include roughly $0.04 of assessments associated with the State of Colorado dissolution of their co-op, an expense that was not expected when we last stated our full year earnings outlook. 
I'm very pleased with our 2015 performance, and I believe the growing diversification of our company and the complementary nature of our pending Cigna acquisition will position us well to capitalize on market growth opportunities over the next several years. We remain focused on improving health care affordability, quality and choice to our growing membership base. 
I'm going to start with some overview comments on our fourth quarter and 2015 result and then move to discuss our 2016 outlook in more detail. Fourth quarter results capped a successful 2015 with underlying fundamentals that tracked well versus our expectations. The fourth quarter represented the lowest quarterly adjusted earnings per share during 2015, which reflected our evolving business mix and the timing of medical utilization and operating expenses. As expected, this included lower margins in our Commercial and Government businesses due to a higher benefit expense ratio and an increase in investment spending. Both fully insured and self-funded membership tracked ahead of expectations, and we ended the year with 38.6 million members, a growth of 1.1 million lives or nearly 3% since 2014. Our fourth quarter performance creates a favorable starting point for 2016 enrollment. In particular, during the quarter, we saw better-than-expected membership growth in our large group and Medicaid markets. As expected, we ended the year with 791,000 individual public exchange lives, a decrease of 33,000 from the third quarter. During 2015, we added a total of 84,000 lives on public exchanges. Our small group enrollment declined by just north of 100,000 lives in the quarter to 1.2 million lives as we saw higher-than-expected lapses in plans that had previously early renewed with a December 1 benefit start date. 
During the quarter, medical cost trends continued to come in favorably versus our stated range. Our 2015 medical cost trend came in at the lower half of our previously guided range of 6.5% to 7.5%. For 2016, we anticipate Local Group medical cost trends will be slightly higher in the range of 7% to 7.5%. 
Operating revenue was $78.4 billion during 2015, an increase of $5.4 billion or 7.4% versus 2014, reflecting strong enrollment growth in the Government Business, additional premium revenue to cover overall cost trends and increased fees associated with health care reform. Also contributing was the growth in administrative fee revenue as a result of our strong self-funded membership trends. This was partially offset by fully insured membership losses in our Commercial business. 
The full year 2015 benefit expense ratio was 83.3%, an increase of 20 basis points from the prior year. The year-over-year increase reflected the change in our business mix towards the Government Business division and a higher benefit expense ratio in the individual exchange business. 
Our SG&A expense ratio came in at 16% for the full year 2015, a decrease of 10 basis points from the prior year. This was driven by the changing mix of our membership to the Government Business and a continued focus on administrative expense control, reflecting the need to ensure that we have the right cost structure for our public exchange membership outlook through 2016. 
Supporting the strong quality of our earnings during 2015, we reported operating cash flow of approximately $4.1 billion or 1.6x net income with cash flow in the fourth quarter of $949 million. While we're pleased with our run rate cash flow performance, our 2015 results included the benefit of approximately $500 million in timing items related to government and vendor payments. These items are simply timing and accelerated our 2015 cash flow, which we originally expected to be in 2016. Including the impact of these timing items, we expect 2016 operating cash flow to be greater than $3 billion. 
Commercial operating margins in 2015 were 7.6%, reflecting year-over-year improvements in all lines of business, with the exception of individual. As we have previously discussed, operating results on the public exchanges have lagged expectations during the year as membership was more than 30% behind our original expectations. As expected, Commercial fourth quarter margins represented the lowest of the year, reflecting the timing of benefits, expense and our evolving mix of business. 
Our Government Business continued its strong year into the fourth quarter with an ending operating margin of 4.8%, an improvement of 130 basis points versus 2014 along with better-than-expected membership results. In particular, our Medicare and Medicaid margins improved meaningfully versus 2014. We're very encouraged by the turnaround plan put into place by our Medicare team, now finishing the second year of a 3-year plan. Their recent performance is an encouraging next step towards driving meaningful long-term earnings growth. We expect margins will continue to improve in 2016 towards our expected long-term sustainable level, and we have positioned our portfolio to grow enrollment in the right markets with the right products in 2017. 
For Medicaid, our team has built a process that is focused on the basic blocking-and-tackling aspects of managing our members' total cost of care and quality. We're leveraging our assets to provide industry-leading solutions for our government partners to help control their population's health care cost without sacrificing the quality of care. While this year's margin performance is above our long-term expectations, we feel confident in our team's ability to continue to outperform on a wide variety of care management and performance metrics. 
Regarding our balance sheet metrics. We have included a roll-forward of our medical claims payable balance in this morning's press release. For the full year 2015, we experienced favorable prior year reserve development of $800 million, which was moderately better than our expectations. While the favorable development was higher than what was recognized during 2014, it resulted in offsetting adjustments for the risk-stabilization programs from Health Care Reform. We continued to maintain our upper single-digit margin for adverse deviation and believe our reserve balance remains consistent and strong as of December 31, 2015. 
For the 3Rs related to the 2015 benefit year, we continue to book reinsurance as appropriate and continue to expect to be in a net payable position for risk adjusters and in a net neutral position for risk corridors. We continue to record a valuation allowance against the risk corridor receivables in certain markets as we do not believe those receivables will ultimately be collected. We believe our estimates are prudent, given the dynamic nature of available information. 
Our days in claims payable was 42.7 days as of December 31, an increase of 0.4 days from the 42.3 days as of September 30, 2015. The increase was primarily due to changes in the timing of claims payments between periods. As previously discussed, we do still expect days in claims payable to come back down closer to 40 over time. Our debt-to-capital ratio was 40.8% at December 31, 2015, down 40 basis points from 41.2% as of September 30, which reflects the impact of reducing our outstanding balance and commercial paper during the quarter. We ended the fourth quarter with approximately $1.4 billion in cash and investments at the parent company, and our investment portfolio was in an unrealized gain position of approximately $368 million as of December 31. 
Turning to our 2016 outlook. We currently expect operating revenues to grow to a range of $80 billion to $81 billion, which is light of the long-term projections we laid out at our Investor Day in early 2014. The shortfall is primarily due to our individual exchange membership being meaningfully behind our projections, as we've discussed with you previously. In Commercial, we expect relatively steady enrollment during the year. We expect growth of over 300,000 lives for National Accounts in 2016 with strong momentum in securing new contract wins and exceeding our retention expectations. We also expect growth in large groups self-funded enrollment, reflecting new contract wins. While we expect strong growth in ASO, our commercial fully-insured enrollment will be pressured. We expect membership declines of approximately 300,000 in our individual business as we aren't experiencing the overall market growth on the public exchange that we projected when we laid out our 5-year plan and unsustainable pricing in some markets is hurting our historic market share. We're encouraged that early indicators of the open enrollment activity are slightly better than our muted expectations. Recent actions taken by CMS to begin addressing the special enrollment period challenges, as well as the elimination of the health insurer fee in 2017, are important first steps towards improving affordability for our customers. And you can be assured we are contributing to the dialogue to form a long-term, sustainable and affordable marketplace. We also expect Local Group fully insured membership losses of approximately 250,000, as members continue to transition into self-funded product offerings. It is important to note that while this trend is in line with recent history, we now do not expect a meaningful offset to this trend from growth on the private exchanges. Additionally, we expect continued pressure from the impact of higher levels of attrition due to the ending of insurance policies that were early renewed by our clients before the implementation of the Affordable Care Act. For Government, we expect another strong enrollment growth year. We expect Medicaid to add more than 350,000 lives, reflecting the addition of new businesses in the State of Iowa as well as continued organic growth in core and expansion products. We continue to see states gravitate towards managed care to be the solution for more complex populations and services, and we expect to be front and center supporting these states' initiatives. 
Within our Medicare business, we continue to expect enrollment to be relatively steady as growth in our existing markets will be mostly offset by membership losses as we finalize the repositioning of our book in certain markets as part of our turnaround plan. 
Turning to financial metrics. We expect relatively stable margins in 2016. We currently expect an MLR midpoint of 83.6%, an increase of 30 basis points versus 2015. This reflects the impact of a change in the mix of our business as we expect strong growth in Medicaid, a business with a higher MLR than the consolidated average. 
Related to cost trend expectations, again, we expect 2016 Local Group medical cost trend to be in the range of 7% to 7.5%. We expect our SG&A ratio in 2016 to be 15.4% at the midpoint. This reflects the impact of the changing mix of our business, strong growth in Medicaid and the impact of the administrative efficiency initiatives our management team is taking to work through the challenging public exchange environment. 
Below the line, we expect investment income of approximately $650 million and interest expense of approximately $630 million. Note that our interest expense projection does not include the cost we expect to incur related to the bridge loan financing we have in place for the pending Cigna acquisition. We also currently expect our tax rate to be in the range of 43.5% to 45.5% for the year. We expect some benefit from the impact of capital deployment activities next year. [ph] 
While we suspended share repurchases after the announcement of the Cigna acquisition in 2015, we plan to resume our capital deployment program in 2016, subject to market conditions, albeit at a lower level than in recent years. As a result, we currently expect our share count for the year to be in the range of 266 to 270 million shares. We remain committed to at least maintaining our current dividend. We plan to review our capital deployment strategies at our next board meeting in February, and we expect to make an announcement on our first quarter 2016 dividend shortly thereafter. 
To conclude, our 2016 GAAP earnings per share estimate is greater than $10.35. Our adjusted earnings per share outlook is greater than $10.80. The difference between these 2 estimates is the exclusion of the amortization of deal-related intangibles. It's important to note that our 2016 outlook does not include any benefits or transaction costs associated with the pending acquisition of Cigna, which we continue to expect will close in the second half of the year. 
With that, operator, please open the queue for questions."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","[Operator Instructions] Your first question comes from the line of A.J. Rice from UBS.",14,"[Operator Instructions] Your first question comes from the line of A.J. Rice from UBS."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I noticed on your guidance, you're forecasting a medical cost trend to a range of 50 basis points. Traditionally, you guys have always used 100 basis points in forecasting that. I'm just curious on your thinking of narrowing that. Obviously, the step-up s",69,"I noticed on your guidance, you're forecasting a medical cost trend to a range of 50 basis points. Traditionally, you guys have always used 100 basis points in forecasting that. I'm just curious on your thinking of narrowing that. Obviously, the step-up sort of seem similar to what you assumed last year, and you came out at the low end. But I'm just curious of the thinking behind that."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","A.J., good morning. Essentially, the thinking was the last several years, I would think it's fair to say there's been a lot of volatility regarding the exchanges, the Affordable Care Act, a number of the specialty drugs coming in. From our perspective, we",126,"A.J., good morning. Essentially, the thinking was the last several years, I would think it's fair to say there's been a lot of volatility regarding the exchanges, the Affordable Care Act, a number of the specialty drugs coming in. From our perspective, we generally have a point of view that's within 50 basis points. We've been hanging pretty tight to that. And so it's more just to make sure that you understood that, in fact, we were raising our trend assumptions and our pricing going into this year and try to tighten that band within a 50 basis point range as we're getting better clarity now on the underlying activity associated with our commercial book as well as the new drugs that are coming in."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then just a follow-up on the -- I know in a conference earlier in the month, you guys had made some comments about where you were at your PBM, and I don't assume there's no assumptions or anything in the guidance related to this to any kind of c",70,"Okay. And then just a follow-up on the -- I know in a conference earlier in the month, you guys had made some comments about where you were at your PBM, and I don't assume there's no assumptions or anything in the guidance related to this to any kind of changes in that contract. But is there any update on what you're thinking there and what the opportunity might be?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","A.J., good morning. It's Joe. Nothing's changed since our statements last month -- or excuse me, earlier this month in the conference, and nothing's been included in the materials regarding the PBM dialogue that we've had thus far. So I guess, more to com",53,"A.J., good morning. It's Joe. Nothing's changed since our statements last month -- or excuse me, earlier this month in the conference, and nothing's been included in the materials regarding the PBM dialogue that we've had thus far. So I guess, more to come later, but nothing is embedded at the moment."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Josh Raskin from Barclays.",12,"Your next question comes from the line of Josh Raskin from Barclays."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First question, I just wanted to ask about the CMS sanctions at Cigna. I just want to see how does that fit with your understanding, sort of when did you guys find out about it? Did you know about this as part of due diligence? And does this change anythi",62,"First question, I just wanted to ask about the CMS sanctions at Cigna. I just want to see how does that fit with your understanding, sort of when did you guys find out about it? Did you know about this as part of due diligence? And does this change anything in terms of your outlook, your financial outlook for the combined entities?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, thank you. It's Joe again. First, let me clearly state, we have 2 separate companies. And obviously, activities of that nature within their company we do not have line of sight of, nor should we, I think. And we are kind of considering it, as you wou",172,"Yes, thank you. It's Joe again. First, let me clearly state, we have 2 separate companies. And obviously, activities of that nature within their company we do not have line of sight of, nor should we, I think. And we are kind of considering it, as you would expect. But at the moment, we really don't have enough line of sight to pass judgment on what effect it may have, if any, for that matter. So we will be vigilant, and I'm certain that as time marches on, we'll learn more on. But quite frankly, at this stage, there's really nothing for us to say regarding what impact it may have regarding Cigna. And with respect to the transaction itself, we are clearly and unwavering with respect to our commitment to the deal. This does not have an effect on the deal process. And obviously, as we learn more, we'll certainly feather it into our considerations. But at this stage, we just do not believe it has material effect on our transaction."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Got you. That's what I was looking for. And then just on the commercial business, the MLR, I think, in the past, you guys have been attributing the increase, at least last quarter, to the individual business. Now you're adding Local Group into that sort o",116,"Got you. That's what I was looking for. And then just on the commercial business, the MLR, I think, in the past, you guys have been attributing the increase, at least last quarter, to the individual business. Now you're adding Local Group into that sort of discussion for the MLR driver. So just trying to figure out what's driving that increase. Did the individual business deteriorate more? Or is this now more of a small group issue? And as we look about the overall margin for the Commercial segment this quarter, being just over breakeven, is it fair to assume you're losing money now? Obviously, in individual, but also in the Local Group side as well?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","No, Josh. Let me clarify. There's normal seasonality that we see in all books of business as deductibles are met throughout the year. So I want emphasize that relative to the group business, no concerns at all. The primary MLR drivers are mix in the quart",213,"No, Josh. Let me clarify. There's normal seasonality that we see in all books of business as deductibles are met throughout the year. So I want emphasize that relative to the group business, no concerns at all. The primary MLR drivers are mix in the quarter, and as we've been talking about, the public exchanges. So again, I don't want to create any alarms there. Trend finished at the low end -- lower half of our range, as we said earlier, and the metrics remain strong. One thing I would like to highlight, though, for each of you on the call is that we try to maintain a conservative posture on the 3Rs as well while maintaining our reserve balance sheet strength with our high single-digit margin for adverse deviation at year-end. So when you look at our run rate individual business, we still made a very slight, I'd call it, closer to breakeven for the year, but keep in mind that's with us maintaining a very conservative position on the 3Rs as well. And going into '16, we are still assuming we will be profitable on our individual and exchange business, albeit below our targeted 3% to 5% margins as we continue to see those markets hopefully begin to harden around pricing."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Kevin Fischbeck from Bank of America.",14,"Your next question comes from the line of Kevin Fischbeck from Bank of America."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Great. Just -- I just want to understand the concept of the mix shift impacting the MLR and the SG&A ratios, but it looks like given that you're growing earnings faster than revenue, [indiscernible] margin expansion next year. Can you point to one divisio",54,"Great. Just -- I just want to understand the concept of the mix shift impacting the MLR and the SG&A ratios, but it looks like given that you're growing earnings faster than revenue, [indiscernible] margin expansion next year. Can you point to one division that you would point to seeing stronger margin improvement year-over-year?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Kevin, the primary thing I would highlight is a lot of the initiatives that we took is to take the G&A leveraging out of the organization that if we weren't going to see the membership growth that we expected on the exchanges and the more important, I thi",91,"Kevin, the primary thing I would highlight is a lot of the initiatives that we took is to take the G&A leveraging out of the organization that if we weren't going to see the membership growth that we expected on the exchanges and the more important, I think, as Joe said, he's committed to us driving towards the $14 in 2018, and so we've had a very aggressive G&A initiative, which allows both margin maintenance as well as some expansion of all lines of business, if that was an enterprisewide effort."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So the Commercial side that you would say is where more margin expansion would be?",15,"So the Commercial side that you would say is where more margin expansion would be?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes.",1,"Yes."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And I guess, as far as that comment about the 2014 number, I guess, last quarter you kind of said, ""Hey, the individual numbers is coming in below what we might have thought and long-term targets that could be a drag on towards hitting that."" Are you sayi",81,"And I guess, as far as that comment about the 2014 number, I guess, last quarter you kind of said, ""Hey, the individual numbers is coming in below what we might have thought and long-term targets that could be a drag on towards hitting that."" Are you saying now that you found some offsets that are still going to -- that you'd be comfortable with $14 on a stand-alone basis before Express? Or is that still a risk in your view?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Kevin, I would say that relative to the revenue line item, if the individual membership fully insured market doesn't ramp up over the next several years, I think that $100 billion in organic revenue will be at risk. But I think relative to the $14 of earn",139,"Kevin, I would say that relative to the revenue line item, if the individual membership fully insured market doesn't ramp up over the next several years, I think that $100 billion in organic revenue will be at risk. But I think relative to the $14 of earnings per share, as we've been able to show in '15 going into '16, there are many levers that we can pull, and Joe has aggressively pushed the management team to pull those levers with a high degree of confidence hopefully in our ability to execute against them. And so I think, at this point, I would tell you -- and I'll let Joe say for himself, he's committed to this management team is committed to driving towards the $14, but we may get there different than we've laid out 2 years ago."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, and kind of -- thanks, Wayne. Just to reiterate and emphasize there -- we recognize the $100 billion might be somewhat flexible in terms of where we may end up in '18 on that metric. However, we're incredibly committed to the $14. We believe there's",121,"Yes, and kind of -- thanks, Wayne. Just to reiterate and emphasize there -- we recognize the $100 billion might be somewhat flexible in terms of where we may end up in '18 on that metric. However, we're incredibly committed to the $14. We believe there's certainly a lot of variables in the equation that map to what the ultimate revenue capture will be. But nonetheless, all parts and pieces are going to line up, we believe, very effectively for us to make that $14 commitment. And so again, we've got all actions in place regarding matters like people, the G&A controls and a variety of other puts and takes on the management side that will get us to $14 target."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Kevin, as we said previously to the PPM and the rising interest rates both serve as hedges against other risks that we see in the business and potential opportunities for upside as well. Kevin, one other item I want to highlight is you asked what other bu",94,"Kevin, as we said previously to the PPM and the rising interest rates both serve as hedges against other risks that we see in the business and potential opportunities for upside as well. Kevin, one other item I want to highlight is you asked what other businesses with margin in addition to G&A. The Medicare improvement, as Joe laid out, our efforts over the last 2 years have been quite substantial, and the results have been very promising. And so we will see very nice margin improvement in Medicare going into 2016 as well."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Gary Taylor from JPMorgan.",12,"Your next question comes from the line of Gary Taylor from JPMorgan."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I had one question and one follow-up. Just in terms of your cost trend guidance for 2016, would you care to kind of go through components of that? So hospital inpatient, outpatient position, pharma, even just qualitatively in terms of expectations would b",45,"I had one question and one follow-up. Just in terms of your cost trend guidance for 2016, would you care to kind of go through components of that? So hospital inpatient, outpatient position, pharma, even just qualitatively in terms of expectations would be helpful."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","We won't break it down necessarily, although I can tell you that we expect very little change in the physician aspects of it. It's very much driven more towards the specialty pharma being one of the primary drivers. We are expecting an increase in utiliza",72,"We won't break it down necessarily, although I can tell you that we expect very little change in the physician aspects of it. It's very much driven more towards the specialty pharma being one of the primary drivers. We are expecting an increase in utilization on inpatient. Whether or not that plays out, will remain to be seen. But it's primarily utilization and unit cost on pharma that are the drivers."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then just a clarification on the reported operating gain for the Commercial segment for 4Q. It's $56 million, that 0.6% margin. Is that figure normalized excluding the California franchise tax ruling? Or is that -- or is there pretax number that",50,"Okay. And then just a clarification on the reported operating gain for the Commercial segment for 4Q. It's $56 million, that 0.6% margin. Is that figure normalized excluding the California franchise tax ruling? Or is that -- or is there pretax number that's weighing upon that reported operating income margin?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","No. The only item that is of a unique nature that would be in there from an operating gain perspective is our desire to maintain a strong balance sheet associated with the 3Rs, and that has a direct impact on that. I'd like to be optimistic in hope there",141,"No. The only item that is of a unique nature that would be in there from an operating gain perspective is our desire to maintain a strong balance sheet associated with the 3Rs, and that has a direct impact on that. I'd like to be optimistic in hope there will be upside there, but it appears even in the last year, our conservative nature on some of these 3Rs has proven to be prudent. And so we decided to take that same posture in the fourth quarter and strengthen even further some of the 3R assumptions. Based on the public been available, it would imply we're conservative. But at the same time, the data would imply that last year ended up not being the case. So we try to strengthen even further. And of course, it hits the Commercial segment directly."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","That's primarily a risk adjustment number we'll see in the 10-K?",12,"That's primarily a risk adjustment number we'll see in the 10-K?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Both the risk adjustment as well as a position that we don't see value in the corridors and assume 100% valuation allowance as well as on the reinsurance. We have stuck with strictly what the law currently says we are entitled to, not what maybe excess fu",65,"Both the risk adjustment as well as a position that we don't see value in the corridors and assume 100% valuation allowance as well as on the reinsurance. We have stuck with strictly what the law currently says we are entitled to, not what maybe excess funding maybe in the pool. And so those are the 3 positions we've taken a conservative posture in."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Ralph Giacobbe from Citi.",12,"Your next question comes from the line of Ralph Giacobbe from Citi."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I may have missed this. I'm not sure if they give it. Did you say where you ended the year in terms of exchange, enrollment and maybe what's embedded into terms of exchange enrollment in 2016? And then just extending on that, maybe where you're at in term",55,"I may have missed this. I'm not sure if they give it. Did you say where you ended the year in terms of exchange, enrollment and maybe what's embedded into terms of exchange enrollment in 2016? And then just extending on that, maybe where you're at in terms of versus off-exchange for your individual book?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","We ended the year just shy of 800,000 members on the exchange enrollment, around 791,000 which was below our planned expectations by about 30%. We now are looking at the book in a more fungible way. We're looking at on-exchange and off-exchange now becaus",157,"We ended the year just shy of 800,000 members on the exchange enrollment, around 791,000 which was below our planned expectations by about 30%. We now are looking at the book in a more fungible way. We're looking at on-exchange and off-exchange now because it's becoming quite fungible between the 2 as grandmother is doing away. And so for next year, we have individual declining by another 300,000 lives all in going into '16. At least, that's our assumption. As Joe said in the prepared remarks, the early enrollment application is encouraging against that assumption, but it's very important that we wait and see how lapses actually occur because we'll know who ultimately pays and doesn't pay, but we won't know the answer until the end of this month. So again, the applications and they would imply that we may be conservative there, but until we see actual payments in this enrollment, it's hard to declare."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay, all right. That's helpful. And then just on the ASO book, your continued to show nice growth there. Are you seeing and capturing sort of existing ASO business or maybe seeing continued shift from sort of risk to ASO? Are you seeing more penetration",62,"Okay, all right. That's helpful. And then just on the ASO book, your continued to show nice growth there. Are you seeing and capturing sort of existing ASO business or maybe seeing continued shift from sort of risk to ASO? Are you seeing more penetration downstream to mid or smaller employers? Just try to get a sense of the dynamics at play."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's a little bit of both. Clearly, on the national accounts, those were a lot of new wins for us. Obviously, some very sizable wins, including the Bank of America account. So from that perspective, it's a big chunk of ASOs is really new membership and ne",155,"It's a little bit of both. Clearly, on the national accounts, those were a lot of new wins for us. Obviously, some very sizable wins, including the Bank of America account. So from that perspective, it's a big chunk of ASOs is really new membership and new lives to us. When you look at the shift from ASO -- I'm sorry, from fully insured ASO, that shift continues. I wouldn't call it an accelerated pace anymore. It seems to have slowed down, but nonetheless, it's still occurring. And so we are retaining a lot of that membership moving from fully insured to ASO. But as you know, on a revenue basis, that really dampens the revenue if you're not getting the offset through either the public exchanges, or for that matter, what we felt would have been a faster pace in the private exchanges, which we believe is a much more muted pace now."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Dave Windley from Jefferies.",12,"Your next question comes from the line of Dave Windley from Jefferies."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So on the premium number, Wayne, you are just hitting on the guidance relative to expectations, as you call it, $2.5 billion, $3 billion light, the ASO shift accounts for some of that but may be less than half. I'm wondering if you believe you're getting",74,"So on the premium number, Wayne, you are just hitting on the guidance relative to expectations, as you call it, $2.5 billion, $3 billion light, the ASO shift accounts for some of that but may be less than half. I'm wondering if you believe you're getting -- if there's anything in mix that would be affecting yield? And are you getting full premium yield relative to cost trend expectations you are expecting for 2016?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Dave, great question. Let me first highlight this revenue shortfall is almost predominantly associated with the lack of growth on the public exchanges. I mean I just I can't emphasize that point enough. And ultimately, that would be the one area I would s",159,"Dave, great question. Let me first highlight this revenue shortfall is almost predominantly associated with the lack of growth on the public exchanges. I mean I just I can't emphasize that point enough. And ultimately, that would be the one area I would say, while we're projecting profitability still in the 2016, clearly, at margins below what we think are the long-term margins for sustainable program and product. So that would be the one area I would point to relative to yields. We are still able to cover our cost of capital on them and be profitable, but we are looking for the some of the structural changes that I know the administration is looking at to make these programs even more viable in the long term. But our revenue issue is really a fully insured public exchange issue at this point. The rest of the book of business is performing well versus our 5-year expectations we've laid out."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay, my follow-up would be -- on a follow-up on the PBM. Would you guys be willing to comment on how the analysis bridge from the $500 million to $700 million number that you talked about, say, mid to early second half of 2015 to the $3 billion number th",58,"Okay, my follow-up would be -- on a follow-up on the PBM. Would you guys be willing to comment on how the analysis bridge from the $500 million to $700 million number that you talked about, say, mid to early second half of 2015 to the $3 billion number that you've now talked about in January of '16?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, this is Joe. Let me comment on that. Going back in time to '15 at earnings day, we did land on the $500 million to $700 million as a proxy statement regarding what may be possible related to market check analysis, et cetera. Then fast forward to toda",238,"Yes, this is Joe. Let me comment on that. Going back in time to '15 at earnings day, we did land on the $500 million to $700 million as a proxy statement regarding what may be possible related to market check analysis, et cetera. Then fast forward to today, we've gone through a very deliberate analytical process. We vectored toward an answer related to multiple checks in the marketplace and that brought us to the $3 billion finding that we believe is very, very credible. And obviously, having made that statement, which we believe kind of recalibrates the number from that $500 million to $700 million into something that we believe is much more realistic. So what we said back in '15 is that we would update you in '16, actually hoping to communicate, I guess, call it, a solution to you regarding our PBM inquiry regarding what we would have to do to reposition ourselves to get to the end of the contract in 2019. So having made statement about the $3 billion, our market check expectations, we believe we've set the table now for conversations in and around the possibility of recasting our pricing relationship with the SI. So all I can tell you at this stage is that dialogue will continue and we are hopeful that still in '16 we will reach a resolution to this matter that we are engaged in with the SI."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Christine Arnold from Cowen.",12,"Your next question comes from the line of Christine Arnold from Cowen."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I'm looking at the MLR. And as those third quarter '15, you expected the full year to be 82 9, plus or minus 30. And you're above that range at 83 3 for the full year. So was individual entirely the shortfall on that loss ratio?",47,"I'm looking at the MLR. And as those third quarter '15, you expected the full year to be 82 9, plus or minus 30. And you're above that range at 83 3 for the full year. So was individual entirely the shortfall on that loss ratio?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Christine, good morning. Individual was substantially shortfall. That's correct. And again, it's important to recognize that some of the balance sheet strengthening we've been will all flow through that as well regarding not only the 3Rs but maintaining t",90,"Christine, good morning. Individual was substantially shortfall. That's correct. And again, it's important to recognize that some of the balance sheet strengthening we've been will all flow through that as well regarding not only the 3Rs but maintaining that high single-digit for adverse deviation. So I would point you almost solely to that. Medicaid enrollment was a little bit stronger in the quarter than we anticipated as well. There's a little bit of an mix shift rate that is predominantly individual and in the strengthening we did in the 3Rs."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Great. And first half of the year, we're looking at the 3% to 5% margin. Second half of the year, we're looking at breakeven. So we've completed erased that 3% to 5%. Yet the biz we're doing May and June. So can you help me understand how when you didn't",70,"Great. And first half of the year, we're looking at the 3% to 5% margin. Second half of the year, we're looking at breakeven. So we've completed erased that 3% to 5%. Yet the biz we're doing May and June. So can you help me understand how when you didn't know about this 3% to 5% of erosion in profitability you're confident that this is going to improve next year?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Christine, it's a really great question, and it's one of the reasons that we issue we had though on our margins this year was the inability to deleverage G&A quick enough. So we were still assuming a 3% to 5% margin, but we're also assuming a 30% growth r",177,"Christine, it's a really great question, and it's one of the reasons that we issue we had though on our margins this year was the inability to deleverage G&A quick enough. So we were still assuming a 3% to 5% margin, but we're also assuming a 30% growth rate. We're starting see that growth rate not only not occur, but beginning to see some attrition in the latter part of the year, we realized it was imperative to get the G&A out. And I can tell you that those initiatives have occurred. Those actions around headcount and other costs have already been taken out now, and we'll get a run rate effect going into the year. So from that perspective, we feel fairly confident. And again, I would emphasize the public data that we're getting regarding risk adjusters from Weekly, regarding how 3Rs [indiscernible] new insurance last year, et cetera, would imply we're being conservative in that outlook, but we've chosen to take that posture in '15 and that's part of the reason getting close to breakeven."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Ana Gupte from Leerink Partners.",13,"Your next question comes from the line of Ana Gupte from Leerink Partners."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","The question firstly is around the captured mix strategy that you articulated. Now we're 2 years into exchanges. As you're looking at your small group, that $800 million EBIT headwind -- sorry, $800 million to $400 million that you articulated, when you l",95,"The question firstly is around the captured mix strategy that you articulated. Now we're 2 years into exchanges. As you're looking at your small group, that $800 million EBIT headwind -- sorry, $800 million to $400 million that you articulated, when you look at it across, firstly, is that standard at this point? And when you look at it across small group and individual, are you coming out net positive? Is it net neutral? Or is it continuing to be a headwind? And how do you expect that going forward into '16 and then '17?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Morning, thanks for the question. I would say the catcher's mitt strategy itself is working as we would have expected as we are clearly seeing attrition in lines of business. Small group alone lost over 100,000 lives in the fourth quarter. Clearly, we're",206,"Morning, thanks for the question. I would say the catcher's mitt strategy itself is working as we would have expected as we are clearly seeing attrition in lines of business. Small group alone lost over 100,000 lives in the fourth quarter. Clearly, we're picking those lives elsewhere as we're able to exceed our membership targets for the year. I would say that part of the strategy that's not coming to light at this point isn't about capturing the number now, but where exactly that member is caught and the revenue associated with that number. And I think, at this point, when built our 5-year plan, we fully expected more of these lives to be picked up in the public exchanges as a fully insured. And we're finding that some of those lives are actually getting employed and more in the ASO market and or taking them up on Medicaid, which in some cases are lower PMPM we got on the public exchange. So ultimately, I would say the strategy of the catcher's mitt itself is working terms of getting the customers and continuing to grow membership, but I would say the mix of membership and how it translates revenues is not panning out as we anticipated."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And then following up on that. Now the public exchanges, with your decline in individual from the third quarter to the fourth quarter, was that mainly the special enrollment period folk that did that? And as you're looking out into 2017, as reinsurance go",76,"And then following up on that. Now the public exchanges, with your decline in individual from the third quarter to the fourth quarter, was that mainly the special enrollment period folk that did that? And as you're looking out into 2017, as reinsurance goes away, do you think the policy changes that the administration is making would still allow you to remain on exchange and be profitable into '17 just again part of your catcher's mitt?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, this is Joe. Let me comment on the kind of a continued engagement that we envision in the exchanges. Yes, we are certainly very observant of the shifts and changes that the administration is enacting, especially paying a lot of attention to special e",209,"Yes, this is Joe. Let me comment on the kind of a continued engagement that we envision in the exchanges. Yes, we are certainly very observant of the shifts and changes that the administration is enacting, especially paying a lot of attention to special enrollment period, very thankful the administration has made some changes. I suspect there may be more changes in the near future, which we want to consider very carefully, so that we can judge the sustainability of the exchange marketplace and how well we can engage in that marketplace going forward. So we're very observant regarding these moves and changes. We feel that, as Wayne pointed out a moment ago, we're extremely well positioned with respect to matters like G&A. That allows us to perform in this space reasonably well. Notwithstanding member deterioration, it's presumably stabilized, given what we're observing regarding some uptick in membership for '16, which obviously, as Wayne pointed out, we'll probably know more within the month. But nonetheless, we're really carefully observing it, looking at special enrollment in terms of its potential impact. And again, we're very hopeful that some of the issues will be [indiscernible] in terms of the risk and we'll have a much more sustainable marketplace to engage in."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Scott Fidel from Credit Suisse.",13,"Your next question comes from the line of Scott Fidel from Credit Suisse."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First question, just if you can give us an update on just how the implementations of Iowa Medicaid is coming along. And just interested, just in the context of the state having remove WellCare from the contract, what your updated enrollment expectation is",70,"First question, just if you can give us an update on just how the implementations of Iowa Medicaid is coming along. And just interested, just in the context of the state having remove WellCare from the contract, what your updated enrollment expectation is for Iowas? And what type of losses you're building and expecting. Obviously, United did increase there. PDR for Iowa's resulted. I'm just interested how you're approaching this."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Scott, good morning. First of all, relative to Iowa, we continue to be optimistic about this program in the long term in that it will have a similar trajectory. We expect to lose money in year 1, get closer to breakeven in year 2 and then return to profit",303,"Scott, good morning. First of all, relative to Iowa, we continue to be optimistic about this program in the long term in that it will have a similar trajectory. We expect to lose money in year 1, get closer to breakeven in year 2 and then return to profitability by year 3. We got an update from the team yesterday. Actually, Joe and the senior leadership team got a full deep dive on where things are progressing. And things are moving exactly as we would have expected at this point. We're very close to starting that implementation on 3 1. We don't have line of sight on what membership we may or may not get. As you know, number of appeals that have been filed both by the one individual that was selected that has been told they were being removed, as well as others that were not selected in the first round. So we have not included any of that, and we want to see how all that pans out. That being said, if you were to look at Medicaid all in, both margin compression that we are seeing throughout the year that we expect assuming even further margin effects in the back half of '16 from states as well as expansion. There's about a few hundred million dollar headwind baked in, but I would tell you that Iowa is less than 25% of that. So it gives you kind of a gauge of how we're envisioning year 1 to evolve and migrate more in year 2 and then from there, to the normal profitability have in these programs. The delay of 2 months as part of the reason for that level of loss in year 1 because ultimately, we've got the G&A float happening, but we don't have the revenue yet."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Got it, okay. Then just had a -- follow-up question is a small group in. Actually number a number that I don't we've talked about for a few quarters. But just interested, remember couple of years back, you talked about how small group would potentially ha",117,"Got it, okay. Then just had a -- follow-up question is a small group in. Actually number a number that I don't we've talked about for a few quarters. But just interested, remember couple of years back, you talked about how small group would potentially have to absorb maybe $400 million EBIT hit from ACA as thinking about what sort of margin abasement and then enrollment penetration and is interested if you could give us an update on sort of how you're tracking relative to that number. Obviously, there has been some recent attrition. But just if your sort of at that number or still some ways to go or just where we stand relative to that?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","So relative to the $400 million, Scott, which is all about margin reset,. I'd say we've taken our medicine in that $400 million over the last couple of years. Now it becomes a question of will small group migrate to other lines of this overtime or just pu",137,"So relative to the $400 million, Scott, which is all about margin reset,. I'd say we've taken our medicine in that $400 million over the last couple of years. Now it becomes a question of will small group migrate to other lines of this overtime or just pure membership. But we have taken that sizable hit. As we saw in the fourth quarter, a very sizable chunk of that membership migrated away from fully insured, and the question is will recover that with the public exchanges in open enrollment or others. Again, our early open enrollment data would imply we are recovering it, but we want to see what actually converts to a pay by the end of the month. So but it's in terms of the margin compression, we've taken substantial portion of that $400 million."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Matthew Borsch from Goldman Sachs.",13,"Your next question comes from the line of Matthew Borsch from Goldman Sachs."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","If I could just go back to the exchanges for a moment again. A couple of questions there. When you talked about the unsustainable price competition and also the lack of market growth, should we read that the decline that you're expecting of 300,000 is all",121,"If I could just go back to the exchanges for a moment again. A couple of questions there. When you talked about the unsustainable price competition and also the lack of market growth, should we read that the decline that you're expecting of 300,000 is all about the unsustainable price competition since if the market didn't grow, then maybe you would expect it to be flat? And my follow-up question to that is, as we look to 2017, how much impact -- favorable impact do you think you'll get from the risk pool as grandmothering plans work their way into the exchanges, albeit I know that's not going to be the case for your 2 largest markets, California and New York."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Matt, I appreciate the question. A couple of thoughts or at least insights. One is, yes, we are assuming that some of the pricing that we continue to see in our markets, our 14 states, is still well below what we think appropriate rates are for the sustai",354,"Matt, I appreciate the question. A couple of thoughts or at least insights. One is, yes, we are assuming that some of the pricing that we continue to see in our markets, our 14 states, is still well below what we think appropriate rates are for the sustainable environment. I think the fact that we're closer to breakeven in '15 and a profit margin that's below the targeted 3% to 5% in '16 I think is a good indication that price point isn't wrong, as much as I see the strength of the price points. So we're going to assume that the strengthening is not occurring. In fact, in many states, it hasn't occurred, and that we will continue to trip members. That being said, we are starting to see individual start to recognize problems in their books. They are starting to strength in our pricing quite meaningfully. We are seeing co-op struggle in the moment with more than half of those insolvent. And so the question becomes now will the markets start to harden going to '17, which has really 2 effects for us, one is we no longer have the diminishing membership base, but more importantly, we should be hopefully a net recipient of that and hopefully start getting that revenue back that we talked about in our original 5-year outlook. And then relative to 2017, Matt, to your comment, it's the grand mothering, it's really hard to say at this point. I mean the behaviors of kind of the dynamics of what will be market look like in '17, not to see changes in how grandmother that's just what's a global economy and the U.S., what as well. But the theory of what you laid out would imply that you're going to get more of those lives and a healthier population and should help improve the overall profitability of the book as well. But as indicated in our largest markets, we did not allow grandfathering in many cases, and we migrated already. So it won't have as big as impact, but if the market has hardened, it should improve for us."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Peter Costa from Wells Fargo.",13,"Your next question comes from the line of Peter Costa from Wells Fargo."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","A couple of years ago, and 2 actually years, we've talked about the consumerization of health care and the growth of private exchanges. And really we haven't seen that come through in a significant way here. We are in second year with that not delivering",64,"A couple of years ago, and 2 actually years, we've talked about the consumerization of health care and the growth of private exchanges. And really we haven't seen that come through in a significant way here. We are in second year with that not delivering much membership growth. What -- can you tell us how you're evolving your strategy on consumerization and private exchanges?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, this is Joe. Thanks for the question. Yes, I think private exchanges have had a slow uptake probably for a few reasons, but I think it was considered a sort of an to the Cadillac tax exposure and other necessities that business is an industry conside",262,"Yes, this is Joe. Thanks for the question. Yes, I think private exchanges have had a slow uptake probably for a few reasons, but I think it was considered a sort of an to the Cadillac tax exposure and other necessities that business is an industry considered in terms of moving their pose to a private exchange marketplace. It didn't materialize to the level of the speed that anybody anticipated in the early going. And our position at the moment is that we're kind of taking a more muted response to the private exchange formation and execution. Nonetheless, we're going to be ready if and when it does accelerate, and it may very well do so in the future. But at this stage, it really is a sort of a muted response to that strategy, and we believe what you're seeing nationally is sort of an in-market standard in terms of private exchanges, just simply not picking up the speed the folks have had originally anticipated. So we're basically waiting -- wait and see, and we're positioned. And in fact, we do have private exchange membership that is not as substantial part of our membership, but certainly, we are in the space. I guess bottom line is, affordability is still the key and remains critical to long-term positioning as part of the employers and, private exchange presents itself as a solution. We are ready, willing and able to engage any meaningful way. But again, I think our response at this stage is fairly muted given there's just been such a slow uptake."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And just a follow-up, if you don't mind. Can you talk about the premium taxation in California and your exposure to that in terms of litigation against the -- your company?",32,"Okay. And just a follow-up, if you don't mind. Can you talk about the premium taxation in California and your exposure to that in terms of litigation against the -- your company?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Peter, let me just first highlight that, in California, the tax laws differ based on legal entity [indiscernible] to any legal entity in the United States, very different tax laws. We pay our taxes exactly as the law states within the State of California",142,"Peter, let me just first highlight that, in California, the tax laws differ based on legal entity [indiscernible] to any legal entity in the United States, very different tax laws. We pay our taxes exactly as the law states within the State of California as do our competitors that have similar legal entities filed there in the DMHC. Actually, we agreed to paying taxes in accordance with the law. At this point, I can simply state that it is fully our intention to follow the law, as we've done so far, and it's fully our intention to litigate any action brought against us that we're going to imply otherwise. There's nothing more to comment on beyond that other than you should be aware that it is the law that we are following on there and the DMHC has supported us in that."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Chris Rigg from Susquehanna.",12,"Your next question comes from the line of Chris Rigg from Susquehanna."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just quickly here in the government segment. I know, Wayne, I think you said you're expecting to earn about $200 million less in Medicaid, but grow a little bit in Medicare. Net-net, is it going to be flattish or down in the Government segment in '16?",46,"Just quickly here in the government segment. I know, Wayne, I think you said you're expecting to earn about $200 million less in Medicaid, but grow a little bit in Medicare. Net-net, is it going to be flattish or down in the Government segment in '16?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Good question. It's good to be slightly down, which gives you pretty good idea of how well our Medicaid is actually performing, but it will be slightly down between those. And again, it's important to recognize without it was prudent to have a cautious po",75,"Good question. It's good to be slightly down, which gives you pretty good idea of how well our Medicaid is actually performing, but it will be slightly down between those. And again, it's important to recognize without it was prudent to have a cautious posture now Medicaid rates may evolve as the year progresses. And not just the rates we know about in October, but what happens in mid July as well as next October."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Great. And then just on the reinsurance. Can you quantify how much you expect for -- from -- how much you expect to receive in 2015? And -- would you have lost money without that amount?",36,"Great. And then just on the reinsurance. Can you quantify how much you expect for -- from -- how much you expect to receive in 2015? And -- would you have lost money without that amount?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, I think the first thing to keep mind, we assume we just keep slightly over 50%. I don't think you can look at it is whether you would lose money with or without that amount, because it's important to recognize we're collecting that premium within our",168,"Yes, I think the first thing to keep mind, we assume we just keep slightly over 50%. I don't think you can look at it is whether you would lose money with or without that amount, because it's important to recognize we're collecting that premium within our premium base in there for the government and then submitting that into the reinsurance pool. So our pricing is baked with an assumption that we will get what the law says were entitled to get without it. So I don't think you can look at it with or without the program because the pricing is built with that program. That being said, as you know, there's data points out there that would imply that people may recover as much as 55% to 60%. And again, we're much more in line with where the laws. When I say slightly over 50%, doesn't even round up to 51%. So gives you a little bit of a feel for what is barely over 50%."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Andy Schenker from Morgan Stanley.",13,"Your next question comes from the line of Andy Schenker from Morgan Stanley."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Can you maybe talk a little bit more on Medicare? Obviously, seeing some significant improvements in '15, calling for continued improvements in '16, but how should we think about how much room is left beyond that as well as maybe the level of investments",60,"Can you maybe talk a little bit more on Medicare? Obviously, seeing some significant improvements in '15, calling for continued improvements in '16, but how should we think about how much room is left beyond that as well as maybe the level of investments currently in Medicare for the repositioning and some of that start winding down in '16, '17?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well -- Joe again. Since I joined the company a few years ago, we really put a stake in the ground that we were going to reposition ourselves in a Medicare space very aggressively we established, as I said a moment ago, a 3-year plan. And we're well into",173,"Well -- Joe again. Since I joined the company a few years ago, we really put a stake in the ground that we were going to reposition ourselves in a Medicare space very aggressively we established, as I said a moment ago, a 3-year plan. And we're well into that 3-year plan realization in terms of our targets. The margins, we expect to expand over time, and we do believe that we're really heavily focused on medical cost management capabilities. And we have an increased focus on our administrative cost structure as being a key contributor to margin improvement. So when you put all that together, we are witnessing a substantial, I'd call it, even a turnaround in our Medicare in both that really gives us cause for optimism going forward. We really do remain very pleased with the success that we've created with the team, and I'm hopeful that as we get through '16 and well into '17 that we'll be able to report on a trajectory that's on a positive track."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","That's -- and then just real quick on seasonality here. I mean, it's obviously increasing front half loaded. To review '15 seasonality as kind of the framework for '16? Or is there any changes that could swing those numbers?",40,"That's -- and then just real quick on seasonality here. I mean, it's obviously increasing front half loaded. To review '15 seasonality as kind of the framework for '16? Or is there any changes that could swing those numbers?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Andy, great question. I would think the seasonality in '15 will much be much more reflective of what you'll see in '16. Just keep in mind the wild card in all of this is really going to be around how 3Rs settle out from our perspective. It -- again, we be",116,"Andy, great question. I would think the seasonality in '15 will much be much more reflective of what you'll see in '16. Just keep in mind the wild card in all of this is really going to be around how 3Rs settle out from our perspective. It -- again, we believe we've been prudent at looking to a conservative point of view, but as more data comes out on those 3Rs, that could create some unique nuances throughout the year. And also, how these co-ops evolve throughout the United States plan to solve for that could create nuances into 2016. But generally speaking, '15 is a pretty good proxy for the seasonality you should expect '16."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","And your final question today comes from the line of Sarah James from Wedbush Securities.",15,"And your final question today comes from the line of Sarah James from Wedbush Securities."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","To mention some potential headwinds on Medicaid rates for 2016 and you're not the first company to spike out that concerned. So what are you currently building interventions for your blended rates in '16? What was it in '15? And can you talk about how you",71,"To mention some potential headwinds on Medicaid rates for 2016 and you're not the first company to spike out that concerned. So what are you currently building interventions for your blended rates in '16? What was it in '15? And can you talk about how you view margins on that business for legacy Medicaid, so excluding Iowa or any new contracts, how do you think about margins developing for Medicaid?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","So good question. One is what highlight is we don't get funding increase as you know it varies by state because economics of each state vary dramatically. We prefer not a blend of the getter in a broad discussion. That being said though, Sarah, I think a",211,"So good question. One is what highlight is we don't get funding increase as you know it varies by state because economics of each state vary dramatically. We prefer not a blend of the getter in a broad discussion. That being said though, Sarah, I think a fair question understand that we have margins that are exceeding what we believe our long term, sustainable, optimal margins. But know that we are still assuming that we will blend closer to a 5% margin all in going into next year. Now that's higher than what you typically heard from Medicaid, which will be the 2% to 3% margin edge. But is supported to recognize that we do get a gross up on the health insurer fee as well. So that bounces margins further. But we think that the guidance we provided puts us at what hopefully will be sustainable outperformance margin for us. We believe we should of the better margin because we believe we can execute on this better in the team that we brought in from the America of almost 3 years now is that an exceptional job in that space. But our pricing is up slowly leading the plane of the margins to get more that's sustainable, long term margin."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay, and was there anything -- moving pieces in the quarter for Medicaid like benefit in the past you'd mentioned the potential for a rec track the premium payments us or anything out of period or unusual that we should think about with this quarter's Me",47,"Okay, and was there anything -- moving pieces in the quarter for Medicaid like benefit in the past you'd mentioned the potential for a rec track the premium payments us or anything out of period or unusual that we should think about with this quarter's Medicaid performance?"
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","No, nothing unusual in terms of actual numbers. Things tied out where we thought we were tired what was a little bit unusual more than cash mathematical March of [indiscernible] estates in particular bears on the last day of the year for which we typicall",73,"No, nothing unusual in terms of actual numbers. Things tied out where we thought we were tired what was a little bit unusual more than cash mathematical March of [indiscernible] estates in particular bears on the last day of the year for which we typically get the first 5 days in the new year. So it affected cash flow but didn't actually affect the underlying economics of what we had the same period."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Thank you. I'd now like to turn the conference back to the company's measurement for closing comments.",17,"Thank you. I'd now like to turn the conference back to the company's measurement for closing comments."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you all for your questions this morning. In summary, we're pleased with our 2015 results and believe the increasing diversification of our business positions us well for 2016 and beyond. As you've heard, our team remains focused on executing on our",115,"Thank you all for your questions this morning. In summary, we're pleased with our 2015 results and believe the increasing diversification of our business positions us well for 2016 and beyond. As you've heard, our team remains focused on executing on our core business while preparing for the integration of our Cigna acquisition. We expect to close in the second half of the year. I want to thank you all for being with us today and I especially want to thank our associates for their ongoing contributions and their commitment to serving our 38.6 million customers every day. Thank you all for your interest in Anthem, and we look forward to speaking with you soon."
160077,280495834,921362,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern time today through February 9. You may access the AT&T Teleconference Replay System at anytime by dialing 1 (800) 475-6701 and entering the access code 378815. Intern",67,"Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern time today through February 9. You may access the AT&T Teleconference Replay System at anytime by dialing 1 (800) 475-6701 and entering the access code 378815. International participants dial (320) 365-3844. That does conclude your conference for today. Thank you for your participation and for using AT&T executive teleconference. You may now disconnect."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management.",38,"Ladies and gentlemen, thank you for standing by, and welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Good morning, and welcome to Anthem's Fourth Quarter 2015 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and Wayne DeVeydt, our CFO. Joe will offer an overview",182,"Good morning, and welcome to Anthem's Fourth Quarter 2015 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and Wayne DeVeydt, our CFO. Joe will offer an overview of our fourth quarter 2015 financial results and will walk through the financials and provide the details of our initial 2016 outlook. We are then available for Q&A. 
During the call, we will reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website at antheminc.com. 
We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Anthem. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in today's press release and in our quarterly and annual filings with the SEC. 
I will now turn the call over to Joe."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Doug, and good morning. We're pleased to announced fourth quarter 2015 adjusted earnings per share of $1.14. On a GAAP basis, we reported earnings per share of $0.68. For the full year 2015, adjusted earnings per share was $10.16, representing",2108,"Thank you, Doug, and good morning. We're pleased to announced fourth quarter 2015 adjusted earnings per share of $1.14. On a GAAP basis, we reported earnings per share of $0.68. For the full year 2015, adjusted earnings per share was $10.16, representing year-over-year growth of 8.7% and GAAP earnings per share of $9.38. It's important to note that our results include roughly $0.04 of assessments associated with the State of Colorado dissolution of their co-op, an expense that was not expected when we last stated our full year earnings outlook. 
I'm very pleased with our 2015 performance, and I believe the growing diversification of our company and the complementary nature of our pending Cigna acquisition will position us well to capitalize on market growth opportunities over the next several years. We remain focused on improving health care affordability, quality and choice to our growing membership base. 
I'm going to start with some overview comments on our fourth quarter and 2015 result,, and then move to discuss our 2016 outlook in more detail. Fourth quarter results capped a successful 2015 with underlying fundamentals that tracked well versus our expectations. The fourth quarter represented the lowest quarterly adjusted earnings per share during 2015, which reflected our evolving business mix and the timing of medical utilization and operating expenses. As expected, this included lower margins in our Commercial and Government Businesses due to a higher benefit expense ratio and an increase in investment spending. 
Both fully insured and self-funded membership tracked ahead of expectations, and we ended the year with 38.6 million members, a growth of 1.1 million lives or nearly 3% since 2014. Our fourth quarter performance creates a favorable starting point for 2016 enrollment. In particular, during the quarter, we saw better-than-expected membership growth in our large group and Medicaid markets. As expected, we ended the year with 791,000 individual public exchange lives, a decrease of 33,000 from the third quarter. During 2015, we added a total of 84,000 lives on public exchanges. Our small group enrollment declined by just north of 100,000 lives in the quarter to 1.2 million lives as we saw higher-than-expected lapses in plans that had previously early renewed with a December 1 benefit start date. 
During the quarter, medical cost trends continued to come in favorably versus our stated range. Our 2015 medical cost trend came in at the lower half of our previously guided range of 6.5% to 7.5%. For 2016, we anticipate Local Group medical cost trends will be slightly higher in the range of 7% to 7.5%. 
Operating revenue was $78.4 billion during 2015, an increase of $5.4 billion or 7.4% versus 2014, reflecting strong enrollment growth in the Government Business, additional premium revenue to cover overall cost trends and increased fees associated with health care reform. Also contributing was the growth in administrative fee revenue as a result of our strong self-funded membership trends. This was partially offset by fully insured membership losses in our Commercial business. 
The full year 2015 benefit expense ratio was 83.3%, an increase of 20 basis points from the prior year. The year-over-year increase reflected the change in our business mix towards the Government Business division and a higher benefit expense ratio in the individual exchange business. 
Our SG&A expense ratio came in at 16% for the full year 2015, a decrease of 10 basis points from the prior year. This was driven by the changing mix of our membership to the Government Business and a continued focus on administrative expense control, reflecting the need to ensure that we have the right cost structure for our public exchange membership outlook through 2016. 
Supporting the strong quality of our earnings during 2015, we reported operating cash flow of approximately $4.1 billion or 1.6x net income, with cash flow in the fourth quarter of $949 million. While we're pleased with our run rate cash flow performance, our 2015 results included the benefit of approximately $500 million in timing items related to government and vendor payments. These items are simply timing and accelerated our 2015 cash flow, which we originally expected to be in 2016. Including the impact of these timing items, we expect 2016 operating cash flow to be greater than $3 billion. 
Commercial operating margins in 2015 were 7.6%, reflecting year-over-year improvements in all lines of business, with the exception of individual. As we have previously discussed, operating results on the public exchanges have lagged expectations during the year as membership was more than 30% behind our original expectations. As expected, Commercial fourth quarter margins represented the lowest of the year, reflecting the timing of benefits, expense and our evolving mix of business. 
Our Government Business continued its strong year into the fourth quarter with an ending operating margin of 4.8%, an improvement of 130 basis points versus 2014, along with better-than-expected membership results. In particular, our Medicare and Medicaid margins improved meaningfully versus 2014. We're very encouraged by the turnaround plan put into place by our Medicare team, now finishing the second year of a 3-year plan. Their recent performance is an encouraging next step towards driving meaningful long-term earnings growth. We expect margins will continue to improve in 2016 towards our expected long-term sustainable level, and we have positioned our portfolio to grow enrollment in the right markets with the right products in 2017. 
For Medicaid, our team has built a process that is focused on the basic blocking and tackling aspects of managing our members' total cost of care and quality. We're leveraging our assets to provide industry-leading solutions for our government partners to help control their population's health care cost without sacrificing the quality of care. While this year's margin performance is above our long-term expectations, we feel confident in our team's ability to continue to outperform on a wide variety of care management and performance metrics. 
Regarding our balance sheet metrics. We have included a roll-forward of our medical claims payable balance in this morning's press release. For the full year 2015, we experienced favorable prior year reserve development of $800 million, which was moderately better than our expectations. While the favorable development was higher than what was recognized during 2014, it resulted in offsetting adjustments for the risk stabilization programs from Health Care Reform. We continue to maintain our upper single-digit margin for adverse deviation and believe our reserve balance remains consistent and strong as of December 31, 2015. 
For the 3Rs related to the 2015 benefit year, we continue to book reinsurance as appropriate and continue to expect to be in a net payable position for risk adjusters and in a net neutral position for risk corridors. We continue to record a valuation allowance against the risk corridor receivables in certain markets as we do not believe those receivables will ultimately be collected. We believe our estimates are prudent, given the dynamic nature of available information. 
Our Days in Claims Payable was 42.7 days as of December 31, an increase of 0.4 days from the 42.3 days as of September 30, 2015. The increase was primarily due to changes in the timing of claims payments between periods. As previously discussed, we do still expect Days in Claims Payable to come back down closer to 40 over time. 
Our debt-to-capital ratio was 40.8% at December 31, 2015, down 40 basis points from 41.2% as of September 30, which reflects the impact of reducing our outstanding balance in commercial paper during the quarter. We ended the fourth quarter with approximately $1.4 billion in cash and investments at the parent company, and our investment portfolio was in an unrealized gain position of approximately $368 million as of December 31. 
Turning to our 2016 outlook. We currently expect operating revenues to grow to a range of $80 billion to $81 billion, which is light of the long-term projections we laid out at our Investor Day in early 2014. The shortfall is primarily due to our individual exchange membership being meaningfully behind our projections, as we've discussed with you previously. In Commercial, we expect relatively steady enrollment during the year. We expect growth of over 300,000 lives for National Accounts in 2016 with strong momentum in securing new contract wins and exceeding our retention expectations. We also expect growth in large group self-funded enrollment, reflecting new contract wins. 
While we expect strong growth in ASO, our commercial fully-insured enrollment will be pressured. We expect membership declines of approximately 300,000 in our Individual business as we aren't experiencing the overall market growth on the public exchange that we projected when we laid out our 5-year plan, and unsustainable pricing in some markets is hurting our historic market share. We're encouraged that early indicators of the open enrollment activity are slightly better than our muted expectations. Recent actions taken by CMS to begin addressing the special enrollment period challenges as well as the elimination of the health insurer fee in 2017 are important first steps towards improving affordability for our customers. And you can be assured we are contributing to the dialogue to form a long-term, sustainable and affordable marketplace. 
We also expect Local Group fully insured membership losses of approximately 250,000 as members continue to transition into self-funded product offerings. It is important to note that while this trend is in line with recent history, we now do not expect a meaningful offset to this trend from growth on the private exchanges. Additionally, we expect continued pressure from the impact of higher levels of attrition due to the ending of insurance policies that were early renewed by our clients before the implementation of the Affordable Care Act. 
For Government, we expect another strong enrollment growth year. We expect Medicaid to add more than 350,000 lives, reflecting the addition of new business in the State of Iowa as well as continued organic growth in core and expansion products. We continue to see states gravitate towards managed care to be the solution for more complex populations and services, and we expect to be front and center, supporting these states' initiatives. 
Within our Medicare business, we continue to expect enrollment to be relatively steady as growth in our existing markets will be mostly offset by membership losses as we finalize the repositioning of our book in certain markets as part of our turnaround plan. 
Turning to financial metrics. We expect relatively stable margins in 2016. We currently expect an MLR midpoint of 83.6%, an increase of 30 basis points versus 2015. This reflects the impact of a change in the mix of our business as we expect strong growth in Medicaid, a business with a higher MLR than the consolidated average. 
Related to cost trend expectations. Again, we expect 2016 Local Group medical cost trends to be in the range of 7% to 7.5%. We expect our SG&A ratio in 2016 to be 15.4% at the midpoint. This reflects the impact of the changing mix of our business, strong growth in Medicaid and the impact of the administrative efficiency initiatives our management team is taking to work through the challenging public exchange environment. 
Below the line, we expect investment income of approximately $650 million and interest expense of approximately $630 million. Note that our interest expense projection does not include the costs we expect to incur related to the bridge loan financing we have in place for the pending Cigna acquisition. We also currently expect our tax rate to be in the range of 43.5% to 45.5% for the year. We expect some benefit from the impact of capital deployment activities next year. 
While we suspended share repurchases after the announcement of the Cigna acquisition in 2015, we plan to resume our capital deployment program in 2016, subject to market conditions, albeit at a lower level than in recent years. As a result, we currently expect our share count for the year to be in the range of 266 million to 270 million shares. 
We remain committed to at least maintaining our current dividend. We plan to review our capital deployment strategies at our next board meeting in February, and we expect to make an announcement on our first quarter 2016 dividend shortly thereafter. 
To conclude, our 2016 GAAP earnings per share estimate is greater than $10.35. Our adjusted earnings per share outlook is greater than $10.80. The difference between these 2 estimates is the exclusion of the amortization of deal-related intangibles. It's important to note that our 2016 outlook does not include any benefits or transaction costs associated with the pending acquisition of Cigna, which we continue to expect will close in the second half of the year. 
With that, operator, please open the queue for questions."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","[Operator Instructions] Your first question comes from the line of A.J. Rice from UBS.",14,"[Operator Instructions] Your first question comes from the line of A.J. Rice from UBS."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I noticed on your guidance you're forecasting your medical cost trend to a range of 50 basis points. Traditionally, you guys have always used 100 basis points in forecasting that. I'm just curious on your thinking of narrowing that. Obviously, the step-up",69,"I noticed on your guidance you're forecasting your medical cost trend to a range of 50 basis points. Traditionally, you guys have always used 100 basis points in forecasting that. I'm just curious on your thinking of narrowing that. Obviously, the step-up sort of seems similar to what you assumed last year. You came in at the low end. But I'm just curious of the thinking behind that."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Essentially, the thinking was that the last several years, I would think it's fair to say there's been a lot of volatility regarding the exchanges, the Affordable Care Act, a number of new specialty drugs coming in. From our perspective, we generally have",124,"Essentially, the thinking was that the last several years, I would think it's fair to say there's been a lot of volatility regarding the exchanges, the Affordable Care Act, a number of new specialty drugs coming in. From our perspective, we generally have a point of view that's within 50 basis points. We've been hanging pretty tight to that. And so it's more just to make sure that you understood that, in fact, we were raising our trend assumptions and our pricing going into this year, and then try to tighten that band within a 50 basis point range as we're getting better clarity now on the underlying activity associated with our commercial book as well as the new drugs that are coming in."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then just a follow-up on the -- I know at a conference earlier in the month, you guys have made some comments about where you were at with your PBM, and I don't assume there's no assumptions and anything in the guidance related to this to any ki",71,"Okay. And then just a follow-up on the -- I know at a conference earlier in the month, you guys have made some comments about where you were at with your PBM, and I don't assume there's no assumptions and anything in the guidance related to this to any kind of changes in that contract. But is there any update on what you're thinking there and what the opportunity might be?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","This is Joe. Nothing's changed since our statements last month -- or excuse me, earlier this month at the conference, and nothing's been included in the materials regarding the PBM dialogue that we've had thus far. So I guess, more to come later, but noth",50,"This is Joe. Nothing's changed since our statements last month -- or excuse me, earlier this month at the conference, and nothing's been included in the materials regarding the PBM dialogue that we've had thus far. So I guess, more to come later, but nothing is embedded at the moment."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Josh Raskin from Barclays.",12,"Your next question comes from the line of Josh Raskin from Barclays."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First question, I just want to ask about the CMS sanctions at Cigna. And I just want to see, how does that fit with your understanding? Sort of when did you guys find out about it? Did you know about this as part of the diligence? And does this change any",64,"First question, I just want to ask about the CMS sanctions at Cigna. And I just want to see, how does that fit with your understanding? Sort of when did you guys find out about it? Did you know about this as part of the diligence? And does this change anything in terms of your outlook -- your financial outlook for the combined entities?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, thank you. This is Joe again. First, let me clearly state, we have 2 separate companies. And obviously, activities of that nature within their company, we do not have line of sight of, nor should we, I think. And we are kind of considering it, as you",174,"Yes, thank you. This is Joe again. First, let me clearly state, we have 2 separate companies. And obviously, activities of that nature within their company, we do not have line of sight of, nor should we, I think. And we are kind of considering it, as you would expect. But at the moment, we really don't have enough line of sight to pass judgment on what effect it may have, if any, for that matter. So we will be vigilant, and I'm certain that as time marches on, we'll learn more on. But quite frankly, at this stage, there's really nothing for us to say regarding what impact it may have regarding Cigna. And with respect to the transaction itself, we are clearly and unwavering with respect to our commitment to the deal. This does not have an effect on the deal process. And obviously, as we learn more, we'll certainly feather it into our considerations. But at this stage, we just do not believe it has a material effect on our transaction."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Got you. That's what I was looking for. And then just on the commercial business, the MLR, I think, in the past, you guys have been attributing the increase, at least last quarter, to the individual business. Now you're adding Local Group into that sort o",116,"Got you. That's what I was looking for. And then just on the commercial business, the MLR, I think, in the past, you guys have been attributing the increase, at least last quarter, to the individual business. Now you're adding Local Group into that sort of discussion for the MLR driver. So just trying to figure out what's driving that increase. Did the individual business deteriorate more? Or is this now more of a small group issue? And as we look about the overall margin for the Commercial segment this quarter, being just over breakeven, is it fair to assume you're losing money now, obviously, in Individual, but also on the Local Group side as well?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","No, Josh. Let me clarify. There's normal seasonality that we see in all books of business as deductibles are met throughout the year. So I want to emphasize that relative to the group business, no concerns at all. The primary MLR drivers are mixed in the",215,"No, Josh. Let me clarify. There's normal seasonality that we see in all books of business as deductibles are met throughout the year. So I want to emphasize that relative to the group business, no concerns at all. The primary MLR drivers are mixed in the quarter and as we've been talking about, the public exchanges. So again, I don't want to create any alarms there. Trend finished at the low end -- or lower half of our range, as we said earlier, and the metrics remain strong. One thing I would like to highlight, though, for each of you on the call is that we try to maintain a conservative posture on the 3Rs as well while maintaining our reserve balance sheet strength with our high single-digit margin for adverse deviation at year-end. So when you look at our run rate Individual business, we still made a very slight, I call it, closer to breakeven for the year. But keep in mind, that's with us maintaining a very conservative position on the 3Rs as well. And going into '16, we are still assuming we will be profitable on our individual and exchange business, albeit below our targeted 3% to 5% margins as we continue to see those markets hopefully begin to harden around pricing."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Kevin Fischbeck from Bank of America.",14,"Your next question comes from the line of Kevin Fischbeck from Bank of America."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Great. Just, I guess, I understand the concept of the mix shift impacting the MLR and the SG&A ratios, but it looks like given that you're growing earnings faster than revenue, [indiscernible] margin expansion next year. Can you point to one division that",53,"Great. Just, I guess, I understand the concept of the mix shift impacting the MLR and the SG&A ratios, but it looks like given that you're growing earnings faster than revenue, [indiscernible] margin expansion next year. Can you point to one division that you would point to as seeing stronger margin improvement year-over-year?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Kevin, the primary thing I would highlight is a lot of the initiatives we took was to take the G&A deleveraging out across the organization that if we weren't going to see the membership growth that we expected on the exchanges. And then more importantly,",92,"Kevin, the primary thing I would highlight is a lot of the initiatives we took was to take the G&A deleveraging out across the organization that if we weren't going to see the membership growth that we expected on the exchanges. And then more importantly, I think, as Joe has said, he's committed to us driving towards the $14 in 2018. And so we've had a very aggressive G&A initiative, which allows both margin maintenance as well as some expansion in all lines of business as that effort was an enterprise-wide effort."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So then the Commercial side that you would say is where more of the margin expansion would be?",19,"Okay. So then the Commercial side that you would say is where more of the margin expansion would be?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes.",1,"Yes."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And I guess, as far as that comment about the 2014 number, I guess, last quarter, you kind of said, ""Hey, the individual numbers are just coming in below what we might have thought. And over the long-term targets, that could be a drag towards hitting that",82,"And I guess, as far as that comment about the 2014 number, I guess, last quarter, you kind of said, ""Hey, the individual numbers are just coming in below what we might have thought. And over the long-term targets, that could be a drag towards hitting that."" Are you saying now that you found some offsets that are still going to make you comfortable with hitting $14 on a stand-alone basis before Express? Or is that still a risk, in your view?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Kevin, I would say that relative to the revenue line item, if the individual membership fully insured market doesn't ramp up over the next several years, I think that $100 billion in organic revenue will be at risk. But I think relative to the $14 of earn",141,"Kevin, I would say that relative to the revenue line item, if the individual membership fully insured market doesn't ramp up over the next several years, I think that $100 billion in organic revenue will be at risk. But I think relative to the $14 of earnings per share, as we've been able to show in '15 going into '16, there are many levers that we can pull, and Joe has aggressively pushed the management team to pull those levers with a high degree of confidence, hopefully, in our ability to execute against them. And so I think, at this point, I would tell you -- and I'll let Joe say it for himself, he's committed, and this management team is committed to driving towards the $14, but we may get there different than we had laid out 2 years ago."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. And I kind of -- thanks, Wayne. Just to reiterate and emphasize there, we recognize the $100 billion might be somewhat flexible in terms of where we may end up in '18 on that metric. However, we're incredibly committed to the $14. We believe there ar",124,"Yes. And I kind of -- thanks, Wayne. Just to reiterate and emphasize there, we recognize the $100 billion might be somewhat flexible in terms of where we may end up in '18 on that metric. However, we're incredibly committed to the $14. We believe there are certainly a lot of variables in the equation that will map to what the ultimate revenue capture will be. But nonetheless, all parts and pieces are going to line up, we believe, very effectively for us to make that $14 commitment. And so again, we've got all actions in place regarding matters like people, the G&A controls and a variety of other puts and takes on the management side that will get us to the $14 target."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Kevin, as we've said previously, too, the PBM and the rising interest rates both serve as hedges against other risks that we see in the business and potential opportunities for upside as well. Kevin, one other item I want to highlight is you had asked abo",95,"Kevin, as we've said previously, too, the PBM and the rising interest rates both serve as hedges against other risks that we see in the business and potential opportunities for upside as well. Kevin, one other item I want to highlight is you had asked about other businesses with margin in addition to G&A. The Medicare improvement, as Joe laid out, our efforts over the last 2 years have been quite substantial, and the results have been very promising. And so we will see very nice margin improvement in Medicare going into 2016 as well."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Gary Taylor from JPMorgan.",12,"Your next question comes from the line of Gary Taylor from JPMorgan."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I had one question and one follow-up. Just in terms of your cost trend guidance for 2016, would you care to kind of go through components of that, so hospital inpatient, outpatient position, pharma? Even just qualitatively in terms of expectations would b",45,"I had one question and one follow-up. Just in terms of your cost trend guidance for 2016, would you care to kind of go through components of that, so hospital inpatient, outpatient position, pharma? Even just qualitatively in terms of expectations would be helpful."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","We won't break it down necessarily, although I can tell you that we typically expect very little change in the physician aspects of it. It's very much driven more towards the specialty pharma being one of the primary drivers. We are expecting an increase",76,"We won't break it down necessarily, although I can tell you that we typically expect very little change in the physician aspects of it. It's very much driven more towards the specialty pharma being one of the primary drivers. We are expecting an increase in utilization on inpatient. Whether or not that plays out will remain to be seen. But it's primarily utilization, and then it's a unit cost on pharma that are the drivers."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then just a clarification on the reported operating gain for the Commercial segment for 4Q. It's $56 million, that 0.6% margin. Is that figure normalized, excluding the California franchise tax ruling? Or is that -- or is there a pretax number t",51,"Okay. And then just a clarification on the reported operating gain for the Commercial segment for 4Q. It's $56 million, that 0.6% margin. Is that figure normalized, excluding the California franchise tax ruling? Or is that -- or is there a pretax number that's weighing upon that reported operating income margin?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","No. The only item that is of a unique nature that would be in there from an operating gain perspective is our desire to maintain a strong balance sheet associated with the 3Rs, and that has a direct impact on that. I'd like to be optimistic and hope there",143,"No. The only item that is of a unique nature that would be in there from an operating gain perspective is our desire to maintain a strong balance sheet associated with the 3Rs, and that has a direct impact on that. I'd like to be optimistic and hope there'll be upside there, but it appears, even in the last year, our conservative nature on some of these 3Rs has proved to be prudent. And so we decided to take that same posture in the fourth quarter and strengthen even further some of the 3R assumptions. Based on the public data available, it would imply we're conservative. But at the same time, that data would have implied that last year, and that ended up not being the case. So we try to strengthen even further. And of course, that hits the Commercial segment directly."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","That's primarily a risk adjustment number we'll see in the 10-K?",12,"That's primarily a risk adjustment number we'll see in the 10-K?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Both the risk adjustment as well as a position that we don't see value in the corridors and assume the -- a 100% valuation allowance as well as on the reinsurance. We have stuck with strictly what the law currently says we're entitled to, not what maybe e",68,"Both the risk adjustment as well as a position that we don't see value in the corridors and assume the -- a 100% valuation allowance as well as on the reinsurance. We have stuck with strictly what the law currently says we're entitled to, not what maybe excess funding may be in the pool. And so those are the 3 positions we've taken a conservative posture in."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Ralph Giacobbe from Citi.",12,"Your next question comes from the line of Ralph Giacobbe from Citi."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I may have missed this. I'm not sure if you gave it. Did you say where you ended the year in terms of exchange enrollment and maybe what's embedded into expectations in terms of exchange enrollment for 2016? And then just extending on that, maybe where yo",58,"I may have missed this. I'm not sure if you gave it. Did you say where you ended the year in terms of exchange enrollment and maybe what's embedded into expectations in terms of exchange enrollment for 2016? And then just extending on that, maybe where you're at in terms of on- versus off-exchange for your individual book."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","So we ended the year just shy of 800,000 members on the exchange enrollment, around 791,000, which was below our planned expectations by about 30%. We now are looking at the book in a more fungible way. We're looking on-exchange and off-exchange now becau",155,"So we ended the year just shy of 800,000 members on the exchange enrollment, around 791,000, which was below our planned expectations by about 30%. We now are looking at the book in a more fungible way. We're looking on-exchange and off-exchange now because it's becoming quite fungible between the 2 as grandmothering is moving away. And so for next year, we have individual declining by another 300,000 lives all-in going into '16. At least, that's our assumption. As Joe said in the prepared remarks, the early enrollment application is encouraging against that assumption, but it's very important that we wait and see how lapses actually occur because we'll know who ultimately pays and doesn't pay. We won't know that answer until the end of this month. So again, the applications to date would imply that we may be conservative there. But until we see actual payments in this enrollment, it's hard to declare."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay, all right. That's helpful. And then just on the ASO book, you continue to show nice growth there. Are you seeing and capturing sort of existing ASO business? Are you maybe seeing a continued shift from sort of risk to ASO? Are you seeing more penetr",64,"Okay, all right. That's helpful. And then just on the ASO book, you continue to show nice growth there. Are you seeing and capturing sort of existing ASO business? Are you maybe seeing a continued shift from sort of risk to ASO? Are you seeing more penetration downstream to mid or smaller employers? Just trying to get a sense of the dynamics at play."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's a little bit of both. Clearly, on the national accounts, those were a lot of new wins for us. Obviously, some very sizable wins, including the Bank of America account. So from that perspective, I would say a big chunk of the ASOs is really new member",160,"It's a little bit of both. Clearly, on the national accounts, those were a lot of new wins for us. Obviously, some very sizable wins, including the Bank of America account. So from that perspective, I would say a big chunk of the ASOs is really new membership and new lives to us. When you look at the shift from ASO -- I'm sorry, from fully insured to ASO, that shift continues. I wouldn't call it in an accelerated pace anymore. It seems to have slowed down. But nonetheless, it's still occurring. And so we are retaining a lot of that membership moving from fully insured to ASO. But as you know, on a revenue basis, that really dampens the revenue if you're not getting the offset through either the public exchanges or, for that matter, what we felt would have been a faster pace in the private exchanges, which, we believe, is a much more muted pace now."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Dave Windley from Jefferies.",12,"Your next question comes from the line of Dave Windley from Jefferies."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So on the premium number, Wayne, that you were just hitting on the guidance relative to expectations as, call it, $2.5 billion to $3 billion light, the ASO shift accounts for some of that, but maybe less than half. I'm wondering if you believe you're gett",75,"So on the premium number, Wayne, that you were just hitting on the guidance relative to expectations as, call it, $2.5 billion to $3 billion light, the ASO shift accounts for some of that, but maybe less than half. I'm wondering if you believe you're getting -- if there's anything in mix that would be affecting yield. And are you getting full premium yield relative to the cost trend expectations you are expecting for 2016?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Dave, great question. Let me first highlight that this revenue shortfall is almost predominantly associated with the lack of growth on the public exchanges. I mean, I just -- I can't emphasize that point enough. And ultimately, that would be the one area",161,"Dave, great question. Let me first highlight that this revenue shortfall is almost predominantly associated with the lack of growth on the public exchanges. I mean, I just -- I can't emphasize that point enough. And ultimately, that would be the one area I would say why we're projecting profitability still in 2016, clearly, at margins below what we think are the long-term margins for a sustainable program and product. So that would be the one area I would point to relative to yields. We are still able to cover our cost of capital on them and be profitable, but we are looking forward to some of the structural changes that I know the administration is looking at to make these programs even more viable in the long term. But our revenue issue is really a fully insured public exchange issue at this point. The rest of the book of business is performing well versus our 5-year expectations we've laid out."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. My follow-up would be on -- a follow-up on the PBM. Would you guys be willing to comment on how the analysis bridge from the $500 million to $700 million number that you talked about, say, mid to early second half of 2015 to the $3 billion number th",58,"Okay. My follow-up would be on -- a follow-up on the PBM. Would you guys be willing to comment on how the analysis bridge from the $500 million to $700 million number that you talked about, say, mid to early second half of 2015 to the $3 billion number that you've now talked about in January of '16?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, this is Joe. Let me comment on that. Going back in time to '15 at earnings day, we did land on the $500 million to $700 million as a proxy statement regarding what may be possible related to market check analysis, et cetera. Then, fast forward to tod",233,"Yes, this is Joe. Let me comment on that. Going back in time to '15 at earnings day, we did land on the $500 million to $700 million as a proxy statement regarding what may be possible related to market check analysis, et cetera. Then, fast forward to today, we've gone through a very deliberate analytical process. We vectored toward an answer related to multiple checks in the marketplace, and that brought us to the $3 billion finding that we believe is very, very credible. And obviously, having made that statement, which we believe kind of recalibrates the number from that $500 million to $700 million was something that we believe is much more realistic. So what we said back in '15 is that we would update you in '16 actually hoping to communicate, I guess, call it, a solution to you regarding our PBM inquiry regarding what we would have to do to reposition ourselves to get to the end of the contract in 2019. So having made statement about $3 billion, our market check expectations, we believe we've set the table now for conversations in and around the possibility of recasting our pricing relationship with ESI. So all I can tell you at this stage is that dialogue will continue, and we're hopeful that still in '16, we will reach a resolution to this matter that we're engaged in with ESI."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Christine Arnold from Cowen.",12,"Your next question comes from the line of Christine Arnold from Cowen."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I'm looking at the MLR. And as of third quarter '15, you expected the full year to be 82.9%, plus or minus 30. And you're above that range at 83.3% for the full year. So was individual entirely the shortfall on that loss ratio?",45,"I'm looking at the MLR. And as of third quarter '15, you expected the full year to be 82.9%, plus or minus 30. And you're above that range at 83.3% for the full year. So was individual entirely the shortfall on that loss ratio?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Individual was substantially the shortfall. That's correct. And again, it's important to recognize that some of the balance sheet strengthening we've done would all flow through that as well regarding not only the 3Rs, but maintaining that high single dig",94,"Individual was substantially the shortfall. That's correct. And again, it's important to recognize that some of the balance sheet strengthening we've done would all flow through that as well regarding not only the 3Rs, but maintaining that high single digit for adverse deviation. So I would point you almost solely to that. Medicaid enrollment was a little bit stronger in the quarter than we had anticipated as well. So that is a little bit of an MLR mix shift to it, but it's predominantly individual and then the strengthening we did on the 3Rs."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And first half of the year, we were looking at a 3% to 5% margin. Second half of the year, we're looking at breakeven. So we've completely erased that 3% to 5%, yet the biz were due in May and June. So can you help me understand how, when you didn't",71,"Okay. And first half of the year, we were looking at a 3% to 5% margin. Second half of the year, we're looking at breakeven. So we've completely erased that 3% to 5%, yet the biz were due in May and June. So can you help me understand how, when you didn't know about this 3% to 5% erosion in profitability, you're confident that this is going to improve next year?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Christine, it's a really great question, and it's one of the reasons that -- the issue we had, though, on our margins this year was the inability to deleverage G&A quick enough. So we were still assuming a 3% to 5% margin, but we're also assuming a 30% gr",182,"Christine, it's a really great question, and it's one of the reasons that -- the issue we had, though, on our margins this year was the inability to deleverage G&A quick enough. So we were still assuming a 3% to 5% margin, but we're also assuming a 30% growth rate. As we started seeing that growth rate not only not occur, but beginning to see some attrition in the latter part of the year, we realized it was imperative to get the G&A out. And I can tell you that those initiatives have occurred. Those actions around headcount and other costs have already been taken out now, and we'll get the run rate effect going into the year. So from that perspective, we feel fairly confident. And again, I would emphasize, the public data that we're getting regarding risk adjusters from Wakely, regarding how 3Rs settled up on reinsurance last year, et cetera, would imply we are being conservative in that outlook. But we've chosen to take that posture in '15, and that's part of the reason of getting closer to breakeven."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Ana Gupte from Leerink Partners.",13,"Your next question comes from the line of Ana Gupte from Leerink Partners."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","The question, firstly, is around the catcher's mitt strategy that you had articulated. Now we're 2 years into exchanges. As you're looking at your small group, that $800 million EBIT headwind -- sorry, $800 million to $400 million that you had articulated",97,"The question, firstly, is around the catcher's mitt strategy that you had articulated. Now we're 2 years into exchanges. As you're looking at your small group, that $800 million EBIT headwind -- sorry, $800 million to $400 million that you had articulated, when you look at it across, firstly, is that stemmed at this point? And when you look at it across small group and Individual, are you coming out net positive? Is it net neutral? Or is it continuing to be a headwind? And how do you expect that going forward into '16 and then '17?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thanks for the question. I would say the catcher's mitt strategy itself is working as we would have expected as we are clearly seeing attrition in lines of business. Small group alone lost over 100,000 lives in the fourth quarter. Clearly, we're picking t",216,"Thanks for the question. I would say the catcher's mitt strategy itself is working as we would have expected as we are clearly seeing attrition in lines of business. Small group alone lost over 100,000 lives in the fourth quarter. Clearly, we're picking those lives up elsewhere as we were able to exceed our membership targets for the year. I would say the part of the strategy that's not coming to light at this point isn't about capturing the member now, but where exactly that member is caught and the revenue associated with that member. And I think, at this point, when we built our 5-year plan, we fully expected more of these lives to be picked up in the public exchanges as a fully insured. And we're finding that some of those lives now are actually getting employed and more in ASO market and -- or we're picking them up on Medicaid, which, in some cases, are lower PMPM that we would have got on the public exchange. And so ultimately, I would say the strategy of the catcher's mitt itself is working terms of getting the customers and continuing to grow membership. But I would say the mix of membership and how it translates to revenue is not panning out as we had anticipated."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And then following up on that, just now on the public exchanges, with your decline in individual from the third quarter to the fourth quarter, was that mainly the special enrollment period folks that did that? And as you're looking out into 2017, as reins",78,"And then following up on that, just now on the public exchanges, with your decline in individual from the third quarter to the fourth quarter, was that mainly the special enrollment period folks that did that? And as you're looking out into 2017, as reinsurance goes away, do you think the policy changes that the administration is making would still allow you to remain on exchange and be profitable into '17 just, again, part of your catcher's mitt?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, this is Joe. Let me comment on the kind of the continued engagement that we envision in the exchanges. Yes, we are certainly very observant of the shifts and changes that the administration is enacting. Especially, we're paying a lot of attention to",210,"Yes, this is Joe. Let me comment on the kind of the continued engagement that we envision in the exchanges. Yes, we are certainly very observant of the shifts and changes that the administration is enacting. Especially, we're paying a lot of attention to special enrollment period. Very thankful the administration has made some changes. I suspect there may be more changes in the near future, which we want to consider very carefully so that we can judge the sustainability of the exchange marketplace and how well we can engage in that marketplace going forward. So we're very observant regarding these moves and changes. We feel that, as Wayne pointed out a moment ago, we're extremely well positioned with respect to matters like G&A that allows us to perform in this space reasonably well. Notwithstanding member deterioration, it's presumably stabilized, given what we're observing regarding some uptick in membership for '16, which, obviously, as Wayne pointed out, we'll probably know more within the month. But nonetheless, we're really carefully observing it, looking at special enrollment in terms of its potential impact. And again, we're very hopeful that some of the issues will be ameliorated in terms of the risk and will have a much more sustainable marketplace to engage in."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Scott Fidel from Crdit Suisse.",13,"Your next question comes from the line of Scott Fidel from Crdit Suisse."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First question, just if you can give us an update on how the implementation of Iowa Medicaid is coming along. And just interested, just in the context of the state having removed WellCare from the contract, what your updated enrollment expectation is for",76,"First question, just if you can give us an update on how the implementation of Iowa Medicaid is coming along. And just interested, just in the context of the state having removed WellCare from the contract, what your updated enrollment expectation is for Iowa? And then, what type of losses you're building in and expecting? Obviously, United did increase their PDR for Iowa as a result of that. So just interested in how you're approaching this."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","First of all, relative to Iowa, we continue to be optimistic about this program in the long term and that it will have the similar trajectory of we expect to lose money in year 1, get closer to breakeven in year 2 and then return to profitability by year",306,"First of all, relative to Iowa, we continue to be optimistic about this program in the long term and that it will have the similar trajectory of we expect to lose money in year 1, get closer to breakeven in year 2 and then return to profitability by year 3. We got an update from the team yesterday. Actually, Joe and the senior leadership team got a full deep dive on where things are progressing. And things are moving exactly as we would have expected at this point. We're very close to starting that implementation on 3/1. We don't have line of sight of what membership we may or may not get. As you know, there are a number of appeals that have been filed both by the -- one individual that was selected that has been told they were being removed as well as others that were not selected in the first round. So we have not included any of that, and we want to see how that pans out. That being said, if you were to look at Medicaid all-in, both margin compressions that we're receiving throughout the year that we expect, plus we're assuming even further margin pressure in the back half of '16 from states as well as expansion, there's about a few hundred million dollar headwind baked in. But I would tell you that Iowa is less than 25% of that. So it gives you kind of a gauge of how we're envisioning year 1 to evolve and then migrate more to year 2, and then from there, to the normal profitability we would have in these programs. The delay of 2 months is part of the reason for that level of loss in year 1 because, ultimately, we've got the G&A float happening, but we don't have the revenue yet."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Got it, okay. And then just had -- a follow-up question just on small group and actually, a number that I don't think we've talked about for a few quarters. But just interested, remember, a couple of years back, you had talked about how small group would",123,"Got it, okay. And then just had -- a follow-up question just on small group and actually, a number that I don't think we've talked about for a few quarters. But just interested, remember, a couple of years back, you had talked about how small group would potentially have to absorb maybe a $400 million EBIT hit from ACA as thinking about both sort of margin rebasement and then enrollment attrition. And just interested if you can give us an update on sort of how you're tracking relative to that number. Obviously, there has been some recent attrition. But just interested if you were sort of at that number or still some ways to go or just where we stand relative to that."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","So relative to the $400 million, Scott, which is more about margin reset, I would say we've taken our medicine on that $400 million over the last couple of years. Now it becomes a question of, will small group continue to migrate to other lines of busines",146,"So relative to the $400 million, Scott, which is more about margin reset, I would say we've taken our medicine on that $400 million over the last couple of years. Now it becomes a question of, will small group continue to migrate to other lines of business over time around just pure membership? But we have taken that sizable hit. As we saw in the fourth quarter, a very sizable chunk of that membership migrated away from fully insured. And the question is, will we recover that even through the public exchanges, in open enrollment or others? Again, our early open enrollment data would imply we are recovering it, but we want to see what actually converts to a pay by the end of the month. So -- but I'd say in terms of the margin compression, we've taken a substantial portion of that $400 million."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Matthew Borsch from Goldman Sachs.",13,"Your next question comes from the line of Matthew Borsch from Goldman Sachs."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","If I could just go back to the exchanges for a moment again. A couple of questions there. When you talked about the unsustainable price competition and also the lack of market growth, should we read that the decline that you're expecting of 300,000 is all",121,"If I could just go back to the exchanges for a moment again. A couple of questions there. When you talked about the unsustainable price competition and also the lack of market growth, should we read that the decline that you're expecting of 300,000 is all about the unsustainable price competition since if the market didn't grow, then maybe you would expect it to be flat? And my follow-up question to that is, as we look to 2017, how much impact -- favorable impact do you think you'll get from the risk pool as grandmothering plans work their way into the exchanges, albeit I know that's not going to be the case for your 2 largest markets, California and New York?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Matt, I appreciate the question. A couple of thoughts or at least, insights. One is, yes, we are assuming that some of the pricing that we continue to see in our markets, our 14 states, is still well below what we think appropriate rates are for a sustain",371,"Matt, I appreciate the question. A couple of thoughts or at least, insights. One is, yes, we are assuming that some of the pricing that we continue to see in our markets, our 14 states, is still well below what we think appropriate rates are for a sustainable environment. I think the fact that we're closer to breakeven in '15 and a profit margin that's below the targeted 3% to 5% in '16 I think is a good indication of -- our price point isn't wrong as much as others need to strengthen their price points. So we are going to assume that the strengthening is not occurring. In fact, we know in many states it hadn't occurred and that we will continue to treat members. That being said, we are starting to see Individual start to recognize the problems in their books. They are starting to strengthen their pricing quite meaningfully. We are seeing co-op struggle in the moment with more than half of those now insolvent. And so the question becomes, will the markets start to harden going into '17, which has really 2 effects for us: one is we no longer have the diminishing membership base; but more importantly, we should be hopefully a net recipient of that and hopefully start getting some of that revenue back that we had talked about in our original 5-year outlook? And then relative to 2017, Matt, to your comment, it's -- with grandmothering, it's really hard to say at this point. I mean, the behaviors of kind of the dynamics of what will the market look like in '17, not just the exchanges and how grandmothering, but just what's the global economy and the U.S. economy doing, what implications does that have as well. But the theory of what you laid out would imply that you're going to get more of those lives in that are a healthier population and should help improve the overall profitability of the book as well. But as you indicated, in our largest markets, we did not allow grandfathering in many cases, and we migrated already. So it won't have as big of an impact, but if the market has hardened, it should improve for us."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Peter Costa from Wells Fargo.",13,"Your next question comes from the line of Peter Costa from Wells Fargo."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","A couple of years ago and through the last few years, we've talked about consumerization of health care and the growth of private exchanges, and we really haven't seen that come through in a significant way here. We are second year with that not deliverin",67,"A couple of years ago and through the last few years, we've talked about consumerization of health care and the growth of private exchanges, and we really haven't seen that come through in a significant way here. We are second year with that not delivering much membership growth. Do you -- what -- can you tell us how you're evolving your strategy on consumerization and private exchanges?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, this is Joe. Thanks for the question. Yes, I think private exchanges have had a slow uptake probably for a few reasons. But I think it was considered as sort of an offset to the Cadillac tax exposure and other necessities that businesses and industry",262,"Yes, this is Joe. Thanks for the question. Yes, I think private exchanges have had a slow uptake probably for a few reasons. But I think it was considered as sort of an offset to the Cadillac tax exposure and other necessities that businesses and industry considered in terms of moving their employees into a private exchange marketplace. It didn't materialize to the level of the speed that anybody anticipated in the early going, and our position at the moment is that we're kind of taking a more muted response to the private exchange formation and execution. Nonetheless, we're going to be ready if and when it does accelerate, and it may very well do so in the future. But at this stage, it really is a sort of a muted response to that strategy. And we believe what you're seeing nationally is sort of an in-market standard in terms of private exchanges just simply not picking up the speed that folks had originally anticipated. So we're basically waiting -- wait and see, and we're positioned. And in fact, we do have private exchange membership that is not a substantial part of our membership. But certainly, we are in the space. I guess bottom line is, affordability is still the key and remains critical to long-term positioning on the part of employers. And as private exchange presents itself as a solution, we're ready, willing and able to engage in a meaningful way. But again, I think our response at this stage is fairly muted, given there's just been such a slow uptake."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then just a follow-up, if you don't mind. Can you talk about the premium tax issue in California and your exposure to that in terms of the litigation against the -- your company?",35,"Okay. And then just a follow-up, if you don't mind. Can you talk about the premium tax issue in California and your exposure to that in terms of the litigation against the -- your company?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Pete, let me first just highlight that in California, the tax laws differ based on legal entity, very similar to any legal entity in the United States has differing tax laws. We pay our taxes exactly as the law states within the State of California, as do",146,"Pete, let me first just highlight that in California, the tax laws differ based on legal entity, very similar to any legal entity in the United States has differing tax laws. We pay our taxes exactly as the law states within the State of California, as do our competitors that have similar legal entities filed there. And the DMHC has actually agreed that we're paying taxes in accordance with the law. So at this point, I can simply state that it is fully our intention to follow the law, as we've done so far, and it's fully our intention to litigate any action brought against us that would imply otherwise. And so I -- there's nothing more to comment on beyond that, other than you should be aware that it is the law that we are following under, and the DMHC has supported us in that."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Chris Rigg from Susquehanna.",12,"Your next question comes from the line of Chris Rigg from Susquehanna."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just quickly here on the Government segment. I know -- Wayne, I think you said you're expecting to earn about $200 million less in Medicaid, but grow a little bit in Medicare. Net-net, is it going to be flattish or down in the Government segment in '16?",47,"Just quickly here on the Government segment. I know -- Wayne, I think you said you're expecting to earn about $200 million less in Medicaid, but grow a little bit in Medicare. Net-net, is it going to be flattish or down in the Government segment in '16?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Good question. It's going to be slightly down, which gives you a pretty good idea of how well our Medicare is actually performing. But it will be slightly down between those. And again, it's important to recognize, we thought it was prudent to have a caut",78,"Good question. It's going to be slightly down, which gives you a pretty good idea of how well our Medicare is actually performing. But it will be slightly down between those. And again, it's important to recognize, we thought it was prudent to have a cautious posture on how Medicaid rates may evolve as the year progresses. So not just the rates we know about in October, but what happens in mid July as well as next October."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Great. And then just on the reinsurance. Can you quantify how much you expect for -- from -- how much you expect to receive in 2015? And would you have lost money without that amount?",35,"Great. And then just on the reinsurance. Can you quantify how much you expect for -- from -- how much you expect to receive in 2015? And would you have lost money without that amount?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. I think the first thing to keep in mind, we're just assuming just slightly over 50%. I don't think you can look at it as whether you would lose money with or without that amount because it's important to recognize we're collecting net premium within",171,"Yes. I think the first thing to keep in mind, we're just assuming just slightly over 50%. I don't think you can look at it as whether you would lose money with or without that amount because it's important to recognize we're collecting net premium within our premium base on behalf of the government, and then submitting that into the reinsurance pool. So our pricing is baked with an assumption that we will get what the law says we're entitled to get without it. So I don't think you can look at it with or without the program because the pricing is built with that program. That being said, as you know, there's data points out there that would imply that people may recover as much as 55% to 60%. And again, we're much more in line with where the law is. When I say slightly over 50%, it doesn't even round up to 51%. So it gives you a little bit of a feel for we're just barely over 50%."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Andy Schenker from Morgan Stanley.",13,"Your next question comes from the line of Andy Schenker from Morgan Stanley."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Can you maybe talk a little bit more on Medicare? Obviously, seeing some significant improvements in '15, calling for continued improvements in '16. But how should we think about how much room is left beyond that as well as maybe the level of investments",61,"Can you maybe talk a little bit more on Medicare? Obviously, seeing some significant improvements in '15, calling for continued improvements in '16. But how should we think about how much room is left beyond that as well as maybe the level of investments currently in Medicare for the repositioning? And will some of that start winding down in '16, '17?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, this is Joe again. Since I joined the company a few years ago, we really put a stake in the ground that we were going to reposition ourselves in the Medicare space very aggressively. We established, as I said a moment ago, a 3-year plan, and we're w",173,"Well, this is Joe again. Since I joined the company a few years ago, we really put a stake in the ground that we were going to reposition ourselves in the Medicare space very aggressively. We established, as I said a moment ago, a 3-year plan, and we're well into that 3-year plan realization in terms of our targets. The margins, we expect to expand over time. And we do believe that we're really heavily focused on medical cost management capabilities. And we have an increased focus on our administrative cost structure as being a key contributor to margin improvement. So when you put all that together, we are witnessing a substantial, I'd call it, even a turnaround in our Medicare book that really gives us cause for optimism going forward. We really do remain very pleased with the success that we've created with the team, and I'm hopeful that as we get through '16 and well into '17 that we'll be able to report on a trajectory that's on a positive track."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay, that's helpful. And then just real quick on seasonality here. I mean, it's obviously increasingly front half-loaded. Should we view '15 seasonality as kind of the framework for '16? Or is there any changes that could swing those numbers?",40,"Okay, that's helpful. And then just real quick on seasonality here. I mean, it's obviously increasingly front half-loaded. Should we view '15 seasonality as kind of the framework for '16? Or is there any changes that could swing those numbers?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Andy, great question. I would think the seasonality in '15 will much be much more reflective of what you'll see in '16. Just keep in mind, the wild card in all of this is really going to be around how these 3Rs ultimately settle out. From our perspective,",122,"Andy, great question. I would think the seasonality in '15 will much be much more reflective of what you'll see in '16. Just keep in mind, the wild card in all of this is really going to be around how these 3Rs ultimately settle out. From our perspective, it -- again, we believe we've been prudent at booking to a conservative point of view. But as more data comes out on those 3Rs, that could create some unique nuances throughout the year. And also, how these co-ops evolve throughout the year and how the states plan to solve for that could create nuances into 2016. But generally speaking, '15 is a pretty good proxy for the seasonality you should expect in '16."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","And your final question today comes from the line of Sarah James from Wedbush Securities.",15,"And your final question today comes from the line of Sarah James from Wedbush Securities."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","You mentioned some potential headwinds on Medicaid rates for 2016, and you're not the first company to spike out that concern. So what are you currently building into guidance for your blended rates in '16? What was it in '15? And can you talk about how y",71,"You mentioned some potential headwinds on Medicaid rates for 2016, and you're not the first company to spike out that concern. So what are you currently building into guidance for your blended rates in '16? What was it in '15? And can you talk about how you view margins on that business for legacy Medicaid? So excluding Iowa or any new contracts, how do you think about margins developing for Medicaid?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","So a good question. One is, I do want to highlight, we don't generally give blended rate increases. As you know, it varies by state. And because the underlying economics of each state vary dramatically, we will prefer not to blend them together in a broad",219,"So a good question. One is, I do want to highlight, we don't generally give blended rate increases. As you know, it varies by state. And because the underlying economics of each state vary dramatically, we will prefer not to blend them together in a broad discussion. That being said, though, Sarah, I think it's a fair question. Understand that we have margins that are exceeding what we believe are long-term, sustainable, optimal margins. But know that we are still assuming that we will blend closer to a 5% margin all-in going into next year. Now that's higher than what you've typically heard from Medicaid, which will be the 2% to 3% margin range. But it's important to recognize that we do get a gross up for the health insurer fee as well, so that bumps those margins further. But we think that the guidance we provided puts us at what hopefully will be a sustainable outperformance margin for us. We believe we should have a better margin because we believe we can execute on this better, and the team that we brought in from the Amerigroup almost 3 years now has done an exceptional job in that space. But our pricing is slowly landing the plane on those margins to get to more of that sustainable, long-term margin."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And was there anything moving pieces-wise in the quarter for Medicaid like a flu benefit? Or I think in the past, you had mentioned the potential for retroactive premium payments. Or is there anything out-of-period or unusual that we should think ab",48,"Okay. And was there anything moving pieces-wise in the quarter for Medicaid like a flu benefit? Or I think in the past, you had mentioned the potential for retroactive premium payments. Or is there anything out-of-period or unusual that we should think about with this quarter's Medicaid performance?"
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","No, nothing unusual in terms of the actual numbers. Things tied out where we thought they would tie out. What was a little unusual was more on the cash flow. We actually had a couple of large vendors. And a couple of states, in particular, pay us on the l",86,"No, nothing unusual in terms of the actual numbers. Things tied out where we thought they would tie out. What was a little unusual was more on the cash flow. We actually had a couple of large vendors. And a couple of states, in particular, pay us on the last day of the year for rates we typically get in the first 5 days of the new year. So it affected cash flow, but it didn't actually affect the underlying economics of what we had assumed."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Thank you. I'd now like to turn the conference back to the company's management for closing comments.",17,"Thank you. I'd now like to turn the conference back to the company's management for closing comments."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Thank you all for your questions this morning. In summary, we're pleased with our 2015 results and believe the increasing diversification of our business positions us well for 2016 and beyond. As you've heard, our team remains focused on executing on",116,"Yes. Thank you all for your questions this morning. In summary, we're pleased with our 2015 results and believe the increasing diversification of our business positions us well for 2016 and beyond. As you've heard, our team remains focused on executing on our core business while preparing for the integration of our Cigna acquisition we expect to close in the second half of the year. I want to thank you all for being with us today, and I especially want to thank our associates for their ongoing contributions and their commitment to serving our 38.6 million customers every day. Thank you all for your interest in Anthem, and we look forward to speaking with you soon."
160077,280495834,921582,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern Time today through February 9. You may access the AT&T Teleconference Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378815. Inter",68,"Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern Time today through February 9. You may access the AT&T Teleconference Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378815. International participants, dial (320) 365-3844. That does conclude your conference for today. Thank you for your participation and for using AT&T executive teleconference. You may now disconnect."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management.",38,"Ladies and gentlemen, thank you for standing by, and welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Good morning, and welcome to Anthem's Fourth Quarter 2015 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and Wayne DeVeydt, our CFO. Joe will offer an overview",182,"Good morning, and welcome to Anthem's Fourth Quarter 2015 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and Wayne DeVeydt, our CFO. Joe will offer an overview of our fourth quarter 2015 financial results and will walk through the financials and provide the details of our initial 2016 outlook. We are then available for Q&A. 
During the call, we will reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website at antheminc.com. 
We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Anthem. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in today's press release and in our quarterly and annual filings with the SEC. 
I will now turn the call over to Joe."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Doug, and good morning. We're pleased to announced fourth quarter 2015 adjusted earnings per share of $1.14. On a GAAP basis, we reported earnings per share of $0.68. For the full year 2015, adjusted earnings per share was $10.16, representing",2110,"Thank you, Doug, and good morning. We're pleased to announced fourth quarter 2015 adjusted earnings per share of $1.14. On a GAAP basis, we reported earnings per share of $0.68. For the full year 2015, adjusted earnings per share was $10.16, representing year-over-year growth of 8.7% and GAAP earnings per share of $9.38. It's important to note that our results include roughly $0.04 of assessments associated with the State of Colorado dissolution of their co-op, an expense that was not expected when we last stated our full year earnings outlook. 
I'm very pleased with our 2015 performance, and I believe the growing diversification of our company and the complementary nature of our pending Cigna acquisition will position us well to capitalize on market growth opportunities over the next several years. We remain focused on improving health care affordability, quality and choice to our growing membership base. 
I'm going to start with some overview comments on our fourth quarter and 2015 result and then move to discuss our 2016 outlook in more detail. Fourth quarter results capped a successful 2015 with underlying fundamentals that tracked well versus our expectations. The fourth quarter represented the lowest quarterly adjusted earnings per share during 2015, which reflected our evolving business mix and the timing of medical utilization and operating expenses. As expected, this included lower margins in our Commercial and Government Businesses due to a higher benefit expense ratio and an increase in investment spending. 
Both fully insured and self-funded membership tracked ahead of expectations, and we ended the year with 38.6 million members, a growth of 1.1 million lives or nearly 3% since 2014. Our fourth quarter performance creates a favorable starting point for 2016 enrollment. In particular, during the quarter, we saw better-than-expected membership growth in our large group and Medicaid markets. As expected, we ended the year with 791,000 individual public exchange lives, a decrease of 33,000 from the third quarter. During 2015, we added a total of 84,000 lives on the public exchanges. Our small group enrollment declined by just north of 100,000 lives in the quarter to 1.2 million lives as we saw higher-than-expected lapses in plans that had previously early renewed with a December 1 benefit start date. 
During the quarter, medical cost trends continued to come in favorably versus our stated range. Our 2015 medical cost trend came in at the lower half of our previously guided range of 6.5% to 7.5%. For 2016, we anticipate Local Group medical cost trends will be slightly higher in the range of 7% to 7.5%. 
Operating revenue was $78.4 billion during 2015, an increase of $5.4 billion or 7.4% versus 2014, reflecting strong enrollment growth in the Government Business, additional premium revenue to cover overall cost trends and increased fees associated with health care reform. Also contributing was the growth in administrative fee revenue as a result of our strong self-funded membership trends. This was partially offset by fully insured membership losses in our Commercial business. 
The full year 2015 benefit expense ratio was 83.3%, an increase of 20 basis points from the prior year. The year-over-year increase reflected the change in our business mix towards the Government Business division and a higher benefit expense ratio in the individual exchange business. 
Our SG&A expense ratio came in at 16% for the full year 2015, a decrease of 10 basis points from the prior year. This was driven by the changing mix of our membership to the Government Business and a continued focus on administrative expense control, reflecting the need to ensure that we have the right cost structure for our public exchange membership outlook through 2016. 
Supporting the strong quality of our earnings during 2015, we reported operating cash flow of approximately $4.1 billion or 1.6x net income, with cash flow in the fourth quarter of $949 million. While we're pleased with our run rate cash flow performance, our 2015 results included the benefit of approximately $500 million in timing items related to government and vendor payments. These items are simply timing and accelerated our 2015 cash flow, which we originally expected to be in 2016. Including the impact of these timing items, we expect 2016 operating cash flow to be greater than $3 billion. 
Commercial operating margins in 2015 were 7.6%, reflecting year-over-year improvements in all lines of business, with the exception of individual. As we have previously discussed, operating results on the public exchanges have lagged expectations during the year as membership was more than 30% behind our original expectations. As expected, Commercial fourth quarter margins represented the lowest of the year, reflecting the timing of benefits, expense and our evolving mix of business. 
Our Government Business continued its strong year into the fourth quarter with an ending operating margin of 4.8%, an improvement of 130 basis points versus 2014, along with better-than-expected membership results. In particular, our Medicare and Medicaid margins improved meaningfully versus 2014. We're very encouraged about [ph] the turnaround plan put into place by our Medicare team, now finishing the second year of a 3-year plan. Their recent performance is an encouraging next step towards driving meaningful long-term earnings growth. We expect margins will continue to improve in 2016 towards our expected long-term sustainable level, and we have positioned our portfolio to grow enrollment in the right markets with the right products in 2017. 
For Medicaid, our team has built a process that is focused on the basic blocking and tackling aspects of managing our members' total cost of care and quality. We're leveraging our assets to provide industry-leading solutions for our government partners to help control their population's health care cost without sacrificing the quality of care. While this year's margin performance is above our long-term expectations, we feel confident in our team's ability to continue to outperform on a wide variety of care management and performance metrics. 
Regarding our balance sheet metrics. We have included a roll-forward of our medical claims payable balance in this morning's press release. For the full year 2015, we experienced favorable prior year reserve development of $800 million, which was moderately better than our expectations. While the favorable development was higher than what was recognized during 2014, it resulted in offsetting adjustments for the risk stabilization programs from Health Care Reform. We continue to maintain our upper single-digit margin for adverse deviation and believe our reserve balance remains consistent and strong as of December 31, 2015. 
For the 3Rs related to the 2015 benefit year, we continue to book reinsurance as appropriate and continue to expect to be in a net payable position for risk adjusters and in a net neutral position for risk corridors. We continue to record a valuation allowance against the risk corridor receivables in certain markets as we do not believe those receivables will ultimately be collected. We believe our estimates are prudent, given the dynamic nature of available information. 
Our Days in Claims Payable was 42.7 days as of December 31, an increase of 0.4 days from the 42.3 days as of September 30, 2015. The increase was primarily due to changes in the timing of claims payments between periods. As previously discussed, we do still expect Days in Claims Payable to come back down closer to 40 over time. 
Our debt-to-capital ratio was 40.8% at December 31, 2015, down 40 basis points from 41.2% as of September 30, which reflects the impact of reducing our outstanding balance in commercial paper during the quarter. We ended the fourth quarter with approximately $1.4 billion in cash and investments at the parent company, and our investment portfolio was in an unrealized gain position of approximately $368 million as of December 31. 
Turning to our 2016 outlook. We currently expect operating revenues to grow to a range of $80 billion to $81 billion, which is light of the long-term projections we laid out at our Investor Day in early 2014. The shortfall is primarily due to our individual exchange membership being meaningfully behind our projections, as we've discussed with you previously. In Commercial, we expect relatively steady enrollment during the year. We expect growth of over 300,000 lives for National Accounts in 2016 with strong momentum in securing new contract wins and exceeding our retention expectations. We also expect growth in large group self-funded enrollment, reflecting new contract wins. 
While we expect strong growth in ASO, our commercial fully-insured enrollment will be pressured. We expect membership declines of approximately 300,000 in our Individual business as we aren't experiencing the overall market growth on the public exchange that we projected when we laid out our 5-year plan, and unsustainable pricing in some markets is hurting our historic market share. We're encouraged that early indicators of the open enrollment activity are slightly better than our muted expectations. Recent actions taken by CMS to begin addressing the special enrollment period challenges as well as the elimination of the health insurer fee in 2017 are important first steps towards improving affordability for our customers. And you can be assured we are contributing to the dialogue to form a long-term, sustainable and affordable marketplace. 
We also expect Local Group fully insured membership losses of approximately 250,000 as members continue to transition into self-funded product offerings. It is important to note that while this trend is in line with recent history, we now do not expect a meaningful offset to this trend from growth on the private exchanges. Additionally, we expect continued pressure from the impact of higher levels of attrition due to the ending of insurance policies that were early renewed by our clients before the implementation of the Affordable Care Act. 
For Government, we expect another strong enrollment growth year. We expect Medicaid to add more than 350,000 lives, reflecting the addition of new business in the State of Iowa as well as continued organic growth in core and expansion products. We continue to see states gravitate towards managed care to be the solution for more complex populations and services, and we expect to be front and center, supporting these states' initiatives. 
Within our Medicare business, we continue to expect enrollment to be relatively steady as growth in our existing markets will be mostly offset by membership losses as we finalize the repositioning of our book in certain markets as part of our turnaround plan. 
Turning to financial metrics. We expect relatively stable margins in 2016. We currently expect an MLR midpoint of 83.6%, an increase of 30 basis points versus 2015. This reflects the impact of a change in the mix of our business as we expect strong growth in Medicaid, a business with a higher MLR than the consolidated average. 
Related to cost trend expectations. Again, we expect 2016 Local Group medical cost trends to be in the range of 7% to 7.5%. We expect our SG&A ratio in 2016 to be 15.4% at the midpoint. This reflects the impact of the changing mix of our business, strong growth in Medicaid and the impact of the administrative efficiency initiatives our management team is taking to work through the challenging public exchange environment. 
Below the line, we expect investment income of approximately $650 million and interest expense of approximately $630 million. Note that our interest expense projection does not include the costs we expect to incur related to the bridge loan financing we have in place for the pending Cigna acquisition. We also currently expect our tax rate to be in the range of 43.5% to 45.5% for the year. We expect some benefit from the impact of capital deployment activities next year. 
While we suspended share repurchases after the announcement of the Cigna acquisition in 2015, we plan to resume our capital deployment program in 2016, subject to market conditions, albeit at a lower level than in recent years. As a result, we currently expect our share count for the year to be in the range of 266 million to 270 million shares. 
We remain committed to at least maintaining our current dividend. We plan to review our capital deployment strategies at our next board meeting in February, and we expect to make an announcement on our first quarter 2016 dividend shortly thereafter. 
To conclude, our 2016 GAAP earnings per share estimate is greater than $10.35. Our adjusted earnings per share outlook is greater than $10.80. The difference between these 2 estimates is the exclusion of the amortization of deal-related intangibles. It's important to note that our 2016 outlook does not include any benefits or transaction costs associated with the pending acquisition of Cigna, which we continue to expect will close in the second half of the year. 
With that, operator, please open the queue for questions."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","[Operator Instructions] Your first question comes from the line of A.J. Rice from UBS.",14,"[Operator Instructions] Your first question comes from the line of A.J. Rice from UBS."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I noticed on your guidance you're forecasting your medical cost trend to a range of 50 basis points. Traditionally, you guys have always used 100 basis points in forecasting that. I'm just curious on your thinking of narrowing that. Obviously, the step-up",70,"I noticed on your guidance you're forecasting your medical cost trend to a range of 50 basis points. Traditionally, you guys have always used 100 basis points in forecasting that. I'm just curious on your thinking of narrowing that. Obviously, the step-up sort of seems similar to what you assumed last year and you came in at the low end. But I'm just curious of the thinking behind that."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Essentially, the thinking was that the last several years, I would think it's fair to say there's been a lot of volatility regarding the exchanges, the Affordable Care Act, a number of new specialty drugs coming in. From our perspective, we generally have",125,"Essentially, the thinking was that the last several years, I would think it's fair to say there's been a lot of volatility regarding the exchanges, the Affordable Care Act, a number of new specialty drugs coming in. From our perspective, we generally have a point of view that's within 50 basis points. We've been hanging pretty tight to that. And so it was more just to make sure that you understood that, in fact, we were raising our trend assumptions and our pricing going into this year, and to try to tighten that band within a 50 basis point range as we're getting better clarity now on the underlying activity associated with our commercial book as well as the new drugs that are coming in."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then just to follow-up on the -- I know at a conference earlier in the month, you guys had made some comments about where you were at with your PBM, and I don't assume there's no assumptions in anything in the guidance related to this, to any ki",71,"Okay. And then just to follow-up on the -- I know at a conference earlier in the month, you guys had made some comments about where you were at with your PBM, and I don't assume there's no assumptions in anything in the guidance related to this, to any kind of changes in that contract. But is there any update on what you're thinking there and what the opportunity might be?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","This is Joe. Nothing's changed since our statements last month -- or excuse me, earlier this month at the conference, and nothing's been included in the materials regarding the PBM dialogue that we've had thus far. So I guess, more to come later, but noth",50,"This is Joe. Nothing's changed since our statements last month -- or excuse me, earlier this month at the conference, and nothing's been included in the materials regarding the PBM dialogue that we've had thus far. So I guess, more to come later, but nothing is embedded at the moment."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Josh Raskin from Barclays.",12,"Your next question comes from the line of Josh Raskin from Barclays."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First question, I just wanted to ask about the CMS sanctions at Cigna. And I just want to see, how does that fit with your understanding? Sort of when did you guys find out about it? Did you know about this as part of the diligence? And does this change a",64,"First question, I just wanted to ask about the CMS sanctions at Cigna. And I just want to see, how does that fit with your understanding? Sort of when did you guys find out about it? Did you know about this as part of the diligence? And does this change anything in terms of your outlook -- your financial outlook for the combined entities?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, thank you. This is Joe again. First, let me clearly state, we have 2 separate companies. And obviously, activities of that nature are within their company. We do not have line of sight of, nor should we, I think. And we are kind of considering it, as",175,"Yes, thank you. This is Joe again. First, let me clearly state, we have 2 separate companies. And obviously, activities of that nature are within their company. We do not have line of sight of, nor should we, I think. And we are kind of considering it, as you would expect. But at the moment, we really don't have enough line of sight to pass judgment on what effect it may have, if any, for that matter. So we will be vigilant, and I'm certain that as time marches on, we'll learn more on. But quite frankly, at this stage, there's really nothing for us to say regarding what impact it may have regarding Cigna. And with respect to the transaction itself, we are clearly and unwavering with respect to our commitment to the deal. This does not have an effect on the deal process. And obviously, as we learn more, we'll certainly feather it into our considerations. But at this stage, we just do not believe it has a material effect on our transaction."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Got you. That's what I was looking for. And then just on the commercial business, the MLR, I think, in the past, you guys had been attributing the increase, at least last quarter, to the individual business. Now you're adding Local Group into that sort of",116,"Got you. That's what I was looking for. And then just on the commercial business, the MLR, I think, in the past, you guys had been attributing the increase, at least last quarter, to the individual business. Now you're adding Local Group into that sort of discussion for the MLR driver. So just trying to figure out what's driving that increase. Did the individual business deteriorate more? Or is this now more of a small group issue? And as we look about the overall margin for the Commercial segment this quarter, being just over breakeven, is it fair to assume you're losing money now, obviously, in Individual, but also on the Local Group side as well?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","No, Josh. Let me clarify. There's normal seasonality that we see in all books of business as deductibles are met throughout the year. So I want to emphasize that relative to the group business, no concerns at all. The primary MLR drivers are mix in the qu",215,"No, Josh. Let me clarify. There's normal seasonality that we see in all books of business as deductibles are met throughout the year. So I want to emphasize that relative to the group business, no concerns at all. The primary MLR drivers are mix in the quarter and as we've been talking about, the public exchanges. So again, I don't want to create any alarms there. Trend finished at the low end -- or lower half of our range, as we said earlier, and the metrics remain strong. One thing I would like to highlight, though, for each of you on the call is that we tried to maintain a conservative posture on the 3Rs as well while maintaining our reserve balance sheet strength with our high single-digit margin for adverse deviation at year-end. So when you look at our run rate Individual business, we still made a very slight, I'd call it closer to breakeven for the year. But keep in mind, that's with us maintaining a very conservative position on the 3Rs as well. And going into '16, we are still assuming we will be profitable on our individual and exchange business, albeit below our targeted 3% to 5% margins as we continue to see those markets hopefully begin to harden around pricing."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Kevin Fischbeck from Bank of America.",14,"Your next question comes from the line of Kevin Fischbeck from Bank of America."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Great. Just, I guess, I understand the concept of mix shift impacting the MLR and the SG&A ratios, but it looks like given that you're growing earnings faster than revenue, you're looking for actual margin expansion next year. Can you point to one divisio",55,"Great. Just, I guess, I understand the concept of mix shift impacting the MLR and the SG&A ratios, but it looks like given that you're growing earnings faster than revenue, you're looking for actual margin expansion next year. Can you point to one division that you would point to as seeing stronger margin improvement year-over-year?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Kevin, the primary thing I would highlight is a lot of the initiatives we took was to take the G&A deleveraging out across the organization that if we weren't going to see the membership growth that we expected on the exchanges. And then more importantly,",92,"Kevin, the primary thing I would highlight is a lot of the initiatives we took was to take the G&A deleveraging out across the organization that if we weren't going to see the membership growth that we expected on the exchanges. And then more importantly, I think, as Joe has said, he's committed to us driving towards the $14 in 2018. And so we've had a very aggressive G&A initiative, which allows both margin maintenance as well as some expansion in all lines of business as that effort was an enterprise-wide effort."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So it's on the Commercial side that you would say is where more of the margin expansion would be?",20,"Okay. So it's on the Commercial side that you would say is where more of the margin expansion would be?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes.",1,"Yes."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And I guess, as far as that comment about the 2014 number, I guess, last quarter, you kind of said, ""Hey, the individual membership is just coming in below what we might have thought. And over our long-term targets, that could be a drag towards hitting th",82,"And I guess, as far as that comment about the 2014 number, I guess, last quarter, you kind of said, ""Hey, the individual membership is just coming in below what we might have thought. And over our long-term targets, that could be a drag towards hitting that."" Are you saying now that you found some offsets that are still going to leave you comfortable with hitting $14 on a stand-alone basis before Express? Or is that still a risk, in your view?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Kevin, I would say that relative to the revenue line item, if the individual membership fully insured market doesn't ramp up over the next several years, I think that $100 billion in organic revenue will be at risk. But I think relative to the $14 of earn",141,"Kevin, I would say that relative to the revenue line item, if the individual membership fully insured market doesn't ramp up over the next several years, I think that $100 billion in organic revenue will be at risk. But I think relative to the $14 of earnings per share, as we've been able to show in '15 going into '16, there are many levers that we can pull, and Joe has aggressively pushed the management team to pull those levers with a high degree of confidence, hopefully, in our ability to execute against them. And so I think, at this point, I would tell you -- and I'll let Joe say it for himself, he's committed, and this management team is committed to driving towards the $14, but we may get there different than we had laid out 2 years ago."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. And I kind of -- thanks, Wayne. Just to reiterate and emphasize there, we recognize the $100 billion might be somewhat flexible in terms of where we may end up in '18 on that metric. However, we're incredibly committed to the $14. We believe there ar",124,"Yes. And I kind of -- thanks, Wayne. Just to reiterate and emphasize there, we recognize the $100 billion might be somewhat flexible in terms of where we may end up in '18 on that metric. However, we're incredibly committed to the $14. We believe there are certainly a lot of variables in the equation that will map to what the ultimate revenue capture will be. But nonetheless, all parts and pieces are going to line up, we believe, very effectively for us to make that $14 commitment. And so again, we've got all actions in place regarding matters like [indiscernible] the G&A controls and a variety of other puts and takes on the management side that will get us to the $14 target."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Kevin, as we've said previously, too, the PBM and rising interest rates both serve as hedges against other risks that we see in the business and potential opportunities for upside as well. Kevin, one other item I want to highlight is you had asked about o",94,"Kevin, as we've said previously, too, the PBM and rising interest rates both serve as hedges against other risks that we see in the business and potential opportunities for upside as well. Kevin, one other item I want to highlight is you had asked about other businesses with margin in addition to G&A. The Medicare improvement, as Joe laid out, our efforts over the last 2 years have been quite substantial, and the results have been very promising. And so we will see very nice margin improvement in Medicare going into 2016 as well."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Gary Taylor from JPMorgan.",12,"Your next question comes from the line of Gary Taylor from JPMorgan."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I had one question and one follow-up. Just in terms of your cost trend guidance for 2016, would you care to kind of go through components of that, so hospital inpatient, outpatient physician, pharma? Even just qualitatively in terms of expectations would",45,"I had one question and one follow-up. Just in terms of your cost trend guidance for 2016, would you care to kind of go through components of that, so hospital inpatient, outpatient physician, pharma? Even just qualitatively in terms of expectations would be helpful."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","We won't break it down necessarily, although I can tell you that we typically expect very little change in the physician aspects of it. It's very much driven more towards the specialty pharma being one of the primary drivers. We are expecting an increase",76,"We won't break it down necessarily, although I can tell you that we typically expect very little change in the physician aspects of it. It's very much driven more towards the specialty pharma being one of the primary drivers. We are expecting an increase in utilization on inpatient. Whether or not that plays out will remain to be seen. But it's primarily utilization, and then it's a unit cost on pharma that are the drivers."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then just a clarification on the reported operating gain for the Commercial segment for 4Q. It's $56 million, it's that 0.6% margin. Is that figure normalized, excluding the California franchise tax ruling? Or is that -- or is there a pretax num",52,"Okay. And then just a clarification on the reported operating gain for the Commercial segment for 4Q. It's $56 million, it's that 0.6% margin. Is that figure normalized, excluding the California franchise tax ruling? Or is that -- or is there a pretax number that's weighing upon that reported operating income margin?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","No. The only item that is of a unique nature that would be in there from an operating gain perspective is our desire to maintain a strong balance sheet associated with the 3Rs, and that has a direct impact on that. I'd like to be optimistic and hope there",143,"No. The only item that is of a unique nature that would be in there from an operating gain perspective is our desire to maintain a strong balance sheet associated with the 3Rs, and that has a direct impact on that. I'd like to be optimistic and hope there'll be upside there, but it appears, even in the last year, our conservative nature on some of these 3Rs has proved to be prudent. And so we decided to take that same posture in the fourth quarter and strengthen even further some of the 3R assumptions. Based on the public data available, it would imply we're conservative. But at the same time, that data would have implied that last year, and that ended up not being the case. So we tried to strengthen even further. And of course, that hits the Commercial segment directly."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","That's primarily a risk adjustment number we'll see in the 10-K?",12,"That's primarily a risk adjustment number we'll see in the 10-K?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Both risk adjustment as well as a position that we don't see value in the corridors and assume the 100% valuation allowance as well as on the reinsurance. We have stuck with strictly what the law currently says we're entitled to, not what maybe excess fun",65,"Both risk adjustment as well as a position that we don't see value in the corridors and assume the 100% valuation allowance as well as on the reinsurance. We have stuck with strictly what the law currently says we're entitled to, not what maybe excess funding may be in the pool. And so those are the 3 positions we've taken a conservative posture in."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Ralph Giacobbe from Citi.",12,"Your next question comes from the line of Ralph Giacobbe from Citi."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I may have missed this. I'm not sure if you gave it. Did you say where you ended the year in terms of exchange enrollment and maybe what's embedded into expectations in terms of exchange enrollment for 2016? And then just extending on that, maybe where yo",58,"I may have missed this. I'm not sure if you gave it. Did you say where you ended the year in terms of exchange enrollment and maybe what's embedded into expectations in terms of exchange enrollment for 2016? And then just extending on that, maybe where you're at in terms of on- versus off-exchange for your individual book."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","So we ended the year just shy of 800,000 members on the exchange enrollment, around 791,000, which was below our planned expectations by about 30%. We now are looking at the book in a more fungible way, where we looking on-exchange and off-exchange now be",156,"So we ended the year just shy of 800,000 members on the exchange enrollment, around 791,000, which was below our planned expectations by about 30%. We now are looking at the book in a more fungible way, where we looking on-exchange and off-exchange now because it's becoming quite fungible between the 2 as grandmothering is moving away. And so for next year, we have individual declining by another 300,000 lives all-in going into '16. At least, that's our assumption. As Joe said in the prepared remarks, the early enrollment application is encouraging against that assumption, but it's very important that we wait and see how lapses actually occur because we'll know who ultimately pays and doesn't pay. And we won't know that answer until the end of this month. So again, the applications to date would imply that we may be conservative there. But until we see actual payments and disenrollment, it's hard to declare."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay, all right. That's helpful. And then just on the ASO book, you continue to show nice growth there. Are you seeing and capturing sort of existing ASO business? Are you maybe seeing a continued shift from sort of risk to ASO? Are you seeing more penetr",64,"Okay, all right. That's helpful. And then just on the ASO book, you continue to show nice growth there. Are you seeing and capturing sort of existing ASO business? Are you maybe seeing a continued shift from sort of risk to ASO? Are you seeing more penetration downstream to mid or smaller employers? Just trying to get a sense of the dynamics at play."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's a little bit of both. Clearly, on the national accounts, those were a lot of new wins for us. Obviously, some very sizable wins, including the Bank of America account. So from that perspective, I would say a big chunk of the ASO is really new members",160,"It's a little bit of both. Clearly, on the national accounts, those were a lot of new wins for us. Obviously, some very sizable wins, including the Bank of America account. So from that perspective, I would say a big chunk of the ASO is really new membership and new lives to us. When you look at the shift from ASO -- I'm sorry, from fully insured to ASO, that shift continues. I wouldn't call it at an accelerated pace anymore. It seems to have slowed down. But nonetheless, it's still occurring. And so we are retaining a lot of that membership moving from fully insured to ASO. But as you know, on a revenue basis, that really dampens the revenue if you're not getting the offset through either the public exchanges or, for that matter, what we felt would have been a faster pace in the private exchanges, which, we believe, is a much more muted pace now."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Dave Windley from Jefferies.",12,"Your next question comes from the line of Dave Windley from Jefferies."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So on the premium number, Wayne, that you were just hitting on, the guidance relative to expectations is, call it, $2.5 billion to $3 billion light, the ASO shift accounts for some of that, but maybe less than half. I'm wondering if you believe you're get",75,"So on the premium number, Wayne, that you were just hitting on, the guidance relative to expectations is, call it, $2.5 billion to $3 billion light, the ASO shift accounts for some of that, but maybe less than half. I'm wondering if you believe you're getting -- if there's anything in mix that would be affecting yield. And are you getting full premium yield relative to the cost trend expectations you are expecting for 2016?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Dave, great question. Let me first highlight that this revenue shortfall is almost predominantly associated with the lack of growth on the public exchanges. I mean, I just -- I can't emphasize that point enough. And ultimately, that would be the one area",161,"Dave, great question. Let me first highlight that this revenue shortfall is almost predominantly associated with the lack of growth on the public exchanges. I mean, I just -- I can't emphasize that point enough. And ultimately, that would be the one area I would say while we're projecting profitability still in 2016, clearly, at margins below what we think are the long-term margins for a sustainable program and product. So that would be the one area I would point to relative to yields. We are still able to cover our cost of capital on them and be profitable, but we are looking forward to some of the structural changes that I know the administration is looking at to make these programs even more viable in the long term. But our revenue issue is really a fully insured public exchange issue at this point. The rest of the book of business is performing well versus our 5-year expectations we've laid out."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. My follow-up would be on -- a follow-up on the PBM. Would you guys be willing to comment on how the analysis bridged from the $500 million to $700 million number that you talked about, say, mid to early second half of 2015 to the $3 billion number t",58,"Okay. My follow-up would be on -- a follow-up on the PBM. Would you guys be willing to comment on how the analysis bridged from the $500 million to $700 million number that you talked about, say, mid to early second half of 2015 to the $3 billion number that you've now talked about in January of '16?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, this is Joe. Let me comment on that. Going back in time to '15 at earnings [ph] day, we did land on the $500 million to $700 million as a proxy statement regarding what may be possible related to market check analysis, et cetera. Then, fast forward t",236,"Yes, this is Joe. Let me comment on that. Going back in time to '15 at earnings [ph] day, we did land on the $500 million to $700 million as a proxy statement regarding what may be possible related to market check analysis, et cetera. Then, fast forward to today, we've gone through a very deliberate analytical process. We vectored toward an answer related to multiple checks in the marketplace, and that brought us to the $3 billion finding that we believe is very, very credible. And obviously, having made that statement, which we believe kind of recalibrates the number from that $500 million to $700 million to something that we believe is much more realistic. So what we said back in '15 is that we would update you in '16 actually hoping to communicate, I guess, call it, a solution to you regarding our PBM inquiry regarding what we would have to do to reposition ourselves to get to the end of the contract in 2019. So having made the statement about the $3 billion, our market check expectations, we believe we've set the table now for conversations in and around the possibility of recasting our pricing relationship with ESI. So all I can tell you at this stage is that dialogue will continue, and we're hopeful that still in '16, we will reach a resolution to this matter that we're engaged in with ESI."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Christine Arnold from Cowen.",12,"Your next question comes from the line of Christine Arnold from Cowen."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I'm looking at the MLR. And as of third quarter '15, you expected the full year to be 82.9%, plus or minus 30. And you are above that range at 83.3% for the full year. So was individual entirely the shortfall on that loss ratio?",46,"I'm looking at the MLR. And as of third quarter '15, you expected the full year to be 82.9%, plus or minus 30. And you are above that range at 83.3% for the full year. So was individual entirely the shortfall on that loss ratio?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Individual was substantially the shortfall. That's correct. And again, it's important to recognize that some of the balance sheet strengthening we've done would all flow through that as well regarding not only the 3Rs, but maintaining that high single dig",94,"Individual was substantially the shortfall. That's correct. And again, it's important to recognize that some of the balance sheet strengthening we've done would all flow through that as well regarding not only the 3Rs, but maintaining that high single digit for adverse deviation. So I would point you almost solely to that. Medicaid enrollment was a little bit stronger in the quarter than we had anticipated as well. So that is a little bit of an MLR mix shift to it, but it's predominantly individual and then the strengthening we did on the 3Rs."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And first half of the year, we were looking at a 3% to 5% margin. Second half of the year, we're looking at breakeven. So we've completely erased that 3% to 5%, yet the bids were due in May and June. So can you help me understand how, when you didn'",71,"Okay. And first half of the year, we were looking at a 3% to 5% margin. Second half of the year, we're looking at breakeven. So we've completely erased that 3% to 5%, yet the bids were due in May and June. So can you help me understand how, when you didn't know about this 3% to 5% erosion in profitability, you're confident that this is going to improve next year?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Christine, it's a really great question, and it's one of the reasons that -- the issue we had, though, on our margins this year was the inability to deleverage G&A quick enough. So we were still assuming a 3% to 5% margin, but we were also assuming a 30%",183,"Christine, it's a really great question, and it's one of the reasons that -- the issue we had, though, on our margins this year was the inability to deleverage G&A quick enough. So we were still assuming a 3% to 5% margin, but we were also assuming a 30% growth rate. As we started seeing that growth rate not only not occur, but beginning to see some attrition in the latter part of the year, we realized it was imperative to get the G&A out. And I can tell you that those initiatives have occurred. Those actions around headcount and other costs have already been taken out now, and we'll get the run rate effect going into the year. So from that perspective, we feel fairly confident. And again, I would emphasize, the public data that we're getting regarding risk adjusters from Wakely, regarding how 3Rs settled up on reinsurance last year, et cetera, would imply we are being conservative in that outlook. But we've chosen to take that posture in '15, and that's part of the reason of getting closer to breakeven."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Ana Gupte from Leerink Partners.",13,"Your next question comes from the line of Ana Gupte from Leerink Partners."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","The question, firstly, is around the catcher's mitt strategy that you had articulated. Now we're 2 years into exchanges. As you're looking at your small group, that $800 million EBIT headwind -- sorry, $800 million to $400 million that you had articulated",97,"The question, firstly, is around the catcher's mitt strategy that you had articulated. Now we're 2 years into exchanges. As you're looking at your small group, that $800 million EBIT headwind -- sorry, $800 million to $400 million that you had articulated, when you look at it across, firstly, is that stemmed at this point? And when you look at it across small group and Individual, are you coming out net positive? Is it net neutral? Or is it continuing to be a headwind? And how do you expect it going forward into '16 and then '17?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thanks for the question. I would say the catcher's mitt strategy itself is working as we would have expected as we are clearly seeing attrition in lines of business. Small group alone lost over 100,000 lives in the fourth quarter. Clearly, we're picking t",217,"Thanks for the question. I would say the catcher's mitt strategy itself is working as we would have expected as we are clearly seeing attrition in lines of business. Small group alone lost over 100,000 lives in the fourth quarter. Clearly, we're picking those lives up elsewhere as we were able to exceed our membership targets for the year. I would say the part of the strategy that's not coming to light at this point isn't about capturing the member now, but where exactly that member is caught and the revenue associated with that member. And I think, at this point, when we built our 5-year plan, we fully expected more of these lives to be picked up in the public exchanges as a fully insured. And we're finding that some of those lives now are actually getting employed and more in an ASO market and -- or we're picking them up on Medicaid, which, in some cases, is a lower PMPM that we would have got on the public exchange. And so ultimately, I would say the strategy of the catcher's mitt itself is working terms of getting the customers, continuing to grow membership. But I would say the mix of membership and how it translates to revenue is not panning out as we had anticipated."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And then following up on that, just now on the public exchanges, with your decline in individual from the third quarter to the fourth quarter, was that mainly the special enrollment period folks that did that? And as you're looking out into 2017, as reins",78,"And then following up on that, just now on the public exchanges, with your decline in individual from the third quarter to the fourth quarter, was that mainly the special enrollment period folks that did that? And as you're looking out into 2017, as reinsurance goes away, do you think the policy changes that the administration is making would still allow you to remain on exchange and be profitable into '17 just, again, part of your catcher's mitt?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, this is Joe. Let me comment on the kind of the continued engagement that we envision in the exchanges. Yes, we are certainly very observant of the shifts and changes that the administration is enacting. Especially, we're paying a lot of attention to",210,"Yes, this is Joe. Let me comment on the kind of the continued engagement that we envision in the exchanges. Yes, we are certainly very observant of the shifts and changes that the administration is enacting. Especially, we're paying a lot of attention to special enrollment period. Very thankful the administration has made some changes. I suspect there may be more changes in the near future, which we want to consider very carefully so that we can judge the sustainability of the exchange marketplace and how well we can engage in that marketplace going forward. So we're very observant regarding these moves and changes. We feel that, as Wayne pointed out a moment ago, we're extremely well positioned with respect to matters like G&A that allows us to perform in this space reasonably well. Notwithstanding member deterioration, it's presumably stabilized, given what we're observing regarding some uptick in membership for '16, which, obviously, as Wayne pointed out, we'll probably know more within the month. But nonetheless, we're really carefully observing it, looking at special enrollment in terms of its potential impact. And again, we're very hopeful that some of the issues will be ameliorated in terms of the risk and we'll have a much more sustainable marketplace to engage in."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Scott Fidel from Crdit Suisse.",13,"Your next question comes from the line of Scott Fidel from Crdit Suisse."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First question, just if you can give us an update on how the implementation of Iowa Medicaid is coming along. And just interested, just in the context of the state having removed WellCare from the contract, what your updated enrollment expectation is for",76,"First question, just if you can give us an update on how the implementation of Iowa Medicaid is coming along. And just interested, just in the context of the state having removed WellCare from the contract, what your updated enrollment expectation is for Iowa? And then, what type of losses you're building in and expecting? Obviously, United did increase their PDR for Iowa as a result of that. So just interested in how you're approaching this."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","First of all, relative to Iowa, we continue to be optimistic about this program in the long term and that it will have the similar trajectory of we expect to lose money in year 1, get closer to breakeven in year 2 and then return to profitability by year",306,"First of all, relative to Iowa, we continue to be optimistic about this program in the long term and that it will have the similar trajectory of we expect to lose money in year 1, get closer to breakeven in year 2 and then return to profitability by year 3. We got an update from the team yesterday. Actually, Joe and the senior leadership team got a full deep dive on where things are progressing. And things are moving exactly as we would have expected at this point. We're very close to starting that implementation on 3/1. We don't have line of sight of what membership we may or may not get. As you know, there are a number of appeals that have been filed both by the -- one individual that was selected that has been told they were being removed as well as others that were not selected in the first round. So we have not included any of that, and we want to see how that pans out. That being said, if you were to look at Medicaid all-in, both margin compressions that we're receiving throughout the year that we expect, plus we're assuming even further margin pressure in the back half of '16 from states as well as expansion, there's about a few hundred million dollar headwind baked in. But I would tell you that Iowa is less than 25% of that. So it gives you kind of a gauge of how we're envisioning year 1 to evolve and then migrate more to year 2, and then from there, to the normal profitability we would have in these programs. The delay of 2 months is part of the reason for that level of loss in year 1 because, ultimately, we've got the G&A float happening, but we don't have the revenue yet."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Got it, okay. And then just had -- a follow-up question just on small group and actually, a number that I don't think we've talked about for a few quarters. But just interested, remember, a couple of years back, you had talked about how small group would",122,"Got it, okay. And then just had -- a follow-up question just on small group and actually, a number that I don't think we've talked about for a few quarters. But just interested, remember, a couple of years back, you had talked about how small group would potentially have to absorb maybe a $400 million EBIT hit from ACA as thinking about both sort of margin rebasement and then enrollment attrition. And just interested if you can give us an update on sort of how you're tracking relative to that number. Obviously, there has been some recent attrition. But just interested if we're sort of at that number or still some ways to go or just where we stand relative to that."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","So relative to the $400 million, Scott, which was more about margin reset, I would say we've taken our medicine on that $400 million over the last couple of years. Now it becomes a question of, will small group continue to migrate to other lines of busine",146,"So relative to the $400 million, Scott, which was more about margin reset, I would say we've taken our medicine on that $400 million over the last couple of years. Now it becomes a question of, will small group continue to migrate to other lines of business over time around just pure membership? But we have taken that sizable hit. As we saw in the fourth quarter, a very sizable chunk of that membership migrated away from fully insured. And the question is, will we recover that even through the public exchanges, in open enrollment or others? Again, our early open enrollment data would imply we are recovering it, but we want to see what actually converts to a pay by the end of the month. So -- but I'd say in terms of the margin compression, we've taken a substantial portion of that $400 million."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Matthew Borsch from Goldman Sachs.",13,"Your next question comes from the line of Matthew Borsch from Goldman Sachs."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","If I could just go back to the exchanges for a moment again. A couple of questions there. When you talked about the unsustainable price competition and also the lack of market growth, should we read that the decline that you're expecting of 300,000 is all",121,"If I could just go back to the exchanges for a moment again. A couple of questions there. When you talked about the unsustainable price competition and also the lack of market growth, should we read that the decline that you're expecting of 300,000 is all about the unsustainable price competition since if the market didn't grow, then maybe you would expect it to be flat? And my follow-up question to that is, as we look to 2017, how much impact -- favorable impact do you think you'll get from the risk pool as grandmothering plans work their way into the exchanges, albeit I know that's not going to be the case for your 2 largest markets, California and New York?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Matt, I appreciate the question. A couple of thoughts or at least, insights. One is, yes, we are assuming that some of the pricing that we continue to see in our markets, our 14 states, is still well below what we think appropriate rates are for a sustain",372,"Matt, I appreciate the question. A couple of thoughts or at least, insights. One is, yes, we are assuming that some of the pricing that we continue to see in our markets, our 14 states, is still well below what we think appropriate rates are for a sustainable environment. I think the fact that we're closer to breakeven in '15 and a profit margin that's below the targeted 3% to 5% in '16 I think is a good indication of -- our price point isn't wrong as much as others need to strengthen their price points. So we are going to assume that the strengthening is not occurring. In fact, we know in many states it hadn't occurred and that we will continue to attrit members. That being said, we are starting to see individuals start to recognize the problems in their books. They are starting to strengthen their pricing quite meaningfully. We are seeing co-ops struggle in the moment with more than half of those now insolvent. And so the question becomes, will the markets start to harden going into '17, which has really 2 effects for us: one is we no longer have the diminishing membership base; but more importantly, we should be hopefully a net recipient of that and hopefully start getting some of that revenue back that we had talked about in our original 5-year outlook? And then relative to 2017, Matt, to your comment, it's -- with grandmothering, it's really hard to say at this point. I mean, the behaviors of kind of the dynamics of what will the market look like in '17, not just the exchanges and how grandmothering, but just what's the global economy and the U.S. economy doing, what implications does that have as well. But the theory of what you laid out would imply that you're going to get more of those lives in that are in a healthier population and should help improve the overall profitability of the book as well. But as you indicated, in our largest markets, we did not allow grandfathering in many cases, and we migrated already. So it won't have as big of an impact, but if the market has hardened, it should improve for us."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Peter Costa from Wells Fargo.",13,"Your next question comes from the line of Peter Costa from Wells Fargo."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","A couple of years ago and through the last few years, we've talked about consumerization of health care and the growth of private exchanges, and we really haven't seen that come through in a significant way here. We are second year with that not deliverin",66,"A couple of years ago and through the last few years, we've talked about consumerization of health care and the growth of private exchanges, and we really haven't seen that come through in a significant way here. We are second year with that not delivering much membership growth to you. What -- can you tell us how you're evolving your strategy on consumerization and private exchanges?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, this is Joe. Thanks for the question. Yes, I think private exchanges have had a slow uptake probably for a few reasons. But I think it was considered as sort of an offset to the Cadillac tax exposure and other necessities that business and industry c",263,"Yes, this is Joe. Thanks for the question. Yes, I think private exchanges have had a slow uptake probably for a few reasons. But I think it was considered as sort of an offset to the Cadillac tax exposure and other necessities that business and industry considered in terms of moving their employees into a private exchange marketplace. It didn't materialize to the level of the speed that anybody anticipated in the early going, and our position at the moment is that we're kind of taking a more muted response to the private exchange formation and execution. Nonetheless, we're going to be ready if and when it does accelerate, and it may very well do so in the future. But at this stage, it really is a sort of a muted response to that strategy. And we believe what you're seeing nationally is sort of an in-market standard in terms of private exchanges just simply not picking up the speed that folks had originally anticipated. So we're basically waiting -- wait and see, and we're positioned. And in fact, we do have private exchange membership that is not a substantial part of our membership. But certainly, we are in the space. I guess the bottom line is, affordability is still the key and remains critical to long-term positioning on the part of employers. And as private exchange presents itself as a solution, we're ready, willing and able to engage in a meaningful way. But again, I think our response at this stage is fairly muted, given there's just been such a slow uptake."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then just a follow-up, if you don't mind. Can you talk about the premium tax issue in California and your exposure to that in terms of the litigation against the -- your company?",35,"Okay. And then just a follow-up, if you don't mind. Can you talk about the premium tax issue in California and your exposure to that in terms of the litigation against the -- your company?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Pete, let me first just highlight that in California, the tax laws differ based on legal entity, very similar to any legal entity in the United States has differing tax laws. We pay our taxes exactly as the law states within the State of California, as do",146,"Pete, let me first just highlight that in California, the tax laws differ based on legal entity, very similar to any legal entity in the United States has differing tax laws. We pay our taxes exactly as the law states within the State of California, as do our competitors that have similar legal entities filed there. And the DMHC has actually agreed that we're paying taxes in accordance with the law. So at this point, I can simply state that it is fully our intention to follow the law, as we've done so far, and it's fully our intention to litigate any action brought against us that would imply otherwise. And so I -- there's nothing more to comment on beyond that, other than you should be aware that it is the law that we are filing under, and the DMHC has supported us in that."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Chris Rigg from Susquehanna.",12,"Your next question comes from the line of Chris Rigg from Susquehanna."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just quickly here on the Government segment. I know -- Wayne, I think you said you're expecting to earn about $200 million less in Medicaid, but grow a little bit in Medicare. Net-net, is it going to be flattish or down in the Government segment in '16?",47,"Just quickly here on the Government segment. I know -- Wayne, I think you said you're expecting to earn about $200 million less in Medicaid, but grow a little bit in Medicare. Net-net, is it going to be flattish or down in the Government segment in '16?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Good question. It's going to be slightly down, which gives you a pretty good idea of how well our Medicare is actually performing. But it will be slightly down between those. And again, it's important to recognize, we thought it was prudent to have a caut",78,"Good question. It's going to be slightly down, which gives you a pretty good idea of how well our Medicare is actually performing. But it will be slightly down between those. And again, it's important to recognize, we thought it was prudent to have a cautious posture on how Medicaid rates may evolve as the year progresses. So not just the rates we know about in October, but what happens in mid July as well as next October."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Great. And then just on the reinsurance. Can you quantify how much you expect for -- from -- how much you expect to receive in 2015? And would you have lost money without that amount?",35,"Great. And then just on the reinsurance. Can you quantify how much you expect for -- from -- how much you expect to receive in 2015? And would you have lost money without that amount?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. I think the first thing to keep in mind, we're just assuming just slightly over 50%. I don't think you can look at it as whether you would lose money with or without that amount because it's important to recognize we're collecting that premium within",171,"Yes. I think the first thing to keep in mind, we're just assuming just slightly over 50%. I don't think you can look at it as whether you would lose money with or without that amount because it's important to recognize we're collecting that premium within our premium base on behalf of the government, and then submitting that into the reinsurance pool. So our pricing is baked with an assumption that we will get what the law says we're entitled to get without it. So I don't think you can look at it with or without the program because the pricing is built with that program. That being said, as you know, there's data points out there that would imply that people may recover as much as 55% to 60%. And again, we're much more in line with where the law is. When I say slightly over 50%, it doesn't even round up to 51%. So it gives you a little bit of a feel for we're just barely over 50%."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Andy Schenker from Morgan Stanley.",13,"Your next question comes from the line of Andy Schenker from Morgan Stanley."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Can you maybe talk a little bit more on Medicare? Obviously, seeing some significant improvements in '15, calling for continued improvements in '16. But how should we think about how much room is left beyond that as well as maybe the level of investments",61,"Can you maybe talk a little bit more on Medicare? Obviously, seeing some significant improvements in '15, calling for continued improvements in '16. But how should we think about how much room is left beyond that as well as maybe the level of investments currently in Medicare for the repositioning? And will some of that start winding down in '16, '17?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, this is Joe again. Since I joined the company a few years ago, we really put a stake in the ground that we were going to reposition ourselves in the Medicare space very aggressively. We established, as I said a moment ago, a 3-year plan, and we're w",173,"Well, this is Joe again. Since I joined the company a few years ago, we really put a stake in the ground that we were going to reposition ourselves in the Medicare space very aggressively. We established, as I said a moment ago, a 3-year plan, and we're well into that 3-year plan realization in terms of our targets. The margins, we expect to expand over time. And we do believe that we're really heavily focused on medical cost management capabilities. And we have an increased focus on our administrative cost structure as being a key contributor to margin improvement. So when you put all that together, we are witnessing a substantial, I'd call it, even a turnaround in our Medicare book that really gives us cause for optimism going forward. We really do remain very pleased with the success that we've created with the team, and I'm hopeful that as we get through '16 and well into '17 that we'll be able to report on a trajectory that's on a positive track."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay, that's helpful. And then just real quick on seasonality here. I mean, it's obviously increasingly front half-loaded. Should we view '15 seasonality as kind of the framework for '16? Or is there any changes that could swing those numbers?",40,"Okay, that's helpful. And then just real quick on seasonality here. I mean, it's obviously increasingly front half-loaded. Should we view '15 seasonality as kind of the framework for '16? Or is there any changes that could swing those numbers?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Andy, great question. I would think the seasonality in '15 will much be much more reflective of what you'll see in '16. Just keep in mind, the wild card in all of this is really going to be around how these 3Rs ultimately settle out. From our perspective,",122,"Andy, great question. I would think the seasonality in '15 will much be much more reflective of what you'll see in '16. Just keep in mind, the wild card in all of this is really going to be around how these 3Rs ultimately settle out. From our perspective, it -- again, we believe we've been prudent at booking to a conservative point of view. But as more data comes out on those 3Rs, that could create some unique nuances throughout the year. And also, how these co-ops evolve throughout the year and how the states plan to solve for that could create nuances into 2016. But generally speaking, '15 is a pretty good proxy for the seasonality you should expect in '16."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","And your final question today comes from the line of Sarah James from Wedbush Securities.",15,"And your final question today comes from the line of Sarah James from Wedbush Securities."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","You mentioned some potential headwinds on Medicaid rates for 2016, and you're not the first company to spike out that concern. So what are you currently building into guidance for your blended rates in '16? What was it in '15? And can you talk about how y",71,"You mentioned some potential headwinds on Medicaid rates for 2016, and you're not the first company to spike out that concern. So what are you currently building into guidance for your blended rates in '16? What was it in '15? And can you talk about how you view margins on that business for legacy Medicaid? So excluding Iowa or any new contracts, how do you think about margins developing for Medicaid?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","So a good question. One is, I do want to highlight, we don't generally give blended rate increases. As you know, it varies by state. And because the underlying economics of each state vary dramatically, we would prefer not to blend them together in a broa",219,"So a good question. One is, I do want to highlight, we don't generally give blended rate increases. As you know, it varies by state. And because the underlying economics of each state vary dramatically, we would prefer not to blend them together in a broad discussion. That being said, though, Sarah, I think it's a fair question. Understand that we have margins that are exceeding what we believe are long-term, sustainable, optimal margins. But know that we are still assuming that we will blend closer to a 5% margin all-in going into next year. Now that's higher than what you've typically heard from Medicaid, which would be the 2% to 3% margin range. But it's important to recognize that we do get a gross up for the health insurer fee as well, so that bumps those margins further. But we think that the guidance we provided puts us at what hopefully will be a sustainable outperformance margin for us. We believe we should have a better margin because we believe we can execute on this better, and the team that we brought in from the Amerigroup almost 3 years now has done an exceptional job in that space. But our pricing assumes slowly landing the plane on those margins to get to more of that sustainable, long-term margin."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And was there anything moving pieces-wise in the quarter for Medicaid like a flu benefit? Or I think in the past, you had mentioned the potential for retroactive premium payments. Or is there anything out-of-period or unusual that we should think ab",48,"Okay. And was there anything moving pieces-wise in the quarter for Medicaid like a flu benefit? Or I think in the past, you had mentioned the potential for retroactive premium payments. Or is there anything out-of-period or unusual that we should think about with this quarter's Medicaid performance?"
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","No, nothing unusual in terms of the actual numbers. Things tied out where we thought they would tie out. What was a little unusual was more on the cash flow. We actually had a couple of large vendors and a couple of states, in particular, pay us on the la",86,"No, nothing unusual in terms of the actual numbers. Things tied out where we thought they would tie out. What was a little unusual was more on the cash flow. We actually had a couple of large vendors and a couple of states, in particular, pay us on the last day of the year for rates we typically get in the first 5 days of the new year. So it affected cash flow, but it didn't actually affect the underlying economics of what we had assumed."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Thank you. I'd now like to turn the conference back to the company's management for closing comments.",17,"Thank you. I'd now like to turn the conference back to the company's management for closing comments."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Thank you all for your questions this morning. In summary, we're pleased with our 2015 results and believe the increasing diversification of our business positions us well for 2016 and beyond. As you've heard, our team remains focused on executing on",116,"Yes. Thank you all for your questions this morning. In summary, we're pleased with our 2015 results and believe the increasing diversification of our business positions us well for 2016 and beyond. As you've heard, our team remains focused on executing on our core business while preparing for the integration of our Cigna acquisition we expect to close in the second half of the year. I want to thank you all for being with us today, and I especially want to thank our associates for their ongoing contributions and their commitment to serving our 38.6 million customers every day. Thank you all for your interest in Anthem, and we look forward to speaking with you soon."
160077,280495834,921648,"Anthem, Inc., Q4 2015 Earnings Call, Jan 27, 2016",2016-01-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern Time today through February 9. You may access the AT&T Teleconference Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378815. Inter",68,"Ladies and gentlemen, this conference will be available for replay after 11 a.m. Eastern Time today through February 9. You may access the AT&T Teleconference Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378815. International participants, dial (320) 365-3844. That does conclude your conference for today. Thank you for your participation and for using AT&T executive teleconference. You may now disconnect."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management.",38,"Ladies and gentlemen, thank you for standing by, and welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Good morning, and welcome to Anthem's First Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and Wayne DeVeydt, our CFO. Joe will offer an overview o",183,"Good morning, and welcome to Anthem's First Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and Wayne DeVeydt, our CFO. Joe will offer an overview of our first quarter 2016 financial results and will walk through the financials and provide some incremental commentary on our updated 2016 outlook. We are then available for Q&A. 
During the call, we will reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website at antheminc.com. 
We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Anthem. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in today's press release and in our quarterly and annual filings with the SEC. 
I will now turn the call over to Joe."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Doug, and good morning. We're pleased to announce first quarter of 2016 adjusted earnings per share of $3.46, with membership tracking above our previous expectations. On a GAAP basis, we reported earnings per share of $2.63. I'm pleased with o",1919,"Thank you, Doug, and good morning. We're pleased to announce first quarter of 2016 adjusted earnings per share of $3.46, with membership tracking above our previous expectations. On a GAAP basis, we reported earnings per share of $2.63. I'm pleased with our first quarter results, which represent a solid start to 2016 as the company continues to benefit from the growing diversification of our businesses. The complementary nature of our pending Cigna acquisition will allow us to further advance affordability and quality for our members. 
I'm going to start with some overview comments on our first quarter 2016 results, and then we'll discuss a few of the key details of our updated 2016 outlook. First quarter results reflect business performance that tracked well versus our expectations. Specifically, membership is exceeding our expectations, and we reported strong quality of earnings metrics while maintaining appropriate conservativism on our balance sheets to reflect the dynamic nature of the marketplace that exists today. 
Within membership, both fully insured and self-funded membership are tracking ahead of expectations. And we ended the first quarter with 39.6 million members, reflecting growth of 1 million lives or 2.6% since year-end 2015. Specifically, we ended the quarter with 975,000 lives from the individual public exchanges, an increase of 184,000 from year-end 2015 and ahead of our initial expectations. Our self-funded business grew by 906,000 lives or 3.8% in the quarter to 24.6 million members, which was also ahead of our expectations as the company experienced higher-than-expected in-group change in current contracts and BlueCard enrollment. Our Local Group insured enrollment declined by just north of 200,000 lives in the quarter and serves approximately 4 million members as of March 31. In particular, we saw higher-than-expected lapses in plans residing in states that transitioned the 51 to 99 key group size into the small group marketplace. 
Operating revenue was $20.3 billion in the first quarter of 2016, an increase of $1.5 billion or 7.7% versus the first quarter of 2015, reflecting strong enrollment growth in the Government Business and additional premium revenue to cover overall cost trends. Also contributing was the growth in administrative fee revenue as a result of our strong self-funded membership trends. This was partially offset by fully insured membership losses in our Commercial business. 
The first quarter 2016 benefit expense ratio was 81.8%, which increased versus prior year, as expected. The 160 basis point increase reflected the impact of an extra calendar day during the quarter from the leap year, a higher benefit expense ratio in the Medicaid and individual businesses as well as a change in our business mix towards the Government Business division, which carries a higher-than-average benefit expense ratio. While we do not include a reserve rollforward table in our first quarter press release, it is important to note that year-end 2015 reserves have developed moderately better than our expectations so far in 2016. However, we do not believe our first quarter 2016 financial results benefited from that reserve development, and we have maintained an appropriate level of conservativism on our balance sheet as of March 31 for the higher-than-expected individual enrollment. 
Our SG&A expense ratio came in at 15.8% in the first quarter of 2016, a decrease of 90 basis points from the prior year. This was driven by a continued focus on administrative expense control in light of better-than-expected enrollment trends as well as the changing mix of our membership towards the Government Business. 
Supporting those strong quality of our earnings in the first quarter, we reported operating cash flow of approximately $1.3 billion or 1.9x net income. We continue to expect 2016 operating cash flow to be greater than $3 billion. It is important to note that operating cash flow exceeded our expectations in the quarter, which is encouraging. 
Turning to discuss the first quarter financial performance of our business units. Let me say that in our Commercial business, we reported strong membership trends that came in well above our conservative expectations, increasing by 880,000 during the quarter. In particular, we saw strong self-funded membership trends in both our National and Local Group businesses and better-than-expected individual enrollment on the public exchanges. This contributed to the better-than-expected operating revenue during the quarter, which increased by 1.5% versus the prior year to $9.5 billion. 
Operating margins were relatively flat compared to the prior quarter at 13.6%, which reflects the impact of a higher benefit expense ratio, offset by a lower SG&A expense ratio, as expected. 
We were diligent with respect to pricing our exchange product offerings for 2016, as this remains a dynamic marketplace. We believe we have taken a conservative posture in the first quarter regarding our expectations for the profitability of this book of business for 2016. We believe we are well positioned for continued growth in exchange lives as this market stabilizes to a more sustainable level over time. 
Relating to National Accounts, we're pleased that the team has been able to secure some wins recently that should grow membership in both 2016 and 2017. As we said earlier, Local Group membership was down slightly year-over-year, and we continue to see a funding mix shift away from fully insured. We recognize it is vital to offer affordable products with the right network and benefit design in our markets. And our team is focused on improving the historical trends of this book of business. 
Our Government Business segment had another solid quarter, adding 123,000 members and growing year-over-year revenue by 13.9% to $10.8 billion. It is important to note that our results do not yet include an impact from the addition of the Iowa contract, aside from start-up costs incurred in the quarter ahead of the contract launch, where the implementation was delayed from March 1 to April 1. Operating margins for the Government Business in the quarter came in at 3%, a decline of approximately 40 basis points, which was driven by lower gross margins in the Medicaid business. As we communicated previously, we continue to expect Medicaid margins to compress from 2015 levels to a more normalized level, and we are monitoring the performance of this business appropriately.  Within Medicare, I'm pleased with the progress the team continues to make as our first quarter margins reflect continued improvement versus last year. We continue to expect margins to improve as the year progresses towards our expected long-term sustainable level, and we have positioned our portfolio to grow enrollment in the right markets with the right products in 2017. 
The pipeline of opportunity for our Medicaid business remains substantial. We expect $68 billion of new business to be awarded by the end of 2020, split about evenly between traditional Medicaid and new populations and specialized services. We continue to believe our experience and footprint positions us very well to continue our growth as we help states address the challenges of rising health care costs and improving quality for their residents. 
Regarding our balance sheet metrics. Our Days in Claims Payable was 43.4 days as of March 31, an increase of 0.7 days from the 42.7 days as of December 31, 2015. The increase was primarily due to the timing of claims payments driven by the new membership that came online during the quarter. As previously discussed, we expect Days in Claims Payable to come back down closer to 40 over time. 
Our debt-to-capital ratio was 40.2% at March 31, 2016, down 60 basis points from the 40.8% as of December 31, which reflects the impact of an increase in shareholder equity and the reduction of our outstanding balance in the commercial paper during the quarter. 
We ended the first quarter with approximately $2.2 billion of cash and investments at the parent company. And our investment portfolio was in an unrealized gain position of approximately $639 million as of March 31. For the 3Rs related to the 2015 and 2016 benefit years, we continue to book reinsurance as appropriate and continue to reflect a net payable position for risk adjusters and a net neutral position for risk corridors. We continue to record a valuation allowance against the risk corridor receivables in certain markets as we do not believe those receivables will ultimately be collected. We believe our estimates are prudent given the dynamic nature of available information. 
Turning to our financial outlook. We have increased our operating revenue expectation for 2016 by $1 billion to between $81 billion and $82 billion. This increase reflects higher projected membership due to the strong enrollment results seen through the first quarter, as we've discussed. Fully insured membership is now expected to be approximately 14.9 million members at the midpoint of our range at year-end, 250,000 higher than our previous outlook, which reflects stronger than previously expected results in the individual and Medicaid businesses. Self-funded membership is now expected to be approximately 24.5 million members at the midpoint of our range at year-end, also 250,000 higher than our previous outlook. Taken together, we now project our total membership to be approximately 700,000 to 900,000 lives higher than we ended in 2015. We continue to expect our 2016 medical loss ratio to be 83.6%, plus or minus 30 basis points, and now expect our SG&A ratio to be 15.5%, plus or minus 30 basis points, on a GAAP basis, which includes the impact of Cigna-related transaction cost incurred during the first quarter of 2016. We continue to expect 2016 Local Group medical cost trends to be in the range of 7% to 7.5%. We're encouraged with first quarter operating cash flow, and we continue to project operating cash flows to be greater than $3 billion in 2016. 
Regarding capital deployment. We raised our dividend during the first quarter by $0.025 per share and declared our second quarter dividend of $0.65 per share. This represents an annualized dividend of $2.60 per share and continues our track record of increasing our dividend every year since it was implemented in 2011. 
Our 2016 outlook does include some benefit from the impact of capital deployment activities throughout the remainder of the year. While we did not repurchase any shares through the first quarter, we plan to resume our capital deployment program, subject to market conditions, albeit at a lower level than in recent years. 
To conclude, our 2016 earnings per share outlook is greater than $9.65 on a GAAP basis and our adjusted earnings per share outlook is greater than $10.80. Our outlook continues to take an appropriately conservative posture around the expected financial performance on the public exchanges and the expected year-over-year margin compression in the Medicaid business. Our outlook does not include the adoption of new accounting guidance related to employee share-based payments, which we expect to implement in 2017. For context, we estimate the impact in the first quarter of 2016 would have been a benefit to GAAP and adjusted earnings per share of approximately $0.10. Our outlook does include an adverse impact of $0.03 for the additional assessment in 2016 associated with the State of Colorado dissolution of their co-op. It's also important to note that our 2016 outlook does not include any additional benefits or transaction costs associated with the pending acquisition of Cigna beyond those incurred in the first quarter of 2016. We continue to expect this acquisition will close in the second half of this year. It also does not include any benefit from lower pharmaceutical pricing, which we continue to believe we are entitled to under our current contract with the SI. 
With that, operator, please open the queue for questions."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","[Operator Instructions] And the first question will come from the line of A.J. Rice with UBS.",16,"[Operator Instructions] And the first question will come from the line of A.J. Rice with UBS."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I figure I might as well just jump in on the public exchanges and ask you a broad question there, and 3 parts to it, I guess. Obviously, you had good enrollment this open enrollment season. Can you give us any thoughts on the -- what you know so far about",130,"I figure I might as well just jump in on the public exchanges and ask you a broad question there, and 3 parts to it, I guess. Obviously, you had good enrollment this open enrollment season. Can you give us any thoughts on the -- what you know so far about the risk profile of those sign-ups and how you feel about that? Second, I know, last year, your issue really wasn't in terms of dip in profitability on exchanges and the MLR issue was rather an G&A issue, and you've made some adjustments there. Can you sort of update us on what you did there? And then finally, on exchanges, the 2017 early outlook in light of some of the commentary from some of the others in the sector."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Great. A.J., thanks for the question. Good morning. It's Joe. First thing, let me just tell you that we're really pleased overall with how our team has been able to navigate a very challenging landscape that has evolved over the last couple of years. As I",567,"Great. A.J., thanks for the question. Good morning. It's Joe. First thing, let me just tell you that we're really pleased overall with how our team has been able to navigate a very challenging landscape that has evolved over the last couple of years. As I stated in my remarks, we're really glad to now be serving 975,000 members across all of our markets, which I think really highlights an incredibly meaningful value proposition to the customers that have chosen to align with us. Over time, we do believe we're well positioned for continued growth in the exchange marketplace if the market stabilizes to a more sustainable level. I think that is a key consideration. Clearly, the performance of the exchange marketplaces lagged expectations throughout the industry, as some of our peers have been recognized. And in consideration of that, we are monitoring the market very closely to see that our offerings continue to be: number one, very rational, sustainable for the customers, but also it is built on a platform that is constructed appropriately with respect to costs that need to drive our presence in that market. Again, at a very sustainable and appropriate level. We -- I think it's really critical for me to underscore that we are actively engaged with our government partners to help build that long-term sustainable model that we believe will ultimately create an affordable marketplace. And in doing so, we believe we can continue to develop the kind of rate structure in the marketplace that's adequate for us and appropriate in terms of affordability for members. And for example, I think the elimination of the health insurer fee in 2014 sets the stage nicely as we move into that new year with respect to a rate picture. And I think our combination with Cigna is going to present a meaningful improvement in affordability for our membership. So I think, put all that together, we're very kind of pleased with how we've performed this year. We think we're engaged in a fairly sustainable platform that has potential for continued growth, again, to underscore, as long as the model that we are engaged in in the marketplace is a sustainable model. Let me close my remarks in that regard by saying that I think there's some really key drivers to building that sustainable, affordable marketplace that I mentioned. Some of the key elements include what has already been put in place for '17, which is the health insurer tax adjustment. And the second thing would be, I think, a careful consideration of updating the risk adjustment model, further consideration of special enrollment period adjustments, and that would narrow the variety and number of special enrollment considerations. And we'd like to be able to begin offering some very innovative product designs in the marketplace. And hopefully, our government partners will be receptive to some of those creative, innovative model. And finally, I'd like to underscore modification of grace period for nonpayment of premiums to prevent abuse. So when you put all that together in a mosaic, I think, maybe a sustainable model can be built, and we will continue to perform in marketplace in a way that continues to maybe try to achieve the membership that we have originally anticipated back when this effort first began in '14. Wayne, you may want to speak to the MLR question that A.J. put to us."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","So A.J., so address kind of at least our views on '17 and beyond [indiscernible] the membership we received, and I would say we still have a slightly higher silver mix, which we think is a generally positive regarding how we price our book and our product",171,"So A.J., so address kind of at least our views on '17 and beyond [indiscernible] the membership we received, and I would say we still have a slightly higher silver mix, which we think is a generally positive regarding how we price our book and our product. The age distribution in subsidy-eligible mix is consistent with those expectations. But I would tell you that we've chosen to maintain a conservative posture in Q1 until we see ultimately how this develops. So we've maintained a conservative posture on risk adjusters despite [indiscernible] data that would imply that we should be booking more, and we are really now booking to the normal seasonality profitability. You would see this book in Q1. Because again, I think, from our perspective, we like to see this membership at least get through 2Q to really understand the book is performing. So from that perspective, we think it's the prudent thing to do. And then as 2Q evolves, we'll give more commentary on how it's actually developing."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. Great. And then maybe just on that part, just expanding. I know you talked about pulling back on your marketing and trimming your G&A directly related to the exchanges. You've had better-than-expected enrollment growth. Did you still pull in on thos",48,"Okay. Great. And then maybe just on that part, just expanding. I know you talked about pulling back on your marketing and trimming your G&A directly related to the exchanges. You've had better-than-expected enrollment growth. Did you still pull in on those expense items on the G&A side?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, we did. And I think, lesson learned, last year, '15, is that we need to really true up a nice platform that was a appropriately built for the type of market we were dealing with. And quite frankly, I think we really built a very stabilized platform t",109,"Yes, we did. And I think, lesson learned, last year, '15, is that we need to really true up a nice platform that was a appropriately built for the type of market we were dealing with. And quite frankly, I think we really built a very stabilized platform that helped us move into '16 to capture this kind of uptake in membership based on a cost structure that I think was very appropriately built out for the marketplace. And so our -- quite frankly, our G&A structure, I think, is well under control. It's appropriately sized and well configured for us to continue grow in the space as appropriate."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Tom Carroll with Stifel.",11,"And our next question will come from Tom Carroll with Stifel."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just quick follow-up on the exchange business. Are you seeing any signs of adverse selection at all? And maybe could you remind us of kind of the items that you're looking for within that book of business? And then secondly, I'd like you to chat a little",109,"Just quick follow-up on the exchange business. Are you seeing any signs of adverse selection at all? And maybe could you remind us of kind of the items that you're looking for within that book of business? And then secondly, I'd like you to chat a little bit about the Medicaid business. Anthem had a great 2015, and you indicated that the Medicaid MLR was likely going to be up and was up during first quarter. Was it in line with your expectations, higher, lower, from what you expected? And I wonder if you could comment also on the Medicaid managed care rates that were out on Monday."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Got it. Maybe I can pick back up where I left off regarding A.J.'s question on risk profile, which I think relates back to your question on what are we seeing in terms of membership capture. It's a little early. I think we're going to continue to dig into",113,"Got it. Maybe I can pick back up where I left off regarding A.J.'s question on risk profile, which I think relates back to your question on what are we seeing in terms of membership capture. It's a little early. I think we're going to continue to dig into the risk profile that we have brought on, and our sense is that probably somewhere in the 2Q range, we're going to be able to get line of sight on risk profile and have more to report to you at the end of 2Q. So it's a little early for us to give you a kind of a line of sight on risk profile."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","So Tom, a couple of other items. I think, as Joe said, we like what we're seeing in early mix. But ultimately, as this business comes on, we'll see how it really develops in Q2. As you know, a lot of the claims activity always has a little bit of a lag wh",397,"So Tom, a couple of other items. I think, as Joe said, we like what we're seeing in early mix. But ultimately, as this business comes on, we'll see how it really develops in Q2. As you know, a lot of the claims activity always has a little bit of a lag when individuals switches to a new carrier. And then ultimately, that reporting time line that occurs with the providers and ultimately to us. So I think in 2Q, we get a much better feel. What we want you to be aware of is, one, we're not seeing any early indicators across our broader book on trend or anything that would have change our overall trend assumptions. Two is, we've maintained a conservative posture going into 2Q around the risk adjuster data and not only for what we believe that '15 would true up to be, but what we think the impact would be in '16 in light of this mix. That's not just based on our assumptions but actually using the updated weekly [ph] data we receive as well as recent CMIS data. But as you know, ultimate settlements on those will be very dependent upon who owes the risk adjuster and how that will settle out. So we're going to wait and see how that pans out in 2Q. But I would say, at each of these 3Rs, we've been in a posture that should give us some contingency if the book doesn't develop as we would've expected. And if it does develop as we would expect, then it would give us some upside going in the second half of this year and into Q2. On the Medicaid front, again no real surprise. As a reminder, that we have a lot of new markets that we're rolling out. We continue to have that book evolve. As you know, Iowa now starts on April 1 as well. So we would expect to see MLR pressure there in 2Q as well. But consistent with our expectations in new markets that are rolling out and we continue to be bullish in the Medicaid top line as well as bottom line. And as we've mentioned previously, we're going to be slow landing those margins down to what we think a more sustainable. And then on the Medicaid regs, no real surprises. We were fine with the regs, [indiscernible]"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Josh Raskin with Barclays.",11,"And our next question will come from Josh Raskin with Barclays."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First question. Just on the 975,000 exchange lives. Could you help us break down how many of those are new to Anthem versus existing, previously managed life last year? And then any sense of how many of the new ones came from other plans versus sort of [i",109,"First question. Just on the 975,000 exchange lives. Could you help us break down how many of those are new to Anthem versus existing, previously managed life last year? And then any sense of how many of the new ones came from other plans versus sort of [indiscernible] in the market? And then the follow-up would just be on the MLR, up 160 bps in the first quarter, but guidance up 30% for the year. What are -- I understand the leap year, but what are some of the deltas? What changes as we sort of progress through the year that would make those year-over-year comparisons look much better?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Let me take a shot at the first question. The -- we just don't know yet, quite frankly, in terms of what carryover membership brought over from '15. Obviously, we're going to learn more about that getting into 2Q. So it's rather simple answer to the",62,"Yes. Let me take a shot at the first question. The -- we just don't know yet, quite frankly, in terms of what carryover membership brought over from '15. Obviously, we're going to learn more about that getting into 2Q. So it's rather simple answer to the question. Wish I had more to give you, but we just don't know this early."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, Josh. A couple of other items we would highlight those, that generally what we've seen, what I would call the unexpected uptake, those have been markets were the [indiscernible] become insolvent. So I don't think there's a surprise there. I think whe",168,"Yes, Josh. A couple of other items we would highlight those, that generally what we've seen, what I would call the unexpected uptake, those have been markets were the [indiscernible] become insolvent. So I don't think there's a surprise there. I think where we're probably surprised on the uptake, though, has been that we weren't the next lowest-cost carrier. And in many cases, we were substantially higher than the next or several next lowest-cost carriers. So there appears to be a little bit of a flight to safety, if you will, and security. And so again, it's another reason why we want to see how this ultimately pans out our pricing. It's obviously much higher than what the -- would've been available in the market. So the question would be does that adequately reflect the book that we're inheriting over from the co-ops on that end. Frankly, how given 2015 played out, we want to take a more conservative posture earlier this year and see how that develops."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Great. And you don't know which lives were Anthem members previously and still signed on?",15,"Great. And you don't know which lives were Anthem members previously and still signed on?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","You ultimately get the data, but I would say have to look at it -- we look at it as an will single member by the state. We look at the broad mix both on and off exchange membership. And so while we have a feel for some of that, at the same time, I would t",87,"You ultimately get the data, but I would say have to look at it -- we look at it as an will single member by the state. We look at the broad mix both on and off exchange membership. And so while we have a feel for some of that, at the same time, I would tell you that the majority of the new membership growth that we're seeing is obviously new to us and it's coming from other organizations. And clearly, it's in the co-ops space."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So do you have like a net sales versus net lapses number or anything like that even if you don't if they're the same?",25,"Okay. So do you have like a net sales versus net lapses number or anything like that even if you don't if they're the same?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","We do. We do, Josh. But we obviously are not going to discuss that data.",15,"We do. We do, Josh. But we obviously are not going to discuss that data."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And MLR year-over-year?",4,"And MLR year-over-year?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Ultimately, we showed that -- we understand the impact of the year in the leap year. The thing to keep in mind though is the premium. As you know, inherently, the leap year alone, the premium is spread over the entire year, but you're getting a full day o",217,"Ultimately, we showed that -- we understand the impact of the year in the leap year. The thing to keep in mind though is the premium. As you know, inherently, the leap year alone, the premium is spread over the entire year, but you're getting a full day of claims within the quarter. So clearly, there's a positive effect that happens in the out years as the leap year continues. That's one dynamic. I think another dynamic to keep in mind is that when you look at our mix shift and how that's evolving, we've actually didn't do the typical seasonality you would see for individuals. So we try to book a little more of an MLR factor in the first quarter. That typically would've been lower, and then you would have a high in the fourth quarter in this case in this case because the new membership we're doing a little more little, I wouldn't call it straight line, but we're trying to get much more of upfront view and a conservative posture. So as that develops again, I would basically put it that we're seeing out '15 play out. We're just trying to take a much conservative posture earlier in the year and then let that hopefully blend its way down as the year progresses."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And your next question will come from Gary Taylor with JPMorgan.",11,"And your next question will come from Gary Taylor with JPMorgan."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I just want to follow up a little bit, and I think, Wayne, your last response kind of tips into my question a little bit. So I'll be brief. But I'd guess I'm trying to understand where the individual enrollment came. You mentioned a few of the states wher",90,"I just want to follow up a little bit, and I think, Wayne, your last response kind of tips into my question a little bit. So I'll be brief. But I'd guess I'm trying to understand where the individual enrollment came. You mentioned a few of the states where the co-ops were insolvent. I was wondering if there's any more detail you could provide than that, particularly whether there's some of this enrollment would be in states like California, New York where I think your experience was better last year?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, Gary. It is. New York is obviously clearly one of the markets where the co-ops struggled. And we did pick up, I would say, more than our market share that we typically have relative to the co-ops. California is another market where we did perform wel",94,"Yes, Gary. It is. New York is obviously clearly one of the markets where the co-ops struggled. And we did pick up, I would say, more than our market share that we typically have relative to the co-ops. California is another market where we did perform well. And in addition, it would be in Colorado and Kentucky, other markets for the co-ops have the difficulties, and we've picked up -- I would say we've picked up more than our market share So that membership available with their exits were disproportionately picking up market share."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","As a quick follow, I guess I'm having a little difficulty seeing the degree of conservatism maybe that you're talking about in the book, given that versus the original expectation of individual being down 300,000. You're now up 200,000. Days claims payabl",123,"As a quick follow, I guess I'm having a little difficulty seeing the degree of conservatism maybe that you're talking about in the book, given that versus the original expectation of individual being down 300,000. You're now up 200,000. Days claims payable down a couple of days year-over-year. The commercial operating margin was up 10 basis points even though you booked some additional MLR and the individual business. Is in the response to that just that this individual seasonality is so skewed to the front end versus the fourth quarter that -- you still have some modest margin gain year-over-year even though you're booking the traditionally MLR and individual book? Does that maybe just -- the range, the seasonality [indiscernible] not appreciating enough."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. So Gary, yes. So that's one dynamic. Second one is sequentially DCP is actually up since year-end. As we said, year-end did develop favorable to our expectations. Want to emphasize that develop favorable and DCP is up sequentially. Two is I think it'",131,"Yes. So Gary, yes. So that's one dynamic. Second one is sequentially DCP is actually up since year-end. As we said, year-end did develop favorable to our expectations. Want to emphasize that develop favorable and DCP is up sequentially. Two is I think it's important to recognize it on the 3Rs, the data would imply that we have been conservative on 2015. And so we've neither recognized that conservatism yet. And in addition to that, also imply that a run rate that we would have available to us in 2016 based on that data, and again we've not recognized that as well. It's important to recognize that the 3Rs are not part of DCP, so you won't necessarily see that conservatism that we are carrying into Q2 as we move forward."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And would you ever discuss 3Rs? Will we ever get that from you?",13,"And would you ever discuss 3Rs? Will we ever get that from you?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Most likely not, but I will tell you that in 2Q, we will give you a gauge, though, of how we it maybe benefit us more broadly in terms of the pieces. I think that thing I want to highlight for the group, though, is the reason we're being cautious on 3Rs,",146,"Most likely not, but I will tell you that in 2Q, we will give you a gauge, though, of how we it maybe benefit us more broadly in terms of the pieces. I think that thing I want to highlight for the group, though, is the reason we're being cautious on 3Rs, in particular, risk adjusters, would imply that we would have a nice receivable related to '15 as well as some run rate into '16 is the question is, some of the risk corridor, who ultimately going to pay that. And if the receivables due from a co-op, ultimately, we don't want to recognize that unless the co-ops have a financial wherewithal to pay those receivables. So this is just one of many factors that we believe warrants being conservative until we see final settlements and then how those dollars are actually transferred between companies."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Peter Costa with Wells Fargo Securities.",13,"And our next question will come from Peter Costa with Wells Fargo Securities."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I'll move away from the individual exchanges for a minute and take you to the PDM, the contract dispute with Express. Can you talk -- not about what you're going to do, but how would you bring it in house, specifically, if that was the direction this ends",135,"I'll move away from the individual exchanges for a minute and take you to the PDM, the contract dispute with Express. Can you talk -- not about what you're going to do, but how would you bring it in house, specifically, if that was the direction this ends up? Give us some idea of certain time frame it would take from when you have the start planning it as well as what sort of options would you use in terms of perhaps using some of the other PBMs or even express by buying next [indiscernible] back to something like that, to actually manage it given that you don't have the assets anymore to run a PBM? Can you talk about that little bit and specifically how that would work if you're developing it in-house?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Peter, interesting question. I think it spikes at one of our various options and just kind to help us all recall where we started this journey. We talk a lot about optionality and recognize that we had some choices ahead of us, one, bring it in-house",298,"Yes. Peter, interesting question. I think it spikes at one of our various options and just kind to help us all recall where we started this journey. We talk a lot about optionality and recognize that we had some choices ahead of us, one, bring it in-house, as you've just described. And other would be to recast our agreement with DSI. Another would be to go to another vendor, et cetera. So we're considering a full range of options. I think, first, I need to preface my remarks by underscoring that we've got probably a couple of years at a minimum before we need to make that call. And quite frankly, these considerations are -- we're actively involved in some sort of the various pluses and minuses of each options. So it's really too early for us to comment on specificity. And I think that to your point, but bringing it in-house, recognizing it's a complex process to do so. It does have costs associated with it. We recognize that. But again, let me underscore, it's not a decision that is imminent. We have, call it, a journey that we have to administer with respect to our ongoing negotiations with ESI regarding our position that we stated to them clearly and now taken the form of a lawsuit. So I direct you do that with respect to the specificity around our engagement with them at this stage. But optionality, again I want to underscore, we are in the development mode on our choices. But none of those choices do we have to exercise in any way of an imminent nature, and so I'd prefer just kind of maybe delay a response to some future date when that is more of an imminent necessity for us to deal with."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And can you talk about sort of the expected savings if you were to bring it in house? What would that look like relative to the $3 billion that you're seeking from Express on a contract renegotiation?",38,"Okay. And can you talk about sort of the expected savings if you were to bring it in house? What would that look like relative to the $3 billion that you're seeking from Express on a contract renegotiation?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. As I said, I think certainly a lot of analytics will go into discerning savings. We haven't actually gone into the depths of administratively how you build it and the cost associated with building it. That then translates the savings. Again, let me r",94,"Yes. As I said, I think certainly a lot of analytics will go into discerning savings. We haven't actually gone into the depths of administratively how you build it and the cost associated with building it. That then translates the savings. Again, let me restate, emphatically, that it's too early for us to weigh in on that. And at some future moment in time where it is appropriate, we'll certainly bring that your attention. It's just too early now to give you the line of sight on savings for an option of that nature."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question will come from Dave Windley with Jefferies.",10,"Your next question will come from Dave Windley with Jefferies."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I want to go back to Medicaid. First part of the question would be, was the -- was the higher MLR and Medicaid a function of just the lower rates that you've anticipated? Or are there other factors like flu, perhaps or population next acuity of the mix or",121,"I want to go back to Medicaid. First part of the question would be, was the -- was the higher MLR and Medicaid a function of just the lower rates that you've anticipated? Or are there other factors like flu, perhaps or population next acuity of the mix or even rising trend in Medicaid that impacted MLR there? And then second part would be, as we look to the second quarter and the start of Iowa, some of your peers, at least one, I think has established -- have established reserves in 2015 in anticipation of pretty significant pressure from Iowa. How should we think about the progression of Medicaid margin into 2Q and the rest of the year for Iowa?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Dave, good morning. Let me first start with Medicaid. Yes, a significant portion of what you signed in MLR is a function of what we've been talking around rate pressure and those rates coming down. I think our outlook for the year in the Medicaid team con",280,"Dave, good morning. Let me first start with Medicaid. Yes, a significant portion of what you signed in MLR is a function of what we've been talking around rate pressure and those rates coming down. I think our outlook for the year in the Medicaid team continues to be consistent with the outlook that we gave when we give guidance initially, and we expect to be at our MLR and trends playing within the levels that we fully expected within the book. So no real surprises there. Relative to Iowa, as you know, we did not book the PDR. We typically expect to have a higher MLR and to lose money early on when the programs rolled out. And then ultimately, the PR requires you to look over the life of the contract, and we expect to be profitability or the like the contract, which is why we don't have a book on it. But because the contract was delayed, obviously, the MLR will reflect that 9 months of activity instead of 10 months, which means that your MLR will be a little bit pressured in the current year, but only by an additional month. The fact that was delayed by month will have a little bit of pressure this year. But obviously, we expect that to come down next year. But we weren't necessarily pleased with membership been delayed in the revenue impact. We actually think that additional month probably played well for the industry in terms of getting into contracts, finalizing its networks, finalizing a matter of hopefully can make this a very strong, profitable book consistent with our historical margins. So we remain optimistic on the program."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Kevin Fischbeck with Bank of America.",13,"And our next question will come from Kevin Fischbeck with Bank of America."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just wanted to dig into guidance a little bit. You beat consensus expectations for Q1 pretty nicely, particularly on the G&A side, but you didn't raise guidance for the year. In fact, you took your G&A number up and capture MLR stable even they seem to be",95,"Just wanted to dig into guidance a little bit. You beat consensus expectations for Q1 pretty nicely, particularly on the G&A side, but you didn't raise guidance for the year. In fact, you took your G&A number up and capture MLR stable even they seem to be talking about pressure on the MLR in the individual said, at least from a mix perspective. Can you talk a little bit about why the puts and takes ended up the way that they were? And why wouldn't see upward pressure on MLR and downward pressure on G&A?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Let me address a few things. One is I want to highlight again that if we look to relate Q1 and the results, it wouldn't imply that we should have had a raise, which I think is a very valid question that you're asking. I can't emphasize enough that we",300,"Yes. Let me address a few things. One is I want to highlight again that if we look to relate Q1 and the results, it wouldn't imply that we should have had a raise, which I think is a very valid question that you're asking. I can't emphasize enough that we are very pleased with all the metrics in Q1. But with those metrics, we really thought it was best to maintain a lot of conservatism that we can otherwise potentially release in Q1 until we see how this evolves into Q2. I think it's fair to say that the industry last year, and ourselves included, got to see a lot more of how things developed as last year progressed. So it is taking a much more conservative posture till we see more development. The second thing I would highlight again as we did a highlight that we are covering another $0.03 of assessments from co-ops and maintaining the guidance as well. And then last thing I would say is, in terms of the metrics, we like our G&A where it's at. And we think with some additional membership, this is the SG&A leverage we should have gotten a year ago with exchanges. As you know, it was the deleverage impact to us a year ago. This year, it's going to  be a leverageble impact. And so we're holding the line on G&A. And we again -- if the membership plays out with the risk profile we would expect, then the G&A leverage helps improve the margins. If it doesn't, than the G&A leverage will offset surprises. So I'd love to give you a different answer. But I'm in the reality is we just chose to be conservative in Q1 until we can see how this book of business evolves."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And as you mentioned on the small group business that you saw some pressure, particularly in the states that expanded the -- 51 to 100. What percent of your small group business is in the states?",37,"Okay. And as you mentioned on the small group business that you saw some pressure, particularly in the states that expanded the -- 51 to 100. What percent of your small group business is in the states?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. It's actually a decent amount, and I would say it was primarily in California. As you know, California is one of the states that made a decision, as the New York and Colorado. If you look into what I'll call your typical market that would be the most",136,"Yes. It's actually a decent amount, and I would say it was primarily in California. As you know, California is one of the states that made a decision, as the New York and Colorado. If you look into what I'll call your typical market that would be the most significant for us. It's California of that group. And as a result, not only did you historical small group products no longer be allowed to persist, but you actually had to introduce new products and consider product mix of our what it would look like us a little direction to defined as a small group. So we're not happy about the membership we lost in those markets, but we also recognize that not every state adopted the flexibility that was offered them on the Affordable Care Act."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Do you think that that's that's [indiscernible] is going to do that the headwinds we expect to see next year [indiscernible] states [indiscernible] do it by now?",28,"Do you think that that's that's [indiscernible] is going to do that the headwinds we expect to see next year [indiscernible] states [indiscernible] do it by now?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, if you were going to do it, you would've have done it by now. The other states have actually gone and maintained the historical small group definition. I think that's behind us now.",34,"Yes, if you were going to do it, you would've have done it by now. The other states have actually gone and maintained the historical small group definition. I think that's behind us now."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Ralph Giacobbe with Citigroup.",11,"And our next question will come from Ralph Giacobbe with Citigroup."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just wanted to go back to the exchanges. I guess, last quarter, you had mentioned that the exchange book was breakeven for 2015. And as you've talked about, you expected to pull G&A and bring it back to sort of profitable levels. Obviously, you've done be",83,"Just wanted to go back to the exchanges. I guess, last quarter, you had mentioned that the exchange book was breakeven for 2015. And as you've talked about, you expected to pull G&A and bring it back to sort of profitable levels. Obviously, you've done better on the enrollment side. I guess kind of talked about your conservatism. Can you help us in terms of what margins are assumed at this point for the exchange or maybe what's embedded in guidance for 2016?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Ralph, in essence, I would tell you, as we said before, targeted margins are 3% to 5%. When we built our plan for this year, we were targeting lower than the threshold. we're not adjusted that targeted margins. So my point is that to the extent that this",117,"Ralph, in essence, I would tell you, as we said before, targeted margins are 3% to 5%. When we built our plan for this year, we were targeting lower than the threshold. we're not adjusted that targeted margins. So my point is that to the extent that this mentorship does have the risk profile we have, you should expect a better margin as a result of the G&A leverage play. And to the extent that those 3Rs, in fact, not only sell up as we've been notified to date between [indiscernible] and say this, but actually cash flow as well as between the parties that have to settle, and then you could expect margin expansion as well."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. I guess I just wanted to go back to the disconnect to the lack of guidance raised. If the assumption is to make still -- let's call it, 1% to 2% margin or whatever the numbers on the exchange on a bigger book, maybe to help level set, can you give u",74,"Okay. I guess I just wanted to go back to the disconnect to the lack of guidance raised. If the assumption is to make still -- let's call it, 1% to 2% margin or whatever the numbers on the exchange on a bigger book, maybe to help level set, can you give us any sense at all of what you booked for 1Q in terms of sort of a comparable margin on the exchange?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, as you know historically, have an individual member you're very profitable in Q1. That profitability then declines to ultimately a loss in Q4. But I would say is that, from our perspective, we've chosen not to take that profitability in a Q1 but rat",88,"Well, as you know historically, have an individual member you're very profitable in Q1. That profitability then declines to ultimately a loss in Q4. But I would say is that, from our perspective, we've chosen not to take that profitability in a Q1 but rather book to a breakeven perspective and then see how this book evolves in Q2 and thereafter. So to the extent that it involves positively, then you'll get the margin improvement both from Q1 as well as in the run rate for the year."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. All right. That's helpful. And I think it was asked earlier but haven't gotten sort of the answer about our positioning for 2017. Are the new states or territories that you're going to enter and maybe a sense -- I know it's early this point, but whe",83,"Okay. All right. That's helpful. And I think it was asked earlier but haven't gotten sort of the answer about our positioning for 2017. Are the new states or territories that you're going to enter and maybe a sense -- I know it's early this point, but when we think about target margins, you talked about 3% to 5%, is 2017 sort of an area you expect to get there, get closer to there? Any just general commentary around that will be helpful."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","We're not targeting on a stand-alone basis any new markets outside of our 14 states. Our goal is to continue to stabilize the markets in states and start trending towards our targeted 3% to 5% margin. I would not anticipate, at this point in time, that in",140,"We're not targeting on a stand-alone basis any new markets outside of our 14 states. Our goal is to continue to stabilize the markets in states and start trending towards our targeted 3% to 5% margin. I would not anticipate, at this point in time, that in '17 that we would necessarily achieve that level of margin. But nonetheless, this meant a lot of activity around the regulations and ways to improve and create more stability. We'll see. And to be fair, it's a little bit early in the pricing cycle. So we ultimately don't see how pricing evolves and what the states ultimately improve in the pricing cycle and whether or not we can get there as early '17. But right now, I'd be more cautious in getting there in '17 and feel more than an '18 play."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","I think the question is interesting the way you put it about expanding to others state [indiscernible] precluded -- Blue Cross Blue Shield presence in our 14 states and really think we should underscore the value we bring to our markets and our brand lega",169,"I think the question is interesting the way you put it about expanding to others state [indiscernible] precluded -- Blue Cross Blue Shield presence in our 14 states and really think we should underscore the value we bring to our markets and our brand legacy, incredibly well known, with respect to quality, as well as affordability. And to earlier point, we have witnessed or we really do believe this flight to safety is real. And I think flight to safety is very relevant, which is how folks are connecting back to us in terms of a known brand. I think we're going to really seek the leverage that more effectively in every market that we're serving. And the last point I'll, Cigna will help us for future expansion beyond our 14 states. So that's a story that's not yet told. And at what becomes clear that we can, we will express ourselves probably in more depth in terms of potential to expand to other markets relative to public exchanges."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And the next question will come from Chris Rigg with Susquehanna Financial.",12,"And the next question will come from Chris Rigg with Susquehanna Financial."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Apologizing if I missed this. But did you guys say what you're and are you assuming for the reinsurance, coinsurance rate? And at 4Q, said a little above 50%. There's some data from CMS which suggest it could be more like 60% to 65%. Sense for what you're",55,"Apologizing if I missed this. But did you guys say what you're and are you assuming for the reinsurance, coinsurance rate? And at 4Q, said a little above 50%. There's some data from CMS which suggest it could be more like 60% to 65%. Sense for what you're assuming now and what impact on guidance?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Chris, thanks for the question. So we continue to assume a little bit north of 50%. I would tell you that the CMIS data 60% to 65% goes forward, we will have sizable upside relative to those percentages. We're not so sure it will evolve ultimately to that",189,"Chris, thanks for the question. So we continue to assume a little bit north of 50%. I would tell you that the CMIS data 60% to 65% goes forward, we will have sizable upside relative to those percentages. We're not so sure it will evolve ultimately to that level. But based on the most recent data that's been submitted as well as the data received on this, we are at a number below what the data would imply. It's what I would say conservatism going into 2Q and beyond. But again, what's the ultimate settlement. As a reminder, in risk corridors, we continue to maintain 100% valuation allowance against any receivables. And I would tell you the more sizable upside, ultimately, will be on the risk adjusters, if what we've seen in early data related to '15 and '16 is, in fact, holds true into 2Q. And again, if, in fact, it's monetized by the parties that owe it. So I would say all 3 areas represent potential upside, the corridor being the least of -- we just don't see the money in the kitty that can fund those."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And we'll go to the line of Matthew Borsch with Goldman Sachs.",13,"And we'll go to the line of Matthew Borsch with Goldman Sachs."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Was hoping that you could give us some -- or your assessment on the group commercial side. The decline of -- I think it was 245,000 lives in the quarter was in line with what you guided to. Can you -- I know -- you referred to some states where they expan",109,"Was hoping that you could give us some -- or your assessment on the group commercial side. The decline of -- I think it was 245,000 lives in the quarter was in line with what you guided to. Can you -- I know -- you referred to some states where they expanded the definition of small group, and that was a factor. I assume that there's some ASO conversions. Some of that also reflect a conservative pricing posture? I mean, I know you always try to be conservative, but -- have you needed to be more conservative in the current pricing environment? If you could just talk to that."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Matt, yes, let me first start by saying that it has some full conversions from fully insured to ASO. And I think you can see that and how strong our ASO book has done, and not just in National but in the Large Group business as well. I think it's fair to",159,"Matt, yes, let me first start by saying that it has some full conversions from fully insured to ASO. And I think you can see that and how strong our ASO book has done, and not just in National but in the Large Group business as well. I think it's fair to say that -- at least half of it though represents those markets that did the switch with the majority of that being in California. And I would say we've maintained our pricing discipline in California. And it seems that most of that membership went to a single carrier, primarily a not-for-profit carrier that we think priced fairly aggressively. And again from our perspective, we'll weather that storm as well as we have in the past. And hopefully, win those numbers back in the next year or so. But that's -- I think is about 50-50 split, and then of the 50 that truly left, it's probably California."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","That's very helpful. And also, if we could ask, what is a approximately the amount by which you need to increase price going into 2017 to reflect the lack of reinsurance? And how much of a problem is that going to be for exacerbating some adverse selectio",59,"That's very helpful. And also, if we could ask, what is a approximately the amount by which you need to increase price going into 2017 to reflect the lack of reinsurance? And how much of a problem is that going to be for exacerbating some adverse selection that's already a program-wide problem to some degree in the exchanges?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Matt, we generally haven't given all the specific pricing. At the reinsurance is one that generally can people mathematically back into range of 5% to 6% range of what it could impact on upper pricing by itself. And so I would say that that 5% to 6% range",139,"Matt, we generally haven't given all the specific pricing. At the reinsurance is one that generally can people mathematically back into range of 5% to 6% range of what it could impact on upper pricing by itself. And so I would say that that 5% to 6% range that we've had others asked about his reasonable proxy what you should expect for the piece of reinsurance that would run off. Relative to all the pricing, we're not necessarily talk in specifics, in process now filing with our states. But this is continue one we're spending time, making sure everybody's educated on. And I would tell you commissioners regulators understand it. They get it and it is and implications. And so for competitive reasons, I would like to probably not discuss any further rate filings and actions at this point."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And we'll go to the line of Ana Gupte with Leerink Partners.",13,"And we'll go to the line of Ana Gupte with Leerink Partners."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I've been following up on the commercial book, but now to [indiscernible] 2017. 2% gain in the commercial businesses and also in some [indiscernible] looking into [indiscernible]",28,"I've been following up on the commercial book, but now to [indiscernible] 2017. 2% gain in the commercial businesses and also in some [indiscernible] looking into [indiscernible]"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Ana, can you start your question over? We're having trouble hearing you.",12,"Ana, can you start your question over? We're having trouble hearing you."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Yes, [indiscernible] -- is this better?",6,"Yes, [indiscernible] -- is this better?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Sorry. You're cutting in and out. It's very difficult to hear you.",12,"Sorry. You're cutting in and out. It's very difficult to hear you."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Better now?",2,"Better now?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","A little bit, yes. Please try again.",7,"A little bit, yes. Please try again."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So I was asking about the 2017 commercial outlook and whether or not as you look at the 2017, related to see a better operating gain growth rate because the not-for-profit Blues [indiscernible] everywhere, they're all losing money on exchanges and y",70,"Okay. So I was asking about the 2017 commercial outlook and whether or not as you look at the 2017, related to see a better operating gain growth rate because the not-for-profit Blues [indiscernible] everywhere, they're all losing money on exchanges and you don't overlap revenue for the Blues. But as you think about Cigna and the post-Cigna world, is the pricing and underwriting spread will get better in 2017?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, I would say our -- well, we haven't given '17 outlook yet. As you can imagine, we'll see how '16 develops. But we would expect to see the margins begin to trend in a more sustainable levels of 3% to 5%, I don't think again we'll be there by '17. But",184,"Well, I would say our -- well, we haven't given '17 outlook yet. As you can imagine, we'll see how '16 develops. But we would expect to see the margins begin to trend in a more sustainable levels of 3% to 5%, I don't think again we'll be there by '17. But ultimately, it seems that the environment is starting to recognize the true cost of operating the changes in the membership that resides with it. These are large risk pool. So I think the industry is getting the point would have enough data to support the pricing that belongs with it. And we think that our job now is to continue to educate our regulators on the risk profile of the polls, actions we can take out that the cost down for affordability. And at the same time, though, to the extent that we're limited on actions, to make sure people understand the pricing that goes with it. So I think for '17, today -- as best we can say committed the expectation that marks would improve and pricing would continue to improve."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Talk about exchanges our commercial -- I'm talking about the [indiscernible] and the spread between trend and pricing, more sort of is it likely to be a silver lining on the cloud just because companies are losing money on exchanges so they become more co",49,"Talk about exchanges our commercial -- I'm talking about the [indiscernible] and the spread between trend and pricing, more sort of is it likely to be a silver lining on the cloud just because companies are losing money on exchanges so they become more conservative on the commercial pricing."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's hard to know what others may do in their pricing. Clearly, in California, we did not see a player who we know loss money on exchanges necessarily take a more rational pricing on their small group book. I guess what I would say is, we've seen our mark",127,"It's hard to know what others may do in their pricing. Clearly, in California, we did not see a player who we know loss money on exchanges necessarily take a more rational pricing on their small group book. I guess what I would say is, we've seen our market and one competitor, you seen one market and one a better it's hard for us. I think I would say is this, our philosophies, you got a cover cost of capital. We got a given shareholders a fair return for the risk that we bear and reprice accordingly and then we'll just have to weather the markets, whatever they bring her in the short term as we did on the public changes the last couple of years."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And then finally on the 51 to 100. Once you get past that had been, is there a reduced tendency toward dumping some employers because exchanges haven't been as stable and there's a lot of volatility there?",37,"And then finally on the 51 to 100. Once you get past that had been, is there a reduced tendency toward dumping some employers because exchanges haven't been as stable and there's a lot of volatility there?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","We think there is. It seems like the big fact as we move that having this was cut [indiscernible] product description and size under a say that had to be implemented. Yes, I think from our perspective as kind of stability and I would say internally, we're",58,"We think there is. It seems like the big fact as we move that having this was cut [indiscernible] product description and size under a say that had to be implemented. Yes, I think from our perspective as kind of stability and I would say internally, we're targeting actually turning it back to small group with again, though."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And we'll go to the last question here. It will come from Scott Fidel with Credit Suisse.",18,"And we'll go to the last question here. It will come from Scott Fidel with Credit Suisse."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just had a question on cost trends overall. just interested, just within the guidance range that you talked about, how trend maybe behaving within that range in the first quarter? United, talked about seeing a bit of an uplift in cost trend in the first q",76,"Just had a question on cost trends overall. just interested, just within the guidance range that you talked about, how trend maybe behaving within that range in the first quarter? United, talked about seeing a bit of an uplift in cost trend in the first quarter to maybe around 50 basis points. And then just also just specifically, whether you've been seeing an increase in surgical volumes year-over-year in the first quarter relative to last year?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Scott, thanks for the question. Yes -- well, first of all, it's important we recognize that we have assumed the trends would move up [indiscernible] last year versus to what we guided to this year. So the trends have moved up but within our expectations a",235,"Scott, thanks for the question. Yes -- well, first of all, it's important we recognize that we have assumed the trends would move up [indiscernible] last year versus to what we guided to this year. So the trends have moved up but within our expectations and our pricing. So as we look at various factors, think we would've said early on that trend might have been favorably impacted by the flu. But the fact that the late season happened ultimately, we think for the full year, that won't have upside to us nor a downside [indiscernible] expectations. We did expect a fairly sizable uptick in trend in Q1 regarding really hep C. And we saw that, which is good and the good news is at least on a rolling 3-month average [indiscernible] it's right in line with our expectations, slightly better than our expectations, but I would tell you that we're not going to bank that yet. We think that maybe some warehousing because there's [indiscernible] news drugs that are coming out that people may be holding off on until those are available. So I think ultimately, when a look at what could be the big surprise on it as like a hep C or a flu everything seems to be playing pretty well relative to our expectations. And we did expect it to be high in the quarter, it was, but within our pricing."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Scott, it's Joe. I think it's probably fair to also comment on a lot of what you can see regarding the internal activity of the company. we are obviously vigilant regarding trend changes. Internally, we're building a really robust, collaboration models, r",131,"Scott, it's Joe. I think it's probably fair to also comment on a lot of what you can see regarding the internal activity of the company. we are obviously vigilant regarding trend changes. Internally, we're building a really robust, collaboration models, really driven towards value-based contracting, that then tries to ameliorate the risk of trend escalation. Our data analytics infrastructure has been a remarkable uplift in the company with respect to investments and result of insights that we've captured in order to better manage the cost of care. So there's kind of the macro level that you see. But with the micro level within the company, it's amazing how well we position ourselves to really address the kind of the prevailing winds that come at us in and around trend changes."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Got it. And then just on the surgical [indiscernible] able to tease out whether what you saw year-over-year there? Is it still little bit too early to tell?",28,"Got it. And then just on the surgical [indiscernible] able to tease out whether what you saw year-over-year there? Is it still little bit too early to tell?"
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's a little early. We honestly look for different areas that might spike. I mean it was a little bit more there. But again relative to expectations, I think things are playing okay. So nothing of any specificity that I can provide at this point.",46,"It's a little early. We honestly look for different areas that might spike. I mean it was a little bit more there. But again relative to expectations, I think things are playing okay. So nothing of any specificity that I can provide at this point."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Let me just kind of express the thanks to all of you for your questions. In summary, I'm pleased with our first quarter results and believe that these results positioned us very well for the remainder of the year. Hopefully, you got a sense of that with r",169,"Let me just kind of express the thanks to all of you for your questions. In summary, I'm pleased with our first quarter results and believe that these results positioned us very well for the remainder of the year. Hopefully, you got a sense of that with respect to our commentaries today. We do remain committed to increasing access to high-quality health care. Specifically, we believe our ability to serve our customers will be advanced by the pending acquisition of Cigna, which we still remain of the belief that is expected to close in the second half of 2016. And also, this includes our continued focus on improving matters like drug pricing. The -- I also want to thank all of our associates for their continued commitment to serving our nearly 40 million members, and I'd like to also again thank all of you on the call for your interest in Anthem and look forward to speaking with you soon. Again, thank you very much. Have a great day."
160077,308029053,963919,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And ladies and gentlemen, this conference will be available for replay after 11:00 this morning and running through Wednesday, May 11 at midnight. You can access the AT&T Executive Playback service by dialing 1 (800) 475-6701 and then entering the access",72,"And ladies and gentlemen, this conference will be available for replay after 11:00 this morning and running through Wednesday, May 11 at midnight. You can access the AT&T Executive Playback service by dialing 1 (800) 475-6701 and then entering the access code 378816. International parties may dial 1 (320) 365-3844. That does conclude our conference for today. Thanks for your participation and for using AT&T executive teleconference service. You may now disconnect."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management.",38,"Ladies and gentlemen, thank you for standing by, and welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Good morning, and welcome to Anthem's First Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and Wayne DeVeydt, our CFO. Joe will offer an overview o",183,"Good morning, and welcome to Anthem's First Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and Wayne DeVeydt, our CFO. Joe will offer an overview of our first quarter 2016 financial results and will walk through the financials and provide some incremental commentary on our updated 2016 outlook. We are then available for Q&A. 
During the call, we will reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website at antheminc.com. 
We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Anthem. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in today's press release and in our quarterly and annual filings with the SEC. 
I will now turn the call over to Joe."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Doug, and good morning. We're pleased to announce first quarter of 2016 adjusted earnings per share of $3.46, with membership tracking above our previous expectations. On a GAAP basis, we reported earnings per share of $2.63. I'm pleased with o",1918,"Thank you, Doug, and good morning. We're pleased to announce first quarter of 2016 adjusted earnings per share of $3.46, with membership tracking above our previous expectations. On a GAAP basis, we reported earnings per share of $2.63. I'm pleased with our first quarter results, which represent a solid start to 2016 as the company continues to benefit from the growing diversification of our businesses. The complementary nature of our pending Cigna acquisition will allow us to further advance affordability and quality for our members. 
I'm going to start with some overview comments on our first quarter 2016 results, and then we'll discuss a few of the key details of our updated 2016 outlook. First quarter results reflect business performance that tracked well versus our expectations. Specifically, membership is exceeding our expectations, and we reported strong quality of earnings metrics while maintaining appropriate conservativism on our balance sheets to reflect the dynamic nature of the marketplace that exists today. 
Within membership, both fully insured and self-funded membership are tracking ahead of expectations. And we ended the first quarter with 39.6 million members, reflecting growth of 1 million lives or 2.6% since year-end 2015. Specifically, we ended the quarter with 975,000 lives from the individual public exchanges, an increase of 184,000 from year-end 2015 and ahead of our initial expectations. Our self-funded business grew by 906,000 lives or 3.8% in the quarter to 24.6 million members, which was also ahead of our expectations as the company experienced higher-than-expected in-group change in current contracts and BlueCard enrollment. Our Local Group insured enrollment declined by just north of 200,000 lives in the quarter and serves approximately 4 million members as of March 31. In particular, we saw higher-than-expected lapses in plans residing in states that transitioned the 51 to 99 key group size into the small group marketplace. 
Operating revenue was $20.3 billion in the first quarter of 2016, an increase of $1.5 billion or 7.7% versus the first quarter of 2015, reflecting strong enrollment growth in the Government Business and additional premium revenue to cover overall cost trends. Also contributing was the growth in administrative fee revenue as a result of our strong self-funded membership trends. This was partially offset by fully insured membership losses in our Commercial business. 
The first quarter 2016 benefit expense ratio was 81.8%, which increased versus prior year, as expected. The 160 basis point increase reflected the impact of an extra calendar day during the quarter from the leap year, a higher benefit expense ratio in the Medicaid and individual businesses as well as a change in our business mix towards the Government Business division, which carries a higher-than-average benefit expense ratio. While we do not include a reserve rollforward table in our first quarter press release, it is important to note that year-end 2015 reserves have developed moderately better than our expectations so far in 2016. However, we do not believe our first quarter 2016 financial results benefited from that reserve development, and we have maintained an appropriate level of conservativism on our balance sheet as of March 31 for the higher-than-expected individual enrollment. 
Our SG&A expense ratio came in at 15.8% in the first quarter of 2016, a decrease of 90 basis points from the prior year. This was driven by a continued focus on administrative expense control in light of better-than-expected enrollment trends as well as the changing mix of our membership towards the Government Business. 
Supporting those strong quality of our earnings in the first quarter, we reported operating cash flow of approximately $1.3 billion or 1.9x net income. We continue to expect 2016 operating cash flow to be greater than $3 billion. It is important to note that operating cash flow exceeded our expectations in the quarter, which is encouraging. 
Turning to discuss the first quarter financial performance of our business units. Let me say that in our Commercial business, we reported strong membership trends that came in well above our conservative expectations, increasing by 880,000 during the quarter. In particular, we saw strong self-funded membership trends in both our National and Local Group businesses and better-than-expected individual enrollment on the public exchanges. This contributed to the better-than-expected operating revenue during the quarter, which increased by 1.5% versus the prior year to $9.5 billion. 
Operating margins were relatively flat compared to the prior quarter at 13.6%, which reflects the impact of a higher benefit expense ratio, offset by a lower SG&A expense ratio, as expected. 
We were diligent with respect to pricing our exchange product offerings for 2016, as this remains a dynamic marketplace. We believe we have taken a conservative posture in the first quarter regarding our expectations for the profitability of this book of business for 2016. We believe we are well positioned for continued growth in exchange lives as this market stabilizes to a more sustainable level over time. 
Relating to National Accounts, we're pleased that the team has been able to secure some wins recently that should grow membership in both 2016 and 2017. As we said earlier, Local Group membership was down slightly year-over-year, and we continue to see a funding mix shift away from fully insured. We recognize it is vital to offer affordable products with the right network and benefit design in our markets. And our team is focused on improving the historical trends of this book of business. 
Our Government Business segment had another solid quarter, adding 123,000 members and growing year-over-year revenue by 13.9% to $10.8 billion. It is important to note that our results do not yet include an impact from the addition of the Iowa contract, aside from start-up costs incurred in the quarter ahead of the contract launch, where the implementation was delayed from March 1 to April 1. Operating margins for the Government Business in the quarter came in at 3%, a decline of approximately 40 basis points, which was driven by lower gross margins in the Medicaid business. As we communicated previously, we continue to expect Medicaid margins to compress from 2015 levels to a more normalized level, and we are monitoring the performance of this business appropriately.  Within Medicare, I'm pleased with the progress the team continues to make as our first quarter margins reflect continued improvement versus last year. We continue to expect margins to improve as the year progresses towards our expected long-term sustainable level, and we have positioned our portfolio to grow enrollment in the right markets with the right products in 2017. 
The pipeline of opportunity for our Medicaid business remains substantial. We expect $68 billion of new business to be awarded by the end of 2020, split about evenly between traditional Medicaid and new populations and specialized services. We continue to believe our experience and footprint positions us very well to continue our growth as we help states address the challenges of rising health care costs and improving quality for their residents. 
Regarding our balance sheet metrics. Our Days in Claims Payable was 43.4 days as of March 31, an increase of 0.7 days from the 42.7 days as of December 31, 2015. The increase was primarily due to the timing of claims payments driven by the new membership that came online during the quarter. As previously discussed, we expect Days in Claims Payable to come back down closer to 40 over time. 
Our debt-to-capital ratio was 40.2% at March 31, 2016, down 60 basis points from the 40.8% as of December 31, which reflects the impact of an increase in shareholder equity and the reduction of our outstanding balance in the commercial paper during the quarter. 
We ended the first quarter with approximately $2.2 billion of cash and investments at the parent company. And our investment portfolio was in an unrealized gain position of approximately $639 million as of March 31. For the 3Rs related to the 2015 and 2016 benefit years, we continue to book reinsurance as appropriate and continue to reflect a net payable position for risk adjusters and a net neutral position for risk corridors. We continue to record a valuation allowance against the risk corridor receivables in certain markets as we do not believe those receivables will ultimately be collected. We believe our estimates are prudent given the dynamic nature of available information. 
Turning to our financial outlook. We have increased our operating revenue expectation for 2016 by $1 billion to between $81 billion and $82 billion. This increase reflects higher projected membership due to the strong enrollment results seen through the first quarter, as we've discussed. Fully insured membership is now expected to be approximately 14.9 million members at the midpoint of our range at year-end, 250,000 higher than our previous outlook, which reflects stronger than previously expected results in the individual and Medicaid businesses. Self-funded membership is now expected to be approximately 24.5 million members at the midpoint of our range at year-end, also 250,000 higher than our previous outlook. Taken together, we now project our total membership to be approximately 700,000 to 900,000 lives higher than we ended in 2015. We continue to expect our 2016 medical loss ratio to be 83.6%, plus or minus 30 basis points, and now expect our SG&A ratio to be 15.5%, plus or minus 30 basis points, on a GAAP basis, which includes the impact of Cigna-related transaction cost incurred during the first quarter of 2016. We continue to expect 2016 Local Group medical cost trends to be in the range of 7% to 7.5%. We're encouraged with first quarter operating cash flow, and we continue to project operating cash flows to be greater than $3 billion in 2016. 
Regarding capital deployment. We raised our dividend during the first quarter by $0.025 per share and declared our second quarter dividend of $0.65 per share. This represents an annualized dividend of $2.60 per share and continues our track record of increasing our dividend every year since it was implemented in 2011. 
Our 2016 outlook does include some benefit from the impact of capital deployment activities throughout the remainder of the year. While we did not repurchase any shares through the first quarter, we plan to resume our capital deployment program, subject to market conditions, albeit at a lower level than in recent years. 
To conclude, our 2016 earnings per share outlook is greater than $9.65 on a GAAP basis and our adjusted earnings per share outlook is greater than $10.80. Our outlook continues to take an appropriately conservative posture around the expected financial performance on the public exchanges and the expected year-over-year margin compression in the Medicaid business. Our outlook does not include the adoption of new accounting guidance related to employee share-based payments, which we expect to implement in 2017. For context, we estimate the impact in the first quarter of 2016 would have been a benefit to GAAP and adjusted earnings per share of approximately $0.10. Our outlook does include an adverse impact of $0.03 for the additional assessment in 2016 associated with the State of Colorado dissolution of their co-op. It's also important to note that our 2016 outlook does not include any additional benefits or transaction costs associated with the pending acquisition of Cigna beyond those incurred in the first quarter of 2016. We continue to expect this acquisition will close in the second half of this year. It also does not include any benefit from lower pharmaceutical pricing, which we continue to believe we are entitled to under our current contract with ESI. 
With that, operator, please open the queue for questions."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","[Operator Instructions] And our first question will come from the line of A.J. Rice with UBS.",16,"[Operator Instructions] And our first question will come from the line of A.J. Rice with UBS."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I figure I might as well just jump in on the public exchanges and ask you a broad question there, and 3 parts to it, I guess. Obviously, you had good enrollment this open enrollment season. Can you give us any thoughts on the -- what you know so far about",132,"I figure I might as well just jump in on the public exchanges and ask you a broad question there, and 3 parts to it, I guess. Obviously, you had good enrollment this open enrollment season. Can you give us any thoughts on the -- what you know so far about the risk profile of those sign-ups and how you feel about that? And second, I know, last year, your issue really wasn't in terms of dip in profitability on exchanges and the MLR issue was rather a G&A issue, and you've made some adjustments there. Can you sort of update us on what you did there? And then finally, on the exchanges, the 2017 early outlook in light of some of the commentary from some of the others in the sector."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Great. A.J., thanks for the question. Good morning. It's Joe. First of all, let me just tell you that we're really pleased overall with how our team has been able to navigate a very challenging landscape that has evolved over the last couple of years. As",567,"Great. A.J., thanks for the question. Good morning. It's Joe. First of all, let me just tell you that we're really pleased overall with how our team has been able to navigate a very challenging landscape that has evolved over the last couple of years. As I stated in my remarks, we're really glad to now be serving 975,000 members across all of our markets, which I think really highlights an incredibly meaningful value proposition to the customers that have chosen to align with us. Over time, we do believe we're well positioned for continued growth in the exchange marketplace if the market stabilizes to a more sustainable level, I think that is a key consideration. Clearly, the performance of the exchange marketplaces lagged expectations throughout the industry, as some of our peers have recognized. And in consideration of that, we are monitoring the market very closely to see that our offerings continue to be: number one, very rational, sustainable for the customers, but also it is built on a platform that is constructed appropriately with respect to costs that need to drive our presence in that market. Again, at a very sustainable and appropriate level. We -- I think it's really critical for me to underscore that we are actively engaged with our government partners to help build that long-term sustainable model that we believe will ultimately create an affordable marketplace. And in doing so, we believe we can continue to develop the kind of rate structure in the marketplace that's adequate for us and appropriate in terms of affordability for members. And for example, I think the elimination of the health insurer fee in 2014 sets the stage nicely as we move into that new year with respect to a rate picture. And I think our combination with Cigna is going to present a meaningful improvement in affordability for our membership. So I think, put all that together, we're very kind of pleased with how we've performed this year. We think we're engaged in a fairly sustainable platform that has potential for continued growth, again, underscore, as long as the model that we are engaged in in the marketplace is a sustainable model. Let me close my remarks in that regard by saying that, I think there's some really key drivers to building that sustainable, affordable marketplace that I mentioned. Some of the key elements include what has already been put in place for '17, which is the health insurer tax adjustment. And the second thing would be, I think, a careful consideration of updating the risk adjustment model, further consideration of special enrollment period adjustments, and that would narrow the variety and number of special enrollment considerations. And we'd like to be able to begin offering some very innovative product designs in the marketplace. And hopefully, our government partners will be receptive to some of those creative, innovative models. And finally, I'd like to underscore modification of grace period for nonpayment of premiums to prevent abuse. So when you put all that together in a mosaic, I think, maybe a sustainable model can be built, and we will continue to perform in the marketplace in a way that continues to maybe try to achieve the membership that we had originally anticipated back when this effort first began in '14. Wayne, you may want to speak to the MLR question that A.J. put to us."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","So A.J., as Joe addressed kind of at least our views on '17 and beyond, in terms of the membership we received, and I would say we have a slightly higher silver mix, which we think is a generally a positive regarding how we price our book and our product.",176,"So A.J., as Joe addressed kind of at least our views on '17 and beyond, in terms of the membership we received, and I would say we have a slightly higher silver mix, which we think is a generally a positive regarding how we price our book and our product. The age distribution in subsidy-eligible mix is consistent with those expectations. But I would tell you that we've chosen to maintain a conservative posture in Q1 until we see ultimately how this develops. So we've maintained a conservative posture on risk adjusters despite weekly data that would imply that we should be booking more, and we are really now booking to the normal seasonality profitability. You would see in this book in Q1. Because again, I think, from our perspective, we like to see this membership at least get through 2Q to really understand how the book is performing. So from that perspective, we think it's the prudent thing to do. And then as 2Q evolves, we'll give more commentary on how it's actually developing."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. Great. And then maybe just on that part, just expanding. I know you talked about pulling back on your marketing and trimming your G&A directly related to the exchanges. You've had better-than-expected enrollment growth. Did you still pull in on thos",48,"Okay. Great. And then maybe just on that part, just expanding. I know you talked about pulling back on your marketing and trimming your G&A directly related to the exchanges. You've had better-than-expected enrollment growth. Did you still pull in on those expense items on the G&A side?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, we did. And I think, lesson learned last year, '15, is that, we need to really true-up a very nice platform that was appropriately built for the type of market we were dealing with. And quite frankly, I think we really built a very stabilized platfor",109,"Yes, we did. And I think, lesson learned last year, '15, is that, we need to really true-up a very nice platform that was appropriately built for the type of market we were dealing with. And quite frankly, I think we really built a very stabilized platform that helped us move into '16 to capture this kind of uptake in membership based on a cost structure that I think was very appropriately built out for the marketplace. And so our -- quite frankly, our G&A structure, I think, is well under control. It's appropriately sized and well configured for us to continue to grow in this space as appropriate."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Tom Carroll with Stifel.",11,"And our next question will come from Tom Carroll with Stifel."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just quick follow-up on the exchange business. Are you seeing any signs of adverse selection at all? And maybe could you remind us of kind of the items that you're looking for within that book of business? And then secondly, I'd like you to chat a little",109,"Just quick follow-up on the exchange business. Are you seeing any signs of adverse selection at all? And maybe could you remind us of kind of the items that you're looking for within that book of business? And then secondly, I'd like you to chat a little bit about the Medicaid business. Anthem had a great 2015, and you indicated that the Medicaid MLR was likely going to be up and was up during first quarter. Was it in line with your expectations, higher, lower, from what you expected? And I wonder if you could comment also on the Medicaid managed care regs that were out on Monday."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Got it. Maybe I can pick back up where I left off regarding A.J.'s question on risk profile, which I think relates back to your question on what are we seeing in terms of membership capture. It's a little early. I think we're going to continue to dig into",113,"Got it. Maybe I can pick back up where I left off regarding A.J.'s question on risk profile, which I think relates back to your question on what are we seeing in terms of membership capture. It's a little early. I think we're going to continue to dig into the risk profile that we have brought on. And our sense is that probably somewhere in the 2Q range, we're going to be able to get line of sight on risk profile and have more to report to you at the end of 2Q. So it's a little early for us to give you a kind of a line of sight on risk profile."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","So Tom, a couple of other items. So I think, as Joe said, we like what we're seeing in early mix. But ultimately, as this business comes on, we'll see how it really develops in Q2. As you know, a lot of the claims activity always has a little bit of a lag",399,"So Tom, a couple of other items. So I think, as Joe said, we like what we're seeing in early mix. But ultimately, as this business comes on, we'll see how it really develops in Q2. As you know, a lot of the claims activity always has a little bit of a lag when individuals switches to a new carrier. And then ultimately, that reporting time line that occurs with the providers, ultimately to us. So I think in 2Q, we'll get a much better feel. What we want you to be aware of is, one, we're not seeing any early indicators across our broader book on trend or anything that would have us change our overall trend assumptions. Two is, we've maintained a conservative posture going into 2Q around the risk adjuster data and not only for what we believe '15 would true up to be, but what we think the impact would be on '16 in light of this mix. That's not based on just our assumptions, but actually using the updated weekly data we receive as well as some recent CMS data. But as you know, ultimate settlement on those will be very dependent upon who owes the risk adjuster and how that will settle out. So we're going to wait and see how that pans out in 2Q. But I would say, in each of the 3Rs, we've maintained a posture that should give us some contingency if the book doesn't develop as we would've expected. And if it does develop as we would expect, then it would give us some upside going into the second half of this year and into Q2. On the Medicaid front, again no real surprise, it's just a reminder that we had a lot of new markets that we're rolling out. We continue to have that book evolve. As you know, Iowa now starts on April 1 as well. So we would expect to see MLR pressure there in 2Q as well. But consistent with our expectations in new markets that are rolling out and continue to be bullish on the Medicaid top line as well as bottom line. And as we've mentioned previously, we're going to be slow landing those margins down to what we think are more sustainable. And then on the Medicaid regs, no real surprises. We were fine with the new regs, if you will."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Josh Raskin with Barclays.",11,"And our next question will come from Josh Raskin with Barclays."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First question. Just on the 975,000 exchange lives. Could you help us break down how many of those are new to Anthem versus existing, previously managed life last year? And then any sense of how many of the new ones came from other plans versus sort of ne",109,"First question. Just on the 975,000 exchange lives. Could you help us break down how many of those are new to Anthem versus existing, previously managed life last year? And then any sense of how many of the new ones came from other plans versus sort of new to the market? And then the follow-up would just be on the MLR, up 160 bps in the first quarter, but guidance up 30% for the year. What are -- I understand the leap year, but what are some of the deltas? What changes as we sort of progress through the year that would make those year-over-year comparisons look much better?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Let me take a shot at the first question. The -- we just don't know yet, quite frankly, in terms of what carryover membership brought over from '15. Obviously, we're going to learn more about that getting into 2Q. So it's rather simple answer to the",63,"Yes. Let me take a shot at the first question. The -- we just don't know yet, quite frankly, in terms of what carryover membership brought over from '15. Obviously, we're going to learn more about that getting into 2Q. So it's rather simple answer to the question. I wish I had more to give you, but we just don't know this early."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, Josh, a couple of other items we would highlight those, that generally what we've seen, what I would call the unexpected uptake, there has been markets where the co-ops have become insolvent. So I don't think there is a surprise there. I think where",171,"Yes, Josh, a couple of other items we would highlight those, that generally what we've seen, what I would call the unexpected uptake, there has been markets where the co-ops have become insolvent. So I don't think there is a surprise there. I think where we're probably surprised on the uptake, though, has been that we weren't the next lowest-cost carrier. And in many cases, we were substantially higher than the next or several next lowest-cost carriers. So it appears to be a little bit of a flight to safety, if you will, and security. And so again, it's another reason why we want to see how this ultimately pans out our pricing. It's obviously much higher than what the -- would've been available in the market. And so the question will be does that adequately reflect the book that we're inheriting over from the co-ops on that end. Frankly, given how 2015 played out, we want to take a more conservative posture earlier this year and see how that develops."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Great. And you don't know which lives were Anthem members previously and still signed on?",15,"Great. And you don't know which lives were Anthem members previously and still signed on?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","You ultimately get the data, but I would say that, you also have to look at it -- we don't look at it as a single member by state, we look at the broad mix both on and off exchange membership. And so while we have a feel for some of that, at the same time",89,"You ultimately get the data, but I would say that, you also have to look at it -- we don't look at it as a single member by state, we look at the broad mix both on and off exchange membership. And so while we have a feel for some of that, at the same time, I would tell you that the majority of the new membership growth that we're seeing is obviously new to us and it's coming from other organizations. And clearly, it's in the co-op space."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So do you have like a net sales versus a net lapses number or anything like that even if you don't if they're the same?",26,"Okay. So do you have like a net sales versus a net lapses number or anything like that even if you don't if they're the same?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","We do. We do, Josh. But we're obviously not going to disclose that data.",14,"We do. We do, Josh. But we're obviously not going to disclose that data."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then the MLR year-over-year?",6,"Okay. And then the MLR year-over-year?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Ultimately, we show that -- we obviously have the impact of the leap year and new year. The thing to keep in mind though is the premium. As you know, just inherently, the leap year alone, the premium is spread over the entire year, but you're getting a fu",221,"Ultimately, we show that -- we obviously have the impact of the leap year and new year. The thing to keep in mind though is the premium. As you know, just inherently, the leap year alone, the premium is spread over the entire year, but you're getting a full day of claims within the quarter. So clearly, there is a positive effect that happens in the out years as the leap year continues, that's one dynamic. I think another dynamic to keep in mind is that, when we look at our mix shift and how that's evolving, we've actually didn't do the typical seasonality that you would see for individuals. So we've tried to book a little more of an MLR factor in the first quarter, that typically would have been lower, and then you would have a higher in the fourth quarter in this case because of the new membership we're doing a little more, I wouldn't call it straight line, but we're trying to get much more of a upfront view and a conservative posture. So as that develops again, I would basically put it that we're seeing how '15 played out. We're just trying to take a much more conservative posture earlier in the year and then let that hopefully blend its way down as the year progresses."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Gary Taylor with JPMorgan.",11,"And our next question will come from Gary Taylor with JPMorgan."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I just want to follow-up a little bit. And I think, Wayne, your last response kind of gets into my question a little bit. So I'll be brief. But I'd guess I'm trying to understand where the individual enrollment came. You mentioned a few of the states wher",90,"I just want to follow-up a little bit. And I think, Wayne, your last response kind of gets into my question a little bit. So I'll be brief. But I'd guess I'm trying to understand where the individual enrollment came. You mentioned a few of the states where the co-ops were insolvent. I was wondering if there was any more detail you could provide than that, particularly whether some of this enrollment would be in states like California, New York, where I think your experience was better last year?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, Gary, it is. New York is obviously clearly one of the markets where the co-ops struggled. And we did pick up, I would say, more than our market share that we typically have relative to the co-ops. California is another market where we did perform wel",95,"Yes, Gary, it is. New York is obviously clearly one of the markets where the co-ops struggled. And we did pick up, I would say, more than our market share that we typically have relative to the co-ops. California is another market where we did perform well. And in addition, it would be in Colorado and Kentucky, other markets where the co-ops had their difficulties, and we've picked up -- I would say we've picked up more than our market share, so that the membership available with their exits were disproportionately picking up market share."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","As a quick follow, I guess I'm having a little difficulty seeing the degree of conservatism maybe that you're talking about in the book, given that versus the original expectation of individual being down 300,000. You're now up 200,000. Days claims payabl",125,"As a quick follow, I guess I'm having a little difficulty seeing the degree of conservatism maybe that you're talking about in the book, given that versus the original expectation of individual being down 300,000. You're now up 200,000. Days claims payable down a couple of days year-over-year. The commercial operating margin was up 10 basis points even though you booked some additional MLR in the individual business. Is the response to that just that this individual seasonality is so skewed to the front end versus the fourth quarter that -- you still have some modest margin gain year-over-year even though you're booking the traditionally MLR in the individual book? Does that maybe just -- the range or seasonality, maybe I'm just not appreciating enough?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. So Gary, yes. That's one dynamic. Second one is sequentially DCP is actually up since year-end. And as we said, year-end did develop favorable to our expectations. I want to emphasize that develop favorable and DCP is up sequentially. Two is, I think",139,"Yes. So Gary, yes. That's one dynamic. Second one is sequentially DCP is actually up since year-end. And as we said, year-end did develop favorable to our expectations. I want to emphasize that develop favorable and DCP is up sequentially. Two is, I think it's important to recognize it on the 3Rs, the data would imply that we have been conservative on 2015. And so we've neither recognized that conservatism yet. And in addition to that, it would also imply in a run rate that we would have available to us in 2016 based on that data, and again we've not recognized that as well. And it's important to recognize that the 3Rs are not part of DCP, so you won't necessarily get to see that add a conservatism that we are carrying into Q2 as we move forward."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And would you ever disclose 3Rs? Will we ever get that from you?",13,"And would you ever disclose 3Rs? Will we ever get that from you?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Most likely not, but I will tell you that in 2Q, we will give you a gauge, though, of how it maybe benefit us more broadly in terms of the pieces. I think the thing I want to highlight for the group, though, is the reason we're being cautious on 3Rs, in p",150,"Most likely not, but I will tell you that in 2Q, we will give you a gauge, though, of how it maybe benefit us more broadly in terms of the pieces. I think the thing I want to highlight for the group, though, is the reason we're being cautious on 3Rs, in particular, risk adjusters, which would imply that we would have a nice receivable related to '15 as well as some run rate into '16 is, the question is, some of the risk corridor, who ultimately is going to pay that. And if the receivables due from a co-op, ultimately, we don't want to recognize that unless we know the co-ops have a financial wherewithal to pay those receivables. And so this is just one of many factors that we believe warrants being conservative until we see final settlements and then how those dollars are actually transferred between companies."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Peter Costa with Wells Fargo Securities.",13,"And our next question will come from Peter Costa with Wells Fargo Securities."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I'll move away from the individual exchanges for a minute and take you to the PBM, the contract dispute with Express. Can you talk, not about what you're going to do, but how would you bring it in-house specifically, if that was the direction this ends up",140,"I'll move away from the individual exchanges for a minute and take you to the PBM, the contract dispute with Express. Can you talk, not about what you're going to do, but how would you bring it in-house specifically, if that was the direction this ends up? Give us some idea of sort of the time frame it would take from when you have to start planning it as well as what sort of options would you use in terms of perhaps using some of the other PBMs or even Express by buying next [indiscernible] back or something like that, to actually manage it given that you don't have the assets anymore to run a PBM? Can you talk about that a little bit and specifically how that would work if you were to try to bring it in-house?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Peter, interesting question. I think it strikes at one of our various options and just kind to help us all recall where we started this journey. We talked a lot about optionality and recognize that we had some choices ahead of us, one, bring it in-ho",298,"Yes. Peter, interesting question. I think it strikes at one of our various options and just kind to help us all recall where we started this journey. We talked a lot about optionality and recognize that we had some choices ahead of us, one, bring it in-house, as you've just described, another would be to recast our agreement with ESI. Another would be to go to another vendor, et cetera. So we're considering a full range of options. I think, first, I need to preface my remarks by underscoring that we've got probably a couple of years at a minimum before we need to make that call. And quite frankly, these considerations are -- we're actively involved in some sort of the various pluses and minuses of each options. So it's really too early for us to comment on specificity. And I think that to your point about bringing it in-house, recognize it's a complex process to do so. It does have costs associated with it. We recognize that. But again, let me underscore, it's not a decision that is imminent. We have, call it, a journey that we have to administer with respect to our ongoing negotiations with ESI regarding our position that we stated to them clearly and now taken the form of a lawsuit. So I direct you to that with respect to the specificity around our engagement with them at this stage. But optionality, again I want to underscore, we are in the development mode on our choices. But none of those choices do we have to exercise in any way of an imminent nature, and so I'd prefer just to kind of maybe delay a response to some future date when that is more of an imminent necessity for us to deal with."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And can you talk about sort of the expected savings if you were to bring it in-house? What would that look like relative to the $3 billion that you're seeking from Express on a contract renegotiation?",37,"Okay. And can you talk about sort of the expected savings if you were to bring it in-house? What would that look like relative to the $3 billion that you're seeking from Express on a contract renegotiation?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. As I said, I think certainly a lot of analytics will go into discerning savings. We haven't actually gone into the depths of administratively how you build it and the cost associated with building it, that then translates into savings. Again, let me",95,"Yes. As I said, I think certainly a lot of analytics will go into discerning savings. We haven't actually gone into the depths of administratively how you build it and the cost associated with building it, that then translates into savings. Again, let me restate, emphatically, that it's too early for us to weigh in on that. And at some future moment in time where it is appropriate, we'll certainly bring that to your attention. It's just too early now to give you clear line of sight on savings for an option of that nature."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question will come from Dave Windley with Jefferies.",10,"Your next question will come from Dave Windley with Jefferies."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And I wanted to go back to Medicaid. First part of the question would be, was the higher MLR and Medicaid a function of just the lower rates that you've anticipated? Or were there other factors like flu, perhaps or population mix acuity of the mix or even",119,"And I wanted to go back to Medicaid. First part of the question would be, was the higher MLR and Medicaid a function of just the lower rates that you've anticipated? Or were there other factors like flu, perhaps or population mix acuity of the mix or even rising trend in Medicaid that impacted MLR there? And then second part would be, as we look to the second quarter and the start of Iowa, some of your peers, at least one, I think has established -- have established reserves in 2015 in anticipation of pretty significant pressure from Iowa. How should we think about the progression of Medicaid margin into 2Q and the rest of the year for Iowa?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Dave, good morning. Let me first start with Medicaid. Yes, a significant portion of what you saw in the MLR is a function of what we've been talking around the rate pressure and those rates coming down. I think our outlook for the year on the Medicaid tea",292,"Dave, good morning. Let me first start with Medicaid. Yes, a significant portion of what you saw in the MLR is a function of what we've been talking around the rate pressure and those rates coming down. I think our outlook for the year on the Medicaid team continues to be consistent with the outlook that we gave when we give guidance initially, and we expect to be at our MLR and trends playing within the levels that we have fully expected within the book. So no real surprises there. Relative to Iowa, as you know, we did not book a PDR. We typically expect to have a higher MLR and to lose money early on when the programs rolled out. And then ultimately, the PR requires you to look over the life of the contract, and we clearly expect it to be a profitability over the life of the contract, which is why we don't have a PDR booked on it. But because the contract was delayed, obviously, the MLR will reflect that 9 months of activity instead of 10 months, which means that your MLR will be a little bit pressured in the current year, but only by an additional month. The fact that it was delayed by a month will create a little bit of pressure this year. But obviously, we expect that to come down next year. But while we weren't necessarily pleased with membership been delayed in the revenue impact, we actually think that additional month probably played well for the industry in terms of getting into contracts, finalizing its networks, finalize in a manner that hopefully can make this a very strong, profitable book consistent with our historical margins. So we remain optimistic on the program."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Kevin Fischbeck with Bank of America.",13,"And our next question will come from Kevin Fischbeck with Bank of America."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just wanted to dig into guidance a little bit. You beat consensus expectations for Q1 pretty nicely, particularly on the G&A side, but you didn't raise guidance for the year. In fact, you took your G&A number up and kept your MLR stable even though you se",98,"Just wanted to dig into guidance a little bit. You beat consensus expectations for Q1 pretty nicely, particularly on the G&A side, but you didn't raise guidance for the year. In fact, you took your G&A number up and kept your MLR stable even though you seem to be talking about pressure on the MLR on the individual said, at least from a mix perspective. Can you talk a little bit about why the puts and takes ended up the way that they were? And why we didn't see upward pressure on MLR and downward pressure on G&A?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Let me address a few things. One is, I want to highlight again that if we look clearly at Q1 and the results, it would imply that we should have had a raise, which I think is a very valid question that you're asking. I can't emphasize enough that we",303,"Yes. Let me address a few things. One is, I want to highlight again that if we look clearly at Q1 and the results, it would imply that we should have had a raise, which I think is a very valid question that you're asking. I can't emphasize enough that we are very pleased with all the metrics in Q1. But with those metrics, we really thought it was best to maintain a lot of conservatism that we could have otherwise potentially released in Q1 until we see how this book evolves into Q2. I think it's fair to say that the industry last year, and ourselves included, got to see a lot more of how things developed as last year progressed. So we're just taking a much more conservative posture till we see more development. The second thing I would highlight again is, we did highlight that we are covering another $0.03 of assessments from co-ops and maintaining that guidance as well. And then last thing I would say is that, in terms of the metrics, we like our G&A where it's at. And we think with this additional membership, this is the G&A leverage we should have gotten a year ago with exchanges. As you know, it was a deleverage impact to us a year ago. This year, it's going to  be a leverageble impact. And so we're holding a line on G&A. And we again -- if the membership plays out with the risk profile we would expect, then that G&A leverage helps improve the margins. If it doesn't, then the G&A leverage helps offset any surprises. So I'd love to give you a different answer. But I mean, the reality is, we just chose to be conservative in Q1 until we can see how this book of business evolves."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then as you mentioned on the small group business that you saw some pressure, particularly in the states that expanded the -- to 51 to 100, what percent of your small group business is in the states?",39,"Okay. And then as you mentioned on the small group business that you saw some pressure, particularly in the states that expanded the -- to 51 to 100, what percent of your small group business is in the states?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. It's actually a decent amount, and I would say it was primarily in California. As you know, California was one of the states that made a decision, as did New York and Colorado. So if you're looking at what I'd call your typical market that would be t",144,"Yes. It's actually a decent amount, and I would say it was primarily in California. As you know, California was one of the states that made a decision, as did New York and Colorado. So if you're looking at what I'd call your typical market that would be the most significant for us, it's California of that group. And as a result, not only did your historical small group products no longer be allowed to persist, but you actually had to reintroduce all new products and reconsider the product mix of what it would look like as they went to a different direction from what was defined as a small group. So we're not happy about the membership we lost in those markets, but we also recognize that not every state adopted the flexibility that was offered to them under the Affordable Care Act."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Do you think that that's -- the more states are going end up doing that [indiscernible] headwind we would expect to see next year in more states? Or if you were going to do it, you would have done it by now?",43,"Do you think that that's -- the more states are going end up doing that [indiscernible] headwind we would expect to see next year in more states? Or if you were going to do it, you would have done it by now?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, I think if you were going to do it, you would've have done it by now. The other states have actually gone and maintained the historical small group definition. So I think that's behind us now.",37,"Yes, I think if you were going to do it, you would've have done it by now. The other states have actually gone and maintained the historical small group definition. So I think that's behind us now."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Ralph Giacobbe with Citigroup.",11,"And our next question will come from Ralph Giacobbe with Citigroup."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just wanted to go back to the exchanges. I guess, last quarter, you had mentioned that the exchange book was breakeven for 2015. And as you've talked about, you expected to pull G&A and bring it back to sort of profitable levels. Obviously, you've done be",84,"Just wanted to go back to the exchanges. I guess, last quarter, you had mentioned that the exchange book was breakeven for 2015. And as you've talked about, you expected to pull G&A and bring it back to sort of profitable levels. Obviously, you've done better on the enrollment side. So I guess you have talked about your conservatism. Can you help us in terms of what margins are assumed at this point for the exchange or maybe what's embedded in guidance for 2016?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Ralph, yes, in essence, I would tell you, as we said before, our targeted margins are 3% to 5%. And when we built our plan for this year, we were targeting lower than that threshold. We have not adjusted that targeted margins. So my point is that to the e",118,"Ralph, yes, in essence, I would tell you, as we said before, our targeted margins are 3% to 5%. And when we built our plan for this year, we were targeting lower than that threshold. We have not adjusted that targeted margins. So my point is that to the extent this mentorship does have the risk profile we have, you should expect a better margin as a result of the G&A leverage play. And to the extent that those 3Rs, in fact, not only settle up as we've been notified to date between weekly and CMS, but actually cash flow as well between the parties that have to settle up, then you could expect margin expansion as well."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So I guess I just want to go back to the disconnect to the lack of guidance raised. If the assumption is to make still, let's call it, 1% to 2% margin or whatever that numbers is on the exchange on a bigger book, maybe to help level set, can you giv",75,"Okay. So I guess I just want to go back to the disconnect to the lack of guidance raised. If the assumption is to make still, let's call it, 1% to 2% margin or whatever that numbers is on the exchange on a bigger book, maybe to help level set, can you give us any sense at all of what you booked for 1Q in terms of sort of a comparable margin on the exchange?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","As you know, historically, when you have an individual member, you're very profitable in Q1, that profitability then declines down to ultimately a loss in Q4. What I would say is that, from our perspective, we've chosen not to take that profitability in i",90,"As you know, historically, when you have an individual member, you're very profitable in Q1, that profitability then declines down to ultimately a loss in Q4. What I would say is that, from our perspective, we've chosen not to take that profitability in in Q1, but rather book to a breakeven perspective and then see how this book evolves in Q2 and thereafter. So to the extent that it evolves positively, then you'll get the margin improvement both from Q1 as well as in the run rate for the year."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. All right. That's helpful. And then I think it was asked earlier, but I don't think we got to sort of the answer around how you're positioning for 2017. Are there new states or territory that you're going to want to enter? And maybe a sense -- I kno",93,"Okay. All right. That's helpful. And then I think it was asked earlier, but I don't think we got to sort of the answer around how you're positioning for 2017. Are there new states or territory that you're going to want to enter? And maybe a sense -- I know it's early at this point, but when we think about target margins, you talked about 3% to 5%, is 2017 sort of an area where you expect to get there, get closer to there? Any just general commentary around that will be helpful."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","We're not targeting on a stand-alone basis in any new markets outside of our 14 states. I think our goal is to continue to stabilize the market in those states and start trending towards our targeted 3% to 5% margin. I would not anticipate, at this point",149,"We're not targeting on a stand-alone basis in any new markets outside of our 14 states. I think our goal is to continue to stabilize the market in those states and start trending towards our targeted 3% to 5% margin. I would not anticipate, at this point in time, that in '17 we would necessarily achieve that level of margin. But nonetheless, there has been a lot of activity around the regulations and ways to improve and create more stability. So we'll see. And to be fair, it's a little bit early in the pricing cycle. So we ultimately need to see how pricing evolves and what the states will ultimately approve in the pricing cycle and whether or not we can get there as early as '17. But right now, I'd be more cautious on getting there in '17, and view it more as an '18 play."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, I think the question is interesting the way you put it about expanding to other states, I mean, obviously, [indiscernible] precluded because of our Blue Cross Blue Shield presence in our 14 states and really think we should underscore the value we br",187,"Yes, I think the question is interesting the way you put it about expanding to other states, I mean, obviously, [indiscernible] precluded because of our Blue Cross Blue Shield presence in our 14 states and really think we should underscore the value we bring to our markets, our brand legacy, incredibly well known with respect to quality, as well as affordability. And to Wayne's earlier point, we have witnessed and we really do believe this flight to safety is real. And I think flight to safety is very relevant, with respect to how folks are connecting back to us in terms of a known brand. I think we're going to really seek the leverage that more effectively in every market that we're serving. And the last point I'll make I think is very -- both underscores that Cigna will help us with future expansion beyond our 14 states. So that's a story that's not yet told. And when it becomes clear that we can, we will express ourselves probably in more depth in terms of the potential to expand to other markets relative to the public exchanges."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And the next question will come from Chris Rigg with Susquehanna Financial.",12,"And the next question will come from Chris Rigg with Susquehanna Financial."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Apologize if I missed this. But did you guys say what you're now assuming for the reinsurance, coinsurance rate? I know at 4Q, you said a little above 50%. There's some data from CMS, which suggest it could be more like 60% to 65%. Just want to get a sens",63,"Apologize if I missed this. But did you guys say what you're now assuming for the reinsurance, coinsurance rate? I know at 4Q, you said a little above 50%. There's some data from CMS, which suggest it could be more like 60% to 65%. Just want to get a sense for what you're assuming now and whether that's had an impact on guidance?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Chris, thanks for the question. So we continue to assume a little bit north of 50%. I would tell you that if the CMS data of 60% to 65% goes forward, we will have sizable upside relative to those percentages. We're not so sure it will evolve ultimately to",199,"Chris, thanks for the question. So we continue to assume a little bit north of 50%. I would tell you that if the CMS data of 60% to 65% goes forward, we will have sizable upside relative to those percentages. We're not so sure it will evolve ultimately to that level. But based on the most recent data that's been submitted as well as the weekly data we received on this, we are at a number below what the data would imply, that's what I would say and should have some conservatism going into 2Q and beyond. But again, we want to see ultimate settlement. As a reminder, on risk corridors, we continue to maintain a 100% valuation allowance against any receivables. And I would tell you the more sizable upside ultimately, will be on the risk adjusters, if what we've seen in early data related to '15 and '16 is, in fact, holds true into 2Q. And again, if, in fact, it's monetized by the parties that owe it. So I would say all 3 areas represent potential upside, the corridor being the least of -- we just don't see the money in the kitty to fund those."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And we'll go to the line of Matthew Borsch with Goldman Sachs.",13,"And we'll go to the line of Matthew Borsch with Goldman Sachs."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I was hoping that you could give us some -- your assessment on the group commercial side. The decline of -- I think it was 245,000 lives in the quarter was in line with what you had guided to. Can you -- I know, you referred to some states where they expa",110,"I was hoping that you could give us some -- your assessment on the group commercial side. The decline of -- I think it was 245,000 lives in the quarter was in line with what you had guided to. Can you -- I know, you referred to some states where they expanded the definition of small group, and that was a factor. I assume that there's some ASO conversions. Did some of that also reflect a conservative pricing posture? I mean, I know you always try to be conservative, but -- have you needed to be more conservative in the current pricing environment? If you could just talk to that."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Matt, yes, let me first start by saying well, it has some conversions from fully insured to ASO. And I think clearly you can see that and how strong our ASO book has done, and not just in National, but in the Large Group business as well. I think it's fai",156,"Matt, yes, let me first start by saying well, it has some conversions from fully insured to ASO. And I think clearly you can see that and how strong our ASO book has done, and not just in National, but in the Large Group business as well. I think it's fair to say that, at least half of it though represents those markets that did the switch with the majority of that being in California. And I would say we've maintained our pricing discipline in California. And it seems that most of that membership went to a single carrier, primarily a not-for-profit carrier that we think priced fairly aggressively. And again from our perspective, we'll weather that storm as we have in the past, and hopefully win those members back in the next year or so. But that's -- I'd say it's about 50-50 split, and then of the 50 that truly left, it's primarily California."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","That's very helpful. And also, if I could ask, what is approximately the amount by which you need to increase price going into 2017 to reflect the lack of reinsurance? And how much of a problem is that going to be for exacerbating some adverse selection t",58,"That's very helpful. And also, if I could ask, what is approximately the amount by which you need to increase price going into 2017 to reflect the lack of reinsurance? And how much of a problem is that going to be for exacerbating some adverse selection that's already a program-wide problem to some degree in the exchanges?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Matt, well, we generally haven't given all the specifics and pricing. I think the reinsurance is one that mathematically people can generally back into a range in the 5% to 6% range of what it could impact on upward pricing by itself. And so I would say t",157,"Matt, well, we generally haven't given all the specifics and pricing. I think the reinsurance is one that mathematically people can generally back into a range in the 5% to 6% range of what it could impact on upward pricing by itself. And so I would say that that 5% to 6% range that we've had others ask about is a reasonable proxy of what you should expect for the piece of reinsurance that would run off. Relative to all other pricing, we're not necessarily talking to specifics, we're just in the process now of filing with our states. But this is clearly one area where we're spending time, making sure everybody is educated on. And I would tell you insurance regulators understand it, they get it, and they understand the implications of it. And so for competitive reasons, I would like to probably not discuss any further though our rate filings or actions at this point."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And we'll go to the line of Ana Gupte with Leerink Partners.",13,"And we'll go to the line of Ana Gupte with Leerink Partners."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Again following up on the commercial book, but now taking a view is [ph] 2017, there is a 2% gain in your commercial businesses and also its a mismatch of those things, but as you're looking into '17...",38,"Again following up on the commercial book, but now taking a view is [ph] 2017, there is a 2% gain in your commercial businesses and also its a mismatch of those things, but as you're looking into '17..."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Ana, can you start your question over? We're having trouble hearing you.",12,"Ana, can you start your question over? We're having trouble hearing you."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Yes, I was asking about the trend. Is this better?",10,"Yes, I was asking about the trend. Is this better?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","I'm sorry. You're cutting in and out. It's very difficult to hear you.",14,"I'm sorry. You're cutting in and out. It's very difficult to hear you."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Better now?",2,"Better now?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","A little bit, yes. Please try again.",7,"A little bit, yes. Please try again."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So I was asking about the 2017 commercial outlook and whether or not as you look into 2017, we're likely to see a better operating gain growth rate because the not-for-profit Blues [indiscernible] everywhere, they're all losing money on exchanges an",72,"Okay. So I was asking about the 2017 commercial outlook and whether or not as you look into 2017, we're likely to see a better operating gain growth rate because the not-for-profit Blues [indiscernible] everywhere, they're all losing money on exchanges and I know you don't overlap directly with the Blues. But as you think about Cigna and the post-Cigna world, is the pricing and underwriting spread will get better into 2017?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, I would say our -- well, we haven't given '17 outlook yet. And as you can imagine, well, I first want to see how '16 develops. But what I would highlight is that, we would expect to see the margins begin to trend to the more sustainable levels of 3%",204,"Well, I would say our -- well, we haven't given '17 outlook yet. And as you can imagine, well, I first want to see how '16 develops. But what I would highlight is that, we would expect to see the margins begin to trend to the more sustainable levels of 3% to 5%, I don't think again we'll be there by '17. But ultimately, it seems that the environment is starting to recognize the true cost of operating the exchanges in the membership that resides with it. These are large risk pools. So I think the industry is getting to the point where they have enough data to support the pricing that belongs with it. And we think that our job now is to continue to educate our regulators on the risk profile of the polls, actions we can take to help drive the costs down for affordability. And at the same time, though, to the extent that we're limited on actions, to make sure people understand in the pricing that goes with it. So I think for '17, it would -- today as best we can say it would be our expectation that [ph] marks would improve and pricing would continue to improve."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Are we talking about exchanges or commercial? I was talking about the group that's -- and the spread between trend and pricing, more sort of, is it likely to be a silver lining on the cloud just because companies are losing money on exchanges so they beco",53,"Are we talking about exchanges or commercial? I was talking about the group that's -- and the spread between trend and pricing, more sort of, is it likely to be a silver lining on the cloud just because companies are losing money on exchanges so they become more conservative on the commercial pricing?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's hard to know what others may do in their pricing. Clearly, in California, we did not see a player who we know lost money on exchanges necessarily take a more rational pricing on their small group book. So I guess what I would say is, we've seen one m",137,"It's hard to know what others may do in their pricing. Clearly, in California, we did not see a player who we know lost money on exchanges necessarily take a more rational pricing on their small group book. So I guess what I would say is, we've seen one market and then one competitor, you've seen one market and one competitor, so it's hard for us to understand. I think I would say is, this is -- our philosophy is, we've got to cover our cost of capital. We've got to give our shareholders a fair return for the risk that we bear and we price accordingly and then we'll just have to weather the markets, whatever they bring in in the short-term as we did on the public exchanges in the last couple of years."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And then finally on the 51 to 100. Once you get past that headwind, is there a reduced tendency toward dumping some employers because exchanges haven't been as stable and there's a lot of volatility there?",36,"And then finally on the 51 to 100. Once you get past that headwind, is there a reduced tendency toward dumping some employers because exchanges haven't been as stable and there's a lot of volatility there?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","We think there is. I mean I think it seems like the dumping factor has really moved down and I think this was kind of the last clarification of product description and size under ACA that had to be implemented. So yes, I think from our perspective we view",73,"We think there is. I mean I think it seems like the dumping factor has really moved down and I think this was kind of the last clarification of product description and size under ACA that had to be implemented. So yes, I think from our perspective we view it as kind of stability. And I would say internally, we're targeting actually and trying to get back to small group growth again, now."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And we'll go to the last question here. It will come from Scott Fidel with Crdit Suisse.",18,"And we'll go to the last question here. It will come from Scott Fidel with Crdit Suisse."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just had a question on cost trends overall. And just interested, just within the guidance range that you talked about, how trend maybe behaving within that range in the first quarter? United, I talked about seeing a bit of an uplift in cost trend in the f",77,"Just had a question on cost trends overall. And just interested, just within the guidance range that you talked about, how trend maybe behaving within that range in the first quarter? United, I talked about seeing a bit of an uplift in cost trend in the first quarter maybe around 50 basis points. And then just also just specifically, whether you've been seeing an increase in surgical volumes year-over-year in the first quarter relative to last year?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Scott, thanks for the question. Yes -- well, first of all, it's important we recognize that we had assumed the trends would move up this year, as you know when we finished last year versus to what we guided to this year. So the trends have moved up, but w",265,"Scott, thanks for the question. Yes -- well, first of all, it's important we recognize that we had assumed the trends would move up this year, as you know when we finished last year versus to what we guided to this year. So the trends have moved up, but within our expectations and our pricing. As we look at various factors, I think we would've said early on that trend might have been favorably impacted by the flu. But the fact that the late season happened ultimately, we think for the full year that, that won't have a positive upside to us nor a downside, we think flu is going to play probably within our expectations. We did expect a fairly sizable uptick in trend in Q1 regarding really hep C. And we saw that, which is good and the good news is at least on a rolling 3-month average we looked at it, it seems to be playing right in line with our expectations, slightly better than our expectations, but I would tell you that we're not going to bank that yet because we think there maybe some warehousing because there is new geno-type drugs that are coming out that people may be holding off on until those are available. So I think ultimately, when I look at what could be the big surprise items like a hep C or a flu or other items, everything seems to be playing pretty well relative to our expectations. And where we did expect it to be high in the quarter, it was, but within our pricing."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Scott, it's Joe. I think probably it's fair to also comment on a lot of what you can't see regarding the internal activity of the company, where we're obviously vigilant regarding trend changes. Internally, we're building really a robust provider collabor",133,"Scott, it's Joe. I think probably it's fair to also comment on a lot of what you can't see regarding the internal activity of the company, where we're obviously vigilant regarding trend changes. Internally, we're building really a robust provider collaboration models, really driven towards value-based contracting, that then tries to ameliorate the risk of trend escalation. Our data analytics infrastructure has been a remarkable uplift to the company with respect to our investments and the result and insights that we've captured in order to better manage the cost of care. So there's kind of the macro level that you see. But the micro level within the company, it's amazing how well we positioned ourselves to really address the kind of the prevailing winds that come at us in and around trend changes."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Got it. And then just on the surgical vials, are you able to tease out whether -- what you saw year-over-year there? Is it still a little bit too early to tell?",32,"Got it. And then just on the surgical vials, are you able to tease out whether -- what you saw year-over-year there? Is it still a little bit too early to tell?"
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's a little early. I mean we obviously look for different areas that might spike. I mean we see a little bit more there. But again relative to expectations, I think things are playing okay. So nothing of any specificity that I can provide at this point.",48,"It's a little early. I mean we obviously look for different areas that might spike. I mean we see a little bit more there. But again relative to expectations, I think things are playing okay. So nothing of any specificity that I can provide at this point."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Let me just kind of express the thanks to all of you for your questions. In summary, I'm pleased with our first quarter results and believe that these results position us very well for the remainder of the year. Hopefully, you got a sense of that with res",171,"Let me just kind of express the thanks to all of you for your questions. In summary, I'm pleased with our first quarter results and believe that these results position us very well for the remainder of the year. Hopefully, you got a sense of that with respect to our commentaries today. We do remain committed to increasing access to high-quality affordable health care. Specifically, we believe our ability to serve our customers will be advanced by the pending acquisition of Cigna, which we still remain of the belief that it is expected to close in the second half of 2016. And also, this includes our continued focus on improving matters like drug pricing. The -- I also want to thank all of our associates for their continued commitment to serving our nearly 40 million members, and I'd like to also again thank all of you on the call for your interest in Anthem and look forward to speaking with you soon. Again, thank you very much. Have a great day."
160077,308029053,964274,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And ladies and gentlemen, this conference will be available for replay after 11:00 this morning and running through Wednesday, May 11 at midnight. You can access the AT&T Executive Playback service by dialing 1 (800) 475-6701 and entering the access code",71,"And ladies and gentlemen, this conference will be available for replay after 11:00 this morning and running through Wednesday, May 11 at midnight. You can access the AT&T Executive Playback service by dialing 1 (800) 475-6701 and entering the access code 378816. International parties may dial 1 (320) 365-3844. That does conclude our conference for today. Thanks for your participation and for using AT&T executive teleconference service. You may now disconnect."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management.",38,"Ladies and gentlemen, thank you for standing by, and welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Good morning, and welcome to Anthem's First Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and Wayne DeVeydt, our CFO. Joe will offer an overview o",183,"Good morning, and welcome to Anthem's First Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and Wayne DeVeydt, our CFO. Joe will offer an overview of our first quarter 2016 financial results and will walk through the financials and provide some incremental commentary on our updated 2016 outlook. We are then available for Q&A. 
During the call, we will reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website at antheminc.com. 
We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Anthem. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in today's press release and in our quarterly and annual filings with the SEC. 
I will now turn the call over to Joe."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Doug, and good morning. We're pleased to announce first quarter of 2016 adjusted earnings per share of $3.46, with membership tracking above our previous expectations. On a GAAP basis, we reported earnings per share of $2.63. I'm pleased with o",1919,"Thank you, Doug, and good morning. We're pleased to announce first quarter of 2016 adjusted earnings per share of $3.46, with membership tracking above our previous expectations. On a GAAP basis, we reported earnings per share of $2.63. I'm pleased with our first quarter results, which represent a solid start to 2016 as the company continues to benefit from the growing diversification of our businesses. The complementary nature of our pending Cigna acquisition will allow us to further advance affordability and quality for our members. 
I'm going to start with some overview comments on our first quarter 2016 results, and then we'll discuss a few of the key details of our updated 2016 outlook. First quarter results reflect business performance that tracked well versus our expectations. Specifically, membership is exceeding our expectations, and we reported strong quality of earnings metrics while maintaining appropriate conservativism on our balance sheets to reflect the dynamic nature of the marketplace that exists today. 
Within membership, both fully insured and self-funded membership are tracking ahead of expectations. And we ended the first quarter with 39.6 million members, reflecting growth of 1 million lives or 2.6% since year-end 2015. Specifically, we ended the quarter with 975,000 lives from the individual public exchanges, an increase of 184,000 from year-end 2015 and ahead of our initial expectations. Our self-funded business grew by 906,000 lives or 3.8% in the quarter to 24.6 million members, which was also ahead of our expectations as the company experienced higher-than-expected in-group change in current contracts and BlueCard enrollment. Our Local Group insured enrollment declined by just north of 200,000 lives in the quarter and serves approximately 4 million members as of March 31. In particular, we saw higher-than-expected lapses in plans residing in states that transitioned the 51 to 99 key group size into the small group marketplace. 
Operating revenue was $20.3 billion in the first quarter of 2016, an increase of $1.5 billion or 7.7% versus the first quarter of 2015, reflecting strong enrollment growth in the Government Business and additional premium revenue to cover overall cost trends. Also contributing was the growth in administrative fee revenue as a result of our strong self-funded membership trends. This was partially offset by fully insured membership losses in our Commercial business. 
The first quarter 2016 benefit expense ratio was 81.8%, which increased versus prior year, as expected. The 160 basis point increase reflected the impact of an extra calendar day during the quarter from the leap year, a higher benefit expense ratio in the Medicaid and individual businesses as well as a change in our business mix towards the Government Business division, which carries a higher-than-average benefit expense ratio. While we do not include a reserve roll forward table in our first quarter press release, it is important to note that year-end 2015 reserves have developed moderately better than our expectations so far in 2016. However, we do not believe our first quarter 2016 financial results benefited from that reserve development, and we have maintained an appropriate level of conservativism on our balance sheet as of March 31 for the higher-than-expected individual enrollment. 
Our SG&A expense ratio came in at 15.8% in the first quarter of 2016, a decrease of 90 basis points from the prior year. This was driven by a continued focus on administrative expense control in light of better-than-expected enrollment trends as well as the changing mix of our membership towards the Government Business. 
Supporting those strong quality of our earnings in the first quarter, we reported operating cash flow of approximately $1.3 billion or 1.9x net income. We continue to expect 2016 operating cash flow to be greater than $3 billion. It is important to note that operating cash flow exceeded our expectations in the quarter, which is encouraging. 
Turning to discuss the first quarter financial performance of our business units. Let me say that in our Commercial business, we reported strong membership trends that came in well above our conservative expectations, increasing by 880,000 during the quarter. In particular, we saw strong self-funded membership trends in both our National and Local Group businesses and better-than-expected individual enrollment on the public exchanges. This contributed to the better-than-expected operating revenue during the quarter, which increased by 1.5% versus the prior year to $9.5 billion. 
Operating margins were relatively flat compared to the prior quarter at 13.6%, which reflects the impact of a higher benefit expense ratio, offset by a lower SG&A expense ratio, as expected. 
We were diligent with respect to pricing our exchange product offerings for 2016, as this remains a dynamic marketplace. We believe we have taken a conservative posture in the first quarter regarding our expectations for the profitability of this book of business for 2016. We believe we are well positioned for continued growth in exchange lives as this market stabilizes to a more sustainable level over time. 
Relating to National Accounts, we're pleased that the team has been able to secure some wins recently that should grow membership in both 2016 and 2017. As we said earlier, Local Group membership was down slightly year-over-year, and we continue to see a funding mix shift away from fully insured. We recognize it is vital to offer affordable products with the right network and benefit design in our markets. And our team is focused on improving the historical trends of this book of business. 
Our Government Business segment had another solid quarter, adding 123,000 members and growing year-over-year revenue by 13.9% to $10.8 billion. It is important to note that our results do not yet include an impact from the addition of the Iowa contract, aside from start-up costs incurred in the quarter ahead of the contract launch, where the implementation was delayed from March 1 to April 1. Operating margins for the Government Business in the quarter came in at 3%, a decline of approximately 40 basis points, which was driven by lower gross margins in the Medicaid business. As we communicated previously, we continue to expect Medicaid margins to compress from 2015 levels to a more normalized level, and we are monitoring the performance of this business appropriately.  Within Medicare, I'm pleased with the progress the team continues to make as our first quarter margins reflect continued improvement versus last year. We continue to expect margins to improve as the year progresses towards our expected long-term sustainable level, and we have positioned our portfolio to grow enrollment in the right markets with the right products in 2017. 
The pipeline of opportunity for our Medicaid business remains substantial. We expect $68 billion of new business to be awarded by the end of 2020, split about evenly between traditional Medicaid and new populations and specialized services. We continue to believe our experience and footprint positions us very well to continue our growth as we help states address the challenges of rising health care costs and improving quality for their residents. 
Regarding our balance sheet metrics. Our Days in Claims Payable was 43.4 days as of March 31, an increase of 0.7 days from the 42.7 days as of December 31, 2015. The increase was primarily due to the timing of claims payments driven by the new membership that came online during the quarter. As previously discussed, we expect Days in Claims Payable to come back down closer to 40 over time. 
Our debt-to-capital ratio was 40.2% at March 31, 2016, down 60 basis points from the 40.8% as of December 31, which reflects the impact of an increase in shareholder equity and the reduction of our outstanding balance in the commercial paper during the quarter. 
We ended the first quarter with approximately $2.2 billion of cash and investments at the parent company. And our investment portfolio was in an unrealized gain position of approximately $639 million as of March 31. For the 3Rs related to the 2015 and 2016 benefit years, we continue to book reinsurance as appropriate and continue to reflect a net payable position for risk adjusters and a net neutral position for risk corridors. We continue to record a valuation allowance against the risk corridor receivables in certain markets as we do not believe those receivables will ultimately be collected. We believe our estimates are prudent given the dynamic nature of available information. 
Turning to our financial outlook. We have increased our operating revenue expectation for 2016 by $1 billion to between $81 billion and $82 billion. This increase reflects higher projected membership due to the strong enrollment results seen through the first quarter, as we've discussed. Fully insured membership is now expected to be approximately 14.9 million members at the midpoint of our range at year-end, 250,000 higher than our previous outlook, which reflects stronger than previously expected results in the individual and Medicaid businesses. Self-funded membership is now expected to be approximately 24.5 million members at the midpoint of our range at year-end, also 250,000 higher than our previous outlook. Taken together, we now project our total membership to be approximately 700,000 to 900,000 lives higher than we ended in 2015. We continue to expect our 2016 medical loss ratio to be 83.6%, plus or minus 30 basis points, and now expect our SG&A ratio to be 15.5%, plus or minus 30 basis points, on a GAAP basis, which includes the impact of Cigna-related transaction cost incurred during the first quarter of 2016. We continue to expect 2016 Local Group medical cost trends to be in the range of 7% to 7.5%. We're encouraged with first quarter operating cash flow, and we continue to project operating cash flows to be greater than $3 billion in 2016. 
Regarding capital deployment. We raised our dividend during the first quarter by $0.025 per share and declared our second quarter dividend of $0.65 per share. This represents an annualized dividend of $2.60 per share and continues our track record of increasing our dividend every year since it was implemented in 2011. 
Our 2016 outlook does include some benefit from the impact of capital deployment activities throughout the remainder of the year. While we did not repurchase any shares through the first quarter, we plan to resume our capital deployment program, subject to market conditions, albeit at a lower level than in recent years. 
To conclude, our 2016 earnings per share outlook is greater than $9.65 on a GAAP basis and our adjusted earnings per share outlook is greater than $10.80. Our outlook continues to take an appropriately conservative posture around the expected financial performance on the public exchanges and the expected year-over-year margin compression in the Medicaid business. Our outlook does not include the adoption of new accounting guidance related to employee share-based payments, which we expect to implement in 2017. For context, we estimate the impact in the first quarter of 2016 would have been a benefit to GAAP and adjusted earnings per share of approximately $0.10. Our outlook does include an adverse impact of $0.03 for the additional assessment in 2016 associated with the State of Colorado dissolution of their co-op. It's also important to note that our 2016 outlook does not include any additional benefits or transaction costs associated with the pending acquisition of Cigna beyond those incurred in the first quarter of 2016. We continue to expect this acquisition will close in the second half of this year. It also does not include any benefit from lower pharmaceutical pricing, which we continue to believe we are entitled to under our current contract with ESI. 
With that, operator, please open the queue for questions."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","[Operator Instructions] And our first question will come from the line of A.J. Rice with UBS.",16,"[Operator Instructions] And our first question will come from the line of A.J. Rice with UBS."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I figure I might as well just jump in on the public exchanges and ask you a broad question there, and 3 parts to it, I guess. Obviously, you had good enrollment this open enrollment season. Can you give us any thoughts on the -- what you know so far about",132,"I figure I might as well just jump in on the public exchanges and ask you a broad question there, and 3 parts to it, I guess. Obviously, you had good enrollment this open enrollment season. Can you give us any thoughts on the -- what you know so far about the risk profile of those sign-ups and how you feel about that? And second, I know, last year, your issue really wasn't in terms of dip in profitability on exchanges and the MLR issue was rather a G&A issue, and you've made some adjustments there. Can you sort of update us on what you did there? And then finally, on the exchanges, the 2017 early outlook in light of some of the commentary from some of the others in the sector."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Great. A.J., thanks for the question. Good morning. It's Joe. First of all, let me just tell you that we're really pleased overall with how our team has been able to navigate a very challenging landscape that has evolved over the last couple of years. As",567,"Great. A.J., thanks for the question. Good morning. It's Joe. First of all, let me just tell you that we're really pleased overall with how our team has been able to navigate a very challenging landscape that has evolved over the last couple of years. As I stated in my remarks, we're really glad to now be serving 975,000 members across all of our markets, which I think really highlights an incredibly meaningful value proposition to the customers that have chosen to align with us. Over time, we do believe we're well positioned for continued growth in the exchange marketplace if the market stabilizes to a more sustainable level, I think that is a key consideration. Clearly, the performance of the exchange marketplaces lagged expectations throughout the industry, as some of our peers have recognized. And in consideration of that, we are monitoring the market very closely to see that our offerings continue to be: number one, very rational, sustainable for the customers, but also it is built on a platform that is constructed appropriately with respect to costs that need to drive our presence in that market. Again, at a very sustainable and appropriate level. We -- I think it's really critical for me to underscore that we are actively engaged with our government partners to help build that long-term sustainable model that we believe will ultimately create an affordable marketplace. And in doing so, we believe we can continue to develop the kind of rate structure in the marketplace that's adequate for us and appropriate in terms of affordability for members. And for example, I think the elimination of the health insurer fee in 2014 sets the stage nicely as we move into that new year with respect to a rate picture. And I think our combination with Cigna is going to present a meaningful improvement in affordability for our membership. So I think, put all that together, we're very kind of pleased with how we've performed this year. We think we're engaged in a fairly sustainable platform that has potential for continued growth, again, underscore, as long as the model that we are engaged in, in the marketplace is a sustainable model. Let me close my remarks in that regard by saying that, I think there's some really key drivers to building that sustainable, affordable marketplace that I mentioned. Some of the key elements include what has already been put in place for '17, which is the health insurer tax adjustment. And the second thing would be, I think, a careful consideration of updating the risk adjustment model, further consideration of special enrollment period adjustments, and that would narrow the variety and number of special enrollment considerations. And we'd like to be able to begin offering some very innovative product designs in the marketplace. And hopefully, our government partners will be receptive to some of those creative, innovative models. And finally, I'd like to underscore modification of grace period for nonpayment of premiums to prevent abuse. So when you put all that together in a mosaic, I think, maybe a sustainable model can be built, and we will continue to perform in the marketplace in a way that continues to maybe try to achieve the membership that we had originally anticipated back when this effort first began in '14. Wayne, you may want to speak to the MLR question that A.J. put to us."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","So A.J., as Joe addressed kind of at least our views on '17 and beyond, in terms of the membership we received, and I would say we have a slightly higher silver mix, which we think is a generally a positive regarding how we price our book and our product.",176,"So A.J., as Joe addressed kind of at least our views on '17 and beyond, in terms of the membership we received, and I would say we have a slightly higher silver mix, which we think is a generally a positive regarding how we price our book and our product. The age distribution in subsidy-eligible mix is consistent with those expectations. But I would tell you that we've chosen to maintain a conservative posture in Q1 until we see ultimately how this develops. So we've maintained a conservative posture on risk adjusters despite Wakely data that would imply that we should be booking more, and we are really now booking to the normal seasonality profitability. You would see in this book in Q1. Because again, I think, from our perspective, we like to see this membership at least get through 2Q to really understand how the book is performing. So from that perspective, we think it's the prudent thing to do. And then as 2Q evolves, we'll give more commentary on how it's actually developing."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. Great. And then maybe just on that part, just expanding. I know you talked about pulling back on your marketing and trimming your G&A directly related to the exchanges. You've had better-than-expected enrollment growth. Did you still pull in on thos",48,"Okay. Great. And then maybe just on that part, just expanding. I know you talked about pulling back on your marketing and trimming your G&A directly related to the exchanges. You've had better-than-expected enrollment growth. Did you still pull in on those expense items on the G&A side?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, we did. And I think, lesson learned last year, '15, is that, we need to really true-up a very nice platform that was appropriately built for the type of market we were dealing with. And quite frankly, I think we really built a very stabilized platfor",109,"Yes, we did. And I think, lesson learned last year, '15, is that, we need to really true-up a very nice platform that was appropriately built for the type of market we were dealing with. And quite frankly, I think we really built a very stabilized platform that helped us move into '16 to capture this kind of uptake in membership based on a cost structure that I think was very appropriately built out for the marketplace. And so our -- quite frankly, our G&A structure, I think, is well under control. It's appropriately sized and well configured for us to continue to grow in this space as appropriate."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Tom Carroll with Stifel.",11,"And our next question will come from Tom Carroll with Stifel."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just quick follow-up on the exchange business. Are you seeing any signs of adverse selection at all? And maybe could you remind us of kind of the items that you're looking for within that book of business? And then secondly, I'd like you to chat a little",109,"Just quick follow-up on the exchange business. Are you seeing any signs of adverse selection at all? And maybe could you remind us of kind of the items that you're looking for within that book of business? And then secondly, I'd like you to chat a little bit about the Medicaid business. Anthem had a great 2015, and you indicated that the Medicaid MLR was likely going to be up and was up during first quarter. Was it in line with your expectations, higher, lower, from what you expected? And I wonder if you could comment also on the Medicaid managed care regs that were out on Monday."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Got it. Maybe I can pick back up where I left off regarding A.J.'s question on risk profile, which I think relates back to your question on what are we seeing in terms of membership capture. It's a little early. I think we're going to continue to dig into",113,"Got it. Maybe I can pick back up where I left off regarding A.J.'s question on risk profile, which I think relates back to your question on what are we seeing in terms of membership capture. It's a little early. I think we're going to continue to dig into the risk profile that we have brought on. And our sense is that probably somewhere in the 2Q range, we're going to be able to get line of sight on risk profile and have more to report to you at the end of 2Q. So it's a little early for us to give you a kind of a line of sight on risk profile."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","So Tom, a couple of other items. So I think, as Joe said, we like what we're seeing in early mix. But ultimately, as this business comes on, we'll see how it really develops in Q2. As you know, a lot of the claims activity always has a little bit of a lag",399,"So Tom, a couple of other items. So I think, as Joe said, we like what we're seeing in early mix. But ultimately, as this business comes on, we'll see how it really develops in Q2. As you know, a lot of the claims activity always has a little bit of a lag when individuals switches to a new carrier. And then ultimately, that reporting time line that occurs with the providers, ultimately to us. So I think in 2Q, we'll get a much better feel. What we want you to be aware of is, one, we're not seeing any early indicators across our broader book on trend or anything that would have us change our overall trend assumptions. Two is, we've maintained a conservative posture going into 2Q around the risk adjuster data and not only for what we believe '15 would true up to be, but what we think the impact would be on '16 in light of this mix. That's not based on just our assumptions, but actually using the updated Wakely data we receive as well as some recent CMS data. But as you know, ultimate settlement on those will be very dependent upon who owes the risk adjuster and how that will settle out. So we're going to wait and see how that pans out in 2Q. But I would say, in each of the 3Rs, we've maintained a posture that should give us some contingency if the book doesn't develop as we would've expected. And if it does develop as we would expect, then it would give us some upside going into the second half of this year and into Q2. On the Medicaid front, again no real surprise, it's just a reminder that we had a lot of new markets that we're rolling out. We continue to have that book evolve. As you know, Iowa now starts on April 1 as well. So we would expect to see MLR pressure there in 2Q as well. But consistent with our expectations in new markets that are rolling out and continue to be bullish on the Medicaid top line as well as bottom line. And as we've mentioned previously, we're going to be slow landing those margins down to what we think are more sustainable. And then on the Medicaid regs, no real surprises. We were fine with the new regs that came out."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Josh Raskin with Barclays.",11,"And our next question will come from Josh Raskin with Barclays."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First question. Just on the 975,000 exchange lives. Could you help us break down how many of those are new to Anthem versus existing, previously managed life last year? And then any sense of how many of the new ones came from other plans versus sort of ne",109,"First question. Just on the 975,000 exchange lives. Could you help us break down how many of those are new to Anthem versus existing, previously managed life last year? And then any sense of how many of the new ones came from other plans versus sort of new to the market? And then the follow-up would just be on the MLR, up 160 bps in the first quarter, but guidance up 30% for the year. What are -- I understand the leap year, but what are some of the deltas? What changes as we sort of progress through the year that would make those year-over-year comparisons look much better?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Let me take a shot at the first question. The -- we just don't know yet, quite frankly, in terms of what carryover membership brought over from '15. Obviously, we're going to learn more about that getting into 2Q. So it's rather simple answer to the",63,"Yes. Let me take a shot at the first question. The -- we just don't know yet, quite frankly, in terms of what carryover membership brought over from '15. Obviously, we're going to learn more about that getting into 2Q. So it's rather simple answer to the question. I wish I had more to give you, but we just don't know this early."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, Josh, a couple of other items we would highlight those, that generally what we've seen, what I would call the unexpected uptake, there has been markets where the co-ops have become insolvent. So I don't think there is a surprise there. I think where",171,"Yes, Josh, a couple of other items we would highlight those, that generally what we've seen, what I would call the unexpected uptake, there has been markets where the co-ops have become insolvent. So I don't think there is a surprise there. I think where we're probably surprised on the uptake, though, has been that we weren't the next lowest-cost carrier. And in many cases, we were substantially higher than the next or several next lowest-cost carriers. So it appears to be a little bit of a flight to safety, if you will, and security. And so again, it's another reason why we want to see how this ultimately pans out our pricing. It's obviously much higher than what the -- would've been available in the market. And so the question will be does that adequately reflect the book that we're inheriting over from the co-ops on that end. Frankly, given how 2015 played out, we want to take a more conservative posture earlier this year and see how that develops."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Great. And you don't know which lives were Anthem members previously and still signed on?",15,"Great. And you don't know which lives were Anthem members previously and still signed on?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","You ultimately get the data, but I would say that, you also have to look at it -- we don't look at it as a single member by state, we look at the broad mix both on and off exchange membership. And so while we have a feel for some of that, at the same time",89,"You ultimately get the data, but I would say that, you also have to look at it -- we don't look at it as a single member by state, we look at the broad mix both on and off exchange membership. And so while we have a feel for some of that, at the same time, I would tell you that the majority of the new membership growth that we're seeing is obviously new to us and it's coming from other organizations. And clearly, it's in the co-op space."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So do you have like a net sales versus a net lapses number or anything like that even if you don't if they're the same?",26,"Okay. So do you have like a net sales versus a net lapses number or anything like that even if you don't if they're the same?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","We do. We do, Josh. But we're obviously not going to disclose that data.",14,"We do. We do, Josh. But we're obviously not going to disclose that data."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then the MLR year-over-year?",6,"Okay. And then the MLR year-over-year?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Ultimately, we show that -- we obviously have the impact of the leap year and new year. The thing to keep in mind though is the premium. As you know, just inherently, the leap year alone, the premium is spread over the entire year, but you're getting a fu",221,"Ultimately, we show that -- we obviously have the impact of the leap year and new year. The thing to keep in mind though is the premium. As you know, just inherently, the leap year alone, the premium is spread over the entire year, but you're getting a full day of claims within the quarter. So clearly, there is a positive effect that happens in the out years as the leap year continues, that's one dynamic. I think another dynamic to keep in mind is that, when we look at our mix shift and how that's evolving, we've actually didn't do the typical seasonality that you would see for individuals. So we've tried to book a little more of an MLR factor in the first quarter, that typically would have been lower, and then you would have a higher in the fourth quarter in this case because of the new membership we're doing a little more, I wouldn't call it straight line, but we're trying to get much more of a upfront view and a conservative posture. So as that develops again, I would basically put it that we're seeing how '15 played out. We're just trying to take a much more conservative posture earlier in the year and then let that hopefully blend its way down as the year progresses."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Gary Taylor with JPMorgan.",11,"And our next question will come from Gary Taylor with JPMorgan."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I just want to follow-up a little bit. And I think, Wayne, your last response kind of gets into my question a little bit. So I'll be brief. But I'd guess I'm trying to understand where the individual enrollment came. You mentioned a few of the states wher",90,"I just want to follow-up a little bit. And I think, Wayne, your last response kind of gets into my question a little bit. So I'll be brief. But I'd guess I'm trying to understand where the individual enrollment came. You mentioned a few of the states where the co-ops were insolvent. I was wondering if there was any more detail you could provide than that, particularly whether some of this enrollment would be in states like California, New York, where I think your experience was better last year?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, Gary, it is. New York is obviously clearly one of the markets where the co-ops struggled. And we did pick up, I would say, more than our market share that we typically have relative to the co-ops. California is another market where we did perform wel",95,"Yes, Gary, it is. New York is obviously clearly one of the markets where the co-ops struggled. And we did pick up, I would say, more than our market share that we typically have relative to the co-ops. California is another market where we did perform well. And in addition, it would be in Colorado and Kentucky, other markets where the co-ops had their difficulties, and we've picked up -- I would say we've picked up more than our market share, so that the membership available with their exits were disproportionately picking up market share."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","As a quick follow, I guess I'm having a little difficulty seeing the degree of conservatism maybe that you're talking about in the book, given that versus the original expectation of individual being down 300,000. You're now up 200,000. Days claims payabl",125,"As a quick follow, I guess I'm having a little difficulty seeing the degree of conservatism maybe that you're talking about in the book, given that versus the original expectation of individual being down 300,000. You're now up 200,000. Days claims payable down a couple of days year-over-year. The commercial operating margin was up 10 basis points even though you booked some additional MLR in the individual business. Is the response to that just that this individual seasonality is so skewed to the front end versus the fourth quarter that -- you still have some modest margin gain year-over-year even though you're booking the additional MLR in the individual book? Does that maybe just -- the range of seasonality, maybe I'm just not appreciating enough?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. So Gary, yes. That's one dynamic. Second one is sequentially DCP is actually up since year-end. And as we said, year-end did develop favorable to our expectations. I want to emphasize that develop favorable and DCP is up sequentially. Two is, I think",139,"Yes. So Gary, yes. That's one dynamic. Second one is sequentially DCP is actually up since year-end. And as we said, year-end did develop favorable to our expectations. I want to emphasize that develop favorable and DCP is up sequentially. Two is, I think it's important to recognize it on the 3Rs, the data would imply that we have been conservative on 2015. And so we've neither recognized that conservatism yet. And in addition to that, it would also imply in a run rate that we would have available to us in 2016 based on that data, and again we've not recognized that as well. And it's important to recognize that the 3Rs are not part of DCP, so you won't necessarily get to see that at a conservatism that we are carrying into Q2 as we move forward."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And would you ever disclose 3Rs? Will we ever get that from you?",13,"And would you ever disclose 3Rs? Will we ever get that from you?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Most likely not, but I will tell you that in 2Q, we will give you a gauge, though, of how it maybe benefit us more broadly in terms of the pieces. I think the thing I want to highlight for the group, though, is the reason we're being cautious on 3Rs, in p",150,"Most likely not, but I will tell you that in 2Q, we will give you a gauge, though, of how it maybe benefit us more broadly in terms of the pieces. I think the thing I want to highlight for the group, though, is the reason we're being cautious on 3Rs, in particular, risk adjusters, which would imply that we would have a nice receivable related to '15 as well as some run rate into '16 is, the question is, similar to the risk corridor, who ultimately is going to pay that. And if the receivables do from a co-op, ultimately, we don't want to recognize that unless we know the co-ops have a financial wherewithal to pay those receivables. And so this is just one of many factors that we believe warrants being conservative until we see final settlements and then how those dollars are actually transferred between companies."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Peter Costa with Wells Fargo Securities.",13,"And our next question will come from Peter Costa with Wells Fargo Securities."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I'll move away from the individual exchanges for a minute and take you to the PBM, the contract dispute with Express. Can you talk, not about what you're going to do, but how would you bring it in-house specifically, if that was the direction this ends up",140,"I'll move away from the individual exchanges for a minute and take you to the PBM, the contract dispute with Express. Can you talk, not about what you're going to do, but how would you bring it in-house specifically, if that was the direction this ends up? Give us some idea of sort of the time frame it would take from when you have to start planning it as well as what sort of options would you use in terms of perhaps using some of the other PBMs or even Express by buying next RS back or something like that, to actually manage it given that you don't have the assets anymore to run a PBM? Can you talk about that a little bit and specifically how that would work if you were to try to bring it in-house?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Peter, interesting question. I think it strikes at one of our various options and just kind to help us all recall where we started this journey. We talked a lot about optionality and recognize that we had some choices ahead of us, one, bring it in-ho",298,"Yes. Peter, interesting question. I think it strikes at one of our various options and just kind to help us all recall where we started this journey. We talked a lot about optionality and recognize that we had some choices ahead of us, one, bring it in-house, as you've just described, another would be to recast our agreement with ESI. Another would be to go to another vendor, et cetera. So we're considering a full range of options. I think, first, I need to preface my remarks by underscoring that we've got probably a couple of years at a minimum before we need to make that call. And quite frankly, these considerations are -- we're actively involved in some sort of the various pluses and minuses of each options. So it's really too early for us to comment on specificity. And I think that to your point about bringing it in-house, recognize it's a complex process to do so. It does have costs associated with it. We recognize that. But again, let me underscore, it's not a decision that is imminent. We have, call it, a journey that we have to administer with respect to our ongoing negotiations with ESI regarding our position that we stated to them clearly and now taken the form of a lawsuit. So I direct you to that with respect to the specificity around our engagement with them at this stage. But optionality, again I want to underscore, we are in the development mode on our choices. But none of those choices do we have to exercise in any way of an imminent nature, and so I'd prefer just to kind of maybe delay a response to some future date when that is more of an imminent necessity for us to deal with."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And can you talk about sort of the expected savings if you were to bring it in-house? What would that look like relative to the $3 billion that you're seeking from Express on a contract renegotiation?",37,"Okay. And can you talk about sort of the expected savings if you were to bring it in-house? What would that look like relative to the $3 billion that you're seeking from Express on a contract renegotiation?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. As I said, I think certainly a lot of analytics will go into discerning savings. We haven't actually gone into the depths of administratively how you build it and the cost associated with building it, that then translates into savings. Again, let me",95,"Yes. As I said, I think certainly a lot of analytics will go into discerning savings. We haven't actually gone into the depths of administratively how you build it and the cost associated with building it, that then translates into savings. Again, let me restate, emphatically, that it's too early for us to weigh in on that. And at some future moment in time where it is appropriate, we'll certainly bring that to your attention. It's just too early now to give you clear line of sight on savings for an option of that nature."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question will come from Dave Windley with Jefferies.",10,"Your next question will come from Dave Windley with Jefferies."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And I wanted to go back to Medicaid. First part of the question would be, was the higher MLR and Medicaid a function of just the lower rates that you've anticipated? Or were there other factors like flu, perhaps or population mix acuity of the mix or even",119,"And I wanted to go back to Medicaid. First part of the question would be, was the higher MLR and Medicaid a function of just the lower rates that you've anticipated? Or were there other factors like flu, perhaps or population mix acuity of the mix or even rising trend in Medicaid that impacted MLR there? And then second part would be, as we look to the second quarter and the start of Iowa, some of your peers, at least one, I think has established -- have established reserves in 2015 in anticipation of pretty significant pressure from Iowa. How should we think about the progression of Medicaid margin into 2Q and the rest of the year for Iowa?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Dave, good morning. Let me first start with Medicaid. Yes, a significant portion of what you saw in the MLR is a function of what we've been talking around the rate pressure and those rates coming down. I think our outlook for the year on the Medicaid tea",292,"Dave, good morning. Let me first start with Medicaid. Yes, a significant portion of what you saw in the MLR is a function of what we've been talking around the rate pressure and those rates coming down. I think our outlook for the year on the Medicaid team continues to be consistent with the outlook that we gave when we give guidance initially, and we expect to be at our MLR and trends playing within the levels that we have fully expected within the book. So no real surprises there. Relative to Iowa, as you know, we did not book a PDR. We typically expect to have a higher MLR and to lose money early on when the programs rolled out. And then ultimately, the PR requires you to look over the life of the contract, and we clearly expect it to be a profitability over the life of the contract, which is why we don't have a PDR booked on it. But because the contract was delayed, obviously, the MLR will reflect that 9 months of activity instead of 10 months, which means that your MLR will be a little bit pressured in the current year, but only by an additional month. The fact that it was delayed by a month will create a little bit of pressure this year. But obviously, we expect that to come down next year. But while we weren't necessarily pleased with membership been delayed in the revenue impact, we actually think that additional month probably played well for the industry in terms of getting into contracts, finalizing its networks, finalize in a manner that hopefully can make this a very strong, profitable book consistent with our historical margins. So we remain optimistic on the program."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Kevin Fischbeck with Bank of America.",13,"And our next question will come from Kevin Fischbeck with Bank of America."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just wanted to dig into guidance a little bit. You beat consensus expectations for Q1 pretty nicely, particularly on the G&A side, but you didn't raise guidance for the year. In fact, you took your G&A number up and kept your MLR stable even though you se",98,"Just wanted to dig into guidance a little bit. You beat consensus expectations for Q1 pretty nicely, particularly on the G&A side, but you didn't raise guidance for the year. In fact, you took your G&A number up and kept your MLR stable even though you seem to be talking about pressure on the MLR on the individual side, at least from a mix perspective. Can you talk a little bit about why the puts and takes ended up the way that they were? And why we didn't see upward pressure on MLR and downward pressure on G&A?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Let me address a few things. One is, I want to highlight again that if we look purely at Q1 and the results, it would imply that we should have had a raise, which I think is a very valid question that you're asking. I can't emphasize enough that we a",303,"Yes. Let me address a few things. One is, I want to highlight again that if we look purely at Q1 and the results, it would imply that we should have had a raise, which I think is a very valid question that you're asking. I can't emphasize enough that we are very pleased with all the metrics in Q1. But with those metrics, we really thought it was best to maintain a lot of conservatism that we could have otherwise potentially released in Q1 until we see how this book evolves into Q2. I think it's fair to say that the industry last year, and ourselves included, got to see a lot more of how things developed as last year progressed. So we're just taking a much more conservative posture till we see more development. The second thing I would highlight again is, we did highlight that we are covering another $0.03 of assessments from co-ops and maintaining that guidance as well. And then last thing I would say is that, in terms of the metrics, we like our G&A where it's at. And we think with this additional membership, this is the G&A leverage we should have gotten a year ago with exchanges. As you know, it was a deleverage impact to us a year ago. This year, it's going to  be a leverageable impact. And so we're holding a line on G&A. And we again -- if the membership plays out with the risk profile we would expect, then that G&A leverage helps improve the margins. If it doesn't, then the G&A leverage helps offset any surprises. So I'd love to give you a different answer. But I mean, the reality is, we just chose to be conservative in Q1 until we can see how this book of business evolves."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then as you mentioned on the small group business that you saw some pressure, particularly in the states that expanded the -- to 51 to 100, what percent of your small group business is in the states?",39,"Okay. And then as you mentioned on the small group business that you saw some pressure, particularly in the states that expanded the -- to 51 to 100, what percent of your small group business is in the states?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. It's actually a decent amount, and I would say it was primarily in California. As you know, California was one of the states that made a decision, as did New York and Colorado. So if you're looking at what I'd call your typical market that would be t",144,"Yes. It's actually a decent amount, and I would say it was primarily in California. As you know, California was one of the states that made a decision, as did New York and Colorado. So if you're looking at what I'd call your typical market that would be the most significant for us, it's California of that group. And as a result, not only did your historical small group products no longer be allowed to persist, but you actually had to reintroduce all new products and reconsider the product mix of what it would look like as they went to a different direction from what was defined as a small group. So we're not happy about the membership we lost in those markets, but we also recognize that not every state adopted the flexibility that was offered to them under the Affordable Care Act."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Do you think that that's -- the more states are going end up doing that and it's a headwind we would expect to see next year in more states? Or if you were going to do it, you would have done it by now?",45,"Do you think that that's -- the more states are going end up doing that and it's a headwind we would expect to see next year in more states? Or if you were going to do it, you would have done it by now?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, I think if you were going to do it, you would've have done it by now. The other states have actually gone and maintained the historical small group definition. So I think that's behind us now.",37,"Yes, I think if you were going to do it, you would've have done it by now. The other states have actually gone and maintained the historical small group definition. So I think that's behind us now."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Ralph Giacobbe with Citigroup.",11,"And our next question will come from Ralph Giacobbe with Citigroup."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just wanted to go back to the exchanges. I guess, last quarter, you had mentioned that the exchange book was breakeven for 2015. And as you've talked about, you expected to pull G&A and bring it back to sort of profitable levels. Obviously, you've done be",84,"Just wanted to go back to the exchanges. I guess, last quarter, you had mentioned that the exchange book was breakeven for 2015. And as you've talked about, you expected to pull G&A and bring it back to sort of profitable levels. Obviously, you've done better on the enrollment side. So I guess you have talked about your conservatism. Can you help us in terms of what margins are assumed at this point for the exchange or maybe what's embedded in guidance for 2016?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Ralph, yes, in essence, I would tell you, as we said before, our targeted margins are 3% to 5%. And when we built our plan for this year, we were targeting lower than that threshold. We have not adjusted that targeted margins. So my point is that to the e",118,"Ralph, yes, in essence, I would tell you, as we said before, our targeted margins are 3% to 5%. And when we built our plan for this year, we were targeting lower than that threshold. We have not adjusted that targeted margins. So my point is that to the extent this mentorship does have the risk profile we have, you should expect a better margin as a result of the G&A leverage play. And to the extent that those 3Rs, in fact, not only settle up as we've been notified to date between Wakely and CMS, but actually cash flow as well between the parties that have to settle up, then you could expect margin expansion as well."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So I guess I just want to go back to the disconnect to the lack of guidance raised. If the assumption is to make still, let's call it, 1% to 2% margin or whatever that numbers is on the exchange on a bigger book, maybe to help level set, can you giv",75,"Okay. So I guess I just want to go back to the disconnect to the lack of guidance raised. If the assumption is to make still, let's call it, 1% to 2% margin or whatever that numbers is on the exchange on a bigger book, maybe to help level set, can you give us any sense at all of what you booked for 1Q in terms of sort of a comparable margin on the exchange?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","As you know, historically, when you have an individual member, you're very profitable in Q1, that profitability then declines down to ultimately a loss in Q4. What I would say is that, from our perspective, we've chosen not to take that profitability in,",90,"As you know, historically, when you have an individual member, you're very profitable in Q1, that profitability then declines down to ultimately a loss in Q4. What I would say is that, from our perspective, we've chosen not to take that profitability in, in Q1, but rather book to a breakeven perspective and then see how this book evolves in Q2 and thereafter. So to the extent that it evolves positively, then you'll get the margin improvement both from Q1 as well as in the run rate for the year."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. All right. That's helpful. And then I think it was asked earlier, but I don't think we got to sort of the answer around how you're positioning for 2017. Are there new states or territory that you're going to want to enter? And maybe a sense -- I kno",93,"Okay. All right. That's helpful. And then I think it was asked earlier, but I don't think we got to sort of the answer around how you're positioning for 2017. Are there new states or territory that you're going to want to enter? And maybe a sense -- I know it's early at this point, but when we think about target margins, you talked about 3% to 5%, is 2017 sort of an area where you expect to get there, get closer to there? Any just general commentary around that will be helpful."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","We're not targeting on a stand-alone basis in any new markets outside of our 14 states. I think our goal is to continue to stabilize the market in those states and start trending towards our targeted 3% to 5% margin. I would not anticipate, at this point",149,"We're not targeting on a stand-alone basis in any new markets outside of our 14 states. I think our goal is to continue to stabilize the market in those states and start trending towards our targeted 3% to 5% margin. I would not anticipate, at this point in time, that in '17 we would necessarily achieve that level of margin. But nonetheless, there has been a lot of activity around the regulations and ways to improve and create more stability. So we'll see. And to be fair, it's a little bit early in the pricing cycle. So we ultimately need to see how pricing evolves and what the states will ultimately approve in the pricing cycle and whether or not we can get there as early as '17. But right now, I'd be more cautious on getting there in '17, and view it more as an '18 play."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, I think the question is interesting the way you put it about expanding to other states, I mean, obviously, [indiscernible] precluded because of our Blue Cross Blue Shield presence in our 14 states and really think we should underscore the value we br",188,"Yes, I think the question is interesting the way you put it about expanding to other states, I mean, obviously, [indiscernible] precluded because of our Blue Cross Blue Shield presence in our 14 states and really think we should underscore the value we bring to our markets, our brand legacy, incredibly well known with respect to quality, as well as affordability. And to Wayne's earlier point, we have witnessed and we really do believe this flight to safety is real. And I think flight to safety is very relevant, with respect to how folks are connecting back to us in terms of a known brand. I think we're going to really seek the leverage that more effectively in every market that we're serving. And the last point I'll make I think is very important to underscore is that Cigna will help us with future expansion beyond our 14 states. So that's a story that's not yet told. And when it becomes clear that we can, we will express ourselves probably in more depth in terms of the potential to expand to other markets relative to the public exchanges."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And the next question will come from Chris Rigg with Susquehanna Financial.",12,"And the next question will come from Chris Rigg with Susquehanna Financial."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Apologize if I missed this. But did you guys say what you're now assuming for the reinsurance, coinsurance rate? I know at 4Q, you said a little above 50%. There's some data from CMS, which suggest it could be more like 60% to 65%. Just want to get a sens",63,"Apologize if I missed this. But did you guys say what you're now assuming for the reinsurance, coinsurance rate? I know at 4Q, you said a little above 50%. There's some data from CMS, which suggest it could be more like 60% to 65%. Just want to get a sense for what you're assuming now and whether that's had an impact on guidance?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Chris, thanks for the question. So we continue to assume a little bit north of 50%. I would tell you that if the CMS data of 60% to 65% goes forward, we will have sizable upside relative to those percentages. We're not so sure it will evolve ultimately to",199,"Chris, thanks for the question. So we continue to assume a little bit north of 50%. I would tell you that if the CMS data of 60% to 65% goes forward, we will have sizable upside relative to those percentages. We're not so sure it will evolve ultimately to that level. But based on the most recent data that's been submitted as well as the Wakely data we received on this, we are at a number below what the data would imply, that's what I would say and should have some conservatism going into 2Q and beyond. But again, we want to see ultimate settlement. As a reminder, on risk corridors, we continue to maintain a 100% valuation allowance against any receivables. And I would tell you the more sizable upside ultimately, will be on the risk adjusters, if what we've seen in early data related to '15 and '16 is, in fact, holds true into 2Q. And again, if, in fact, it's monetized by the parties that owe it. So I would say all 3 areas represent potential upside, the corridor being the least of -- we just don't see the money in the kitty to fund those."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And we'll go to the line of Matthew Borsch with Goldman Sachs.",13,"And we'll go to the line of Matthew Borsch with Goldman Sachs."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I was hoping that you could give us some -- your assessment on the group commercial side. The decline of -- I think it was 245,000 lives in the quarter was in line with what you had guided to. Can you -- I know, you referred to some states where they expa",110,"I was hoping that you could give us some -- your assessment on the group commercial side. The decline of -- I think it was 245,000 lives in the quarter was in line with what you had guided to. Can you -- I know, you referred to some states where they expanded the definition of small group, and that was a factor. I assume that there's some ASO conversions. Did some of that also reflect a conservative pricing posture? I mean, I know you always try to be conservative, but -- have you needed to be more conservative in the current pricing environment? If you could just talk to that."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Matt, yes, let me first start by saying well, it has some conversions from fully insured to ASO. And I think clearly you can see that in how strong our ASO book has done, and not just in National, but in the Large Group business as well. I think it's fair",156,"Matt, yes, let me first start by saying well, it has some conversions from fully insured to ASO. And I think clearly you can see that in how strong our ASO book has done, and not just in National, but in the Large Group business as well. I think it's fair to say that, at least half of it though represents those markets that did the switch with the majority of that being in California. And I would say we've maintained our pricing discipline in California. And it seems that most of that membership went to a single carrier, primarily a not-for-profit carrier that we think priced fairly aggressively. And again from our perspective, we'll weather that storm as we have in the past, and hopefully win those members back in the next year or so. But that's -- I'd say it's about 50-50 split, and then of the 50 that truly left, it's primarily California."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","That's very helpful. And also, if I could ask, what is approximately the amount by which you need to increase price going into 2017 to reflect the lack of reinsurance? And how much of a problem is that going to be for exacerbating some adverse selection t",58,"That's very helpful. And also, if I could ask, what is approximately the amount by which you need to increase price going into 2017 to reflect the lack of reinsurance? And how much of a problem is that going to be for exacerbating some adverse selection that's already a program-wide problem to some degree in the exchanges?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Matt, well, we generally haven't given all the specifics in pricing. I think the reinsurance is one that mathematically people can generally back into a range in the 5% to 6% range of what it could impact on upward pricing by itself. And so I would say th",157,"Matt, well, we generally haven't given all the specifics in pricing. I think the reinsurance is one that mathematically people can generally back into a range in the 5% to 6% range of what it could impact on upward pricing by itself. And so I would say that, that 5% to 6% range that we've had others ask about is a reasonable proxy of what you should expect for the piece of reinsurance that would run off. Relative to all other pricing, we're not necessarily talking to specifics, we're just in the process now of filing with our states. But this is clearly one area where we're spending time, making sure everybody is educated on. And I would tell you insurance regulators understand it, they get it, and they understand the implications of it. And so for competitive reasons, I would like to probably not discuss any further though our rate filings or actions at this point."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And we'll go to the line of Ana Gupte with Leerink Partners.",13,"And we'll go to the line of Ana Gupte with Leerink Partners."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Again following up on the commercial book, but now taking a view in '16 and 2017, there is a 2% gain in your commercial businesses and I'd say it's a mismash of various things, but as you're looking into '17...",40,"Again following up on the commercial book, but now taking a view in '16 and 2017, there is a 2% gain in your commercial businesses and I'd say it's a mismash of various things, but as you're looking into '17..."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Ana, can you start your question over? We're having trouble hearing you.",12,"Ana, can you start your question over? We're having trouble hearing you."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Yes, I was asking about the trend. Is this better?",10,"Yes, I was asking about the trend. Is this better?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","I'm sorry. You're cutting in and out. It's very difficult to hear you.",14,"I'm sorry. You're cutting in and out. It's very difficult to hear you."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Better now?",2,"Better now?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","A little bit, yes. Please try again.",7,"A little bit, yes. Please try again."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So I was asking about the 2017 commercial outlook and whether or not as you look into 2017, we're likely to see a better operating gain growth rate because the not-for-profit Blues, Aetna everywhere, they're all losing money on exchanges and I know",72,"Okay. So I was asking about the 2017 commercial outlook and whether or not as you look into 2017, we're likely to see a better operating gain growth rate because the not-for-profit Blues, Aetna everywhere, they're all losing money on exchanges and I know you don't overlap directly with the Blues. But as you think about Cigna and the post-Cigna world, if the pricing and underwriting spread will get better into 2017?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, I would say our -- well, we haven't given '17 outlook yet. And as you can imagine, well, I first want to see how '16 develops. But what I would highlight is that, we would expect to see the margins begin to trend to the more sustainable levels of 3%",203,"Well, I would say our -- well, we haven't given '17 outlook yet. And as you can imagine, well, I first want to see how '16 develops. But what I would highlight is that, we would expect to see the margins begin to trend to the more sustainable levels of 3% to 5%, I don't think again we'll be there by '17. But ultimately, it seems that the environment is starting to recognize the true cost of operating the exchanges in the membership that resides with it. These are large risk pools. So I think the industry is getting to the point where they have enough data to support the pricing that belongs with it. And we think that our job now is to continue to educate our regulators on the risk profile of the pools, actions we can take to help drive the costs down for affordability. And at the same time, though, to the extent that we're limited on actions, to make sure people understand in the pricing that goes with it. So I think for '17, it would -- today as best we can say it would be our expectation that margins would improve and pricing would continue to improve."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Are we talking about exchanges or commercial? I was talking about the group that's -- and the spread between trend and pricing, more sort of, is it likely to be a silver lining on the cloud just because companies are losing money on exchanges so they beco",53,"Are we talking about exchanges or commercial? I was talking about the group that's -- and the spread between trend and pricing, more sort of, is it likely to be a silver lining on the cloud just because companies are losing money on exchanges so they become more conservative on the commercial pricing?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's hard to know what others may do in their pricing. Clearly, in California, we did not see a player who we know lost money on exchanges necessarily take a more rational pricing on their small group book. So I guess what I would say is, we've seen one m",137,"It's hard to know what others may do in their pricing. Clearly, in California, we did not see a player who we know lost money on exchanges necessarily take a more rational pricing on their small group book. So I guess what I would say is, we've seen one market and then one competitor, you've seen one market and one competitor, so it's hard for us to understand. I think I would say is, this is -- our philosophy is, we've got to cover our cost of capital. We've got to give our shareholders a fair return for the risk that we bear and we price accordingly and then we'll just have to weather the markets, whatever they bring in, in the short-term as we did on the public exchanges in the last couple of years."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And then finally on the 51 to 100. Once you get past that headwind, is there a reduced tendency toward dumping some employers because exchanges haven't been as stable and there's a lot of volatility there?",36,"And then finally on the 51 to 100. Once you get past that headwind, is there a reduced tendency toward dumping some employers because exchanges haven't been as stable and there's a lot of volatility there?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","We think there is. I mean I think it seems like the dumping factor has really moved down and I think this was kind of the last clarification of product description and size under ACA that had to be implemented. So yes, I think from our perspective we view",73,"We think there is. I mean I think it seems like the dumping factor has really moved down and I think this was kind of the last clarification of product description and size under ACA that had to be implemented. So yes, I think from our perspective we view it as kind of stability. And I would say internally, we're targeting actually and trying to get back to small group growth again, now."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And we'll go to the last question here. It will come from Scott Fidel with Crdit Suisse.",18,"And we'll go to the last question here. It will come from Scott Fidel with Crdit Suisse."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just had a question on cost trends overall. And just interested, just within the guidance range that you talked about, how trend maybe behaving within that range in the first quarter? United, I talked about seeing a bit of an uplift in cost trend in the f",77,"Just had a question on cost trends overall. And just interested, just within the guidance range that you talked about, how trend maybe behaving within that range in the first quarter? United, I talked about seeing a bit of an uplift in cost trend in the first quarter maybe around 50 basis points. And then just also just specifically, whether you've been seeing an increase in surgical volumes year-over-year in the first quarter relative to last year?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Scott, thanks for the question. Yes -- well, first of all, it's important we recognize that we had assumed the trends would move up this year, as you know when we finished last year versus to what we guided to this year. So the trends have moved up, but w",265,"Scott, thanks for the question. Yes -- well, first of all, it's important we recognize that we had assumed the trends would move up this year, as you know when we finished last year versus to what we guided to this year. So the trends have moved up, but within our expectations and our pricing. As we look at various factors, I think we would've said early on that trend might have been favorably impacted by the flu. But the fact that the late season happened ultimately, we think for the full year that, that won't have a positive upside to us nor a downside, we think flu is going to play probably within our expectations. We did expect a fairly sizable uptick in trend in Q1 regarding really hep C. And we saw that, which is good and the good news is at least on a rolling 3-month average we looked at it, it seems to be playing right in line with our expectations, slightly better than our expectations, but I would tell you that we're not going to bank that yet because we think there maybe some warehousing because there is new geno-type drugs that are coming out that people may be holding off on until those are available. So I think ultimately, when I look at what could be the big surprise items like a hep C or a flu or other items, everything seems to be playing pretty well relative to our expectations. And where we did expect it to be high in the quarter, it was, but within our pricing."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Scott, it's Joe. I think probably it's fair to also comment on a lot of what you can't see regarding the internal activity of the company, where we're obviously vigilant regarding trend changes. Internally, we're building really a robust provider collabor",133,"Scott, it's Joe. I think probably it's fair to also comment on a lot of what you can't see regarding the internal activity of the company, where we're obviously vigilant regarding trend changes. Internally, we're building really a robust provider collaboration models, really driven towards value-based contracting, that then tries to ameliorate the risk of trend escalation. Our data analytics infrastructure has been a remarkable uplift to the company with respect to our investments and the result and insights that we've captured in order to better manage the cost of care. So there's kind of the macro level that you see. But the micro level within the company, it's amazing how well we positioned ourselves to really address the kind of the prevailing winds that come at us in and around trend changes."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Got it. And then just on the surgical vials, are you able to tease out whether -- what you saw year-over-year there? Is it still a little bit too early to tell?",32,"Got it. And then just on the surgical vials, are you able to tease out whether -- what you saw year-over-year there? Is it still a little bit too early to tell?"
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's a little early. I mean we obviously look for different areas that might spike. I mean we see a little bit more there. But again relative to expectations, I think things are playing okay. So nothing of any specificity that I can provide at this point.",48,"It's a little early. I mean we obviously look for different areas that might spike. I mean we see a little bit more there. But again relative to expectations, I think things are playing okay. So nothing of any specificity that I can provide at this point."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Let me just kind of express the thanks to all of you for your questions. In summary, I'm pleased with our first quarter results and believe that these results position us very well for the remainder of the year. Hopefully, you got a sense of that with res",171,"Let me just kind of express the thanks to all of you for your questions. In summary, I'm pleased with our first quarter results and believe that these results position us very well for the remainder of the year. Hopefully, you got a sense of that with respect to our commentaries today. We do remain committed to increasing access to high-quality affordable health care. Specifically, we believe our ability to serve our customers will be advanced by the pending acquisition of Cigna, which we still remain of the belief that it is expected to close in the second half of 2016. And also, this includes our continued focus on improving matters like drug pricing. The -- I also want to thank all of our associates for their continued commitment to serving our nearly 40 million members, and I'd like to also again thank all of you on the call for your interest in Anthem and look forward to speaking with you soon. Again, thank you very much. Have a great day."
160077,308029053,964652,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And ladies and gentlemen, this conference will be available for replay after 11:00 this morning and running through Wednesday, May 11 at midnight. You can access the AT&T Executive Playback service by dialing 1 (800) 475-6701 and entering the access code",71,"And ladies and gentlemen, this conference will be available for replay after 11:00 this morning and running through Wednesday, May 11 at midnight. You can access the AT&T Executive Playback service by dialing 1 (800) 475-6701 and entering the access code 378816. International parties may dial 1 (320) 365-3844. That does conclude our conference for today. Thanks for your participation and for using AT&T executive teleconference service. You may now disconnect."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management.",38,"Ladies and gentlemen, thank you for standing by, and welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Good morning, and welcome to Anthem's First Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and Wayne DeVeydt, our CFO. Joe will offer an overview o",183,"Good morning, and welcome to Anthem's First Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and Wayne DeVeydt, our CFO. Joe will offer an overview of our first quarter 2016 financial results and will walk through the financials and provide some incremental commentary on our updated 2016 outlook. We are then available for Q&A. 
During the call, we will reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website at antheminc.com. 
We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Anthem. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in today's press release and in our quarterly and annual filings with the SEC. 
I will now turn the call over to Joe."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Doug, and good morning. We're pleased to announce first quarter of 2016 adjusted earnings per share of $3.46, with membership tracking above our previous expectations. On a GAAP basis, we reported earnings per share of $2.63. I'm pleased with o",1919,"Thank you, Doug, and good morning. We're pleased to announce first quarter of 2016 adjusted earnings per share of $3.46, with membership tracking above our previous expectations. On a GAAP basis, we reported earnings per share of $2.63. I'm pleased with our first quarter results, which represent a solid start to 2016 as the company continues to benefit from the growing diversification of our businesses. The complementary nature of our pending Cigna acquisition will allow us to further advance affordability and quality for our members. 
I'm going to start with some overview comments on our first quarter 2016 results, and then we'll discuss a few of the key details of our updated 2016 outlook. First quarter results reflect business performance that tracked well versus our expectations. Specifically, membership is exceeding our expectations, and we reported strong quality of earnings metrics while maintaining appropriate conservativism on our balance sheets to reflect the dynamic nature of the marketplace that exists today. 
Within membership, both fully insured and self-funded membership are tracking ahead of expectations. And we ended the first quarter with 39.6 million members, reflecting growth of 1 million lives or 2.6% since year-end 2015. Specifically, we ended the quarter with 975,000 lives from the individual public exchanges, an increase of 184,000 from year-end 2015 and ahead of our initial expectations. Our self-funded business grew by 906,000 lives or 3.8% in the quarter to 24.6 million members, which was also ahead of our expectations as the company experienced higher-than-expected in-group change in current contracts and BlueCard enrollment. Our Local Group insured enrollment declined by just north of 200,000 lives in the quarter and serves approximately 4 million members as of March 31. In particular, we saw higher-than-expected lapses in plans residing in states that transitioned the 51 to 99 key group size into the small group marketplace. 
Operating revenue was $20.3 billion in the first quarter of 2016, an increase of $1.5 billion or 7.7% versus the first quarter of 2015, reflecting strong enrollment growth in the Government Business and additional premium revenue to cover overall cost trends. Also contributing was the growth in administrative fee revenue as a result of our strong self-funded membership trends. This was partially offset by fully insured membership losses in our Commercial business. 
The first quarter 2016 benefit expense ratio was 81.8%, which increased versus prior year, as expected. The 160 basis point increase reflected the impact of an extra calendar day during the quarter from the leap year, a higher benefit expense ratio in the Medicaid and individual businesses as well as a change in our business mix towards the Government Business division, which carries a higher-than-average benefit expense ratio. While we do not include a reserve roll forward table in our first quarter press release, it is important to note that year-end 2015 reserves have developed moderately better than our expectations so far in 2016. However, we do not believe our first quarter 2016 financial results benefited from that reserve development, and we have maintained an appropriate level of conservativism on our balance sheet as of March 31 for the higher-than-expected individual enrollment. 
Our SG&A expense ratio came in at 15.8% in the first quarter of 2016, a decrease of 90 basis points from the prior year. This was driven by a continued focus on administrative expense control in light of better-than-expected enrollment trends as well as the changing mix of our membership towards the Government Business. 
Supporting those strong quality of our earnings in the first quarter, we reported operating cash flow of approximately $1.3 billion or 1.9x net income. We continue to expect 2016 operating cash flow to be greater than $3 billion. It is important to note that operating cash flow exceeded our expectations in the quarter, which is encouraging. 
Turning to discuss the first quarter financial performance of our business units. Let me say that in our Commercial business, we reported strong membership trends that came in well above our conservative expectations, increasing by 880,000 during the quarter. In particular, we saw strong self-funded membership trends in both our National and Local Group businesses and better-than-expected individual enrollment on the public exchanges. This contributed to the better-than-expected operating revenue during the quarter, which increased by 1.5% versus the prior year to $9.5 billion. 
Operating margins were relatively flat compared to the prior quarter at 13.6%, which reflects the impact of a higher benefit expense ratio, offset by a lower SG&A expense ratio, as expected. 
We were diligent with respect to pricing our exchange product offerings for 2016, as this remains a dynamic marketplace. We believe we have taken a conservative posture in the first quarter regarding our expectations for the profitability of this book of business for 2016. We believe we are well positioned for continued growth in exchange lives as this market stabilizes to a more sustainable level over time. 
Relating to National Accounts, we're pleased that the team has been able to secure some wins recently that should grow membership in both 2016 and 2017. As we said earlier, Local Group membership was down slightly year-over-year, and we continue to see a funding mix shift away from fully insured. We recognize it is vital to offer affordable products with the right network and benefit design in our markets. And our team is focused on improving the historical trends of this book of business. 
Our Government Business segment had another solid quarter, adding 123,000 members and growing year-over-year revenue by 13.9% to $10.8 billion. It is important to note that our results do not yet include an impact from the addition of the Iowa contract, aside from start-up costs incurred in the quarter ahead of the contract launch, where the implementation was delayed from March 1 to April 1. Operating margins for the Government Business in the quarter came in at 3%, a decline of approximately 40 basis points, which was driven by lower gross margins in the Medicaid business. As we communicated previously, we continue to expect Medicaid margins to compress from 2015 levels to a more normalized level, and we are monitoring the performance of this business appropriately. Within Medicare, I'm pleased with the progress the team continues to make as our first quarter margins reflect continued improvement versus last year. We continue to expect margins to improve as the year progresses towards our expected long-term sustainable level, and we have positioned our portfolio to grow enrollment in the right markets with the right products in 2017. 
The pipeline of opportunity for our Medicaid business remains substantial. We expect $68 billion of new business to be awarded by the end of 2020, split about evenly between traditional Medicaid and new populations and specialized services. We continue to believe our experience and footprint positions us very well to continue our growth as we help states address the challenges of rising health care costs and improving quality for their residents. 
Regarding our balance sheet metrics. Our Days in Claims Payable was 43.4 days as of March 31, an increase of 0.7 days from the 42.7 days as of December 31, 2015. The increase was primarily due to the timing of claims payments driven by the new membership that came online during the quarter. As previously discussed, we expect Days in Claims Payable to come back down closer to 40 over time. 
Our debt-to-capital ratio was 40.2% at March 31, 2016, down 60 basis points from the 40.8% as of December 31, which reflects the impact of an increase in shareholder equity and the reduction of our outstanding balance in the commercial paper during the quarter. 
We ended the first quarter with approximately $2.2 billion of cash and investments at the parent company. And our investment portfolio was in an unrealized gain position of approximately $639 million as of March 31. For the 3Rs related to the 2015 and 2016 benefit years, we continue to book reinsurance as appropriate and continue to reflect a net payable position for risk adjusters and a net neutral position for risk corridors. We continue to record a valuation allowance against the risk corridor receivables in certain markets as we do not believe those receivables will ultimately be collected. We believe our estimates are prudent given the dynamic nature of available information. 
Turning to our financial outlook. We have increased our operating revenue expectation for 2016 by $1 billion to between $81 billion and $82 billion. This increase reflects higher projected membership due to the strong enrollment results seen through the first quarter, as we've discussed. Fully insured membership is now expected to be approximately 14.9 million members at the midpoint of our range at year-end, 250,000 higher than our previous outlook, which reflects stronger than previously expected results in the individual and Medicaid businesses. Self-funded membership is now expected to be approximately 24.5 million members at the midpoint of our range at year-end, also 250,000 higher than our previous outlook. Taken together, we now project our total membership to be approximately 700,000 to 900,000 lives higher than we ended in 2015. We continue to expect our 2016 medical loss ratio to be 83.6%, plus or minus 30 basis points, and now expect our SG&A ratio to be 15.5%, plus or minus 30 basis points, on a GAAP basis, which includes the impact of Cigna-related transaction cost incurred during the first quarter of 2016. We continue to expect 2016 Local Group medical cost trends to be in the range of 7% to 7.5%. We're encouraged with first quarter operating cash flow, and we continue to project operating cash flows to be greater than $3 billion in 2016. 
Regarding capital deployment. We raised our dividend during the first quarter by $0.025 per share and declared our second quarter dividend of $0.65 per share. This represents an annualized dividend of $2.60 per share and continues our track record of increasing our dividend every year since it was implemented in 2011. 
Our 2016 outlook does include some benefit from the impact of capital deployment activities throughout the remainder of the year. While we did not repurchase any shares through the first quarter, we plan to resume our capital deployment program, subject to market conditions, albeit at a lower level than in recent years. 
To conclude, our 2016 earnings per share outlook is greater than $9.65 on a GAAP basis and our adjusted earnings per share outlook is greater than $10.80. Our outlook continues to take an appropriately conservative posture around the expected financial performance on the public exchanges and the expected year-over-year margin compression in the Medicaid business. Our outlook does not include the adoption of new accounting guidance related to employee share-based payments, which we expect to implement in 2017. For context, we estimate the impact in the first quarter of 2016 would have been a benefit to GAAP and adjusted earnings per share of approximately $0.10. Our outlook does include an adverse impact of $0.03 for the additional assessment in 2016 associated with the State of Colorado dissolution of their co-op. It's also important to note that our 2016 outlook does not include any additional benefits or transaction costs associated with the pending acquisition of Cigna beyond those incurred in the first quarter of 2016. We continue to expect this acquisition will close in the second half of this year. It also does not include any benefit from lower pharmaceutical pricing, which we continue to believe we are entitled to under our current contract with ESI. 
With that, operator, please open the queue for questions."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","[Operator Instructions] And our first question will come from the line of A.J. Rice with UBS.",16,"[Operator Instructions] And our first question will come from the line of A.J. Rice with UBS."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I figure I might as well just jump in on the public exchanges and ask you a broad question there, and 3 parts to it, I guess. Obviously, you had good enrollment this open enrollment season. Can you give us any thoughts on the -- what you know so far about",132,"I figure I might as well just jump in on the public exchanges and ask you a broad question there, and 3 parts to it, I guess. Obviously, you had good enrollment this open enrollment season. Can you give us any thoughts on the -- what you know so far about the risk profile of those sign-ups and how you feel about that? And second, I know, last year, your issue really wasn't in terms of dip in profitability on exchanges and the MLR issue was rather a G&A issue, and you've made some adjustments there. Can you sort of update us on what you did there? And then finally, on the exchanges, the 2017 early outlook in light of some of the commentary from some of the others in the sector."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Great. A.J., thanks for the question. Good morning. It's Joe. First of all, let me just tell you that we're really pleased overall with how our team has been able to navigate a very challenging landscape that has evolved over the last couple of years. As",567,"Great. A.J., thanks for the question. Good morning. It's Joe. First of all, let me just tell you that we're really pleased overall with how our team has been able to navigate a very challenging landscape that has evolved over the last couple of years. As I stated in my remarks, we're really glad to now be serving 975,000 members across all of our markets, which I think really highlights an incredibly meaningful value proposition to the customers that have chosen to align with us. Over time, we do believe we're well positioned for continued growth in the exchange marketplace if the market stabilizes to a more sustainable level, I think that is a key consideration. Clearly, the performance of the exchange marketplaces lagged expectations throughout the industry, as some of our peers have recognized. And in consideration of that, we are monitoring the market very closely to see that our offerings continue to be: number one, very rational, sustainable for the customers, but also it is built on a platform that is constructed appropriately with respect to costs that need to drive our presence in that market. Again, at a very sustainable and appropriate level. We -- I think it's really critical for me to underscore that we are actively engaged with our government partners to help build that long-term sustainable model that we believe will ultimately create an affordable marketplace. And in doing so, we believe we can continue to develop the kind of rate structure in the marketplace that's adequate for us and appropriate in terms of affordability for members. And for example, I think the elimination of the health insurer fee in 2014 sets the stage nicely as we move into that new year with respect to a rate picture. And I think our combination with Cigna is going to present a meaningful improvement in affordability for our membership. So I think, put all that together, we're very kind of pleased with how we've performed this year. We think we're engaged in a fairly sustainable platform that has potential for continued growth, again, underscore, as long as the model that we are engaged in, in the marketplace is a sustainable model. Let me close my remarks in that regard by saying that, I think there's some really key drivers to building that sustainable, affordable marketplace that I mentioned. Some of the key elements include what has already been put in place for '17, which is the health insurer tax adjustment. And the second thing would be, I think, a careful consideration of updating the risk adjustment model, further consideration of special enrollment period adjustments, and that would narrow the variety and number of special enrollment considerations. And we'd like to be able to begin offering some very innovative product designs in the marketplace. And hopefully, our government partners will be receptive to some of those creative, innovative models. And finally, I'd like to underscore modification of grace period for nonpayment of premiums to prevent abuse. So when you put all that together in a mosaic, I think, maybe a sustainable model can be built, and we will continue to perform in the marketplace in a way that continues to maybe try to achieve the membership that we had originally anticipated back when this effort first began in '14. Wayne, you may want to speak to the MLR question that A.J. put to us."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","So A.J., as Joe addressed kind of at least our views on '17 and beyond, in terms of the membership we received, and I would say we have a slightly higher silver mix, which we think is a generally a positive regarding how we price our book and our product.",176,"So A.J., as Joe addressed kind of at least our views on '17 and beyond, in terms of the membership we received, and I would say we have a slightly higher silver mix, which we think is a generally a positive regarding how we price our book and our product. The age distribution in subsidy-eligible mix is consistent with those expectations. But I would tell you that we've chosen to maintain a conservative posture in Q1 until we see ultimately how this develops. So we've maintained a conservative posture on risk adjusters despite Wakely data that would imply that we should be booking more, and we are really now booking to the normal seasonality profitability. You would see in this book in Q1. Because again, I think, from our perspective, we like to see this membership at least get through 2Q to really understand how the book is performing. So from that perspective, we think it's the prudent thing to do. And then as 2Q evolves, we'll give more commentary on how it's actually developing."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. Great. And then maybe just on that part, just expanding. I know you talked about pulling back on your marketing and trimming your G&A directly related to the exchanges. You've had better-than-expected enrollment growth. Did you still pull in on thos",48,"Okay. Great. And then maybe just on that part, just expanding. I know you talked about pulling back on your marketing and trimming your G&A directly related to the exchanges. You've had better-than-expected enrollment growth. Did you still pull in on those expense items on the G&A side?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, we did. And I think, lesson learned last year, '15, is that, we need to really true-up a very nice platform that was appropriately built for the type of market we were dealing with. And quite frankly, I think we really built a very stabilized platfor",109,"Yes, we did. And I think, lesson learned last year, '15, is that, we need to really true-up a very nice platform that was appropriately built for the type of market we were dealing with. And quite frankly, I think we really built a very stabilized platform that helped us move into '16 to capture this kind of uptake in membership based on a cost structure that I think was very appropriately built out for the marketplace. And so our -- quite frankly, our G&A structure, I think, is well under control. It's appropriately sized and well configured for us to continue to grow in this space as appropriate."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Tom Carroll with Stifel.",11,"And our next question will come from Tom Carroll with Stifel."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just quick follow-up on the exchange business. Are you seeing any signs of adverse selection at all? And maybe could you remind us of kind of the items that you're looking for within that book of business? And then secondly, I'd like you to chat a little",109,"Just quick follow-up on the exchange business. Are you seeing any signs of adverse selection at all? And maybe could you remind us of kind of the items that you're looking for within that book of business? And then secondly, I'd like you to chat a little bit about the Medicaid business. Anthem had a great 2015, and you indicated that the Medicaid MLR was likely going to be up and was up during first quarter. Was it in line with your expectations, higher, lower, from what you expected? And I wonder if you could comment also on the Medicaid managed care regs that were out on Monday."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Got it. Maybe I can pick back up where I left off regarding A.J.'s question on risk profile, which I think relates back to your question on what are we seeing in terms of membership capture. It's a little early. I think we're going to continue to dig into",113,"Got it. Maybe I can pick back up where I left off regarding A.J.'s question on risk profile, which I think relates back to your question on what are we seeing in terms of membership capture. It's a little early. I think we're going to continue to dig into the risk profile that we have brought on. And our sense is that probably somewhere in the 2Q range, we're going to be able to get line of sight on risk profile and have more to report to you at the end of 2Q. So it's a little early for us to give you a kind of a line of sight on risk profile."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","So Tom, a couple of other items. So I think, as Joe said, we like what we're seeing in early mix. But ultimately, as this business comes on, we'll see how it really develops in Q2. As you know, a lot of the claims activity always has a little bit of a lag",399,"So Tom, a couple of other items. So I think, as Joe said, we like what we're seeing in early mix. But ultimately, as this business comes on, we'll see how it really develops in Q2. As you know, a lot of the claims activity always has a little bit of a lag when individuals switches to a new carrier. And then ultimately, that reporting time line that occurs with the providers, ultimately to us. So I think in 2Q, we'll get a much better feel. What we want you to be aware of is, one, we're not seeing any early indicators across our broader book on trend or anything that would have us change our overall trend assumptions. Two is, we've maintained a conservative posture going into 2Q around the risk adjuster data and not only for what we believe '15 would true up to be, but what we think the impact would be on '16 in light of this mix. That's not based on just our assumptions, but actually using the updated Wakely data we receive as well as some recent CMS data. But as you know, ultimate settlement on those will be very dependent upon who owes the risk adjuster and how that will settle out. So we're going to wait and see how that pans out in 2Q. But I would say, in each of the 3Rs, we've maintained a posture that should give us some contingency if the book doesn't develop as we would've expected. And if it does develop as we would expect, then it would give us some upside going into the second half of this year and into Q2. On the Medicaid front, again no real surprise, it's just a reminder that we had a lot of new markets that we're rolling out. We continue to have that book evolve. As you know, Iowa now starts on April 1 as well. So we would expect to see MLR pressure there in 2Q as well. But consistent with our expectations in new markets that are rolling out and continue to be bullish on the Medicaid top line as well as bottom line. And as we've mentioned previously, we're going to be slow landing those margins down to what we think are more sustainable. And then on the Medicaid regs, no real surprises. We were fine with the new regs that came out."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Josh Raskin with Barclays.",11,"And our next question will come from Josh Raskin with Barclays."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First question. Just on the 975,000 exchange lives. Could you help us break down how many of those are new to Anthem versus existing, previously managed life last year? And then any sense of how many of the new ones came from other plans versus sort of ne",109,"First question. Just on the 975,000 exchange lives. Could you help us break down how many of those are new to Anthem versus existing, previously managed life last year? And then any sense of how many of the new ones came from other plans versus sort of new to the market? And then the follow-up would just be on the MLR, up 160 bps in the first quarter, but guidance up 30% for the year. What are -- I understand the leap year, but what are some of the deltas? What changes as we sort of progress through the year that would make those year-over-year comparisons look much better?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Let me take a shot at the first question. The -- we just don't know yet, quite frankly, in terms of what carryover membership brought over from '15. Obviously, we're going to learn more about that getting into 2Q. So it's rather simple answer to the",63,"Yes. Let me take a shot at the first question. The -- we just don't know yet, quite frankly, in terms of what carryover membership brought over from '15. Obviously, we're going to learn more about that getting into 2Q. So it's rather simple answer to the question. I wish I had more to give you, but we just don't know this early."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, Josh, a couple of other items we would highlight those, that generally what we've seen, what I would call the unexpected uptake, there has been markets where the co-ops have become insolvent. So I don't think there is a surprise there. I think where",171,"Yes, Josh, a couple of other items we would highlight those, that generally what we've seen, what I would call the unexpected uptake, there has been markets where the co-ops have become insolvent. So I don't think there is a surprise there. I think where we're probably surprised on the uptake, though, has been that we weren't the next lowest-cost carrier. And in many cases, we were substantially higher than the next or several next lowest-cost carriers. So it appears to be a little bit of a flight to safety, if you will, and security. And so again, it's another reason why we want to see how this ultimately pans out our pricing. It's obviously much higher than what the -- would've been available in the market. And so the question will be does that adequately reflect the book that we're inheriting over from the co-ops on that end. Frankly, given how 2015 played out, we want to take a more conservative posture earlier this year and see how that develops."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Great. And you don't know which lives were Anthem members previously and still signed on?",15,"Great. And you don't know which lives were Anthem members previously and still signed on?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","You ultimately get the data, but I would say that, you also have to look at it -- we don't look at it as a single member by state, we look at the broad mix both on and off exchange membership. And so while we have a feel for some of that, at the same time",89,"You ultimately get the data, but I would say that, you also have to look at it -- we don't look at it as a single member by state, we look at the broad mix both on and off exchange membership. And so while we have a feel for some of that, at the same time, I would tell you that the majority of the new membership growth that we're seeing is obviously new to us and it's coming from other organizations. And clearly, it's in the co-op space."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So do you have like a net sales versus a net lapses number or anything like that even if you don't if they're the same?",26,"Okay. So do you have like a net sales versus a net lapses number or anything like that even if you don't if they're the same?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","We do. We do, Josh. But we're obviously not going to disclose that data.",14,"We do. We do, Josh. But we're obviously not going to disclose that data."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then the MLR year-over-year?",6,"Okay. And then the MLR year-over-year?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Ultimately, we show that -- we obviously have the impact of the leap year and new year. The thing to keep in mind though is the premium. As you know, just inherently, the leap year alone, the premium is spread over the entire year, but you're getting a fu",221,"Ultimately, we show that -- we obviously have the impact of the leap year and new year. The thing to keep in mind though is the premium. As you know, just inherently, the leap year alone, the premium is spread over the entire year, but you're getting a full day of claims within the quarter. So clearly, there is a positive effect that happens in the out years as the leap year continues, that's one dynamic. I think another dynamic to keep in mind is that, when we look at our mix shift and how that's evolving, we've actually didn't do the typical seasonality that you would see for individuals. So we've tried to book a little more of an MLR factor in the first quarter, that typically would have been lower, and then you would have a higher in the fourth quarter in this case because of the new membership we're doing a little more, I wouldn't call it straight line, but we're trying to get much more of a upfront view and a conservative posture. So as that develops again, I would basically put it that we're seeing how '15 played out. We're just trying to take a much more conservative posture earlier in the year and then let that hopefully blend its way down as the year progresses."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Gary Taylor with JPMorgan.",11,"And our next question will come from Gary Taylor with JPMorgan."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I just want to follow-up a little bit. And I think, Wayne, your last response kind of gets into my question a little bit. So I'll be brief. But I'd guess I'm trying to understand where the individual enrollment came. You mentioned a few of the states wher",90,"I just want to follow-up a little bit. And I think, Wayne, your last response kind of gets into my question a little bit. So I'll be brief. But I'd guess I'm trying to understand where the individual enrollment came. You mentioned a few of the states where the co-ops were insolvent. I was wondering if there was any more detail you could provide than that, particularly whether some of this enrollment would be in states like California, New York, where I think your experience was better last year?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, Gary, it is. New York is obviously clearly one of the markets where the co-ops struggled. And we did pick up, I would say, more than our market share that we typically have relative to the co-ops. California is another market where we did perform wel",95,"Yes, Gary, it is. New York is obviously clearly one of the markets where the co-ops struggled. And we did pick up, I would say, more than our market share that we typically have relative to the co-ops. California is another market where we did perform well. And in addition, it would be in Colorado and Kentucky, other markets where the co-ops had their difficulties, and we've picked up -- I would say we've picked up more than our market share, so that the membership available with their exits were disproportionately picking up market share."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","As a quick follow, I guess I'm having a little difficulty seeing the degree of conservatism maybe that you're talking about in the book, given that versus the original expectation of individual being down 300,000. You're now up 200,000. Days claims payabl",125,"As a quick follow, I guess I'm having a little difficulty seeing the degree of conservatism maybe that you're talking about in the book, given that versus the original expectation of individual being down 300,000. You're now up 200,000. Days claims payable down a couple of days year-over-year. The commercial operating margin was up 10 basis points even though you booked some additional MLR in the individual business. Is the response to that just that this individual seasonality is so skewed to the front end versus the fourth quarter that -- you still have some modest margin gain year-over-year even though you're booking the additional MLR in the individual book? Does that maybe just -- the range of seasonality, maybe I'm just not appreciating enough?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. So Gary, yes. That's one dynamic. Second one is sequentially DCP is actually up since year-end. And as we said, year-end did develop favorable to our expectations. I want to emphasize that develop favorable and DCP is up sequentially. Two is, I think",139,"Yes. So Gary, yes. That's one dynamic. Second one is sequentially DCP is actually up since year-end. And as we said, year-end did develop favorable to our expectations. I want to emphasize that develop favorable and DCP is up sequentially. Two is, I think it's important to recognize it on the 3Rs, the data would imply that we have been conservative on 2015. And so we've neither recognized that conservatism yet. And in addition to that, it would also imply in a run rate that we would have available to us in 2016 based on that data, and again we've not recognized that as well. And it's important to recognize that the 3Rs are not part of DCP, so you won't necessarily get to see that at a conservatism that we are carrying into Q2 as we move forward."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And would you ever disclose 3Rs? Will we ever get that from you?",13,"And would you ever disclose 3Rs? Will we ever get that from you?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Most likely not, but I will tell you that in 2Q, we will give you a gauge, though, of how it maybe benefit us more broadly in terms of the pieces. I think the thing I want to highlight for the group, though, is the reason we're being cautious on 3Rs, in p",150,"Most likely not, but I will tell you that in 2Q, we will give you a gauge, though, of how it maybe benefit us more broadly in terms of the pieces. I think the thing I want to highlight for the group, though, is the reason we're being cautious on 3Rs, in particular, risk adjusters, which would imply that we would have a nice receivable related to '15 as well as some run rate into '16 is, the question is, similar to the risk corridor, who ultimately is going to pay that. And if the receivables do from a co-op, ultimately, we don't want to recognize that unless we know the co-ops have a financial wherewithal to pay those receivables. And so this is just one of many factors that we believe warrants being conservative until we see final settlements and then how those dollars are actually transferred between companies."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Peter Costa with Wells Fargo Securities.",13,"And our next question will come from Peter Costa with Wells Fargo Securities."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I'll move away from the individual exchanges for a minute and take you to the PBM, the contract dispute with Express. Can you talk, not about what you're going to do, but how would you bring it in-house specifically, if that was the direction this ends up",141,"I'll move away from the individual exchanges for a minute and take you to the PBM, the contract dispute with Express. Can you talk, not about what you're going to do, but how would you bring it in-house specifically, if that was the direction this ends up? Give us some idea of sort of the time frame it would take from when you have to start planning it as well as what sort of options would you use in terms of perhaps using some of the other PBMs or even Express by buying next RS [ph] back or something like that, to actually manage it given that you don't have the assets anymore to run a PBM? Can you talk about that a little bit and specifically how that would work if you were to try to bring it in-house?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Peter, interesting question. I think it strikes at one of our various options and just kind to help us all recall where we started this journey. We talked a lot about optionality and recognize that we had some choices ahead of us, one, bring it in-ho",298,"Yes. Peter, interesting question. I think it strikes at one of our various options and just kind to help us all recall where we started this journey. We talked a lot about optionality and recognize that we had some choices ahead of us, one, bring it in-house, as you've just described, another would be to recast our agreement with ESI. Another would be to go to another vendor, et cetera. So we're considering a full range of options. I think, first, I need to preface my remarks by underscoring that we've got probably a couple of years at a minimum before we need to make that call. And quite frankly, these considerations are -- we're actively involved in some sort of the various pluses and minuses of each options. So it's really too early for us to comment on specificity. And I think that to your point about bringing it in-house, recognize it's a complex process to do so. It does have costs associated with it. We recognize that. But again, let me underscore, it's not a decision that is imminent. We have, call it, a journey that we have to administer with respect to our ongoing negotiations with ESI regarding our position that we stated to them clearly and now taken the form of a lawsuit. So I direct you to that with respect to the specificity around our engagement with them at this stage. But optionality, again I want to underscore, we are in the development mode on our choices. But none of those choices do we have to exercise in any way of an imminent nature, and so I'd prefer just to kind of maybe delay a response to some future date when that is more of an imminent necessity for us to deal with."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And can you talk about sort of the expected savings if you were to bring it in-house? What would that look like relative to the $3 billion that you're seeking from Express on a contract renegotiation?",37,"Okay. And can you talk about sort of the expected savings if you were to bring it in-house? What would that look like relative to the $3 billion that you're seeking from Express on a contract renegotiation?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. As I said, I think certainly a lot of analytics will go into discerning savings. We haven't actually gone into the depths of administratively how you build it and the cost associated with building it, that then translates into savings. Again, let me",95,"Yes. As I said, I think certainly a lot of analytics will go into discerning savings. We haven't actually gone into the depths of administratively how you build it and the cost associated with building it, that then translates into savings. Again, let me restate, emphatically, that it's too early for us to weigh in on that. And at some future moment in time where it is appropriate, we'll certainly bring that to your attention. It's just too early now to give you clear line of sight on savings for an option of that nature."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question will come from Dave Windley with Jefferies.",10,"Your next question will come from Dave Windley with Jefferies."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And I wanted to go back to Medicaid. First part of the question would be, was the higher MLR and Medicaid a function of just the lower rates that you've anticipated? Or were there other factors like flu, perhaps or population mix acuity of the mix or even",119,"And I wanted to go back to Medicaid. First part of the question would be, was the higher MLR and Medicaid a function of just the lower rates that you've anticipated? Or were there other factors like flu, perhaps or population mix acuity of the mix or even rising trend in Medicaid that impacted MLR there? And then second part would be, as we look to the second quarter and the start of Iowa, some of your peers, at least one, I think has established -- have established reserves in 2015 in anticipation of pretty significant pressure from Iowa. How should we think about the progression of Medicaid margin into 2Q and the rest of the year for Iowa?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Dave, good morning. Let me first start with Medicaid. Yes, a significant portion of what you saw in the MLR is a function of what we've been talking around the rate pressure and those rates coming down. I think our outlook for the year on the Medicaid tea",292,"Dave, good morning. Let me first start with Medicaid. Yes, a significant portion of what you saw in the MLR is a function of what we've been talking around the rate pressure and those rates coming down. I think our outlook for the year on the Medicaid team continues to be consistent with the outlook that we gave when we give guidance initially, and we expect to be at our MLR and trends playing within the levels that we have fully expected within the book. So no real surprises there. Relative to Iowa, as you know, we did not book a PDR. We typically expect to have a higher MLR and to lose money early on when the programs rolled out. And then ultimately, the PR requires you to look over the life of the contract, and we clearly expect it to be a profitability over the life of the contract, which is why we don't have a PDR booked on it. But because the contract was delayed, obviously, the MLR will reflect that 9 months of activity instead of 10 months, which means that your MLR will be a little bit pressured in the current year, but only by an additional month. The fact that it was delayed by a month will create a little bit of pressure this year. But obviously, we expect that to come down next year. But while we weren't necessarily pleased with membership been delayed in the revenue impact, we actually think that additional month probably played well for the industry in terms of getting into contracts, finalizing its networks, finalize in a manner that hopefully can make this a very strong, profitable book consistent with our historical margins. So we remain optimistic on the program."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Kevin Fischbeck with Bank of America.",13,"And our next question will come from Kevin Fischbeck with Bank of America."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just wanted to dig into guidance a little bit. You beat consensus expectations for Q1 pretty nicely, particularly on the G&A side, but you didn't raise guidance for the year. In fact, you took your G&A number up and kept your MLR stable even though you se",98,"Just wanted to dig into guidance a little bit. You beat consensus expectations for Q1 pretty nicely, particularly on the G&A side, but you didn't raise guidance for the year. In fact, you took your G&A number up and kept your MLR stable even though you seem to be talking about pressure on the MLR on the individual side, at least from a mix perspective. Can you talk a little bit about why the puts and takes ended up the way that they were? And why we didn't see upward pressure on MLR and downward pressure on G&A?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Let me address a few things. One is, I want to highlight again that if we look purely at Q1 and the results, it would imply that we should have had a raise, which I think is a very valid question that you're asking. I can't emphasize enough that we a",303,"Yes. Let me address a few things. One is, I want to highlight again that if we look purely at Q1 and the results, it would imply that we should have had a raise, which I think is a very valid question that you're asking. I can't emphasize enough that we are very pleased with all the metrics in Q1. But with those metrics, we really thought it was best to maintain a lot of conservatism that we could have otherwise potentially released in Q1 until we see how this book evolves into Q2. I think it's fair to say that the industry last year, and ourselves included, got to see a lot more of how things developed as last year progressed. So we're just taking a much more conservative posture till we see more development. The second thing I would highlight again is, we did highlight that we are covering another $0.03 of assessments from co-ops and maintaining that guidance as well. And then last thing I would say is that, in terms of the metrics, we like our G&A where it's at. And we think with this additional membership, this is the G&A leverage we should have gotten a year ago with exchanges. As you know, it was a deleverage impact to us a year ago. This year, it's going to be a leverageable impact. And so we're holding a line on G&A. And we again -- if the membership plays out with the risk profile we would expect, then that G&A leverage helps improve the margins. If it doesn't, then the G&A leverage helps offset any surprises. So I'd love to give you a different answer. But I mean, the reality is, we just chose to be conservative in Q1 until we can see how this book of business evolves."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then as you mentioned on the small group business that you saw some pressure, particularly in the states that expanded the -- to 51 to 100, what percent of your small group business is in the states?",39,"Okay. And then as you mentioned on the small group business that you saw some pressure, particularly in the states that expanded the -- to 51 to 100, what percent of your small group business is in the states?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. It's actually a decent amount, and I would say it was primarily in California. As you know, California was one of the states that made a decision, as did New York and Colorado. So if you're looking at what I'd call your typical market that would be t",144,"Yes. It's actually a decent amount, and I would say it was primarily in California. As you know, California was one of the states that made a decision, as did New York and Colorado. So if you're looking at what I'd call your typical market that would be the most significant for us, it's California of that group. And as a result, not only did your historical small group products no longer be allowed to persist, but you actually had to reintroduce all new products and reconsider the product mix of what it would look like as they went to a different direction from what was defined as a small group. So we're not happy about the membership we lost in those markets, but we also recognize that not every state adopted the flexibility that was offered to them under the Affordable Care Act."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Do you think that that's -- the more states are going end up doing that and it's a headwind we would expect to see next year in more states? Or if you were going to do it, you would have done it by now?",45,"Do you think that that's -- the more states are going end up doing that and it's a headwind we would expect to see next year in more states? Or if you were going to do it, you would have done it by now?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, I think if you were going to do it, you would've have done it by now. The other states have actually gone and maintained the historical small group definition. So I think that's behind us now.",37,"Yes, I think if you were going to do it, you would've have done it by now. The other states have actually gone and maintained the historical small group definition. So I think that's behind us now."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question will come from Ralph Giacobbe with Citigroup.",11,"And our next question will come from Ralph Giacobbe with Citigroup."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just wanted to go back to the exchanges. I guess, last quarter, you had mentioned that the exchange book was breakeven for 2015. And as you've talked about, you expected to pull G&A and bring it back to sort of profitable levels. Obviously, you've done be",84,"Just wanted to go back to the exchanges. I guess, last quarter, you had mentioned that the exchange book was breakeven for 2015. And as you've talked about, you expected to pull G&A and bring it back to sort of profitable levels. Obviously, you've done better on the enrollment side. So I guess you have talked about your conservatism. Can you help us in terms of what margins are assumed at this point for the exchange or maybe what's embedded in guidance for 2016?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Ralph, yes, in essence, I would tell you, as we said before, our targeted margins are 3% to 5%. And when we built our plan for this year, we were targeting lower than that threshold. We have not adjusted that targeted margins. So my point is that to the e",118,"Ralph, yes, in essence, I would tell you, as we said before, our targeted margins are 3% to 5%. And when we built our plan for this year, we were targeting lower than that threshold. We have not adjusted that targeted margins. So my point is that to the extent this mentorship does have the risk profile we have, you should expect a better margin as a result of the G&A leverage play. And to the extent that those 3Rs, in fact, not only settle up as we've been notified to date between Wakely and CMS, but actually cash flow as well between the parties that have to settle up, then you could expect margin expansion as well."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So I guess I just want to go back to the disconnect to the lack of guidance raised. If the assumption is to make still, let's call it, 1% to 2% margin or whatever that numbers is on the exchange on a bigger book, maybe to help level set, can you giv",75,"Okay. So I guess I just want to go back to the disconnect to the lack of guidance raised. If the assumption is to make still, let's call it, 1% to 2% margin or whatever that numbers is on the exchange on a bigger book, maybe to help level set, can you give us any sense at all of what you booked for 1Q in terms of sort of a comparable margin on the exchange?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","As you know, historically, when you have an individual member, you're very profitable in Q1, that profitability then declines down to ultimately a loss in Q4. What I would say is that, from our perspective, we've chosen not to take that profitability in,",90,"As you know, historically, when you have an individual member, you're very profitable in Q1, that profitability then declines down to ultimately a loss in Q4. What I would say is that, from our perspective, we've chosen not to take that profitability in, in Q1, but rather book to a breakeven perspective and then see how this book evolves in Q2 and thereafter. So to the extent that it evolves positively, then you'll get the margin improvement both from Q1 as well as in the run rate for the year."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. All right. That's helpful. And then I think it was asked earlier, but I don't think we got to sort of the answer around how you're positioning for 2017. Are there new states or territory that you're going to want to enter? And maybe a sense -- I kno",93,"Okay. All right. That's helpful. And then I think it was asked earlier, but I don't think we got to sort of the answer around how you're positioning for 2017. Are there new states or territory that you're going to want to enter? And maybe a sense -- I know it's early at this point, but when we think about target margins, you talked about 3% to 5%, is 2017 sort of an area where you expect to get there, get closer to there? Any just general commentary around that will be helpful."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","We're not targeting on a stand-alone basis in any new markets outside of our 14 states. I think our goal is to continue to stabilize the market in those states and start trending towards our targeted 3% to 5% margin. I would not anticipate, at this point",149,"We're not targeting on a stand-alone basis in any new markets outside of our 14 states. I think our goal is to continue to stabilize the market in those states and start trending towards our targeted 3% to 5% margin. I would not anticipate, at this point in time, that in '17 we would necessarily achieve that level of margin. But nonetheless, there has been a lot of activity around the regulations and ways to improve and create more stability. So we'll see. And to be fair, it's a little bit early in the pricing cycle. So we ultimately need to see how pricing evolves and what the states will ultimately approve in the pricing cycle and whether or not we can get there as early as '17. But right now, I'd be more cautious on getting there in '17, and view it more as an '18 play."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, I think the question is interesting the way you put it about expanding to other states, I mean, obviously, [indiscernible] precluded because of our Blue Cross Blue Shield presence in our 14 states and really think we should underscore the value we br",188,"Yes, I think the question is interesting the way you put it about expanding to other states, I mean, obviously, [indiscernible] precluded because of our Blue Cross Blue Shield presence in our 14 states and really think we should underscore the value we bring to our markets, our brand legacy, incredibly well known with respect to quality, as well as affordability. And to Wayne's earlier point, we have witnessed and we really do believe this flight to safety is real. And I think flight to safety is very relevant, with respect to how folks are connecting back to us in terms of a known brand. I think we're going to really seek the leverage that more effectively in every market that we're serving. And the last point I'll make I think is very important to underscore is that Cigna will help us with future expansion beyond our 14 states. So that's a story that's not yet told. And when it becomes clear that we can, we will express ourselves probably in more depth in terms of the potential to expand to other markets relative to the public exchanges."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And the next question will come from Chris Rigg with Susquehanna Financial.",12,"And the next question will come from Chris Rigg with Susquehanna Financial."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Apologize if I missed this. But did you guys say what you're now assuming for the reinsurance, coinsurance rate? I know at 4Q, you said a little above 50%. There's some data from CMS, which suggest it could be more like 60% to 65%. Just want to get a sens",63,"Apologize if I missed this. But did you guys say what you're now assuming for the reinsurance, coinsurance rate? I know at 4Q, you said a little above 50%. There's some data from CMS, which suggest it could be more like 60% to 65%. Just want to get a sense for what you're assuming now and whether that's had an impact on guidance?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Chris, thanks for the question. So we continue to assume a little bit north of 50%. I would tell you that if the CMS data of 60% to 65% goes forward, we will have sizable upside relative to those percentages. We're not so sure it will evolve ultimately to",199,"Chris, thanks for the question. So we continue to assume a little bit north of 50%. I would tell you that if the CMS data of 60% to 65% goes forward, we will have sizable upside relative to those percentages. We're not so sure it will evolve ultimately to that level. But based on the most recent data that's been submitted as well as the Wakely data we received on this, we are at a number below what the data would imply, that's what I would say and should have some conservatism going into 2Q and beyond. But again, we want to see ultimate settlement. As a reminder, on risk corridors, we continue to maintain a 100% valuation allowance against any receivables. And I would tell you the more sizable upside ultimately, will be on the risk adjusters, if what we've seen in early data related to '15 and '16 is, in fact, holds true into 2Q. And again, if, in fact, it's monetized by the parties that owe it. So I would say all 3 areas represent potential upside, the corridor being the least of -- we just don't see the money in the kitty to fund those."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And we'll go to the line of Matthew Borsch with Goldman Sachs.",13,"And we'll go to the line of Matthew Borsch with Goldman Sachs."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I was hoping that you could give us some -- your assessment on the group commercial side. The decline of -- I think it was 245,000 lives in the quarter was in line with what you had guided to. Can you -- I know, you referred to some states where they expa",110,"I was hoping that you could give us some -- your assessment on the group commercial side. The decline of -- I think it was 245,000 lives in the quarter was in line with what you had guided to. Can you -- I know, you referred to some states where they expanded the definition of small group, and that was a factor. I assume that there's some ASO conversions. Did some of that also reflect a conservative pricing posture? I mean, I know you always try to be conservative, but -- have you needed to be more conservative in the current pricing environment? If you could just talk to that."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Matt, yes, let me first start by saying well, it has some conversions from fully insured to ASO. And I think clearly you can see that in how strong our ASO book has done, and not just in National, but in the Large Group business as well. I think it's fair",156,"Matt, yes, let me first start by saying well, it has some conversions from fully insured to ASO. And I think clearly you can see that in how strong our ASO book has done, and not just in National, but in the Large Group business as well. I think it's fair to say that, at least half of it though represents those markets that did the switch with the majority of that being in California. And I would say we've maintained our pricing discipline in California. And it seems that most of that membership went to a single carrier, primarily a not-for-profit carrier that we think priced fairly aggressively. And again from our perspective, we'll weather that storm as we have in the past, and hopefully win those members back in the next year or so. But that's -- I'd say it's about 50-50 split, and then of the 50 that truly left, it's primarily California."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","That's very helpful. And also, if I could ask, what is approximately the amount by which you need to increase price going into 2017 to reflect the lack of reinsurance? And how much of a problem is that going to be for exacerbating some adverse selection t",58,"That's very helpful. And also, if I could ask, what is approximately the amount by which you need to increase price going into 2017 to reflect the lack of reinsurance? And how much of a problem is that going to be for exacerbating some adverse selection that's already a program-wide problem to some degree in the exchanges?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Matt, well, we generally haven't given all the specifics in pricing. I think the reinsurance is one that mathematically people can generally back into a range in the 5% to 6% range of what it could impact on upward pricing by itself. And so I would say th",157,"Matt, well, we generally haven't given all the specifics in pricing. I think the reinsurance is one that mathematically people can generally back into a range in the 5% to 6% range of what it could impact on upward pricing by itself. And so I would say that, that 5% to 6% range that we've had others ask about is a reasonable proxy of what you should expect for the piece of reinsurance that would run off. Relative to all other pricing, we're not necessarily talking to specifics, we're just in the process now of filing with our states. But this is clearly one area where we're spending time, making sure everybody is educated on. And I would tell you insurance regulators understand it, they get it, and they understand the implications of it. And so for competitive reasons, I would like to probably not discuss any further though our rate filings or actions at this point."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And we'll go to the line of Ana Gupte with Leerink Partners.",13,"And we'll go to the line of Ana Gupte with Leerink Partners."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Again following up on the commercial book, but now taking a view in '16 and 2017, there is a 2% gain in your commercial businesses and I'd say it's a mismash of various things, but as you're looking into '17...",40,"Again following up on the commercial book, but now taking a view in '16 and 2017, there is a 2% gain in your commercial businesses and I'd say it's a mismash of various things, but as you're looking into '17..."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Ana, can you start your question over? We're having trouble hearing you.",12,"Ana, can you start your question over? We're having trouble hearing you."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Yes, I was asking about the trend. Is this better?",10,"Yes, I was asking about the trend. Is this better?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","I'm sorry. You're cutting in and out. It's very difficult to hear you.",14,"I'm sorry. You're cutting in and out. It's very difficult to hear you."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Better now?",2,"Better now?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","A little bit, yes. Please try again.",7,"A little bit, yes. Please try again."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So I was asking about the 2017 commercial outlook and whether or not as you look into 2017, we're likely to see a better operating gain growth rate because the not-for-profit Blues, Aetna everywhere, they're all losing money on exchanges and I know",72,"Okay. So I was asking about the 2017 commercial outlook and whether or not as you look into 2017, we're likely to see a better operating gain growth rate because the not-for-profit Blues, Aetna everywhere, they're all losing money on exchanges and I know you don't overlap directly with the Blues. But as you think about Cigna and the post-Cigna world, if the pricing and underwriting spread will get better into 2017?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, I would say our -- well, we haven't given '17 outlook yet. And as you can imagine, well, I first want to see how '16 develops. But what I would highlight is that, we would expect to see the margins begin to trend to the more sustainable levels of 3%",203,"Well, I would say our -- well, we haven't given '17 outlook yet. And as you can imagine, well, I first want to see how '16 develops. But what I would highlight is that, we would expect to see the margins begin to trend to the more sustainable levels of 3% to 5%, I don't think again we'll be there by '17. But ultimately, it seems that the environment is starting to recognize the true cost of operating the exchanges in the membership that resides with it. These are large risk pools. So I think the industry is getting to the point where they have enough data to support the pricing that belongs with it. And we think that our job now is to continue to educate our regulators on the risk profile of the pools, actions we can take to help drive the costs down for affordability. And at the same time, though, to the extent that we're limited on actions, to make sure people understand in the pricing that goes with it. So I think for '17, it would -- today as best we can say it would be our expectation that margins would improve and pricing would continue to improve."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Are we talking about exchanges or commercial? I was talking about the group that's -- and the spread between trend and pricing, more sort of, is it likely to be a silver lining on the cloud just because companies are losing money on exchanges so they beco",53,"Are we talking about exchanges or commercial? I was talking about the group that's -- and the spread between trend and pricing, more sort of, is it likely to be a silver lining on the cloud just because companies are losing money on exchanges so they become more conservative on the commercial pricing?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's hard to know what others may do in their pricing. Clearly, in California, we did not see a player who we know lost money on exchanges necessarily take a more rational pricing on their small group book. So I guess what I would say is, we've seen one m",137,"It's hard to know what others may do in their pricing. Clearly, in California, we did not see a player who we know lost money on exchanges necessarily take a more rational pricing on their small group book. So I guess what I would say is, we've seen one market and then one competitor, you've seen one market and one competitor, so it's hard for us to understand. I think I would say is, this is -- our philosophy is, we've got to cover our cost of capital. We've got to give our shareholders a fair return for the risk that we bear and we price accordingly and then we'll just have to weather the markets, whatever they bring in, in the short-term as we did on the public exchanges in the last couple of years."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And then finally on the 51 to 100. Once you get past that headwind, is there a reduced tendency toward dumping some employers because exchanges haven't been as stable and there's a lot of volatility there?",36,"And then finally on the 51 to 100. Once you get past that headwind, is there a reduced tendency toward dumping some employers because exchanges haven't been as stable and there's a lot of volatility there?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","We think there is. I mean I think it seems like the dumping factor has really moved down and I think this was kind of the last clarification of product description and size under ACA that had to be implemented. So yes, I think from our perspective we view",73,"We think there is. I mean I think it seems like the dumping factor has really moved down and I think this was kind of the last clarification of product description and size under ACA that had to be implemented. So yes, I think from our perspective we view it as kind of stability. And I would say internally, we're targeting actually and trying to get back to small group growth again, now."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And we'll go to the last question here. It will come from Scott Fidel with Crdit Suisse.",18,"And we'll go to the last question here. It will come from Scott Fidel with Crdit Suisse."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just had a question on cost trends overall. And just interested, just within the guidance range that you talked about, how trend maybe behaving within that range in the first quarter? United, I talked about seeing a bit of an uplift in cost trend in the f",77,"Just had a question on cost trends overall. And just interested, just within the guidance range that you talked about, how trend maybe behaving within that range in the first quarter? United, I talked about seeing a bit of an uplift in cost trend in the first quarter maybe around 50 basis points. And then just also just specifically, whether you've been seeing an increase in surgical volumes year-over-year in the first quarter relative to last year?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Scott, thanks for the question. Yes -- well, first of all, it's important we recognize that we had assumed the trends would move up this year, as you know when we finished last year versus to what we guided to this year. So the trends have moved up, but w",266,"Scott, thanks for the question. Yes -- well, first of all, it's important we recognize that we had assumed the trends would move up this year, as you know when we finished last year versus to what we guided to this year. So the trends have moved up, but within our expectations and our pricing. As we look at various factors, I think we would've said early on that trend might have been favorably impacted by the flu. But the fact that the late season happened ultimately, we think for the full year that, that won't have a positive upside to us nor a downside, we think flu is going to play probably within our expectations. We did expect a fairly sizable uptick in trend in Q1 regarding really hep C. And we saw that, which is good and the good news is at least on a rolling 3-month average we looked at it, it seems to be playing right in line with our expectations, slightly better than our expectations, but I would tell you that we're not going to bank that yet because we think there may be some warehousing because there is new geno-type drugs that are coming out that people may be holding off on until those are available. So I think ultimately, when I look at what could be the big surprise items like a hep C or a flu or other items, everything seems to be playing pretty well relative to our expectations. And where we did expect it to be high in the quarter, it was, but within our pricing."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Scott, it's Joe. I think probably it's fair to also comment on a lot of what you can't see regarding the internal activity of the company, where we're obviously vigilant regarding trend changes. Internally, we're building really a robust provider collabor",133,"Scott, it's Joe. I think probably it's fair to also comment on a lot of what you can't see regarding the internal activity of the company, where we're obviously vigilant regarding trend changes. Internally, we're building really a robust provider collaboration models, really driven towards value-based contracting, that then tries to ameliorate the risk of trend escalation. Our data analytics infrastructure has been a remarkable uplift to the company with respect to our investments and the result and insights that we've captured in order to better manage the cost of care. So there's kind of the macro level that you see. But the micro level within the company, it's amazing how well we positioned ourselves to really address the kind of the prevailing winds that come at us in and around trend changes."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Got it. And then just on the surgical vials, are you able to tease out whether -- what you saw year-over-year there? Is it still a little bit too early to tell?",32,"Got it. And then just on the surgical vials, are you able to tease out whether -- what you saw year-over-year there? Is it still a little bit too early to tell?"
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's a little early. I mean we obviously look for different areas that might spike. I mean we see a little bit more there. But again relative to expectations, I think things are playing okay. So nothing of any specificity that I can provide at this point.",48,"It's a little early. I mean we obviously look for different areas that might spike. I mean we see a little bit more there. But again relative to expectations, I think things are playing okay. So nothing of any specificity that I can provide at this point."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Executives","Let me just kind of express the thanks to all of you for your questions. In summary, I'm pleased with our first quarter results and believe that these results position us very well for the remainder of the year. Hopefully, you got a sense of that with res",171,"Let me just kind of express the thanks to all of you for your questions. In summary, I'm pleased with our first quarter results and believe that these results position us very well for the remainder of the year. Hopefully, you got a sense of that with respect to our commentaries today. We do remain committed to increasing access to high-quality affordable health care. Specifically, we believe our ability to serve our customers will be advanced by the pending acquisition of Cigna, which we still remain of the belief that it is expected to close in the second half of 2016. And also, this includes our continued focus on improving matters like drug pricing. The -- I also want to thank all of our associates for their continued commitment to serving our nearly 40 million members, and I'd like to also again thank all of you on the call for your interest in Anthem and look forward to speaking with you soon. Again, thank you very much. Have a great day."
160077,308029053,965290,"Anthem, Inc., Q1 2016 Earnings Call, Apr 27, 2016",2016-04-27,"Earnings Calls","Elevance Health, Inc.","Operator","And ladies and gentlemen, this conference will be available for replay after 11:00 this morning and running through Wednesday, May 11 at midnight. You can access the AT&T Executive Playback service by dialing 1 (800) 475-6701 and entering the access code",71,"And ladies and gentlemen, this conference will be available for replay after 11:00 this morning and running through Wednesday, May 11 at midnight. You can access the AT&T Executive Playback service by dialing 1 (800) 475-6701 and entering the access code 378816. International parties may dial 1 (320) 365-3844. That does conclude our conference for today. Thanks for your participation and for using AT&T executive teleconference service. You may now disconnect."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management.",37,"Ladies and gentlemen, thank you for standing by. Welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Good morning, and welcome to Anthem's Second Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and John Gallina, our CFO. Joe will offer some commen",196,"Good morning, and welcome to Anthem's Second Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. 
With us this morning are Joe Swedish, Chairman, President and CEO; and John Gallina, our CFO. Joe will offer some commentary on the recent DOJ actions and provide an overview of our second quarter 2016 financial results. And then John will walk through the financials of our business units and provide some incremental commentary around our updated 2016 outlook. We're then available for Q&A. 
During the call, we'll reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website at antheminc.com. We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Anthem. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in today's press release and in our quarterly and annual filings with the SEC. 
I will now turn the call over to Joe."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Doug, and good morning. This morning, we announced second quarter 2016 adjusted earnings per share of $3.33, with membership and revenue tracking above our previous expectations. On a GAAP basis, we reported earnings per share of $2.91. Befor",925,"Thank you, Doug, and good morning. This morning, we announced second quarter 2016 adjusted earnings per share of $3.33, with membership and revenue tracking above our previous expectations. On a GAAP basis, we reported earnings per share of $2.91. 
Before John and I discuss the details of our second quarter financials and our updated 2016 outlook, I think it's appropriate to discuss our perspective on the latest Cigna developments. I'll start by saying we are disappointed by the U.S. Department of Justice's position to block Anthem's acquisition of Cigna, a combination specifically designed to tackle our health care systems challenges head on and deliver greater value to consumers by expanding access to high-quality affordable health care. To be clear, our board and executive leadership team at Anthem is fully committed to challenging the DOJ's decision in court. 
As you may have read in Tuesday's published op-ed, the DOJ has disregarded the issue of access for 2 of the most unstable and at high risk health insurance markets, individuals and small businesses. These populations comprise a meaningful proportion of the still more than 33 million uninsured Americans who will benefit from the Cigna acquisition through expanded and improved access, affordability and quality. 
For example, despite the many and continuing challenges of the health insurance exchanges, Anthem entered into this new and high-risk market at its inception. Though several of our competitors have exited this business, we now serve 923,000 public exchange members across 14 states where we do business as Blue Cross and Blue Shield plan. As shared with the DOJ, our acquisition of Cigna will help stabilize pricing in this volatile market, enabling Anthem to continue its commitment to the public exchanges and provide the opportunity to expand our participation to 9 additional states where neither Anthem nor Cigna currently participate. Additionally, we estimate this acquisition will significantly lower cost for our self-funded consumers with over $2 billion in medical cost savings that we passed directly back to them. 
Finally, we also note this acquisition will benefit our shareholders and the pension, retirement and investment funds that they represent. Specifically, 99% of our shareholders voted in favor of this transaction. 
Now to discuss consolidated financials we reported this morning. Our second quarter adjusted EPS of $3.33 was slightly ahead of our expectations, albeit with mixed financial metrics to get us there. Within membership, both fully-insured and self-funded memberships are tracking ahead of expectations as we ended the second quarter with nearly 39.8 million members. This reflects growth of an additional 148,000 lives during the quarter, bringing our year-to-date enrollment growth to 1.2 million lives or 3%. Specifically, our insured membership increased by 170,000 lives as our Medicaid business grew by a better-than-expected 280,000 lives in the quarter to over 6.3 million members. This reflected better-than-expected enrollment growth from the implementation of the Iowa State contract, which started on April 1, as well as better-than-expected core membership growth within multiple other state contracts. 
Within Commercial, our insured enrollment came in line with expectations. We ended the quarter with 923,000 lives from the individual public exchanges, a decrease of 52,000 from the 975,000 we reported in the first quarter. And Local Group insured business declined modestly and in line with our most recent expectations. 
Our self-funded business was relatively stable during the quarter, which was better than our previous expectations, as we experienced higher-than-expected growth in membership in existing accounts. Our membership results translated into better-than-expected operating revenue of $21.3 billion. Our second quarter 2016 results represent an increase of $1.5 billion or 7.7% versus second quarter of 2015, reflecting strong enrollment growth in the Government Business and additional premium revenue to cover overall cost trends. Also contributing was the growth in administrative fee revenue, as a result of our strong self-funded memberships trends. This was partially offset by fully insured membership losses in our commercial business. 
The second quarter 2016 benefit expense ratio was 84.2%, which increased by 210 basis points versus the prior year. The year-over-year increase was partially driven by a higher benefit expense ratio in the Medicaid business as our medical cost experience exceeded the net impact of annual premium rate adjustments and the impact of growth in membership, which the Medicaid business carries a higher benefit expense ratio than the consolidated company average. Further, the benefit expense ratio reflects the impact of higher medical cost experience in the individual business and the timing of higher medical cost experience in the Local Group business. The increase was partially offset by adjustments to the prior and current year risk adjustment estimates in our ACA-compliant individual and small group products. 
Our SG&A expense ratio came in at a better than previously expected 14% in the second quarter of 2016, a decrease of 140 basis points from the prior year. This was driven by an intentional focus on administrative expense control, coupled with better-than-expected enrollment trends as well as the changing mix of our membership towards the Government Business, which carries a lower than a consolidated average SG&A ratio. 
We reported operating cash flows of approximately $2 billion or 1.3x net income during the first 6 months of 2016. During the quarter, we reported operating cash flow of $662 million or 0.8x net income. As a reminder, we did make our first and second quarter income tax payments during the second quarter, consistent with prior years. 
I'll now turn the call over to our new Chief Financial Officer, John Gallina, to discuss our business segments quarterly results and our updated 2016 outlook in more detail. John?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thanks, Joe, and good morning. Turning to discuss the second quarter financial performance of our business units. We added 290,000 members in our Government Business during the quarter and grew year-over-year revenue by 9.5% to $11.4 billion. These result",1551,"Thanks, Joe, and good morning. Turning to discuss the second quarter financial performance of our business units. We added 290,000 members in our Government Business during the quarter and grew year-over-year revenue by 9.5% to $11.4 billion. These results now include the impact from the addition of the Iowa contract, which was implemented on April 1. Operating margins for the Government Business in the quarter came in at 4%, a decline of 190 basis points versus the prior year quarter, which was driven by lower gross margins in the Medicaid business. As we communicated previously, we have been expecting Medicaid margins to compress from 2015 levels to a more normalized level. We're monitoring rate environment for the remainder of the year. 
During the quarter, we also experienced higher-than-expected claims across Medicaid businesses with the most notable market being the newly implemented Iowa contract. It is important to note that it is not uncommon to have early challenges in a new market, and our team has a long track record of successfully identifying and implementing revenue and cost of care initiatives to help mitigate issues. We will continue to work collaboratively with our state partner to ensure program stability and high-quality care for Iowa's citizens. 
Within Medicare, we are pleased with the progress the team continues to make, and our year-to-date margins continue to reflect improvement versus last year. Our outlook continues to expect margins to improve as the year progresses towards our expected long-term sustainable levels, and we have positioned our portfolio to grow enrollment in 2017. 
The pipeline of opportunity for our Medicaid businesses remained substantial with an estimated $78 billion in contracts to be awarded between now and 2021 in markets that we will consider targeting. A little more than 3/4 of this opportunity is in new and specialized services, with the remainder in traditional Medicaid services. We continue to believe our experience and footprint position us very well to continue our growth as we help states address the challenges of rising health care costs and improving quality for their residents. 
Switching to our Commercial business. Our enrollment decreased by 142,000 lives during the quarter, which was slightly better than our previous expectations. Specifically, we experienced second quarter declines of 86,000 and 51,000 lives in our individual and national businesses, respectively. The better-than-expected enrollment results contributed to a higher-than-expected operating revenue during the quarter, which increased by 5.7% versus the prior year quarter to $9.9 billion. 
Our second quarter operating margin of 10.9% was 120 basis points higher than the 9.7% we reported in the second quarter of 2015. The increase was driven by adjustments to the prior and current year risk adjustment estimates recorded during the quarter, a lower SG&A ratio due to lower administrative costs resulting from expense efficiency initiatives and growth in self-funded enrollment, which carries a higher-than-average operating margin. This increase was partially offset by higher medical cost experience in individual ACA-compliant products and the timing of medical cost experience in our Local Group business. 
Within our individual ACA-compliant population, we had previously taken a conservative stance on our balance sheet with respect to various different estimates. This conservatism was very prudent as our current period claims trends have been higher than expected. We have seen higher-than-expected cost from membership with chronic conditions such as renal disease, COPD, heart disease and diabetes, along with signs of pent-up demand among our new members. We have experienced higher-than-expected payments for dialysis treatments during the first half of the year, which we're in the process of reviewing the drivers of this increase. All in, our updated outlook now expects the individual ACA-compliant business to incur mid-single-digit operating margin losses for the 2016 benefit year. 
It is important to note that we have assumed the higher-than-expected claims rate experienced thus far in the year will continue for the remainder of 2016 in developing our 2017 pricing assumptions. To be clear, we believe our pricing for 2017 fully incorporates our current expectations for 2016 claims, and we are focused on returning to profitability in 2017. 
Relating to national accounts, we continue to be pleased that the team continues to secure wins contributing to the track record of membership growth in 2017. 
Regarding our balance sheet metrics. Consistent with our past practice, we have included a roll-forward of our medical claims payable balance in this morning's press release. For the 6 months ended June 30, 2016, we experienced favorable prior year reserve development of $726 million, which was moderately better than our expectations. We continue to be at the upper end of our range of mid to high single-digit margins for average deviation and believe our reserve balance remains consistent and strong as of June 30, 2016. 
Our Days in Claims Payable is 40.6 days as of June 30, a decrease of 2.8 days from the 43.4 days as of March 31. The decrease is in line with our expectations and consistent with the level of decreased seen between the first and second quarter of 2015. As previously discussed, we expect Days in Claims Payable to come back down and closer to 40 over time. 
Our debt-to-capital ratio was 39.1% at June 30, 2016, now 110 basis points from the 40.2% at the end of the first quarter, which reflects the impact of an increase in shareholder equity and the reduction in our outstanding balance in commercial paper during the quarter. 
We ended the first quarter with approximately $2.1 billion of cash and investments at the parent company, and our investment portfolio was in an unrealized gain position of approximately $958 million as of June 30. 
For the 3Rs, we continue to book reinsurance as appropriate, and we continue to establish a 100% valuation allowance against any unpaid receivables for the 2014, 2015 and 2016 benefit years for risk corridors. 
For risk adjusters, the recent information from CMS shows us in a net receivable position, primarily in our small group market. We have recorded a valuation allowance against certain risk-adjusted receivables in some of our markets based on our assessment of the financial solvency of co-op organizations that are payers into the risk-adjusted program. There is a belief that these receivables may ultimately not be collected. 
As we have said in recent months and in the results we reported this morning, our operating metrics are expected to be different than we previously expected during the last earnings call. That said, we are reaffirming our adjusted earnings guidance and expect full year 2016 adjusted EPS to be greater than $10.80, excluding greater than $1.46 of negative adjustment items. On a GAAP basis, our 2016 earnings per share outlook is greater than $9.34. We are raising our operating revenue outlook by $1.5 billion to a range of $82.5 billion to $83.5 billion, reflecting stronger-than-expected enrollment across our businesses, including the contributions from Medicaid as well as the impact of adjustments to both prior and current year risk adjustment estimates. Fully-insured membership is now expected to be approximately 15 million members at the midpoint of our range, 100,000 higher than our previous outlook, which reflects stronger than previously expected results in the Medicaid business. Self-funded membership is now expected to be 24.7 million members at the midpoint of our range, approximately 200,000 higher than our previous outlook. Taken together, we now project total membership to be approximately 1 million to 1.2 million higher than we ended 2015. 
We now expect our medical loss ratio to be in the range of 84.9%, plus or minus 30 basis points for the year, reflecting our view that higher-than-previously-expected claims rates in our individual ACA-compliant plans as well as our Medicaid businesses remain at elevated levels throughout the year. This includes the worse-than-expected results in the newly implemented Iowa market. Reflecting the expected higher paid claims, we now expect 2016 operating cash flow to be approximately $3 billion. To offset the expected increase in our medical loss ratio, we are continuing the effort started last year to ensure we have an efficient cost structure. We now expect our SG&A ratio for the full year 2016 to be in the range of 14.5%, plus or minus 30 basis points. We continue to expect 2016 Local Group medical cost trends to be in the range of 7% to 7.5%. Our updated 2016 outlook does not include any benefit from the impact of share repurchase activity for the remainder of the year. As a reminder, we did not repurchase any shares for the first 6 months of 2016. 
Our outlook does include the adverse impact of the additional $0.02 in assessments associated with the dissolution of the Ohio co-op. This is in addition to the $0.03 of assessments we previously discussed in our first quarter call associated with the State of Colorado dissolution on their co-op. We have not included any additional assessments beyond those incurred in Colorado and Ohio in our outlook. 
It is important to note that our 2016 outlook does not include any additional benefits or transaction costs associated with the pending acquisition of Cigna beyond those incurred in the first half of 2016, nor does it include any benefit from lower pharmaceutical pricing, which we continue, we believe, we are entitled to, under our current contract with ESI. 
With that, operator, please open the queue for questions."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","[Operator Instructions] Your first question comes from the line of A.J. Rice from UBS.",14,"[Operator Instructions] Your first question comes from the line of A.J. Rice from UBS."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First, just to maybe -- I'm trying to clarify a little bit more on the outlook for the year and particularly what you're assuming for the back half. If my numbers are right, you're allowing for about a 300 to 400 basis point deterioration further from wha",121,"First, just to maybe -- I'm trying to clarify a little bit more on the outlook for the year and particularly what you're assuming for the back half. If my numbers are right, you're allowing for about a 300 to 400 basis point deterioration further from what we saw first half's MLR to back half MLR, and you're getting obviously, as you say, the SG&A leverage. Two parts today. Is that a normal seasonal pattern? Are you allowing for any other contingencies on the MLR assumption in the back half? And as -- would you characterize what you're doing on the SG&A side as something sustainable? Or are these sort of extraordinary measures in light of the MLR pressure you've experienced?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","A.J., this is John. Thank you for the question, and good morning. So a couple of questions there in terms of MLR and G&A. But first of all, on MLR, yes, your math is certainly appropriate from the first half to the last half. And really, what we've seen i",381,"A.J., this is John. Thank you for the question, and good morning. So a couple of questions there in terms of MLR and G&A. But first of all, on MLR, yes, your math is certainly appropriate from the first half to the last half. And really, what we've seen is that we've got an elevated amount of utilization specifically in the ACA Individual-compliant plans as well as in Medicaid and more significantly there in Iowa. And we're, at least, for purposes of our outlook, assuming that that elevated level is going to continue throughout the rest of the year. So while, certainly, if there's any mitigation factors or medical management initiatives end up being more successful than we are planning, then there could be upside. But it's really -- it has to do with taking the elevated levels of utilization we've seen and just essentially run rate again for the rest of the year. In terms of the G&A, I'd say the bulk of the G&A is sustainable. What we've really done is done an outstanding job of fixed cost leveraging. We're increasing membership this year between 1 million and 1.2 million members and maintaining our cost structure relatively constant. We are growing. Our headcount increased in the second quarter, but it increased at a far, far slower rate than our membership increased. Revenue is going up about $2.5 billion -- $2 billion to $2.5 billion for the change in guidance from the beginning of the year until today. Yet, the raw SG&A number is only going up very slightly. And so there's really -- it's really -- it has as much to do with an excellent job of fixed cost leveraging. Clearly, we are looking at some inefficiency and waste in terms of our processes and continue to look at those very closely on a regular basis and try to eliminate those things. And at the end of the day, the last piece of this, really is that we're a pay-for-performance company. And as a pay-for-performance company, in order to get our bonus payments, we have to hit our targets. And to the extent that we don't hit our targets, we'll reduce our benefit -- our bonus structure. So that's something that we're looking at very closely as well."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. If I could do just a quick follow-up. Joe, thanks for the comments about the Cigna transaction. I might just ask, do you have any updated assessment of the time line from here? And then I think the merger agreement goes through the end of this year.",73,"Okay. If I could do just a quick follow-up. Joe, thanks for the comments about the Cigna transaction. I might just ask, do you have any updated assessment of the time line from here? And then I think the merger agreement goes through the end of this year. Can you just mention to us what happens after the end of the year if we're still in the court dealing with the proposed transaction?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thanks, A.J. First of all, when you referenced the end of the year, actually, we had the option, on our side, our call, to extend it to the end of April, which obviously we intend to do so. So I just want to make that record clear. We will continue -- and",125,"Thanks, A.J. First of all, when you referenced the end of the year, actually, we had the option, on our side, our call, to extend it to the end of April, which obviously we intend to do so. So I just want to make that record clear. We will continue -- and obviously we're going to run out the litigation as long as it takes, working towards the end of April. Our expectation is, I guess, under normal or usual circumstances for claims like this, I will -- we expect the trial to begin somewhere around October. And at the outside, we're looking at 4 months. We believe it will be about 4 months. Obviously, it can run a little longer, but that's our expectation."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Josh Raskin from Barclays.",12,"Your next question comes from the line of Josh Raskin from Barclays."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I think I'm going to ask a very similar question to A.J., but just, I guess, a different perspective. So on the MLR, forgetting about sort of the first half versus second half, just on a year-over-year basis, the first half is up 188 basis points, and tha",178,"I think I'm going to ask a very similar question to A.J., but just, I guess, a different perspective. So on the MLR, forgetting about sort of the first half versus second half, just on a year-over-year basis, the first half is up 188 basis points, and that's only 3 months of Iowa, and you get some ACA benefit. But the second half looks more like an increase of 140 basis points. So the way I'm looking at it, year-over-year, you're actually expecting some noticeable improvement in the second half. So my MLR question is, what's causing that improvement on a relative basis? And then, John, on the G&A side, I think you mentioned that growth is going up a lot less than the revenue growth. But the way I look at it, second quarter, you added $1.5 billion to revenues but took $600 million of G&A out. So it looks like there are noticeable savings. I guess I'm just curious. Is that deferred investment? Or is that some other sort of savings on the G&A side?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Sure, Josh. Great question. So yes, first half will be clear on the MLR. First half of the year had the benefit of 3Rs in it. The run rate of claims outside of 3Rs is worse. And so that's obviously been baked into our outlook and our thought process. On t",106,"Sure, Josh. Great question. So yes, first half will be clear on the MLR. First half of the year had the benefit of 3Rs in it. The run rate of claims outside of 3Rs is worse. And so that's obviously been baked into our outlook and our thought process. On the admin side, quite honestly, the single-largest driver of that year-over-year is the bonus program that I referenced at the end of A.J.'s question in terms of being a pay-for-performance company. We adjusted our bonus payable appropriately based on ensuring that we're going to hit our $10.80. So yes, that's certainly a part of the reconciliation."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And John, what was 3R benefit? And I don't know, is there a way to size Iowa's impact in 2Q as well?",22,"And John, what was 3R benefit? And I don't know, is there a way to size Iowa's impact in 2Q as well?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, the 3R benefit in and of itself, we don't provide that level of specificity that you're probably asking for. In terms of Iowa, I'll just say that, Iowa is a brand new market. And we expected it to be dilutive in 2016 as we implemented our various med",218,"Yes, the 3R benefit in and of itself, we don't provide that level of specificity that you're probably asking for. In terms of Iowa, I'll just say that, Iowa is a brand new market. And we expected it to be dilutive in 2016 as we implemented our various medical management and revenue optimization processes. We ended up with about 25,000 more members in Iowa than we originally expected when we did our plan at the beginning of the year. And quite honestly, the MLR in Iowa is 25 to 30 basis points higher than we expected when we did our plan as well. So yet, the additional members and it's more diluted simultaneously, yes, with the elevated claims level. The really good news to that is that we do believe that our plan -- we look at -- at what we've done historically, what the team has  done historically in terms of new markets and implementing the managed care type processes and procedures and the fact that the first year markets have historically been dilutive and that we've got a target margin between 18- to 24-month period of time. There's no reason to believe that that's not going to occur again here in Iowa, even though the starting points may be a little bit bumpier than we'd hoped."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And either 25 to 30 basis points or points higher?",10,"And either 25 to 30 basis points or points higher?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Josh, 25 to 30 points higher, not basis points.",9,"Josh, 25 to 30 points higher, not basis points."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Point. Okay. So it's a huge number. Yes, that makes sense.",11,"Point. Okay. So it's a huge number. Yes, that makes sense."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Dave Windley from Jefferies.",12,"Your next question comes from the line of Dave Windley from Jefferies."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","It's Dave Styblo in for Windley. Just wanted to come back if you guys could help us bridge sort of the puts and takes and obviously the overall guidance remains the same in terms of EPS. But I think -- by the math that you guys presented on the individual",119,"It's Dave Styblo in for Windley. Just wanted to come back if you guys could help us bridge sort of the puts and takes and obviously the overall guidance remains the same in terms of EPS. But I think -- by the math that you guys presented on the individual book being at a mid-single-digit loss, it sounds like that's about a $0.40 change relative to sort of what you're thinking before. And then on top of that, you have the Medicaid challenges that you highlighted. Is -- is that sort of the right way to think about it and then the offset being largely just the SG&A improvement on top of that to offset those 2 negatives?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. The other part of that is the top line growth is very clearly a good guide as part of all that. But yes, those are the most significant pieces. I think the good news is, and just a sort of maybe answer your follow-up question before you ask it, is th",128,"Yes. The other part of that is the top line growth is very clearly a good guide as part of all that. But yes, those are the most significant pieces. I think the good news is, and just a sort of maybe answer your follow-up question before you ask it, is that if we look at 2016 versus 2017, let's be very clear, as I said in the prepared comments, when we did our pricing for 2017, we already had taken this elevated level of claims and utilization into account and baked it into our 2017 outlook. And so we believe this is more of a 1-year type of issue. And that we're very committed to returning the ACA block of the business back to probability in 2017."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So you did address my question earlier in the follow-up. So is it -- I guess, it seems like you priced for these things to happen. And in some ways, it still seems like it's worse than expected. So if you are filing rates and benefit changes earlier in th",92,"So you did address my question earlier in the follow-up. So is it -- I guess, it seems like you priced for these things to happen. And in some ways, it still seems like it's worse than expected. So if you are filing rates and benefit changes earlier in the year, maybe can you just give us more comfort about specifically how you caught these things earlier on when we're starting see more the development come in with higher utilization in dialysis and COPD and other elements that you've talked about?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure. Well, the rates were developed in the April-May time frame. And so when you look back at our -- when we closed the books in March and the information we had available to us at that point in time, we had seen some of the spikes and the elevation",190,"Yes, sure. Well, the rates were developed in the April-May time frame. And so when you look back at our -- when we closed the books in March and the information we had available to us at that point in time, we had seen some of the spikes and the elevations. It's not that it was to the same -- we weren't crystal-clear then it was going to continue for the rest of the year or not. However, we want to be conservative. We wanted to be prudent. And so we believe, we had hoped that it was not trend. However, when we did our pricing, we thought it was best to assume it was a trend. Here we are 90 days later. I believe our conservatism turned out to be prudent. And that's something that we weren't sure if it was going to be a trend or not, probably is. There's still the opportunity that seasonality could be in our favor. And I think things could get a little better in the second half of the year. We just decided not to assume that at this point in time."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And then if I could just ask on Medicaid. I know you obviously highlighted Iowa, and then you mentioned that broadly there is higher trends. Is it predominantly just Iowa being the drag in Medicaid? Or are there some specific other states that maybe if yo",76,"And then if I could just ask on Medicaid. I know you obviously highlighted Iowa, and then you mentioned that broadly there is higher trends. Is it predominantly just Iowa being the drag in Medicaid? Or are there some specific other states that maybe if you could sort of share a percentage of the weighting of the 75% Iowa, 25% other states and highlight what those other states might be and issues that you're seeing there?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","In terms of -- it is both Iowa as well as other states. And we really don't get into specifics state by state. We're just calling out Iowa as a marker because it's brand new and it is a significant driver in and of itself. And we'll all say that the prima",98,"In terms of -- it is both Iowa as well as other states. And we really don't get into specifics state by state. We're just calling out Iowa as a marker because it's brand new and it is a significant driver in and of itself. And we'll all say that the primary drivers of the elevated trends, the pharmacy, nursing facilities, ER and outpatient surgery. Those 4 items are really the most significant part of our trend issue in the other states. So -- but we are seeing elevated trends in several states, and we're addressing those accordingly."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. But fair to say well above 50% is attributable to Iowa, though?",13,"Okay. But fair to say well above 50% is attributable to Iowa, though?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","We really don't get into that level of detail on a state-by-state basis for competitive reasons.",17,"We really don't get into that level of detail on a state-by-state basis for competitive reasons."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Andy Schenker from Morgan Stanley.",13,"Your next question comes from the line of Andy Schenker from Morgan Stanley."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So just going back to the exchange business here. Just thinking about it, big picture, right, in 2014, you guys were actually profitable. Last year, you were close to breakeven. This year, you're now losing money here. So what is really changed over that",117,"So just going back to the exchange business here. Just thinking about it, big picture, right, in 2014, you guys were actually profitable. Last year, you were close to breakeven. This year, you're now losing money here. So what is really changed over that time frame? Is it just the risk pool continue to get worse? And therefore, is this something you can actually rectify with pricing? Or are there structural issues to the exchanges? Or are there other more meaningful benefit changes, i.e. networks or other design changes that you've also incorporated for next year that are going to be necessary to offset what's been a steady deterioration of the profitability of this book every year?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure. No, great question. In terms of, will pricing by itself rectify it? No. Because there's no one single bullet that actually solves the entire problem. The administration is simply focused on having a sustainable marketplace. And we think that we",261,"Yes, sure. No, great question. In terms of, will pricing by itself rectify it? No. Because there's no one single bullet that actually solves the entire problem. The administration is simply focused on having a sustainable marketplace. And we think that we've been a very active participant in the exchanges and been a great partner with CMS in trying to help with the stability of the marketplace. They've made changes over the years of tightening the supplemental enrollment a bit in various other requirements. The penalty continues to increase. We think all those things obviously have to be done. Other things that would certainly help the acceleration with stabilization would be to eliminate the health insurer tax in 2017 -- beyond 2017. The risk adjuster model, it's -- it does a lot of what it's intended to do. But quite honestly, there's a bit of an imbalance that the -- that it overcharges for healthy and over-reimburses for certain moderately unhealthy disease states. We think, as I said, the supplemental moment period, we really do need a better upfront medical verification process and that there should not be any restriction on our efforts to innovative product designs to meet consumer needs and then modifying the grace periods for nonpayment of premiums would be something else. So those are just -- in addition to the pricing, things that we've been working with the administration on and believe should occur. We do believe that with medical management and various other issues that we can help get this back to profitability here in 2017."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. This is Joe. Let me sway in to add to what John just shared with you. Just to reiterate, we've been a very active participant in exchanges from the beginning. And recognize the markets have taken longer than expected to stabilize. And we've stated th",363,"Yes. This is Joe. Let me sway in to add to what John just shared with you. Just to reiterate, we've been a very active participant in exchanges from the beginning. And recognize the markets have taken longer than expected to stabilize. And we've stated that repeatedly. And I think we've been working very closely with the administration in conducting our own modeling to best judgment how we're going to continually engage year-over-year in as profitable a context as possible. It's interesting, reflect back to the end of the first quarter, we told you that, end of June 30, we'd probably have greater insight into the membership we've captured, recognizing that we had a substantial uptick in membership. Deteriorated a little bit at the end of Q2 to around 925,000 or so members. But what we've observed in terms of the intensity of illness is that, as John pointed out in his earlier remarks, we're dealing with some chronic illnesses like cardiac, diabetes, COPD. We've had what we think is a material uptick in dialysis cost that have hit us. So we're going through an appraisal of all that in terms how to better medically manage those members as well as begin pricing it into '17. That's the trick. I mean, John has stated, and I restate it. I mean, we believe we're well positioned for pricing in '17 given what we now know about the membership we captured. And so I guess, when you put all that together, what we're waiting for now is rate approvals by state. And I can assure you that we're going to be extremely prudent in our continued engagement. I think we're in something like 138 or so rating regions. And we're going through an appraisal of every one of those regions. And we'll make prudent business decisions in terms of flexing our engagement in appropriate ways going into '17. And so I just -- I want to assure that, notwithstanding we've been active participants, we're also very -- I'll use the word prudent, very thoughtful, in terms of executing a good business practice in terms of how we continue to stay engaged in the public marketplace."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","That was very helpful. Thinking maybe a little bit more broadly. You kind of reiterated your small group or Local Group, rather, trend assumptions here, but you did kind of call out timing and medical costs experience for Local Group. Maybe if you could j",74,"That was very helpful. Thinking maybe a little bit more broadly. You kind of reiterated your small group or Local Group, rather, trend assumptions here, but you did kind of call out timing and medical costs experience for Local Group. Maybe if you could just talk about more about what you're seeing around trend, if there's any pockets you're seeing in patients, et cetera, as it relates to that -- how you define it?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure. So in terms of trend on the Local Group side, that's actually going very well. And we reaffirmed the 7% to 7.5% outlook for that and feel very comfortable with that, given the results for the first half of the year. In terms of the timing, that",161,"Yes, sure. So in terms of trend on the Local Group side, that's actually going very well. And we reaffirmed the 7% to 7.5% outlook for that and feel very comfortable with that, given the results for the first half of the year. In terms of the timing, that relates to just a couple, really, accounting and calendar quirks. The first quarter of 2016 had an extra workday in it, driven by a leap year. The second quarter of 2016 had an extra work day in it, driven by how the weekend spell. The fourth quarter of 2016 has 1 less work day in it. And so that's significant enough to change the timing pattern on a quarter-over-quarter basis. Then you take that in the fact that our overall product mix in the group side is slightly richer than the overall product mix in the group side a year ago. That changes the timing as well given how the deductibles work."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of the Gary Taylor from JPMorgan.",13,"Your next question comes from the line of the Gary Taylor from JPMorgan."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just a couple of questions. Did you give us the total exchange enrollment as of the end of 2Q? Did I miss that?",23,"Just a couple of questions. Did you give us the total exchange enrollment as of the end of 2Q? Did I miss that?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. It's 923,000.",3,"Yes. It's 923,000."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And the total -- when you talk about the ACA-compliant book now being mid-single-digit losses, what is the total ACA-compliant enrollment that you're speaking to? So presumably, that's some off exchange and small group ACA-compliant as well?",37,"And the total -- when you talk about the ACA-compliant book now being mid-single-digit losses, what is the total ACA-compliant enrollment that you're speaking to? So presumably, that's some off exchange and small group ACA-compliant as well?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","A little more than half of the remainder is ACA-compliant.",11,"A little more than half of the remainder is ACA-compliant."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And I just wanted to come back to the risk adjustment because it seems like potentially it was quite material in the quarter. I know you guys only disclose that you had a payable at year-end. We calculate that payable by the $105 million and the swi",95,"Okay. And I just wanted to come back to the risk adjustment because it seems like potentially it was quite material in the quarter. I know you guys only disclose that you had a payable at year-end. We calculate that payable by the $105 million and the swing factor to $190 million payment that CMS was citing for '15 is about $0.60. You say that you booked some valuation allowances against that because of co-op situations. But I mean should we assume that a material portion of that $0.60 was trued up in this quarter?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","I -- there was a lot of things that went against it, and I'm not going to really comment on your estimate of the payable. But in terms of valuation allowance, it's clearly part of it. Certainly, medical loss ratio rebates were part of it. After all the du",142,"I -- there was a lot of things that went against it, and I'm not going to really comment on your estimate of the payable. But in terms of valuation allowance, it's clearly part of it. Certainly, medical loss ratio rebates were part of it. After all the dust settled, we're going to pay over $100 million in MLR rebates in 2016 related to 2015 calendar year. And so that's part of it. And we've got the small group versus the individual component is clearly a piece of it. Risk corridor true-ups reinsurance -- I mean there's so many moving parts, it's hard to want to call here and pin that down exactly. And then quite honestly, whatever benefits existed after all the other offsets has now been baked into our trend outlook and our guidance for the rest of the year."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay, if I could just -- two quick clarifications. I think Josh was asking about G&A run rate and sustainability of that -- the guidance, the second half certainly implies this reduced G&A is fairly sustainable. But as you head into '17, do you feel like",76,"Okay, if I could just -- two quick clarifications. I think Josh was asking about G&A run rate and sustainability of that -- the guidance, the second half certainly implies this reduced G&A is fairly sustainable. But as you head into '17, do you feel like there's going to be a deferred level that has to rebound? Or is this sort of G&A ratio a number that makes sense as a jumping-off point heading into '17?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","The most significant driver of the G&A benefits here compared to our guidance or our outlook is the top line revenue growth and the fixed cost leveraging associated with that. So that clearly is run rate and sustainable. In terms of -- certainly, as an em",117,"The most significant driver of the G&A benefits here compared to our guidance or our outlook is the top line revenue growth and the fixed cost leveraging associated with that. So that clearly is run rate and sustainable. In terms of -- certainly, as an employee of the company, I'm fully supportive of getting back to the bonus structure back to target levels. But there's a natural hedge associated with that. So as results warrant it, we then record the expense. If they don't warrant it, we don't record the expense. So what the impact that might be on an exact ratio is to be seen, but the bottom line has a natural hedge built in."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","My last one. When we think about the year, the ACA-compliant business, worse than you had anticipated. Iowa and Medicaid overall worse than anticipated. Yet, you maintained the guidance. So the 2 components that were better that allowed you to maintain co",55,"My last one. When we think about the year, the ACA-compliant business, worse than you had anticipated. Iowa and Medicaid overall worse than anticipated. Yet, you maintained the guidance. So the 2 components that were better that allowed you to maintain compliance was risk adjustment and some of the additional enrollment growth. Is that fair?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, certainly, admin, risk adjustment, enrollment growth. We're doing extremely well in the national and large local ASO in terms of enrollment. Our Medicare Advantage and our senior business are growing very, very well and exceeding expectations for th",112,"Well, certainly, admin, risk adjustment, enrollment growth. We're doing extremely well in the national and large local ASO in terms of enrollment. Our Medicare Advantage and our senior business are growing very, very well and exceeding expectations for the year. And quite honestly, we had a bit of an initial conservative posture at the beginning of the year as well. So it's a lot of things. Our specialty product line is beating expectations. So I would hate to just point to 1 or 2 items because there are far more positives than there are negatives. It's just that the 2 negatives have really caused our conservative posture to be more prudent posture."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Justin Lake from Wolfe Research.",13,"Your next question comes from the line of Justin Lake from Wolfe Research."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First, just a follow-up on the SG&A number for that bonus program. I understand that, as you said at the hedge, other things have to improve to offset it. But can you give us a ballpark number there in terms of how much cost comes back into SG&A if you fu",56,"First, just a follow-up on the SG&A number for that bonus program. I understand that, as you said at the hedge, other things have to improve to offset it. But can you give us a ballpark number there in terms of how much cost comes back into SG&A if you fully accrue that for next year?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, in terms of exactly how much that is, the bonus program target is certainly a significant number in and of itself, but just not a number that we're comfortable giving out.",32,"Well, in terms of exactly how much that is, the bonus program target is certainly a significant number in and of itself, but just not a number that we're comfortable giving out."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. Is there any way to proportionate, for instance? You're losing -- you said mid-single digits on the individual side. I mean, can you remind us what's the ACA-compliant premium number for this year, ballpark?",35,"Okay. Is there any way to proportionate, for instance? You're losing -- you said mid-single digits on the individual side. I mean, can you remind us what's the ACA-compliant premium number for this year, ballpark?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's a bit north of $6 billion, close to -- maybe closer to $7 billion.",16,"It's a bit north of $6 billion, close to -- maybe closer to $7 billion."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So you're talking about $300 million-plus in potential -- just getting back to breakeven, right, in the individual business? Right? Or is that how should we think about earnings power of the business? I assume you're not expecting to run losses for",58,"Okay. So you're talking about $300 million-plus in potential -- just getting back to breakeven, right, in the individual business? Right? Or is that how should we think about earnings power of the business? I assume you're not expecting to run losses for -- in a -- even intermediate term here that you talk about? So if we..."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","I'm not going to argue with you, man.",9,"I'm not going to argue with you, man."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So if individual comes back to breakeven or better, does this SG&A basically offset that? Or is it larger or smaller than individual coming back to breakeven?",28,"Okay. So if individual comes back to breakeven or better, does this SG&A basically offset that? Or is it larger or smaller than individual coming back to breakeven?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, there's certainly a -- it's a natural hedge built in. But to answer your question would be to answer the question that you asked the first time. So good luck. It's a big number, but we're not going to size it specifically.",43,"Well, there's certainly a -- it's a natural hedge built in. But to answer your question would be to answer the question that you asked the first time. So good luck. It's a big number, but we're not going to size it specifically."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. But you wouldn't call me crazy if I said it was in the same ballpark as getting back to breakeven individual?",22,"Okay. But you wouldn't call me crazy if I said it was in the same ballpark as getting back to breakeven individual?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","I would never call you crazy.",6,"I would never call you crazy."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","All right. Last question, just on the government side. So you've laid out the issues here. And you're very clear coming into 2016 saying, for instance, Medicaid was -- the margins were unsustainable. They were going to come down, plus you're going to have",124,"All right. Last question, just on the government side. So you've laid out the issues here. And you're very clear coming into 2016 saying, for instance, Medicaid was -- the margins were unsustainable. They were going to come down, plus you're going to have the Medicaid pressure in Iowa. I guess, my -- what I'm trying to think about here is, these margins are down meaningfully for 2016 in the government overall. And you're saying Medicare is actually improving. So Medicaid bears the full brunt. My question is, is Medicaid now at a target margin for 2016 when you think about it overall? Or does the Medicaid margin actually improve going forward from here, given how tough it's been and the worse-than-expected cost overall?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's a -- the Medicaid margins are within our target range. Obviously, we're hopeful that we can improve it to the high end of the range. But even with all these headwinds and the negative comments that we had earlier in the year, we're still within the r",49,"It's a -- the Medicaid margins are within our target range. Obviously, we're hopeful that we can improve it to the high end of the range. But even with all these headwinds and the negative comments that we had earlier in the year, we're still within the range."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","But for the full year, you're within the range, but closer to the midpoint, to the low end, and potentially can improve it towards the higher end again where you've typically been?",32,"But for the full year, you're within the range, but closer to the midpoint, to the low end, and potentially can improve it towards the higher end again where you've typically been?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","That's a reasonable way of thinking about it. Yes.",10,"That's a reasonable way of thinking about it. Yes."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Kevin Fischbeck from Bank of America.",14,"Your next question comes from the line of Kevin Fischbeck from Bank of America."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. Got a couple of questions. I guess, first, on the exchanges. I guess, obviously, you guys believe that you've caught everything as far as pricing for next year and you expect margins to improve next year. But I guess, you've seen now, I don't know,",104,"Okay. Got a couple of questions. I guess, first, on the exchanges. I guess, obviously, you guys believe that you've caught everything as far as pricing for next year and you expect margins to improve next year. But I guess, you've seen now, I don't know, 5 or 6 quarters in a row, where you kind of -- it seems like the costs continue to rise for you, but really for a lot of the plays out there. I mean can you give a sense of to why you feel confident saying that given the experience of most companies over the last 1.5 years?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, why we believe we've caught everything?",7,"Well, why we believe we've caught everything?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Yes, exactly.",2,"Yes, exactly."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, I think -- a lot of it obviously has to do with our data analytics and how we track things. And as you look at the rate increases that we put in, approaching 20% range on a weighted-average basis across our 14 states, very significant. And as we --",242,"Well, I think -- a lot of it obviously has to do with our data analytics and how we track things. And as you look at the rate increases that we put in, approaching 20% range on a weighted-average basis across our 14 states, very significant. And as we -- yes, we also believe that we have some of the best-in-class risk adjuster capabilities of really understanding what really drives risk adjuster and things like that and I think the results that we saw from the CMS true-up really helped verify that. So the other piece that gives us a little bit of comfort in terms of having caught everything is that 2016 risk adjuster that we're assuming in the '17 really is based on 2015 experience. So we think that that gives us a natural cushion associated with how that's being approached. But at the end of the day, the question is, ""How do know we've gotten everything?"" Well, we've got 6 months of information. Obviously, there's a lot of new members associated with those business. You can't provide absolute certainty. But we think we have very, very good line of sight. What we saw at the end of the first quarter, we further predicted from a pricing standpoint. And what we saw at the end of the second quarter was exactly consistent with that pricing prediction. So we feel good that we've got a good line of sight on that."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I guess, is there anything different about you heading into Q3 this year versus you heading into Q3 last year as far as what you're doing from a data analytics perspective? Or anything there that gives you more confidence or visibility this year to what y",55,"I guess, is there anything different about you heading into Q3 this year versus you heading into Q3 last year as far as what you're doing from a data analytics perspective? Or anything there that gives you more confidence or visibility this year to what you had heading into the back half of last year?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well -- this is Joe. I certainly believe that we're always improving year-over-year, especially in the space that we've got more and more data. Certainly, we recognize that this is a company that's had a long-standing engagement of high-risk pools. We hav",147,"Well -- this is Joe. I certainly believe that we're always improving year-over-year, especially in the space that we've got more and more data. Certainly, we recognize that this is a company that's had a long-standing engagement of high-risk pools. We have a lot of data that has backed us up for a long period of time. And I think that we just -- as I said a moment ago, always expect to continue of improving the space. However, I'll reiterate what I've said earlier, we're going to be very surgical with respect to our analytics in and around rating regions. We're going to be very mindful of what price increases are awarded to us by state. And so we'll be making very, I'll call it, accurate business decisions going into '17 and beyond regarding our continued engagement on a broad scale in the public exchange space."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. And in the other comment that I'll just add to that, I think we'll address what will be different going to the third quarter is, 2016, we actually had more members come on board on January 1 than we did in 2015 or 2014. 2014, in particular, if you re",113,"Yes. And in the other comment that I'll just add to that, I think we'll address what will be different going to the third quarter is, 2016, we actually had more members come on board on January 1 than we did in 2015 or 2014. 2014, in particular, if you recall, we had a vast majority of the members come on board early second quarter. And 2015, with the extension of the open enrollment period, a lot of members came on later in the first quarter. 2016, a lot more January 1. We actually do have a full 6 months of information this year. And we had not had that in prior years."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay then. Just last question. Last quarter, you said that -- you expected the exchanges to be pretty much breakeven this year, you said next year was probably going to be below your target 3 to 5. But by 2018, you'll be in your target margin. Do you stil",85,"Okay then. Just last question. Last quarter, you said that -- you expected the exchanges to be pretty much breakeven this year, you said next year was probably going to be below your target 3 to 5. But by 2018, you'll be in your target margin. Do you still feel like you still have that same ramp over the next couple of years? Or does this set you back -- kind of push back when you're going to get to your target margins on exchanges?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","The pricing increases that we've put in really do keep us on that same ramp. And it's very and very important that we do receive the pricing increases that we have filed for in terms of that. Obviously, we expect the market to continue to harden and prici",96,"The pricing increases that we've put in really do keep us on that same ramp. And it's very and very important that we do receive the pricing increases that we have filed for in terms of that. Obviously, we expect the market to continue to harden and pricing to be more reasonable. I mean, clearly, there's a reason that so many co-ops have gone insolvent in terms of their pricing methodologies. So as there's more and more of those folks exit the market, it should provide a more sustainable stable marketplace in 2018 and beyond."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","And your final question today comes from the line of Chris Rigg.",12,"And your final question today comes from the line of Chris Rigg."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just with regard to the ACA-compliant membership, do you have a sense, at this point, how many of the individuals were new members to Anthem? And is there -- if you have that information, is there a pronounced difference in utilization trends among those",60,"Just with regard to the ACA-compliant membership, do you have a sense, at this point, how many of the individuals were new members to Anthem? And is there -- if you have that information, is there a pronounced difference in utilization trends among those or -- new to Anthem those that had been enrolled for a year or 2?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Very quick response to the question, a little less than half of membership was new to us in '16.",20,"Yes. Very quick response to the question, a little less than half of membership was new to us in '16."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then just one quick follow-up here. Of the individual that's not ACA-compliant at this point, will most of them become enrolled into ACA-compliant plans in 2017 because of the grandmothering dynamic? Or will they still stay outside the complaint",42,"Okay. And then just one quick follow-up here. Of the individual that's not ACA-compliant at this point, will most of them become enrolled into ACA-compliant plans in 2017 because of the grandmothering dynamic? Or will they still stay outside the complaint side?"
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes -- no, a great question. Yes, we do expect some attrition in that area as you pointed out. Whether they enroll remains to be seen, but historically, we haven't seen the uptake in ACA-compliant plans that maybe was estimated by the CBO when the law was",57,"Yes -- no, a great question. Yes, we do expect some attrition in that area as you pointed out. Whether they enroll remains to be seen, but historically, we haven't seen the uptake in ACA-compliant plans that maybe was estimated by the CBO when the law was passed. But yes, that's certainly a watch area for us."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","And I would now like to turn the conference back to the company's management for closing comments.",18,"And I would now like to turn the conference back to the company's management for closing comments."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, as usual, thanks for your questions. They're all very insightful. As a company, we remain committed to tackling our health care system challenges head on and deliver greater value to consumers by expanding access to high-quality affordable health ca",100,"Well, as usual, thanks for your questions. They're all very insightful. As a company, we remain committed to tackling our health care system challenges head on and deliver greater value to consumers by expanding access to high-quality affordable health care. That's why we're committed to challenging the DOJ's recent decision to block our acquisition of Cigna in court. We also want to thank all of our associates for their continued commitment to serving our 39.8 million members every day. Thanks for your interest in Anthem, and we look forward to speaking with you very soon. Again, thank you very much."
160077,308029078,1013187,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, this conference will be available for replay after 11:00 a.m. Eastern Time today through August 10. You may access the AT&T Teleconference Replay System at anytime by dialing 1 (800) 475-6701 and entering the access code 378817. Inte",67,"Ladies and gentlemen, this conference will be available for replay after 11:00 a.m. Eastern Time today through August 10. You may access the AT&T Teleconference Replay System at anytime by dialing 1 (800) 475-6701 and entering the access code 378817. International participants, dial (320) 365-3844. That does conclude your conference for today. Thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management.",37,"Ladies and gentlemen, thank you for standing by. Welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Good morning, and welcome to Anthem's Second Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and John Gallina, our CFO. Joe will offer some commen",197,"Good morning, and welcome to Anthem's Second Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. 
With us this morning are Joe Swedish, Chairman, President and CEO; and John Gallina, our CFO. Joe will offer some commentary on the recent DOJ actions and provide an overview of our second quarter 2016 financial results, and then John will walk through the financials of our business units and provide some incremental commentary around our updated 2016 outlook. We're then available for Q&A. 
During the call, we will reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website at antheminc.com. We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Anthem. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in today's press release and in our quarterly and annual filings with the SEC. 
I will now turn the call over to Joe."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Doug, and good morning. This morning, we announced second quarter 2016 adjusted earnings per share of $3.33, with membership and revenue tracking above our previous expectations. On a GAAP basis, we reported earnings per share of $2.91. Befor",923,"Thank you, Doug, and good morning. This morning, we announced second quarter 2016 adjusted earnings per share of $3.33, with membership and revenue tracking above our previous expectations. On a GAAP basis, we reported earnings per share of $2.91. 
Before John and I discuss the details of our second quarter financials and our updated 2016 outlook, I think it's appropriate to discuss our perspective on the latest Cigna developments. I'll start by saying we are disappointed by the U.S. Department of Justice's decision to block Anthem's acquisition of Cigna, a combination specifically designed to tackle our health care system's challenges head on and deliver greater value to consumers by expanding access to high-quality, affordable health care. To be clear, our board and executive leadership team at Anthem is fully committed to challenging the DOJ's decision in court. 
As you may have read in Tuesday's published op-ed, the DOJ has disregarded the issue of access for 2 of the most unstable and at high risk health insurance markets: individuals and small businesses. These populations comprise a meaningful proportion of the still more than 33 million uninsured Americans who will benefit from the Cigna acquisition through expanded and improved access, affordability and quality. 
For example, despite the many and continuing challenges of the health insurance exchanges, Anthem entered into this new and high-risk market at its inception. Though several of our competitors have exited this business, we now serve 923,000 public exchange members across 14 states where we do business as Blue Cross and Blue Shield plan. As shared with the DOJ, our acquisition of Cigna will help stabilize pricing in this volatile market, enabling Anthem to continue its commitment to the public exchanges and provide the opportunity to expand our participation to 9 additional states where neither Anthem nor Cigna currently participate. Additionally, we estimate this acquisition will significantly lower cost for our self-funded consumers, with over $2 billion in medical cost savings that we passed directly back to them. Finally, we also note this acquisition will benefit our shareholders and the pension, retirement and investment funds that they represent. Specifically, 99% of our shareholders voted in favor of this transaction. 
Now to discuss consolidated financials we reported this morning. Our second quarter adjusted EPS of $3.33 was slightly ahead of our expectations, albeit with mixed financial metrics to get us there. Within membership, both fully insured and self-funded memberships are tracking ahead of expectations as we ended the second quarter with nearly 39.8 million members. This reflects growth of an additional 148,000 lives during the quarter, bringing our year-to-date enrollment growth to 1.2 million lives or 3%. Specifically, our insured membership increased by 170,000 lives as our Medicaid business grew by a better-than-expected 280,000 lives in the quarter to over 6.3 million members. This reflected better-than-expected enrollment growth from the implementation of the Iowa state contract, which started on April 1, as well as better-than-expected core membership growth within multiple other state contracts. 
Within commercial, our insured enrollment came in line with expectations. We ended the quarter with 923,000 lives from the individual public exchanges, a decrease of 52,000 from the 975,000 we reported in the first quarter. And Local Group insured business declined modestly and in line with our most recent expectations. 
Our self-funded business was relatively stable during the quarter, which was better than our previous expectations, as we experienced higher-than-expected growth in membership in existing accounts. Our membership results translated into better-than-expected operating revenue of $21.3 billion. Our second quarter 2016 results represent an increase of $1.5 billion or 7.7% versus the second quarter of 2015, reflecting strong enrollment growth in the Government Business and additional premium revenue to cover overall cost trends. Also contributing was the growth in administrative fee revenue as a result of our strong self-funded memberships trends. This was partially offset by fully insured membership losses in our commercial business. 
The second quarter 2016 benefit expense ratio was 84.2%, which increased by 210 basis points versus the prior year. The year-over-year increase was partially driven by higher benefit expense ratio in the Medicaid business as our medical cost experience exceeded the net impact of annual premium rate adjustments and the impact of growth in membership, which the Medicaid business carries a higher benefit expense ratio than the consolidated company average. Further, the benefit expense ratio reflects the impact of higher medical cost experience in the Individual business and the timing of higher medical cost experience in the Local Group business. The increase was partially offset by adjustments to the prior and current year risk adjustment estimates in our ACA-compliant individual and small group products. 
Our SG&A expense ratio came in at a ""better than previously expected"" 14% in the second quarter of 2016, a decrease of 140 basis points from the prior year. This was driven by an intentional focus on administrative expense control, coupled with better-than-expected enrollment trends as well as the changing mix of our membership towards the Government Business, which carries a lower-than-consolidated average SG&A ratio. 
We reported operating cash flows of approximately $2 billion or 1.3x net income during the first 6 months of 2016. During the quarter, we reported operating cash flow of $662 million or 0.8x net income. As a reminder, we did make our first and second quarter income tax payments during the second quarter, consistent with prior years. 
I'll now turn the call over to our new Chief Financial Officer, John Gallina, to discuss our business segments' quarterly results and our updated 2016 outlook in more detail. John?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thanks, Joe, and good morning. Turning to discuss the second quarter financial performance of our business units. We added 290,000 members in our Government Business during the quarter and grew year-over-year revenue by 9.5% to $11.4 billion. These result",1560,"Thanks, Joe, and good morning. Turning to discuss the second quarter financial performance of our business units. We added 290,000 members in our Government Business during the quarter and grew year-over-year revenue by 9.5% to $11.4 billion. These results now include the impact from the addition of the Iowa contract, which was implemented on April 1. Operating margins for the Government Business in the quarter came in at 4%, a decline of 190 basis points versus the prior year quarter, which was driven by lower gross margins in the Medicaid business. As we communicated previously, we have been expecting Medicaid margins to compress from 2015 levels to a more normalized level, and we're monitoring the rate environment for the remainder of the year. 
During the quarter, we also experienced higher-than-expected claims across Medicaid businesses with the most notable market being the newly implemented Iowa contract. It is important to note that it is not uncommon to have early challenges in a new market, and our team has a long track record of successfully identifying and implementing revenue and cost of care initiatives to help mitigate issues. We will continue to work collaboratively with our state partner to ensure program stability and high-quality care for Iowa's most vulnerable citizens. 
Within Medicare, we're pleased with the progress the team continues to make, and our year-to-date margins continue to reflect improvement versus last year. Our outlook continues to expect margins to improve as the year progresses towards our expected long-term, sustainable levels, and we have positioned our portfolio to grow enrollment in 2017. 
The pipeline of opportunity for our Medicaid businesses remain substantial with an estimated $78 billion in contracts to be awarded between now and 2021 in markets that we will consider targeting. A little more than 3/4 of this opportunity is in new and specialized services, with the remainder in traditional Medicaid services. We continue to believe our experience and footprint positions us very well to continue our growth as we help states address the challenges of rising health care cost and improving quality to their residents. 
Switching to our commercial business. Our enrollment decreased by 142,000 lives during the quarter, which was slightly better than our previous expectations. Specifically, we experienced second quarter declines of 86,000 and 51,000 lives in our Individual and national businesses, respectively. The better-than-expected enrollment results contributed to a higher-than-expected operating revenue during the quarter, which increased by 5.7% versus the prior year quarter to $9.9 billion. 
Our second quarter operating margin of 10.9% was 120 basis points higher than the 9.7% we reported in the second quarter of 2015. The increase was driven by adjustments to the prior and current year risk adjustment estimates recorded during the quarter, a lower SG&A ratio due to lower administrative costs resulting from expense efficiency initiatives and growth in self-funded enrollment, which carries a higher-than-average operating margin. This increase was partially offset by higher medical cost experience in the individual ACA-compliant products and the timing of medical cost experience in our Local Group business. 
Within our individual ACA-compliant population, we had previously taken a conservative stance on our balance sheet with respect to various different estimates. This conservatism was very prudent as our current period claims trends have been higher than expected. We have seen higher-than-expected cost from membership with chronic conditions, such as renal disease, COPD, heart disease and diabetes, along with signs of pent-up demand among our new members. We have experienced higher-than-expected payments for dialysis treatments during the first half of the year, which we're in the process of reviewing the drivers of this increase. All in, our updated outlook now expects the Individual ACA-compliant business to incur mid-single-digit operating margin losses for the 2016 benefit year. 
It is important to note that we have assumed the higher-than-expected claims rate experienced thus far in the year will continue for the remainder of 2016 in developing our 2017 pricing assumptions. To be clear, we believe our pricing for 2017 fully incorporates our current expectations for 2016 claims, and we are focused on returning to profitability in 2017. Relating to National Accounts, we continue to be pleased that the team continues to secure wins contributing to the track record of membership growth in 2017. 
Regarding our balance sheet metrics. Consistent with our past practice, we have included a roll forward of our medical claims payable balance in this morning's press release. For the 6 months ended June 30, 2016, we experienced favorable prior year reserve development of $726 million, which was moderately better than our expectations. We continue to be at the upper end of our range of mid- to high single-digit margins for average deviation and believe our reserve balance remains consistent and strong as of June 30, 2016. 
Our Days in Claims Payable is 40.6 days as of June 30, a decrease of 2.8 days from the 43.4 days as of March 31. The decrease is in line with our expectations and consistent with the level of decrease seen between the first and second quarter of 2015. As previously discussed, we expect Days in Claims Payable to come back down and closer to 40 over time. 
Our debt-to-capital ratio was 39.1% at June 30, 2016, down 110 basis points from the 40.2% at the end of the first quarter, which reflects the impact of an increase in shareholder equity and the reduction in our outstanding balance in commercial paper during the quarter. We ended the first quarter with approximately $2.1 billion of cash and investments at the parent company, and our investment portfolio was in an unrealized gain position of approximately $958 million as of June 30. 
For the 3Rs, we continue to book reinsurance as appropriate, and we continue to establish a 100% valuation allowance against any unpaid receivables for the 2014, 2015 and 2016 benefit years for risk corridors. For risk adjusters, the recent information from CMS shows us in a net receivable position, primarily in our small group markets. We have recorded a valuation allowance against certain risk-adjusted receivables in some of our markets based on our assessment of the financial solvency of co-op organizations that are payers into the risk-adjusted program due to the belief that those receivables may ultimately not be collected. 
As we have said in recent months and in the results we reported this morning, our operating metrics are expected to be different than we previously expected during the last earnings call. That said, we are reaffirming our adjusted earnings guidance and expect full year 2016 adjusted EPS to be greater than $10.80, excluding greater than $1.46 of negative adjustment items. On a GAAP basis, our 2016 earnings per share outlook is greater than $9.34. We are raising our operating revenue outlook by $1.5 billion to a range of $82.5 billion to $83.5 billion, reflecting stronger-than-expected enrollment across our businesses, including the contributions from Medicaid as well as the impact of adjustments to both prior and current year risk adjustment estimates. Fully insured membership is now expected to be approximately 15 million members at the midpoint of our range, 100,000 higher than our previous outlook, which reflects stronger than previously expected results in the Medicaid business. Self-funded membership is now expected to be 24.7 million members at the midpoint of our range, approximately 200,000 higher than our previous outlook. Taken together, we now project total membership to be approximately 1 million to 1.2 million higher than we ended 2015. 
We now expect our medical loss ratio to be in the range of 84.9%, plus or minus 30 basis points for the year, reflecting our view that ""higher than previously expected"" claims rates in our individual ACA-compliant plans as well as our Medicaid businesses remain at elevated levels throughout the year. This includes the worse-than-expected results in the newly implemented Iowa market. Reflecting the expected higher paid claims, we now expect 2016 operating cash flow to be approximately $3 billion. To offset the expected increase in our medical loss ratio, we're continuing the effort started last year to ensure we have an efficient cost structure. We now expect our SG&A ratio for the full year 2016 to be in the range of 14.5%, plus or minus 30 basis points. We continue to expect 2016 Local Group medical cost trends to be in the range of 7% to 7.5%. Our updated 2016 outlook does not include any benefit from the impact of share repurchase activity for the remainder of the year. As a reminder, we did not repurchase any shares for the first 6 months of 2016. 
Our outlook does include the adverse impact of the additional $0.02 in assessments associated with the dissolution of the Ohio co-op. This is in addition to the $0.03 of assessments we previously discussed in our first quarter call associated with the State of Colorado dissolution on their co-op. We have not included any additional assessments beyond those incurred in Colorado and Ohio in our outlook. 
It is important to note that our 2016 outlook does not include any additional benefits or transaction costs associated with the pending acquisition of Cigna beyond those incurred in the first half of 2016, nor does it include any benefit from lower pharmaceutical pricing, which we continue -- we believe we are entitled to under our current contract with ESI. 
With that, operator, please open the queue for questions."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","[Operator Instructions] Your first question comes from the line of A.J. Rice from UBS.",14,"[Operator Instructions] Your first question comes from the line of A.J. Rice from UBS."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First, just to maybe -- I'm trying to clarify a little bit more on the outlook for the year and particularly what you're assuming for the back half. If my numbers are right, you're allowing for about a 300 to 400 basis point deterioration further from wha",122,"First, just to maybe -- I'm trying to clarify a little bit more on the outlook for the year and particularly what you're assuming for the back half. If my numbers are right, you're allowing for about a 300 to 400 basis point deterioration further from what we saw first half's MLR to back half MLR, and you're getting obviously, as you say, the SG&A leverage. Two parts to this: Is that a normal seasonal pattern? Are you allowing for any other contingencies on the MLR assumption in the back half? And as -- would you characterize what you're doing on the SG&A side as something sustainable? Or are these sort of extraordinary measures in light of the MLR pressure you've experienced?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","A.J., this is John. Thank you for the question. Yes, so a couple of questions in there in terms of MLR and G&A. But first of all, on MLR, yes, your math is certainly appropriate from the first half to the last half. And really, what we've seen is that we'",374,"A.J., this is John. Thank you for the question. Yes, so a couple of questions in there in terms of MLR and G&A. But first of all, on MLR, yes, your math is certainly appropriate from the first half to the last half. And really, what we've seen is that we've got an elevated amount of utilization specifically in the ACA individual-compliant plans as well as in Medicaid and most significantly there in Iowa. And we're, at least, for purposes of our outlook, assuming that, that elevated level is going to continue throughout the rest of the year. So while, certainly, if there's any mitigation factors or medical management initiatives ended up being more successful than we're planning, there could be upside. But it's really -- it has to do with taking the elevated levels of utilization we've seen and just essentially run rating them for the rest of the year. In terms of the G&A, I'd say the bulk of the G&A is sustainable. What we've really done is done an outstanding job of fixed-cost leveraging. We're increasing membership here this year between 1 million and 1.2 million members and maintaining our cost structure relatively constant. But we are growing. Our headcount increased in the second quarter, but it increased at a far, far slower rate than our membership increased. Revenue's going up about $2.5 billion -- $2 billion to $2.5 billion for the change in guidance from the beginning of the year into -- to today. Yet, the raw SG&A number is only going up very slightly. And so there's really -- it's really has as much to do with an excellent job of fixed-cost leveraging. Clearly, we are looking at some inefficiency and waste in terms of our processes and continue to look at those very closely on a regular basis and try to eliminate those things. And at the end of the day, the last piece of it really is that we're a pay-for-performance company. And as a pay-for-performance company, in order to get our bonus payments, we have to hit our targets. And to the extent that we don't hit our targets, we'll reduce our bonus structure. So that's something that we're looking at very closely as well."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. If I could do just a quick follow-up. Joe, thanks for the comments about the Cigna transaction. I might just ask, do you have any updated assessment of the time line from here? And then I think the merger agreement goes through the end of this year.",73,"Okay. If I could do just a quick follow-up. Joe, thanks for the comments about the Cigna transaction. I might just ask, do you have any updated assessment of the time line from here? And then I think the merger agreement goes through the end of this year. Can you just mention to us what happens after the end of the year if we're still in the court dealing with the proposed transaction?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thanks, A.J. First of all, when you referenced the end of the year, actually, we had the option on our side, our call, to extend it to the end of April, which obviously, we intend to do so. So I just want to make that record clear that we will continue --",126,"Thanks, A.J. First of all, when you referenced the end of the year, actually, we had the option on our side, our call, to extend it to the end of April, which obviously, we intend to do so. So I just want to make that record clear that we will continue -- and that obviously, we're going to run out the litigation as long as it takes, working toward the end of April. Our expectation is, I guess, under normal or usual circumstances for claims like this, I will -- we're expecting the trial to begin somewhere around October. And at the outside, we're looking at 4 months. We believe it'll be about 4 months. Obviously, it could run a little longer, but that's our expectation."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Josh Raskin from Barclays.",12,"Your next question comes from the line of Josh Raskin from Barclays."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I think I'm going to ask very similar questions to A.J., but just, I guess, a different perspective. So on the MLR, forgetting about sort of the first half versus second half, just on a year-over-year basis, the first half is up 188 basis points, and that",179,"I think I'm going to ask very similar questions to A.J., but just, I guess, a different perspective. So on the MLR, forgetting about sort of the first half versus second half, just on a year-over-year basis, the first half is up 188 basis points, and that's only 3 months of Iowa, and you get some ACA benefit. But the second half looks more like an increase of 140 basis points. So the way I'm looking at it, year-over-year, you're actually expecting some noticeable improvement in the second half. So my MLR question is, what's causing that improvement on a relative basis? And then, John, on the G&A side, I think you mentioned that growth is going up a lot less than the revenue growth. But the way I look at it is, second quarter, you added $1.5 billion to revenues but took $600 million of G&A out. So it looks like there are noticeable savings and, I guess, I'm just curious. Is that deferred investment? Or is that some other sort of savings on the G&A side?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Sure, Josh. Great question. So yes, first half will be clear on the MLR. First half of the year had the benefit of 3Rs in it. The run rate of claims outside of 3Rs is worse. And so that's obviously being baked into our outlook and our thought process. On",106,"Sure, Josh. Great question. So yes, first half will be clear on the MLR. First half of the year had the benefit of 3Rs in it. The run rate of claims outside of 3Rs is worse. And so that's obviously being baked into our outlook and our thought process. On the admin side, quite honestly, the single-largest driver of that year-over-year is the bonus program that I referenced at the end of A.J.'s question in terms of being a pay-for-performance company. We adjusted our bonus payable appropriately based on ensuring that we're going to hit our $10.80, and so that's certainly a part of the reconciliation."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And John, what was the 3R benefit? And I don't know, is there a way to size Iowa's impact on 2Q as well?",23,"And John, what was the 3R benefit? And I don't know, is there a way to size Iowa's impact on 2Q as well?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, the 3R benefit in and of itself, we don't provide the level of specificity that you're probably asking for. In terms of Iowa, I'll just say that Iowa is a brand new market. And we expected it to be dilutive in 2016 as we implemented our various medic",216,"Yes, the 3R benefit in and of itself, we don't provide the level of specificity that you're probably asking for. In terms of Iowa, I'll just say that Iowa is a brand new market. And we expected it to be dilutive in 2016 as we implemented our various medical management and revenue optimization processes. We ended up with about 25,000 more members in Iowa than we originally expected when we did our plan at the beginning of the year. And quite honestly, the MLR in Iowa is 25 to 30 basis points higher than we expected when we did our plan as well, so yes, the additional members and it's more dilutive simultaneously with the elevated claims level. The really good news to that is that we do believe that our plan -- when we look at what we've done here historically, what the team has done historically in terms of new markets and implementing the managed care-type processes and procedures and the fact that the first year markets have historically been dilutive, and that we've got target margins within a 18- to 24-month period of time. There's no reason to believe that that's not going to occur again here in Iowa, even though the starting points may be a little bit bumpier than we'd hoped."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And these are 25 to 30 basis points or points higher?",11,"And these are 25 to 30 basis points or points higher?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Josh, 25 to 30 points higher, not basis points.",9,"Josh, 25 to 30 points higher, not basis points."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Points. Okay, so it's a huge number. Yes, okay, that makes sense.",12,"Points. Okay, so it's a huge number. Yes, okay, that makes sense."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Dave Windley from Jefferies.",12,"Your next question comes from the line of Dave Windley from Jefferies."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","It's Dave Styblo in for Windley. Just want to come back to -- maybe, if you guys could help us bridge sort of the puts and takes? And obviously the overall guidance remains the same on -- in terms of EPS. But I think, by the math that you guys presented o",121,"It's Dave Styblo in for Windley. Just want to come back to -- maybe, if you guys could help us bridge sort of the puts and takes? And obviously the overall guidance remains the same on -- in terms of EPS. But I think, by the math that you guys presented on the individual book being on a mid-single-digit loss, it sounds like that's about a $0.40 change relative to sort of what you were thinking before. And then on top of that, you've the Medicaid challenges that you highlighted. Is that sort of the right way to think about it? And then the offset being largely just the SG&A improvement on top of that to offset those 2 negatives."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, the other part of that is the top line growth is very clearly a good guide as part of all that. But yes, those are the most significant pieces. I think the good news is, and just to sort of maybe answer your follow-up question before you ask it, is t",126,"Yes, the other part of that is the top line growth is very clearly a good guide as part of all that. But yes, those are the most significant pieces. I think the good news is, and just to sort of maybe answer your follow-up question before you ask it, is that if we look at 2016 versus 2017, let's be very clear. As I said in the prepared comments, when we did our pricing for 2017, we already had taken this elevated level of claims and utilization into account and baked it into our 2017 outlook. So we believe this is more of a 1-year type of issue. And that we're very committed to returning the ACA block of business back to profitability in 2017."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So you did address my question earlier on the follow-up. So is it -- I guess though, it seems like you priced for these things to happen. And in some ways, it still seems like it's worse than expected. So if you are filing rates and benefit changes earlie",95,"So you did address my question earlier on the follow-up. So is it -- I guess though, it seems like you priced for these things to happen. And in some ways, it still seems like it's worse than expected. So if you are filing rates and benefit changes earlier in the year, maybe you can just give us more comfort about specifically, how you caught these things earlier on when we're starting see more the development come in with higher utilization on the dialysis and COPD and the other elements that you talked about?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure. Well, the rates were developed in the April-May time frame. And so if you look back at our -- when we closed the books in March and the information we had available to us at that point in time, we had seen some of the spikes and the elevations,",190,"Yes, sure. Well, the rates were developed in the April-May time frame. And so if you look back at our -- when we closed the books in March and the information we had available to us at that point in time, we had seen some of the spikes and the elevations, just not to the same -- we weren't crystal clear then it was going to continue for the rest of the year or not. However, we want to be conservative. We wanted to be prudent. And so we believe -- we had hoped that it was not a trend. However, when we did our pricing, we felt it was best to assume it was a trend. Here we are 90 days later. I believe our conservatism turned out to be prudent, and that's something that we weren't sure if that was going to be a trend or not. Probably is. There's still the opportunity that seasonality could be in our favor and that things could get a little bit better in the second half of the year. We just decided not to assume that at this point in time."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then if I could just ask on Medicaid. I know obviously, you highlighted Iowa, and then you mentioned that broadly, there was just higher trends. Is it predominantly just Iowa being the drag in Medicaid? Or are there some specific other states? A",79,"Okay. And then if I could just ask on Medicaid. I know obviously, you highlighted Iowa, and then you mentioned that broadly, there was just higher trends. Is it predominantly just Iowa being the drag in Medicaid? Or are there some specific other states? And maybe, if you could sort of share a percentage of the weighting of the 75% Iowa, 25% other states and highlight what those other states might be and the issues that you're seeing there?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","In terms of -- it is both Iowa as well as other states. And we really don't get into specifics state by state. We're just calling out Iowa as a marker because it's brand new and it is a significant driver in and of itself. I will say that the primary driv",97,"In terms of -- it is both Iowa as well as other states. And we really don't get into specifics state by state. We're just calling out Iowa as a marker because it's brand new and it is a significant driver in and of itself. I will say that the primary drivers of the elevated trends, the pharmacy, nursing facilities, ER and outpatient surgery. Those 4 items are really the most significant part of our trend issue in the other states. So -- but we are seeing elevated trends in several states, and we're addressing those accordingly."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. But fair to say well above 50% is attributable to Iowa, though.",13,"Okay. But fair to say well above 50% is attributable to Iowa, though."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","We really don't get into that level of detail on a state-by-state basis for competitive reasons.",17,"We really don't get into that level of detail on a state-by-state basis for competitive reasons."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Andy Schenker from Morgan Stanley.",13,"Your next question comes from the line of Andy Schenker from Morgan Stanley."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So just going back to the exchange business here. Just thinking about it, big picture, right? In 2014, you guys were actually profitable. Last year, you were close to breakeven. This year, you're now losing money here. So what has really changed over that",118,"So just going back to the exchange business here. Just thinking about it, big picture, right? In 2014, you guys were actually profitable. Last year, you were close to breakeven. This year, you're now losing money here. So what has really changed over that time frame? Is it just the risk pool has continued to get worse? And therefore, is this something you can actually rectify with pricing? Or are there structural issues to the exchanges? Or are there other more meaningful benefit changes, i.e. networks or other design changes, that you've also incorporated for next year that are going to be necessary to offset what's been a steady deterioration of the profitability of this book every year?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure. No, great question. And in terms of, well, pricing by itself, rectify it? No. Because there's no one single bullet that actually solves the entire problem. The administration is extremely focused on having a sustainable marketplace. And we thin",260,"Yes, sure. No, great question. And in terms of, well, pricing by itself, rectify it? No. Because there's no one single bullet that actually solves the entire problem. The administration is extremely focused on having a sustainable marketplace. And we think that we've been a very active participant in the exchanges and been a great partner with CMS in trying to help with the stability of the marketplace. They've made changes over the years of tightening the supplemental enrollment a bit and various other requirements. The penalty continues to increase. We think all those things obviously have to be done. Other things that would certainly help the acceleration of stabilization would be to eliminate the health insurer tax in beyond 2017. The risk adjuster model, it's -- it does a lot of what it's intended to do. But quite honestly, there's a bit of an imbalance that the -- that it overcharges for healthy and over-reimburses for certain moderately unhealthy disease states. We think, as I said, the supplemental enrollment period, we really do need a better upfront verification process and that there should not be any restriction on our efforts to innovate product designs to meet consumer needs. And then modifying the grace periods for nonpayment of premiums would be something else. So those are just -- in addition to the pricing, things that we've been working with the administration on and believe should occur. We do believe that with the medical management and various other issues, that we can help get this back to profitability here in 2017."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, this is Joe. Let me just weigh in to add to what John just shared with you. Just reiterate, we've been a very active participant in the exchanges from the beginning and recognize the markets have taken longer than expected to stabilize. And we've sta",363,"Yes, this is Joe. Let me just weigh in to add to what John just shared with you. Just reiterate, we've been a very active participant in the exchanges from the beginning and recognize the markets have taken longer than expected to stabilize. And we've stated that repeatedly. And I think we've been working very closely with the administration and conducting our own modeling to best judge how we're going to continually engage year-over-year in as profitable a context as possible. It's interesting, reflect back to the end of first quarter, we told you that, end of June 30, we'd probably have greater insight into the membership we've captured, recognizing that we had a substantial uptick in membership. Deteriorated a little bit at the end of Q2 to around 925,000 or so members. But what we've observed in terms of the intensity of illness is that, as John pointed out in his earlier remarks, we're dealing with some chronic illnesses like cardiac, diabetes, COPD. We've had a, what we think, is a material uptick in dialysis cost that have hit us. So we're going through an appraisal of all that in terms how to better medically manage those members as well as begin pricing it into '17. That's the trick. I think John has stated it, and I'll restate it. We believe we're well positioned for pricing in '17, given what we now know about the membership we captured. And so I guess, when you put all that together, what we're waiting for now is rate approvals by state. And I can assure you that we're going to be extremely prudent in our continuing engagement. I think we're in something like 138 or so rating regions. And we're going through an appraisal of every one of those regions. And we'll make prudent business decisions in terms of flexing our engagement in appropriate ways going into '17. And so I just -- I want to assure that, notwithstanding we've been active participants, we're also very -- I'll use the word prudent, very thoughtful, in terms of executing a good business practice, in terms of how we continue to stay engaged in the public marketplace."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Great. That was very helpful. Thinking maybe a little bit more broadly. You kind of reiterated your small group or Local Group, rather, trend assumptions here. But you did kind of call out timing and medical cost experience for Local Group. Maybe, if you",74,"Great. That was very helpful. Thinking maybe a little bit more broadly. You kind of reiterated your small group or Local Group, rather, trend assumptions here. But you did kind of call out timing and medical cost experience for Local Group. Maybe, if you could just talk more about what you're seeing around trend, if there's any pockets you're seeing in patients, et cetera, as it relates to that -- how you define it?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure. So in terms of trend on the Local Group side, that's actually going very well. And we reaffirm the 7% to 7.5% outlook for that and feel very comfortable with that, given the results for the first half of the year. In terms of the timing, that r",158,"Yes, sure. So in terms of trend on the Local Group side, that's actually going very well. And we reaffirm the 7% to 7.5% outlook for that and feel very comfortable with that, given the results for the first half of the year. In terms of the timing, that relates to just a couple, really, accounting and calendar quirks. The first quarter of 2016 had an extra workday in it, driven by leap year. The second quarter of 2016 had an extra workday in it, driven by how the weekends fell. The fourth quarter of 2016 has 1 less workday in it, and so that's significant enough to change the timing pattern on a quarter-over-quarter basis. Then you take that and the fact that our overall product mix in the group side is slightly richer than the overall product mix in the group side a year ago, that changes the timing as well given how the deductibles work."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Gary Taylor from JPMorgan.",12,"Your next question comes from the line of Gary Taylor from JPMorgan."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just a couple of questions. Did you give us the total exchange enrollment as of the end of 2Q? Did I miss that?",23,"Just a couple of questions. Did you give us the total exchange enrollment as of the end of 2Q? Did I miss that?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. It's 923,000.",3,"Yes. It's 923,000."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And the total -- when you talk about the ACA-compliant book now being mid-single-digit losses, what is the total ACA-compliant enrollment that you're speaking to? So presumably, that's some off exchange and some -- and small group ACA-compliant as well.",40,"And the total -- when you talk about the ACA-compliant book now being mid-single-digit losses, what is the total ACA-compliant enrollment that you're speaking to? So presumably, that's some off exchange and some -- and small group ACA-compliant as well."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","A little more than half of the remainder is ACA-compliant.",11,"A little more than half of the remainder is ACA-compliant."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And I just want to come back to the risk adjustment, because it seems like potentially, it was quite material in the quarter. I know you guys only disclose that you had a payable at year-end. We calculate that payable by the $105 million and the swi",95,"Okay. And I just want to come back to the risk adjustment, because it seems like potentially, it was quite material in the quarter. I know you guys only disclose that you had a payable at year-end. We calculate that payable by the $105 million and the swing factor to $190 million payment that CMS was citing for '15 as about $0.60. You say that you booked some valuation allowances against that because of co-op situations. But I mean, should we assume that a material portion of that $0.60 was trued up in this quarter?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","I -- there was a lot of things that went against it, and I'm not going to really comment on your estimate of the payable. But in terms of valuation allowance, it's clearly part of it. Certainly, medical loss ratio rebates were part of it. After all the du",141,"I -- there was a lot of things that went against it, and I'm not going to really comment on your estimate of the payable. But in terms of valuation allowance, it's clearly part of it. Certainly, medical loss ratio rebates were part of it. After all the dust settled, we're going to pay over $100 million in MLR rebates in 2016 related to the 2015 calendar year. And so that's part of it. And you've got the small group versus the individual component as clearly a piece of it. Risk corridor true-ups, reinsure, I mean, there's so many moving parts, it's hard to, on the call here, pin that down exactly. And then quite honestly, whatever benefits existed after all the other offsets have now been baked into our trend outlook and our guidance for the rest of the year."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay, if I could just -- 2 quick clarifications. I think Josh was asking about the G&A run rate and sustainability of that. The guidance for the second half certainly implies this reduced G&A is fairly sustainable. But as you head into '17, do you feel li",77,"Okay, if I could just -- 2 quick clarifications. I think Josh was asking about the G&A run rate and sustainability of that. The guidance for the second half certainly implies this reduced G&A is fairly sustainable. But as you head into '17, do you feel like there's going to be a deferred level that has to rebound? Or is this sort of G&A ratio a number that makes sense as a jumping-off point heading into '17?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","The most significant driver of the G&A benefits here compared to our guidance or our outlook is the top line revenue growth and the fixed-cost leveraging associated with that. And so that clearly is run rate and sustainable. In terms of -- certainly, as a",117,"The most significant driver of the G&A benefits here compared to our guidance or our outlook is the top line revenue growth and the fixed-cost leveraging associated with that. And so that clearly is run rate and sustainable. In terms of -- certainly, as an employee of the company, I'm fully supportive of getting back to the bonus structure, back to target levels. But there's a natural hedge associated with that. So as results warrant it, we then record the expense. If they don't warrant it, we don't record the expense. So what the impact that might be on an exact ratio is to be seen, but the bottom line has a natural hedge built in."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So my last one. When we think about the year, ACA-compliant business, worse than you had anticipated; Iowa and Medicaid overall, worse than anticipated. Yet, you maintained the guidance. So the 2 components that were better that allowed you to maintain co",55,"So my last one. When we think about the year, ACA-compliant business, worse than you had anticipated; Iowa and Medicaid overall, worse than anticipated. Yet, you maintained the guidance. So the 2 components that were better that allowed you to maintain compliance was risk adjustment and some of the additional enrollment growth. Is that fair?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, certainly, admin, risk adjustment, enrollment growth. We're doing extremely well in the national and large local ASO in terms of enrollment. Our Medicare Advantage and our senior business are growing very, very well and exceeding expectations for th",113,"Well, certainly, admin, risk adjustment, enrollment growth. We're doing extremely well in the national and large local ASO in terms of enrollment. Our Medicare Advantage and our senior business are growing very, very well and exceeding expectations for the year. And quite honestly, we had a bit of an initial conservative posture at the beginning of the year as well. So it's a lot of things. Our specialty product line is beating expectations. So I would hate to just point to 1 or 2 items because there are far more positives than there are negatives. It's just that the 2 negatives have really caused our conservative posture to be a more prudent posture."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Justin Lake from Wolfe Research.",13,"Your next question comes from the line of Justin Lake from Wolfe Research."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First, just a follow-up on the SG&A number for that bonus program. I understand that, as you said, that the hedge and other things have to improve to offset it. But can you give us a ballpark number there in terms of how much cost comes back into SG&A if",57,"First, just a follow-up on the SG&A number for that bonus program. I understand that, as you said, that the hedge and other things have to improve to offset it. But can you give us a ballpark number there in terms of how much cost comes back into SG&A if you fully accrue that for next year?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, in terms of exactly how much that is, the bonus program target is certainly a significant number in and of itself but, Justin, that's just not a number that we're comfortable giving out.",34,"Well, in terms of exactly how much that is, the bonus program target is certainly a significant number in and of itself but, Justin, that's just not a number that we're comfortable giving out."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. Is there any way to proportion it? For instance, you're losing, you said, mid-single digits on the individual side. I mean, can you remind us what's the ACA-compliant premium number for this year, ballpark?",35,"Okay. Is there any way to proportion it? For instance, you're losing, you said, mid-single digits on the individual side. I mean, can you remind us what's the ACA-compliant premium number for this year, ballpark?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's a bit north of $6 billion, close to -- maybe closer to $7 billion.",16,"It's a bit north of $6 billion, close to -- maybe closer to $7 billion."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So you're talking about $300 million plus in potential -- just getting back to breakeven, right, in the Individual business, right, is how we should think about the earnings power of the business? I assume you're not expecting to run losses for -- e",59,"Okay. So you're talking about $300 million plus in potential -- just getting back to breakeven, right, in the Individual business, right, is how we should think about the earnings power of the business? I assume you're not expecting to run losses for -- even in the intermediate term here as you talked about. So would -- if we..."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","I'm not going to argue with your math.",9,"I'm not going to argue with your math."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So if Individual comes back to breakeven or better, does this SG&A basically offset that? Or is it larger or smaller than Individual coming back to breakeven?",28,"Okay. So if Individual comes back to breakeven or better, does this SG&A basically offset that? Or is it larger or smaller than Individual coming back to breakeven?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, there's certainly -- it's a natural hedge built in. But to answer your question would be to answer the question that you asked the first time. So good luck. It's a big number, but we're not going to size it specifically.",42,"Well, there's certainly -- it's a natural hedge built in. But to answer your question would be to answer the question that you asked the first time. So good luck. It's a big number, but we're not going to size it specifically."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. But you wouldn't call me crazy if I said it was in the same ballpark as getting back to breakeven in Individual?",23,"Okay. But you wouldn't call me crazy if I said it was in the same ballpark as getting back to breakeven in Individual?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","I would never call you crazy.",6,"I would never call you crazy."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","All right. Last question, just on the government side. So you've laid out the issues here. And you were very clear coming into 2016 saying, for instance, Medicaid, the margins were unsustainable. They were going to come down, plus you were going to have t",123,"All right. Last question, just on the government side. So you've laid out the issues here. And you were very clear coming into 2016 saying, for instance, Medicaid, the margins were unsustainable. They were going to come down, plus you were going to have the Medicaid pressure in Iowa. I guess, my -- what I'm trying to think about here is, these margins are down meaningfully for 2016 in the government overall, and you're saying Medicare is actually improving, so Medicaid, the full brunt. My question is, is Medicaid now at a target margin for 2016 when you think about it overall? Or does the Medicaid margin actually improve going forward from here, given how tough it's been and the worse-than-expected cost overall?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's a -- the Medicaid margins are within our target range. Obviously, we're hopeful that we can improve it to the high end of the range. But even with all these headwinds and the negative comments that we had earlier in the year, we're still within the r",49,"It's a -- the Medicaid margins are within our target range. Obviously, we're hopeful that we can improve it to the high end of the range. But even with all these headwinds and the negative comments that we had earlier in the year, we're still within the range."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So for the full year, you're within the range, but closer to the midpoint, to the low end, and potentially can improve it towards the higher end again, where you've typically been.",32,"So for the full year, you're within the range, but closer to the midpoint, to the low end, and potentially can improve it towards the higher end again, where you've typically been."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","That's a reasonable way of thinking about it, yes.",10,"That's a reasonable way of thinking about it, yes."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Kevin Fischbeck from Bank of America.",14,"Your next question comes from the line of Kevin Fischbeck from Bank of America."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. Got a couple of questions. I guess, first, on the exchanges. I guess, obviously, you guys believe that you've caught everything as far as pricing for next year and you expect margins to improve next year. But I guess, you've seen now, I don't know,",105,"Okay. Got a couple of questions. I guess, first, on the exchanges. I guess, obviously, you guys believe that you've caught everything as far as pricing for next year and you expect margins to improve next year. But I guess, you've seen now, I don't know, 5 or 6 quarters in a row where it kind of -- seems like the cost continue to rise, I mean, for you, but really, for a lot of the players out there. I mean, can you give a sense as to why you feel confident saying that, given the experience of most companies over the last 1.5 years?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, why we believe that we've caught everything?",8,"Well, why we believe that we've caught everything?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Yes, exactly.",2,"Yes, exactly."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","I think -- well, a lot of it, obviously, has to do with our data analytics and how we track things. And as you look at the rate increases that we put in, approaching 20% range on a weighted-average basis across our 14 states, very significant. And as we -",245,"I think -- well, a lot of it, obviously, has to do with our data analytics and how we track things. And as you look at the rate increases that we put in, approaching 20% range on a weighted-average basis across our 14 states, very significant. And as we -- yes, we also believe that we have some of the best-in-class risk adjuster capabilities of really understanding what drives risk adjuster and things like that. And I think the results that we saw from the CMS true-up really helped verify that. So the other piece that gives us a little bit of comfort in terms of having caught everything is that our 2016 risk adjuster that we're assuming into '17 really is based on 2015 experience. So we think that, that gives us a natural cushion associated with how that's being approached. But at the end of the day, the question is, ""How do we know we've gotten everything?"" Well, we've got 6 months of information. Obviously, there's a lot of new members associated with those block of business, and we can't provide absolute certainty. But we think we have very, very good line of sight. What we saw at the end of the first quarter, we further predicted from a pricing standpoint, and what we saw at the end of the second quarter was exactly consistent with that pricing prediction. So we feel good that we've got a good line of sight on that."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I guess, is there anything different about you heading into Q3 this year versus you heading into Q3 last year as far as what you're doing from a data analytics perspective? Or anything there that gives you more confidence or visibility this year than what",55,"I guess, is there anything different about you heading into Q3 this year versus you heading into Q3 last year as far as what you're doing from a data analytics perspective? Or anything there that gives you more confidence or visibility this year than what you had heading into the back half of last year?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, this is Joe. I certainly believe that we're always improving year-over-year, and especially in this space, given we've got more and more data. We certainly recognize that this is a company that's had a long-standing engagement of high-risk pools. An",148,"Well, this is Joe. I certainly believe that we're always improving year-over-year, and especially in this space, given we've got more and more data. We certainly recognize that this is a company that's had a long-standing engagement of high-risk pools. And we have a lot of data that has backed us up for a long period of time. And I think that we just -- as I said a moment ago, always expect to continue of improving the space. However, I'll reiterate what I said earlier. We're going to be very surgical with respect to our analytics in and around rating regions. We're going to be very mindful of what price increases are awarded to us by state. And so we'll be making various, I call it, accurate business decisions going into '17 and beyond regarding our continued engagement on a broad scale in the public exchange space."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, any other comment that I'll just add to that, I think maybe will address your, what would be different going into the third quarter is, 2016, we actually had more members come on board on January 1 than we did in 2015 or 2014. 2014, in particular, if",113,"Yes, any other comment that I'll just add to that, I think maybe will address your, what would be different going into the third quarter is, 2016, we actually had more members come on board on January 1 than we did in 2015 or 2014. 2014, in particular, if you recall, we had a vast majority of the members come on board early second quarter. And 2015, with the extension of the open enrollment period, a lot of members came on later in the first quarter. 2016, a lot more January 1. We actually do have a full 6 months of information this year, and we had not had that in prior years."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay then, just last question. Last quarter, you said that -- when you expected the exchanges to be pretty much breakeven this year, you said next year was probably going to be below your target, 3% to 5%. But by 2018, you'd be in your target margin. Do y",85,"Okay then, just last question. Last quarter, you said that -- when you expected the exchanges to be pretty much breakeven this year, you said next year was probably going to be below your target, 3% to 5%. But by 2018, you'd be in your target margin. Do you still feel like you still have that same ramp over the next couple of years? Or does this set back -- kind of push back when you're going to get to your target margins on exchanges?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","The pricing increases that we've put in really do keep us on that same ramp. And it's very important that we do receive the pricing increases that we've filed for in terms of that. Obviously, we expect the market to continue to harden and pricing to be mo",93,"The pricing increases that we've put in really do keep us on that same ramp. And it's very important that we do receive the pricing increases that we've filed for in terms of that. Obviously, we expect the market to continue to harden and pricing to be more reasonable. I mean, clearly, there's a reason that so many co-ops have gone insolvent in terms of their pricing methodologies. So as there's more and more of those folks exit the market, it should provide a more sustainable stable marketplace in 2018 and beyond."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","And your final question today comes from the line of Chris Rigg.",12,"And your final question today comes from the line of Chris Rigg."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just with regard to the ACA-compliant membership, do you have a sense, at this point, how many of the individuals were new members to Anthem? And is there -- if you have that information, is there a pronounced difference in utilization trends among those",64,"Just with regard to the ACA-compliant membership, do you have a sense, at this point, how many of the individuals were new members to Anthem? And is there -- if you have that information, is there a pronounced difference in utilization trends among those that are -- who are new to Anthem versus those that had been enrolled for a year or 2?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Very quick response to the question. A little less than half of the membership was new to us in '16.",21,"Yes. Very quick response to the question. A little less than half of the membership was new to us in '16."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then just one quick follow-up here. Of the individual that's non-ACA-compliant at this point, will most of them become -- roll into ACA-compliant plans in 2017 because of the grandmothering dynamic? Or will they still stay outside the complaint",42,"Okay. And then just one quick follow-up here. Of the individual that's non-ACA-compliant at this point, will most of them become -- roll into ACA-compliant plans in 2017 because of the grandmothering dynamic? Or will they still stay outside the complaint side?"
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes -- no, a great question. We do expect some attrition in that area, as you pointed out. Whether they enroll remains to be seen. But historically, we haven't seen the uptake in ACA-compliant plans that maybe was estimated by the CBO when the law was pas",56,"Yes -- no, a great question. We do expect some attrition in that area, as you pointed out. Whether they enroll remains to be seen. But historically, we haven't seen the uptake in ACA-compliant plans that maybe was estimated by the CBO when the law was passed. But yes, that's certainly a watch area for us."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","And now I would now like to turn the conference back to the company's management for closing comments.",19,"And now I would now like to turn the conference back to the company's management for closing comments."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, as usual, thanks for your questions. They're all very insightful. As a company, we remain committed to tackling our health care system's challenges head on and deliver greater value to consumers by expanding access to high-quality, affordable health",100,"Well, as usual, thanks for your questions. They're all very insightful. As a company, we remain committed to tackling our health care system's challenges head on and deliver greater value to consumers by expanding access to high-quality, affordable health care. That's why we're committed to challenging the DOJ's recent decision to block our acquisition of Cigna in court. We also want to thank all of our associates for their continued commitment to serving our 39.8 million members every day. 
Thanks for your interest in Anthem, and we look forward to speaking with you very soon. Again, thank you very much."
160077,308029078,1013536,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, this conference will be available for replay after 11:00 a.m. Eastern Time today through August 10. You may access the AT&T Teleconference Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378817. Int",68,"Ladies and gentlemen, this conference will be available for replay after 11:00 a.m. Eastern Time today through August 10. You may access the AT&T Teleconference Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378817. International participants, dial (320) 365-3844. That does conclude your conference for today. Thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management.",37,"Ladies and gentlemen, thank you for standing by. Welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Good morning, and welcome to Anthem's Second Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and John Gallina, our CFO. Joe will offer some commen",197,"Good morning, and welcome to Anthem's Second Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. 
With us this morning are Joe Swedish, Chairman, President and CEO; and John Gallina, our CFO. Joe will offer some commentary on the recent DOJ actions and provide an overview of our second quarter 2016 financial results, and then John will walk through the financials of our business units and provide some incremental commentary around our updated 2016 outlook. We're then available for Q&A. 
During the call, we will reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website at antheminc.com. We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Anthem. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in today's press release and in our quarterly and annual filings with the SEC. 
I will now turn the call over to Joe."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Doug, and good morning. This morning, we announced second quarter 2016 adjusted earnings per share of $3.33, with membership and revenue tracking above our previous expectations. On a GAAP basis, we reported earnings per share of $2.91. Befor",925,"Thank you, Doug, and good morning. This morning, we announced second quarter 2016 adjusted earnings per share of $3.33, with membership and revenue tracking above our previous expectations. On a GAAP basis, we reported earnings per share of $2.91. 
Before John and I discuss the details of our second quarter financials and our updated 2016 outlook, I think it's appropriate to discuss our perspective on the latest Cigna developments. I'll start by saying we are disappointed by the U.S. Department of Justice's decision to block Anthem's acquisition of Cigna, a combination specifically designed to tackle our health care system's challenges head on and deliver greater value to consumers by expanding access to high-quality, affordable health care. To be clear, our board and executive leadership team at Anthem is fully committed to challenging the DOJ's decision in court. 
As you may have read in Tuesday's published op-ed, the DOJ has disregarded the issue of access for 2 of the most unstable and at high risk health insurance markets: individuals and small businesses. These populations comprise a meaningful proportion of the still more than 33 million uninsured Americans who will benefit from the Cigna acquisition through expanded and improved access, affordability and quality. 
For example, despite the many and continuing challenges of the health insurance exchanges, Anthem entered into this new and high-risk market at its inception. Though several of our competitors have exited this business, we now serve 923,000 public exchange members across 14 states where we do business as Blue Cross and Blue Shield plan. As shared with the DOJ, our acquisition of Cigna will help stabilize pricing in this volatile market, enabling Anthem to continue its commitment to the public exchanges and provide the opportunity to expand our participation to 9 additional states where neither Anthem nor Cigna currently participate. Additionally, we estimate this acquisition will significantly lower cost for our self-funded consumers, with over $2 billion in medical cost savings that we pass directly back to them. Finally, we also note this acquisition will benefit our shareholders and the pension, retirement and investment funds they represent. Specifically, 99% of our shareholders voted in favor of this transaction. 
Now to discuss consolidated financials we reported this morning. Our second quarter adjusted EPS of $3.33 was slightly ahead of our expectations, albeit with mixed financial metrics to get us there. Within membership, both fully insured and self-funded memberships are tracking ahead of expectations as we ended the second quarter with nearly 39.8 million members. This reflects growth of an additional 148,000 lives during the quarter, bringing our year-to-date enrollment growth to 1.2 million lives or 3%. Specifically, our insured membership increased by 170,000 lives as our Medicaid business grew by a better-than-expected 280,000 lives in the quarter to over 6.3 million members. This reflected better-than-expected enrollment growth from the implementation of the Iowa state contract, which started on April 1, as well as better-than-expected core membership growth within multiple other state contracts. 
Within commercial, our insured enrollment came in line with expectations. We ended the quarter with 923,000 lives from the individual public exchanges, a decrease of 52,000 from the 975,000 we reported in the first quarter. And Local Group insured business declined modestly and in line with our most recent expectations. 
Our self-funded business was relatively stable during the quarter, which was better than our previous expectations, as we experienced higher-than-expected growth in membership in existing accounts. Our membership results translated into better-than-expected operating revenue of $21.3 billion. Our second quarter 2016 results represent an increase of $1.5 billion or 7.7% versus the second quarter of 2015, reflecting strong enrollment growth in the Government Business and additional premium revenue to cover overall cost trends. Also contributing was the growth in administrative fee revenue as a result of our strong self-funded memberships trends. This was partially offset by fully insured membership losses in our commercial business. 
The second quarter 2016 benefit expense ratio was 84.2%, which increased by 210 basis points versus the prior year. The year-over-year increase was partially driven by higher benefit expense ratio in the Medicaid business as our medical cost experience exceeded the net impact of annual premium rate adjustments and the impact of growth in membership, which the Medicaid business carries a higher benefit expense ratio than the consolidated company average. Further, the benefit expense ratio reflects the impact of higher medical cost experience in the Individual business and the timing of higher medical cost experience in the Local Group business. The increase was partially offset by adjustments to the prior and current year risk adjustment estimates in our ACA-compliant individual and small group products. 
Our SG&A expense ratio came in at a better than previously expected 14% in the second quarter of 2016, a decrease of 140 basis points from the prior year. This was driven by an intentional focus on administrative expense control, coupled with better-than-expected enrollment trends as well as the changing mix of our membership towards the Government Business, which carries a lower than in consolidated average SG&A ratio. 
We reported operating cash flows of approximately $2 billion or 1.3x net income during the first 6 months of 2016. During the quarter, we reported operating cash flow of $662 million or 0.8x net income. As a reminder, we did make our first and second quarter income tax payments during the second quarter, consistent with prior years. 
I'll now turn the call over to our new Chief Financial Officer, John Gallina, to discuss our business segments' quarterly results and our updated 2016 outlook in more detail. John?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thanks, Joe, and good morning. Turning to discuss the second quarter financial performance of our business units. We added 290,000 members in our Government Business during the quarter and grew year-over-year revenue by 9.5% to $11.4 billion. These result",1561,"Thanks, Joe, and good morning. Turning to discuss the second quarter financial performance of our business units. We added 290,000 members in our Government Business during the quarter and grew year-over-year revenue by 9.5% to $11.4 billion. These results now include the impact from the addition of the Iowa contract, which was implemented on April 1. Operating margins for the Government Business in the quarter came in at 4%, a decline of 190 basis points versus the prior year quarter, which was driven by lower gross margins in the Medicaid business. As we communicated previously, we have been expecting Medicaid margins to compress from 2015 levels to a more normalized level, and we are monitoring the rate environment for the remainder of the year. 
During the quarter, we also experienced higher-than-expected claims across Medicaid businesses with the most notable market being the newly implemented Iowa contract. It is important to note that it is not uncommon to have early challenges in a new market, and our team has a long track record of successfully identifying and implementing revenue and cost of care initiatives to help mitigate issues. We will continue to work collaboratively with our state partner to ensure program stability and high-quality care for Iowa's most vulnerable citizens. 
Within Medicare, we're pleased with the progress the team continues to make, and our year-to-date margins continue to reflect improvement versus last year. Our outlook continues to expect margins to improve as the year progresses towards our expected long-term, sustainable levels, and we have positioned our portfolio to grow enrollment in 2017. 
The pipeline of opportunity for our Medicaid businesses remains substantial with an estimated $78 billion in contracts to be awarded between now and 2021 in markets that we will consider targeting. A little more than 3/4 of this opportunity is in new and specialized services, with the remainder in traditional Medicaid services. We continue to believe our experience and footprint positions us very well to continue our growth as we help states address the challenges of rising health care cost and improving quality to their residents. 
Switching to our commercial business. Our enrollment decreased by 142,000 lives during the quarter, which was slightly better than our previous expectations. Specifically, we experienced second quarter declines of 86,000 and 51,000 lives in our Individual and national businesses, respectively. The better-than-expected enrollment results contributed to a higher-than-expected operating revenue during the quarter, which increased by 5.7% versus the prior year quarter to $9.9 billion. 
Our second quarter operating margin of 10.9% was 120 basis points higher than the 9.7% we reported in the second quarter of 2015. The increase was driven by adjustments to the prior and current year risk adjustment estimates recorded during the quarter, a lower SG&A ratio due to lower administrative costs resulting from expense efficiency initiatives and growth in self-funded enrollment, which carries a higher-than-average operating margin. This increase was partially offset by higher medical cost experience in the individual ACA-compliant products and the timing of medical cost experience in our Local Group business. 
Within our individual ACA-compliant population, we had previously taken a conservative stance on our balance sheet with respect to various different estimates. This conservatism was very prudent as our current period claims trends have been higher than expected. We have seen higher-than-expected cost from membership with chronic conditions, such as renal disease, COPD, heart disease and diabetes, along with signs of pent-up demand among our new members. We have experienced higher-than-expected payments for dialysis treatments during the first half of the year, which we're in the process of reviewing the drivers of this increase. All in, our updated outlook now expects the Individual ACA-compliant business to incur mid-single-digit operating margin losses for the 2016 benefit year. 
It is important to note that we have assumed the higher-than-expected claims rate experienced thus far in the year will continue for the remainder of 2016 in developing our 2017 pricing assumptions. To be clear, we believe our pricing for 2017 fully incorporates our current expectations for 2016 claims, and we are focused on returning to profitability in 2017. Relating to National Accounts, we continue to be pleased that the team continues to secure wins contributing to the track record of membership growth in 2017. 
Regarding our balance sheet metrics. Consistent with our past practice, we have included a roll forward of our medical claims payable balance in this morning's press release. For the 6 months ended June 30, 2016, we experienced favorable prior year reserve development of $726 million, which was moderately better than our expectations. We continue to be at the upper end of our range of mid- to high single-digit margins for adverse deviation and believe our reserve balance remains consistent and strong as of June 30, 2016. 
Our Days in Claims Payable is 40.6 days as of June 30, a decrease of 2.8 days from the 43.4 days as of March 31. The decrease is in line with our expectations and consistent with the level of decrease seen between the first and second quarter of 2015. As previously discussed, we expect Days in Claims Payable to come back down closer to 40 over time. 
Our debt-to-capital ratio was 39.1% at June 30, 2016, down 110 basis points from the 40.2% at the end of the first quarter, which reflects the impact of an increase in shareholder equity and the reduction in our outstanding balance in commercial paper during the quarter. We ended the first quarter with approximately $2.1 billion of cash and investments at the parent company, and our investment portfolio was in an unrealized gain position of approximately $958 million as of June 30. 
For the 3Rs, we continue to book reinsurance as appropriate, and we continue to establish a 100% valuation allowance against any unpaid receivables for the 2014, 2015 and 2016 benefit years for risk corridors. For risk adjusters, the recent information from CMS shows us in a net receivable position, primarily in our small group markets. We have recorded a valuation allowance against certain risk-adjusted receivables in some of our markets based on our assessment of the financial solvency of co-op organizations that are payers into the risk-adjusted program due to the belief that those receivables may ultimately not be collected. 
As we have said in recent months and in the results we reported this morning, our operating metrics are expected to be different than we previously expected during the last earnings call. That said, we are reaffirming our adjusted earnings guidance and expect full year 2016 adjusted EPS to be greater than $10.80, excluding greater than $1.46 of negative adjustment items. On a GAAP basis, our 2016 earnings per share outlook is greater than $9.34. We are raising our operating revenue outlook by $1.5 billion to a range of $82.5 billion to $83.5 billion, reflecting stronger-than-expected enrollment across our businesses, including the contributions from Medicaid as well as the impact of adjustments to both prior and current year risk adjustment estimates. Fully insured membership is now expected to be approximately 15 million members at the midpoint of our range, 100,000 higher than our previous outlook, which reflects stronger than previously expected results in the Medicaid business. Self-funded membership is now expected to be 24.7 million members at the midpoint of our range, approximately 200,000 higher than our previous outlook. Taken together, we now project total membership to be approximately 1 million to 1.2 million higher than we ended 2015. 
We now expect our medical loss ratio to be in the range of 84.9%, plus or minus 30 basis points for the year, reflecting our view that higher than previously expected claims rates in our individual ACA-compliant plans as well as our Medicaid businesses remain at elevated levels throughout the year. This includes the worse-than-expected results in the newly implemented Iowa market. Reflecting the expected higher paid claims, we now expect 2016 operating cash flow to be approximately $3 billion. To offset the expected increase in our medical loss ratio, we are continuing the effort started last year to ensure we have an efficient cost structure. We now expect our SG&A ratio for the full year 2016 to be in the range of 14.5%, plus or minus 30 basis points. We continue to expect 2016 Local Group medical cost trends to be in the range of 7% to 7.5%. Our updated 2016 outlook does not include any benefit from the impact of share repurchase activity for the remainder of the year. As a reminder, we did not repurchase any shares for the first 6 months of 2016. 
Our outlook does include the adverse impact of the additional $0.02 in assessments associated with the dissolution of the Ohio co-op. This is in addition to the $0.03 of assessments we previously discussed in our first quarter call associated with the State of Colorado dissolution on their co-op. We have not included any additional assessments beyond those incurred in Colorado and Ohio in our outlook. 
It is important to note that our 2016 outlook does not include any additional benefits or transaction costs associated with the pending acquisition of Cigna beyond those incurred in the first half of 2016, nor does it include any benefit from lower pharmaceutical pricing, which we continue -- we believe we are entitled to under our current contract with ESI. 
With that, operator, please open the queue for questions."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","[Operator Instructions] Your first question comes from the line of A.J. Rice from UBS.",14,"[Operator Instructions] Your first question comes from the line of A.J. Rice from UBS."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First, just to maybe -- I'm trying to clarify a little bit more on the outlook for the year and particularly what you're assuming for the back half. If my numbers are right, you're allowing for about a 300 to 400 basis point deterioration further from wha",123,"First, just to maybe -- I'm trying to clarify a little bit more on the outlook for the year and particularly what you're assuming for the back half. If my numbers are right, you're allowing for about a 300 to 400 basis point deterioration further from what we saw first half's MLR to back half MLR, and you're getting obviously, as you say, the SG&A leverage. Two parts to this: Is that a normal seasonal pattern? Are you allowing for any other contingencies on the MLR assumption in the back half? And as -- would you characterize what you're doing on the SG&A side as something that's sustainable? Or are these sort of extraordinary measures in light of the MLR pressure you've experienced?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","A.J., this is John. Thank you for the question. Yes, so a couple of questions in there in terms of MLR and G&A. But first of all, on MLR, yes, your math is certainly appropriate from the first half to the last half. And really, what we've seen is that we'",374,"A.J., this is John. Thank you for the question. Yes, so a couple of questions in there in terms of MLR and G&A. But first of all, on MLR, yes, your math is certainly appropriate from the first half to the last half. And really, what we've seen is that we've got an elevated amount of utilization specifically in the ACA individual-compliant plans as well as in Medicaid and most significantly there in Iowa. And we're, at least, for purposes of our outlook, assuming that, that elevated level is going to continue throughout the rest of the year. So while, certainly, if there's any mitigation factors or medical management initiatives end up being more successful than we're planning, there could be upside. But it's really -- it has to do with taking the elevated levels of utilization we've seen and just essentially run rating them for the rest of the year. 
In terms of the G&A, I'd say the bulk of the G&A is sustainable. What we've really done is done an outstanding job of fixed-cost leveraging. We're increasing membership here this year between 1 million and 1.2 million members and maintaining our cost structure relatively constant. But we are growing. Our headcount increased in the second quarter, but it increased at a far, far slower rate than our membership increased. Revenue's going up about $2.5 billion -- $2 billion to $2.5 billion for the change in guidance from the beginning of the year until -- to today. Yet, the raw SG&A number is only going up very slightly. And so there's really -- it's really has as much to do with an excellent job of fixed-cost leveraging. Clearly, we are looking at some inefficiency and waste in terms of our processes and continue to look at those very closely on a regular basis and try to eliminate those things. And at the end of the day, the last piece of it really is that we're a pay-for-performance company. And as a pay-for-performance company, in order to get our bonus payments, we have to hit our targets. And to the extent that we don't hit our targets, we'll reduce our bonus structure. So that's something that we're looking at very closely as well."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. If I could do just a quick follow-up. Joe, thanks for the comments about the Cigna transaction. I might just ask, do you have any updated assessment of the time line from here? And then I think the merger agreement goes through the end of this year.",73,"Okay. If I could do just a quick follow-up. Joe, thanks for the comments about the Cigna transaction. I might just ask, do you have any updated assessment of the time line from here? And then I think the merger agreement goes through the end of this year. Can you just mention to us what happens after the end of the year if we're still in the court dealing with the proposed transaction?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thanks, A.J. First of all, when you referenced the end of the year, actually, we have the option on our side, our call, to extend it to the end of April, which obviously, we intend to do so. So I just want to make that record clear that we will continue -",125,"Thanks, A.J. First of all, when you referenced the end of the year, actually, we have the option on our side, our call, to extend it to the end of April, which obviously, we intend to do so. So I just want to make that record clear that we will continue -- and obviously, we're going to run out the litigation as long as it takes, working toward the end of April. Our expectation is, I guess, under normal or usual circumstances for claims like this, I will -- we're expecting the trial to begin somewhere around October. And at the outside, we're looking at 4 months. We believe it'll be about 4 months. Obviously, it could run a little longer, but that's our expectation."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Josh Raskin from Barclays.",12,"Your next question comes from the line of Josh Raskin from Barclays."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I think I'm going to ask very similar questions to A.J., but just, I guess, a different perspective. So on the MLR, forgetting about sort of the first half versus second half, just on a year-over-year basis, the first half is up 188 basis points, and that",179,"I think I'm going to ask very similar questions to A.J., but just, I guess, a different perspective. So on the MLR, forgetting about sort of the first half versus second half, just on a year-over-year basis, the first half is up 188 basis points, and that's only 3 months of Iowa, and you get some ACA benefit. But the second half looks more like an increase of 140 basis points. So the way I'm looking at it, year-over-year, you're actually expecting some noticeable improvement in the second half. So my MLR question is, what's causing that improvement on a relative basis? 
And then, John, on the G&A side, I think you mentioned that growth is going up a lot less than the revenue growth. But the way I look at it is, second quarter, you added $1.5 billion to revenues but took $600 million of G&A out. So it looks like there are noticeable savings and, I guess, I'm just curious. Is that deferred investment? Or is that some other sort of savings on the G&A side?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Sure, Josh. Great question. So yes, first half -- we'll be clear on the MLR, the first half of the year had the benefit of 3Rs in it. The run rate of claims outside of 3Rs is worse. And so that's obviously being baked into our outlook and our thought proc",108,"Sure, Josh. Great question. So yes, first half -- we'll be clear on the MLR, the first half of the year had the benefit of 3Rs in it. The run rate of claims outside of 3Rs is worse. And so that's obviously being baked into our outlook and our thought process. On the admin side, quite honestly, the single-largest driver of that year-over-year is the bonus program that I referenced at the end of A.J.'s question in terms of being a pay-for-performance company. We adjusted our bonus payable appropriately based on ensuring that we're going to hit our $10.80, and so that's certainly a part of the reconciliation."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And John, what was the 3R benefit? And I don't know, is there a way to size Iowa's impact on 2Q as well?",23,"And John, what was the 3R benefit? And I don't know, is there a way to size Iowa's impact on 2Q as well?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, the 3R benefit in and of itself, we don't provide the level of specificity that you're probably asking for. In terms of Iowa, I'll just say that Iowa is a brand new market. And we expected it to be dilutive in 2016 as we implemented our various medic",219,"Yes, the 3R benefit in and of itself, we don't provide the level of specificity that you're probably asking for. In terms of Iowa, I'll just say that Iowa is a brand new market. And we expected it to be dilutive in 2016 as we implemented our various medical management and revenue optimization processes. We ended up with about 25,000 more members in Iowa than we originally expected when we did our plan at the beginning of the year. And quite honestly, the MLR in Iowa is 25 to 30 basis points higher than we expected when we did our plan as well, so you had the additional members and it's more dilutive simultaneously with the elevated claims level. The really good news to that is that we do believe that our plan -- when we look at what we've done here historically, what the team has done historically in terms of new markets and implementing the managed care-type processes and procedures and the fact that the first year markets have historically been dilutive, and that we've got the target margins within a 18- to 24-month period of time. There's no reason to believe that that's not going to occur again here in Iowa, even though the starting points may be a little bit bumpier than we had hoped."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And these are 25 to 30 basis points or points higher?",11,"And these are 25 to 30 basis points or points higher?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Josh, 25 to 30 points higher, not basis points.",9,"Josh, 25 to 30 points higher, not basis points."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Points. Okay, so it's a huge number. Yes, okay, that makes sense.",12,"Points. Okay, so it's a huge number. Yes, okay, that makes sense."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Dave Windley from Jefferies.",12,"Your next question comes from the line of Dave Windley from Jefferies."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","It's Dave Styblo in for Windley. Just want to come back to -- maybe, if you guys could help us bridge sort of the puts and takes? And obviously the overall guidance remains the same on -- in terms of EPS. But I think, by the math that you guys presented o",121,"It's Dave Styblo in for Windley. Just want to come back to -- maybe, if you guys could help us bridge sort of the puts and takes? And obviously the overall guidance remains the same on -- in terms of EPS. But I think, by the math that you guys presented on the individual book being on a mid-single-digit loss, it sounds like that's about a $0.40 change relative to sort of what you were thinking before. And then on top of that, you've the Medicaid challenges that you highlighted. Is that sort of the right way to think about it? And then the offset being largely just the SG&A improvement on top of that to offset those 2 negatives."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, the other part of that is the top line growth is very clearly a good guy as part of all that. But yes, those are the most significant pieces. I think the good news is, and just to sort of maybe answer your follow-up question before you ask it, is tha",126,"Yes, the other part of that is the top line growth is very clearly a good guy as part of all that. But yes, those are the most significant pieces. I think the good news is, and just to sort of maybe answer your follow-up question before you ask it, is that if we look at 2016 versus 2017, let's be very clear. As I said in the prepared comments, when we did our pricing for 2017, we already had taken this elevated level of claims and utilization into account and baked it into our 2017 outlook. So we believe this is more of a 1-year type of issue. And that we're very committed to returning the ACA block of business back to profitability in 2017."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So you did address my question earlier on the follow-up. So is it -- I guess though, it seems like you priced for these things to happen. And in some ways, it still seems like it's worse than expected. So if you are filing rates and benefit changes earlie",96,"So you did address my question earlier on the follow-up. So is it -- I guess though, it seems like you priced for these things to happen. And in some ways, it still seems like it's worse than expected. So if you are filing rates and benefit changes earlier in the year, maybe if you can just give us more comfort about specifically how you caught these things earlier on when we're starting see more the development come in with higher utilization on the dialysis and COPD and the other elements that you talked about?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure. Well, the rates were developed in the April-May time frame. And so if you look back at our -- when we closed the books in March and the information we had available to us at that point in time, we had seen some of the spikes and the elevations,",190,"Yes, sure. Well, the rates were developed in the April-May time frame. And so if you look back at our -- when we closed the books in March and the information we had available to us at that point in time, we had seen some of the spikes and the elevations, just not to the same -- we weren't crystal clear then it was going to continue for the rest of the year or not. However, we wanted to be conservative. We wanted to be prudent. And so we believe -- we had hoped that it was not a trend. However, when we did our pricing, we felt it was best to assume it was a trend. Here we are 90 days later. I believe our conservatism turned out to be prudent, and that something that we weren't sure if that was going to be a trend or not, probably is. There's still the opportunity that seasonality could be in our favor and that things could get a little bit better in the second half of the year. We just decided not to assume that at this point in time."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then if I could just ask on Medicaid. I know obviously, you highlighted Iowa, and then you mentioned that broadly, there was just higher trends. Is it predominantly just Iowa being the drag in Medicaid? Or are there some specific other states? A",79,"Okay. And then if I could just ask on Medicaid. I know obviously, you highlighted Iowa, and then you mentioned that broadly, there was just higher trends. Is it predominantly just Iowa being the drag in Medicaid? Or are there some specific other states? And maybe, if you could sort of share a percentage of the weighting of the 75% Iowa, 25% other states and highlight what those other states might be and the issues that you're seeing there?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","In terms of -- it is both Iowa as well as other states. And we really don't get into specifics state by state. We're just calling out Iowa as a marker because it's brand new and it is a significant driver in and of itself. I will say that the primary driv",99,"In terms of -- it is both Iowa as well as other states. And we really don't get into specifics state by state. We're just calling out Iowa as a marker because it's brand new and it is a significant driver in and of itself. I will say that the primary drivers of the elevated trends, you know, they're pharmacy, nursing facilities, ER and outpatient surgery. Those 4 items are really the most significant part of our trend issue in the other states. So -- but we are seeing elevated trends in several states, and we're addressing those accordingly."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. But fair to say well above 50% is attributable to Iowa, though.",13,"Okay. But fair to say well above 50% is attributable to Iowa, though."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","We really don't get into that level of detail on a state-by-state basis for competitive reasons.",17,"We really don't get into that level of detail on a state-by-state basis for competitive reasons."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Andy Schenker from Morgan Stanley.",13,"Your next question comes from the line of Andy Schenker from Morgan Stanley."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So just going back to the exchange business here. Just thinking about it, big picture, right? In 2014, you guys were actually profitable. Last year, you were close to breakeven. This year, you're now losing money here. So what has really changed over that",118,"So just going back to the exchange business here. Just thinking about it, big picture, right? In 2014, you guys were actually profitable. Last year, you were close to breakeven. This year, you're now losing money here. So what has really changed over that time frame? Is it just the risk pool has continued to get worse? And therefore, is this something you can actually rectify with pricing? Or are there structural issues to the exchanges? Or are there other more meaningful benefit changes, i.e. networks or other design changes, that you've also incorporated for next year that are going to be necessary to offset what's been a steady deterioration of the profitability of this book every year?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure. No, great question. And in terms of will pricing by itself, rectify it? No. Because there's no one single bullet that actually solves the entire problem. The administration is extremely focused on having a sustainable marketplace. And we think",260,"Yes, sure. No, great question. And in terms of will pricing by itself, rectify it? No. Because there's no one single bullet that actually solves the entire problem. The administration is extremely focused on having a sustainable marketplace. And we think that we've been a very active participant in the exchanges and been a great partner with CMS in trying to help with the stability of the marketplace. They've made changes over the years of tightening the supplemental enrollment a bit and various other requirements. The penalty continues to increase. We think all those things obviously have to be done. Other things that would certainly help the acceleration of stabilization would be to eliminate the health insurer tax in beyond 2017. The risk adjuster model, it's -- it does a lot of what it's intended to do. But quite honestly, there's a bit of an imbalance that the -- that it overcharges for healthy and over-reimburses for certain moderately unhealthy disease states. We think, as I said, the supplemental enrollment period, we really do need a better upfront verification process and that there should not be any restriction on our efforts to innovate product designs to meet consumer needs. And then modifying the grace periods for nonpayment of premiums would be something else. So those are just -- in addition to the pricing, things that we've been working with the administration on and believe should occur. We do believe that with the medical management and various other issues, that we can help get this back to profitability here in 2017."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, this is Joe. Let me just weigh in to add to what John just shared with you. Just reiterate, we've been a very active participant in the exchanges from the beginning and recognize the markets have taken longer than expected to stabilize. And we've sta",363,"Yes, this is Joe. Let me just weigh in to add to what John just shared with you. Just reiterate, we've been a very active participant in the exchanges from the beginning and recognize the markets have taken longer than expected to stabilize. And we've stated that repeatedly. And I think we've been working very closely with the administration and conducting our own modeling to best judge how we're going to continually engage year-over-year in as profitable a context as possible. It's interesting, reflect back to the end of first quarter, we told you that, end of June 30, we'd probably have greater insight into the membership we've captured, recognizing that we had a substantial uptick in membership. Deteriorated a little bit at the end of Q2 to around 925,000 or so members. But what we've observed in terms of the intensity of illness is that, as John pointed out in his earlier remarks, we're dealing with some chronic illnesses like cardiac, diabetes, COPD. We've had a, what we think, is a material uptick in dialysis cost that have hit us. So we're going through an appraisal of all that in terms how to better medically manage those members as well as begin pricing it into '17. That's the trick. I think John has stated it, and I'll restate it. We believe we're well positioned for pricing in '17, given what we now know about the membership we captured. And so I guess, when you put all that together, what we're waiting for now is rate approvals by state. And I can assure you that we're going to be extremely prudent in our continuing engagement. I think we're in something like 138 or so rating regions. And we're going through an appraisal of every one of those regions. And we'll make prudent business decisions in terms of flexing our engagement in appropriate ways going into '17. And so I just -- I want to assure that, notwithstanding we've been active participants, we're also very -- I'll use the word prudent, very thoughtful, in terms of executing a good business practice, in terms of how we continue to stay engaged in the public marketplace."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Great. That was very helpful. Thinking maybe a little bit more broadly. You kind of reiterated your small group -- or Local Group, rather, trend assumptions here. But you did kind of call out timing and medical cost experience for Local Group. Maybe, if y",75,"Great. That was very helpful. Thinking maybe a little bit more broadly. You kind of reiterated your small group -- or Local Group, rather, trend assumptions here. But you did kind of call out timing and medical cost experience for Local Group. Maybe, if you could just talk more about what you're seeing around trend, if there's any pockets you're seeing in patients, et cetera, as it relates to that -- how you define it?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure. So in terms of trend on the Local Group side, that's actually going very well. And we reaffirm the 7% to 7.5% outlook for that and feel very comfortable with that, given the results for the first half of the year. In terms of the timing, that r",158,"Yes, sure. So in terms of trend on the Local Group side, that's actually going very well. And we reaffirm the 7% to 7.5% outlook for that and feel very comfortable with that, given the results for the first half of the year. In terms of the timing, that relates to just a couple, really, accounting and calendar quirks. The first quarter of 2016 had an extra workday in it, driven by leap year. The second quarter of 2016 had an extra workday in it, driven by how the weekends fell. The fourth quarter of 2016 has 1 less workday in it, and so that's significant enough to change the timing pattern on a quarter-over-quarter basis. Then you take that and the fact that our overall product mix in the group side is slightly richer than the overall product mix in the group side a year ago, that changes the timing as well given how the deductibles work."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Gary Taylor from JPMorgan.",12,"Your next question comes from the line of Gary Taylor from JPMorgan."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just a couple of questions. Did you give us the total exchange enrollment as of the end of 2Q? Did I miss that?",23,"Just a couple of questions. Did you give us the total exchange enrollment as of the end of 2Q? Did I miss that?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. It's 923,000.",3,"Yes. It's 923,000."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And the total -- when you talk about the ACA-compliant book now being mid-single-digit losses, what is the total ACA-compliant enrollment that you're speaking to? So presumably, that's some off exchange and some -- and small group ACA-compliant as well.",40,"And the total -- when you talk about the ACA-compliant book now being mid-single-digit losses, what is the total ACA-compliant enrollment that you're speaking to? So presumably, that's some off exchange and some -- and small group ACA-compliant as well."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","A little more than half of the remainder is ACA-compliant.",11,"A little more than half of the remainder is ACA-compliant."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And I just want to come back to the risk adjustment, because it seems like potentially, it was quite material in the quarter. I know you guys only disclosed that you had a payable at year-end. We calculate that payable by the $105 million and the sw",95,"Okay. And I just want to come back to the risk adjustment, because it seems like potentially, it was quite material in the quarter. I know you guys only disclosed that you had a payable at year-end. We calculate that payable by the $105 million and the swing factor to $190 million payment that CMS was citing for '15 is about $0.60. You say that you booked some valuation allowances against that because of co-op situations. But I mean, should we assume that a material portion of that $0.60 was trued up in this quarter?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","I -- there was a lot of things that went against it, and I'm not going to really comment on your estimate of the payable. But in terms of valuation allowance, it's clearly part of it. Certainly, medical loss ratio rebates were part of it. After all the du",141,"I -- there was a lot of things that went against it, and I'm not going to really comment on your estimate of the payable. But in terms of valuation allowance, it's clearly part of it. Certainly, medical loss ratio rebates were part of it. After all the dust settled, we're going to pay over $100 million in MLR rebates in 2016 related to the 2015 calendar year. And so that's part of it. And you've got the small group versus the individual component is clearly a piece of it. Risk corridor true-ups, reinsure, I mean, there's so many moving parts, it's hard to, on the call here, pin that down exactly. And then quite honestly, whatever benefits existed after all the other offsets have now been baked into our trend outlook and our guidance for the rest of the year."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay, if I could just -- 2 quick clarifications. I think Josh was asking about the G&A run rate and sustainability of that. The guidance for the second half certainly implies this reduced G&A is fairly sustainable. But as you head into '17, do you feel li",77,"Okay, if I could just -- 2 quick clarifications. I think Josh was asking about the G&A run rate and sustainability of that. The guidance for the second half certainly implies this reduced G&A is fairly sustainable. But as you head into '17, do you feel like there's going to be a deferred level that has to rebound? Or is this sort of G&A ratio a number that makes sense as a jumping-off point heading into '17?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","The most significant driver of the G&A benefits here compared to our guidance or our outlook is the top line revenue growth and the fixed-cost leveraging associated with that. And so that clearly is run rate and sustainable. In terms of -- certainly, as a",117,"The most significant driver of the G&A benefits here compared to our guidance or our outlook is the top line revenue growth and the fixed-cost leveraging associated with that. And so that clearly is run rate and sustainable. In terms of -- certainly, as an employee of the company, I'm fully supportive of getting back to the bonus structure, back to target levels. But there's a natural hedge associated with that. So as results warrant it, we then record the expense. If they don't warrant it, we don't record the expense. So what the impact that might be on an exact ratio is to be seen, but the bottom line has a natural hedge built in."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So my last one. When we think about the year, ACA-compliant business, worse than you had anticipated; Iowa and Medicaid overall, worse than anticipated. Yet, you maintained the guidance. So the 2 components that were better that allowed you to maintain co",55,"So my last one. When we think about the year, ACA-compliant business, worse than you had anticipated; Iowa and Medicaid overall, worse than anticipated. Yet, you maintained the guidance. So the 2 components that were better that allowed you to maintain compliance was risk adjustment and some of the additional enrollment growth. Is that fair?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, certainly, admin, risk adjustment, enrollment growth. We're doing extremely well in the national and large local ASO in terms of enrollment. Our Medicare Advantage and our senior business are growing very, very well and exceeding expectations for th",113,"Well, certainly, admin, risk adjustment, enrollment growth. We're doing extremely well in the national and large local ASO in terms of enrollment. Our Medicare Advantage and our senior business are growing very, very well and exceeding expectations for the year. And quite honestly, we had a bit of an initial conservative posture at the beginning of the year as well. So it's a lot of things. Our specialty product line is beating expectations. So I would hate to just point to 1 or 2 items because there are far more positives than there are negatives. It's just that the 2 negatives have really caused our conservative posture to be a more prudent posture."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Justin Lake from Wolfe Research.",13,"Your next question comes from the line of Justin Lake from Wolfe Research."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First, just a follow-up on the SG&A number for that bonus program. I understand that, as you said, it's a hedge and other things have to improve to offset it. But can you give us a ballpark number there in terms of how much cost comes back into SG&A if yo",57,"First, just a follow-up on the SG&A number for that bonus program. I understand that, as you said, it's a hedge and other things have to improve to offset it. But can you give us a ballpark number there in terms of how much cost comes back into SG&A if you fully accrue that for next year?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, in terms of exactly how much that is, the bonus program target is certainly a significant number in and of itself but, Justin, that's just not a number that we're comfortable giving out.",34,"Well, in terms of exactly how much that is, the bonus program target is certainly a significant number in and of itself but, Justin, that's just not a number that we're comfortable giving out."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. Is there any way to proportion it? For instance, you're losing, you said, mid-single digits on the individual side. I mean, can you remind us what's the ACA-compliant premium number for this year, ballpark?",35,"Okay. Is there any way to proportion it? For instance, you're losing, you said, mid-single digits on the individual side. I mean, can you remind us what's the ACA-compliant premium number for this year, ballpark?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's a bit north of $6 billion, close to -- maybe closer to $7 billion.",16,"It's a bit north of $6 billion, close to -- maybe closer to $7 billion."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So you're talking about $300 million plus in potential -- just getting back to breakeven, right, in the Individual business, right, is how we should think about the earnings power of the business? I assume you're not expecting to run losses for -- e",59,"Okay. So you're talking about $300 million plus in potential -- just getting back to breakeven, right, in the Individual business, right, is how we should think about the earnings power of the business? I assume you're not expecting to run losses for -- even in the intermediate term here as you talked about. So would -- if we..."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","I'm not going to argue with your math.",9,"I'm not going to argue with your math."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So if Individual comes back to breakeven or better, does this SG&A basically offset that? Or is it larger or smaller than Individual coming back to breakeven?",28,"Okay. So if Individual comes back to breakeven or better, does this SG&A basically offset that? Or is it larger or smaller than Individual coming back to breakeven?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, there's certainly -- it's a natural hedge built in. But to answer your question would be to answer the question that you asked the first time. So good luck. It's a big number, but we're not going to size it specifically.",42,"Well, there's certainly -- it's a natural hedge built in. But to answer your question would be to answer the question that you asked the first time. So good luck. It's a big number, but we're not going to size it specifically."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. But you wouldn't call me crazy if I said it was in the same ballpark as getting back to breakeven in Individual?",23,"Okay. But you wouldn't call me crazy if I said it was in the same ballpark as getting back to breakeven in Individual?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","I would never call you crazy.",6,"I would never call you crazy."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","All right. Last question, just on the government side. So you've laid out the issues here. And you were very clear coming into 2016 saying, for instance, Medicaid, the margins were unsustainable. They were going to come down, plus you were going to have t",123,"All right. Last question, just on the government side. So you've laid out the issues here. And you were very clear coming into 2016 saying, for instance, Medicaid, the margins were unsustainable. They were going to come down, plus you were going to have the Medicaid pressure in Iowa. I guess, my -- what I'm trying to think about here is, these margins are down meaningfully for 2016 in the government overall, and you're saying Medicare is actually improving, so Medicaid, the full brunt. My question is, is Medicaid now at a target margin for 2016 when you think about it overall? Or does the Medicaid margin actually improve going forward from here, given how tough it's been and the worse-than-expected costs overall?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's a -- the Medicaid margins are within our target range. Obviously, we're hopeful that we can improve it to the high end of the range. But even with all these headwinds and the negative comments that we had earlier in the year, we're still within the r",49,"It's a -- the Medicaid margins are within our target range. Obviously, we're hopeful that we can improve it to the high end of the range. But even with all these headwinds and the negative comments that we had earlier in the year, we're still within the range."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So for the full year, you're within the range, but closer to the midpoint, to the low end, and potentially can improve it towards the higher end again, where you've typically been.",32,"So for the full year, you're within the range, but closer to the midpoint, to the low end, and potentially can improve it towards the higher end again, where you've typically been."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","That's a reasonable way of thinking about it, yes.",10,"That's a reasonable way of thinking about it, yes."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Kevin Fischbeck from Bank of America.",14,"Your next question comes from the line of Kevin Fischbeck from Bank of America."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. Got a couple of questions. I guess, first, on the exchanges. I guess, obviously, you guys believe that you've caught everything as far as pricing for next year and you expect margins to improve next year. But I guess, we've seen now, I don't know, 5",104,"Okay. Got a couple of questions. I guess, first, on the exchanges. I guess, obviously, you guys believe that you've caught everything as far as pricing for next year and you expect margins to improve next year. But I guess, we've seen now, I don't know, 5 or 6 quarters in a row where it kind of seems like the cost continue to rise, I mean, for you, but really, for a lot of the players out there. I mean, can you give a sense as to why you feel confident saying that, given the experience of most companies over the last 1.5 years?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, why we believe that we've caught everything?",8,"Well, why we believe that we've caught everything?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Yes, exactly.",2,"Yes, exactly."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","I think -- well, a lot of it, obviously, has to do with our data analytics and how we track things. And as you look at the rate increases that we put in, approaching 20% range on a weighted-average basis across our 14 states, very significant. And as we -",245,"I think -- well, a lot of it, obviously, has to do with our data analytics and how we track things. And as you look at the rate increases that we put in, approaching 20% range on a weighted-average basis across our 14 states, very significant. And as we -- yes, we also believe that we have some of the best-in-class risk adjuster capabilities of really understanding what drives risk adjuster and things like that. And I think the results that we saw from the CMS true-up really helped verify that. So the other piece that gives us a little bit of comfort in terms of having caught everything is that our 2016 risk adjuster that we're assuming into '17 really is based on 2015 experience. So we think that, that gives us a natural cushion associated with how that's being approached. But at the end of the day, the question is, ""How do we know we've gotten everything?"" Well, we've got 6 months of information. Obviously, there's a lot of new members associated with this block of business, and we can't provide absolute certainty. But we think we have very, very good line of sight. What we saw at the end of the first quarter, we further predicted from a pricing standpoint, and what we saw at the end of the second quarter was exactly consistent with that pricing prediction. So we feel good that we've got a good line of sight on that."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I guess, is there anything different about you heading into Q3 this year versus you heading into Q3 last year as far as what you're doing from a data analytics perspective? Or anything there that gives you more confidence or visibility this year than what",55,"I guess, is there anything different about you heading into Q3 this year versus you heading into Q3 last year as far as what you're doing from a data analytics perspective? Or anything there that gives you more confidence or visibility this year than what you had heading into the back half of last year?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, this is Joe. I certainly believe that we're always improving year-over-year, and especially in this space, given we've got more and more data. We certainly recognize that this is a company that's had a long-standing engagement of high-risk pools. An",148,"Well, this is Joe. I certainly believe that we're always improving year-over-year, and especially in this space, given we've got more and more data. We certainly recognize that this is a company that's had a long-standing engagement of high-risk pools. And we have a lot of data that has backed us up for a long period of time. And I think that we just -- as I said a moment ago, always expect to continue of improving the space. However, I'll reiterate what I said earlier. We're going to be very surgical with respect to our analytics in and around rating regions. We're going to be very mindful of what price increases are awarded to us by state. And so we'll be making various, I call it, accurate business decisions going into '17 and beyond regarding our continued engagement on a broad scale in the public exchange space."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, and then the other comment that I'll just add to that, I think maybe address here, what would be different going into the third quarter is, 2016, we actually had more members come on board on January 1 than we did in 2015 or 2014. 2014, in particular",115,"Yes, and then the other comment that I'll just add to that, I think maybe address here, what would be different going into the third quarter is, 2016, we actually had more members come on board on January 1 than we did in 2015 or 2014. 2014, in particular, if you recall, we had a vast majority of the members come on board early second quarter. And in 2015, with the extension of the open enrollment period, a lot of members came on later in the first quarter. 2016, a lot more January 1. We actually do have a full 6 months of information this year, and we had not had that in prior years."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay then, just last question. Last quarter, you said that -- when you expected the exchanges to be pretty much breakeven this year, you said next year was probably going to be below your target, 3% to 5%. But by 2018, you'd be in your target margin. Do y",85,"Okay then, just last question. Last quarter, you said that -- when you expected the exchanges to be pretty much breakeven this year, you said next year was probably going to be below your target, 3% to 5%. But by 2018, you'd be in your target margin. Do you still feel like you still have that same ramp over the next couple of years? Or does this set back -- kind of push back when you're going to get to your target margins on exchanges?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","The pricing increases that we've put in really do keep us on that same ramp. And it's very important that we do receive the pricing increases that we've filed for in terms of that. Obviously, we expect the market to continue to harden and pricing to be mo",92,"The pricing increases that we've put in really do keep us on that same ramp. And it's very important that we do receive the pricing increases that we've filed for in terms of that. Obviously, we expect the market to continue to harden and pricing to be more reasonable. I mean, clearly, there's a reason that so many co-ops have gone insolvent in terms of their pricing methodologies. So as more and more of those folks exit the market, it should provide a more sustainable stable marketplace in 2018 and beyond."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","And your final question today comes from the line of Chris Rigg.",12,"And your final question today comes from the line of Chris Rigg."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just with regard to the ACA-compliant membership, do you have a sense, at this point, how many of the individuals were new members to Anthem? And is there -- if you have that information, is there a pronounced difference in utilization trends among those",64,"Just with regard to the ACA-compliant membership, do you have a sense, at this point, how many of the individuals were new members to Anthem? And is there -- if you have that information, is there a pronounced difference in utilization trends among those that are -- who are new to Anthem versus those that had been enrolled for a year or 2?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Very quick response to the question. A little less than half of the membership was new to us in '16.",21,"Yes. Very quick response to the question. A little less than half of the membership was new to us in '16."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then just one quick follow-up here. Of the individual that's non-ACA-compliant at this point, will most of them become -- roll into ACA-compliant plans in 2017 because of the grandmothering dynamic? Or will they still stay outside the complaint",42,"Okay. And then just one quick follow-up here. Of the individual that's non-ACA-compliant at this point, will most of them become -- roll into ACA-compliant plans in 2017 because of the grandmothering dynamic? Or will they still stay outside the complaint side?"
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes -- no, a great question. We do expect some attrition in that area, as you pointed out. Whether they enroll remains to be seen. But historically, we haven't seen the uptake in ACA-compliant plans that maybe was estimated by the CBO when the law was pas",56,"Yes -- no, a great question. We do expect some attrition in that area, as you pointed out. Whether they enroll remains to be seen. But historically, we haven't seen the uptake in ACA-compliant plans that maybe was estimated by the CBO when the law was passed. But yes, that's certainly a watch area for us."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","And now I would now like to turn the conference back to the company's management for closing comments.",19,"And now I would now like to turn the conference back to the company's management for closing comments."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, as usual, thanks for your questions. They're all very insightful. As a company, we remain committed to tackling our health care system's challenges head on and deliver greater value to consumers by expanding access to high-quality, affordable health",100,"Well, as usual, thanks for your questions. They're all very insightful. As a company, we remain committed to tackling our health care system's challenges head on and deliver greater value to consumers by expanding access to high-quality, affordable health care. That's why we're committed to challenging the DOJ's recent decision to block our acquisition of Cigna in court. We also want to thank all of our associates for their continued commitment to serving our 39.8 million members every day. 
Thanks for your interest in Anthem, and we look forward to speaking with you very soon. Again, thank you very much."
160077,308029078,1013768,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, this conference will be available for replay after 11:00 a.m. Eastern Time today through August 10. You may access the AT&T Teleconference Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378817. Int",68,"Ladies and gentlemen, this conference will be available for replay after 11:00 a.m. Eastern Time today through August 10. You may access the AT&T Teleconference Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378817. International participants, dial (320) 365-3844. That does conclude your conference for today. Thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management.",37,"Ladies and gentlemen, thank you for standing by. Welcome to the Anthem conference call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to turn the conference over to the company's management."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Good morning, and welcome to Anthem's Second Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish, Chairman, President and CEO; and John Gallina, our CFO. Joe will offer some commen",197,"Good morning, and welcome to Anthem's Second Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. 
With us this morning are Joe Swedish, Chairman, President and CEO; and John Gallina, our CFO. Joe will offer some commentary on the recent DOJ actions and provide an overview of our second quarter 2016 financial results, and then John will walk through the financials of our business units and provide some incremental commentary around our updated 2016 outlook. We're then available for Q&A. 
During the call, we will reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website at antheminc.com. We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Anthem. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in today's press release and in our quarterly and annual filings with the SEC. 
I will now turn the call over to Joe."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Doug, and good morning. This morning, we announced second quarter 2016 adjusted earnings per share of $3.33, with membership and revenue tracking above our previous expectations. On a GAAP basis, we reported earnings per share of $2.91. Befor",925,"Thank you, Doug, and good morning. This morning, we announced second quarter 2016 adjusted earnings per share of $3.33, with membership and revenue tracking above our previous expectations. On a GAAP basis, we reported earnings per share of $2.91. 
Before John and I discuss the details of our second quarter financials and our updated 2016 outlook, I think it's appropriate to discuss our perspective on the latest Cigna developments. I'll start by saying we are disappointed by the U.S. Department of Justice's decision to block Anthem's acquisition of Cigna, a combination specifically designed to tackle our health care system's challenges head on and deliver greater value to consumers by expanding access to high-quality, affordable health care. To be clear, our board and executive leadership team at Anthem is fully committed to challenging the DOJ's decision in court. 
As you may have read in Tuesday's published op-ed, the DOJ has disregarded the issue of access for 2 of the most unstable and at high risk health insurance markets: individuals and small businesses. These populations comprise a meaningful proportion of the still more than 33 million uninsured Americans who will benefit from the Cigna acquisition through expanded and improved access, affordability and quality. 
For example, despite the many and continuing challenges of the health insurance exchanges, Anthem entered into this new and high-risk market at its inception. Though several of our competitors have exited this business, we now serve 923,000 public exchange members across 14 states where we do business as Blue Cross and Blue Shield plan. As shared with the DOJ, our acquisition of Cigna will help stabilize pricing in this volatile market, enabling Anthem to continue its commitment to the public exchanges and provide the opportunity to expand our participation to 9 additional states where neither Anthem nor Cigna currently participate. Additionally, we estimate this acquisition will significantly lower cost for our self-funded consumers, with over $2 billion in medical cost savings that we pass directly back to them. Finally, we also note this acquisition will benefit our shareholders and the pension, retirement and investment funds they represent. Specifically, 99% of our shareholders voted in favor of this transaction. 
Now to discuss consolidated financials we reported this morning. Our second quarter adjusted EPS of $3.33 was slightly ahead of our expectations, albeit with mixed financial metrics to get us there. Within membership, both fully insured and self-funded memberships are tracking ahead of expectations as we ended the second quarter with nearly 39.8 million members. This reflects growth of an additional 148,000 lives during the quarter, bringing our year-to-date enrollment growth to 1.2 million lives or 3%. Specifically, our insured membership increased by 170,000 lives as our Medicaid business grew by a better-than-expected 280,000 lives in the quarter to over 6.3 million members. This reflected better-than-expected enrollment growth from the implementation of the Iowa state contract, which started on April 1 as well as better-than-expected core membership growth within multiple other state contracts. 
Within commercial, our insured enrollment came in line with expectations. We ended the quarter with 923,000 lives from the individual public exchanges, a decrease of 52,000 from the 975,000 we reported in the first quarter. And Local Group insured business declined modestly and in line with our most recent expectations. 
Our self-funded business was relatively stable during the quarter, which was better than our previous expectations, as we experienced higher-than-expected growth in membership in existing accounts. Our membership results translated into better-than-expected operating revenue of $21.3 billion. Our second quarter 2016 results represent an increase of $1.5 billion or 7.7% versus the second quarter of 2015, reflecting strong enrollment growth in the Government Business and additional premium revenue to cover overall cost trends. Also contributing was the growth in administrative fee revenue as a result of our strong self-funded memberships trends. This was partially offset by fully insured membership losses in our commercial business. 
The second quarter 2016 benefit expense ratio was 84.2%, which increased by 210 basis points versus the prior year. The year-over-year increase was partially driven by higher benefit expense ratio in the Medicaid business as our medical cost experience exceeded the net impact of annual premium rate adjustments and the impact of growth in membership, which the Medicaid business carries a higher benefit expense ratio than the consolidated company average. Further, the benefit expense ratio reflects the impact of higher medical cost experience in the Individual business and the timing of higher medical cost experience in the Local Group business. The increase was partially offset by adjustments to the prior and current year risk adjustment estimates in our ACA-compliant individual and small group products. 
Our SG&A expense ratio came in at a better than previously expected 14% in the second quarter of 2016, a decrease of 140 basis points from the prior year. This was driven by an intentional focus on administrative expense control, coupled with better-than-expected enrollment trends as well as the changing mix of our membership towards the Government Business, which carries a lower than in consolidated average SG&A ratio. 
We reported operating cash flows of approximately $2 billion or 1.3x net income during the first 6 months of 2016. During the quarter, we reported operating cash flow of $662 million or 0.8x net income. As a reminder, we did make our first and second quarter income tax payments during the second quarter, consistent with prior years. 
I'll now turn the call over to our new Chief Financial Officer, John Gallina, to discuss our business segments' quarterly results and our updated 2016 outlook in more detail. John?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thanks, Joe, and good morning. Turning to discuss the second quarter financial performance of our business units. We added 290,000 members in our Government Business during the quarter and grew year-over-year revenue by 9.5% to $11.4 billion. These result",1561,"Thanks, Joe, and good morning. Turning to discuss the second quarter financial performance of our business units. We added 290,000 members in our Government Business during the quarter and grew year-over-year revenue by 9.5% to $11.4 billion. These results now include the impact from the addition of the Iowa contract, which was implemented on April 1. Operating margins for the Government Business in the quarter came in at 4%, a decline of 190 basis points versus the prior year quarter, which was driven by lower gross margins in the Medicaid business. As we communicated previously, we have been expecting Medicaid margins to compress from 2015 levels to a more normalized level, and we are monitoring the rate environment for the remainder of the year. 
During the quarter, we also experienced higher-than-expected claims across Medicaid businesses with the most notable market being the newly implemented Iowa contract. It is important to note that it is not uncommon to have early challenges in a new market, and our team has a long track record of successfully identifying and implementing revenue and cost of care initiatives to help mitigate issues. We will continue to work collaboratively with our state partner to ensure program stability and high-quality care for Iowa's most vulnerable citizens. 
Within Medicare, we're pleased with the progress the team continues to make, and our year-to-date margins continue to reflect improvement versus last year. Our outlook continues to expect margins to improve as the year progresses towards our expected long-term, sustainable levels, and we have positioned our portfolio to grow enrollment in 2017. 
The pipeline of opportunity for our Medicaid businesses remains substantial with an estimated $78 billion in contracts to be awarded between now and 2021 in markets that we will consider targeting. A little more than 3/4 of this opportunity is in new and specialized services, with the remainder in traditional Medicaid services. We continue to believe our experience and footprint positions us very well to continue our growth as we help states address the challenges of rising health care cost and improving quality to their residents. 
Switching to our commercial business. Our enrollment decreased by 142,000 lives during the quarter, which was slightly better than our previous expectations. Specifically, we experienced second quarter declines of 86,000 and 51,000 lives in our Individual and national businesses, respectively. The better-than-expected enrollment results contributed to a higher-than-expected operating revenue during the quarter, which increased by 5.7% versus the prior year quarter to $9.9 billion. 
Our second quarter operating margin of 10.9% was 120 basis points higher than the 9.7% we reported in the second quarter of 2015. The increase was driven by adjustments to the prior and current year risk adjustment estimates recorded during the quarter, a lower SG&A ratio due to lower administrative costs resulting from expense efficiency initiatives and growth in self-funded enrollment, which carries a higher-than-average operating margin. This increase was partially offset by higher medical cost experience in the individual ACA-compliant products and the timing of medical cost experience in our Local Group business. 
Within our individual ACA-compliant population, we had previously taken a conservative stance on our balance sheet with respect to various different estimates. This conservatism was very prudent as our current period claims trends have been higher than expected. We have seen higher-than-expected cost from membership with chronic conditions, such as renal disease, COPD, heart disease and diabetes, along with signs of pent-up demand among our new members. We have experienced higher-than-expected payments for dialysis treatments during the first half of the year, which we're in the process of reviewing the drivers of this increase. All in, our updated outlook now expects the Individual ACA-compliant business to incur mid-single-digit operating margin losses for the 2016 benefit year. 
It is important to note that we have assumed the higher-than-expected claims rate experienced thus far in the year will continue for the remainder of 2016 in developing our 2017 pricing assumptions. To be clear, we believe our pricing for 2017 fully incorporates our current expectations for 2016 claims, and we are focused on returning to profitability in 2017. Relating to National Accounts, we continue to be pleased that the team continues to secure wins contributing to the track record of membership growth in 2017. 
Regarding our balance sheet metrics. Consistent with our past practice, we have included a roll forward of our medical claims payable balance in this morning's press release. For the 6 months ended June 30, 2016, we experienced favorable prior year reserve development of $726 million, which was moderately better than our expectations. We continue to be at the upper end of our range of mid- to high single-digit margins for adverse deviation and believe our reserve balance remains consistent and strong as of June 30, 2016. 
Our Days in Claims Payable is 40.6 days as of June 30, a decrease of 2.8 days from the 43.4 days as of March 31. The decrease is in line with our expectations and consistent with the level of decrease seen between the first and second quarter of 2015. As previously discussed, we expect Days in Claims Payable to come back down closer to 40 over time. 
Our debt-to-capital ratio was 39.1% at June 30, 2016, down 110 basis points from the 40.2% at the end of the first quarter, which reflects the impact of an increase in shareholder equity and the reduction in our outstanding balance in commercial paper during the quarter. We ended the first quarter with approximately $2.1 billion of cash and investments at the parent company, and our investment portfolio was in an unrealized gain position of approximately $958 million as of June 30. 
For the 3Rs, we continue to book reinsurance as appropriate, and we continue to establish a 100% valuation allowance against any unpaid receivables for the 2014, 2015 and 2016 benefit years for risk corridors. For risk adjusters, the recent information from CMS shows us in a net receivable position, primarily in our small group markets. We have recorded a valuation allowance against certain risk-adjusted receivables in some of our markets based on our assessment of the financial solvency of co-op organizations that are payers into the risk-adjusted program due to the belief that those receivables may ultimately not be collected. 
As we have said in recent months and in the results we reported this morning, our operating metrics are expected to be different than we previously expected during the last earnings call. That said, we are reaffirming our adjusted earnings guidance and expect full year 2016 adjusted EPS to be greater than $10.80, excluding greater than $1.46 of negative adjustment items. On a GAAP basis, our 2016 earnings per share outlook is greater than $9.34. We are raising our operating revenue outlook by $1.5 billion to a range of $82.5 billion to $83.5 billion, reflecting stronger-than-expected enrollment across our businesses, including the contributions from Medicaid as well as the impact of adjustments to both prior and current year risk adjustment estimates. Fully insured membership is now expected to be approximately 15 million members at the midpoint of our range, 100,000 higher than our previous outlook, which reflects stronger than previously expected results in the Medicaid business. Self-funded membership is now expected to be 24.7 million members at the midpoint of our range, approximately 200,000 higher than our previous outlook. Taken together, we now project total membership to be approximately 1 million to 1.2 million higher than we ended 2015. 
We now expect our medical loss ratio to be in the range of 84.9%, plus or minus 30 basis points for the year, reflecting our view that higher than previously expected claims rates in our individual ACA-compliant plans as well as our Medicaid businesses remain at elevated levels throughout the year. This includes the worse-than-expected results in the newly implemented Iowa market. Reflecting the expected higher paid claims, we now expect 2016 operating cash flow to be approximately $3 billion. To offset the expected increase in our medical loss ratio, we are continuing the effort started last year to ensure we have an efficient cost structure. We now expect our SG&A ratio for the full year 2016 to be in the range of 14.5%, plus or minus 30 basis points. We continue to expect 2016 Local Group medical cost trends to be in the range of 7% to 7.5%. Our updated 2016 outlook does not include any benefit from the impact of share repurchase activity for the remainder of the year. As a reminder, we did not repurchase any shares for the first 6 months of 2016. 
Our outlook does include the adverse impact of the additional $0.02 in assessments associated with the dissolution of the Ohio co-op. This is in addition to the $0.03 of assessments we previously discussed in our first quarter call associated with the State of Colorado dissolution on their co-op. We have not included any additional assessments beyond those incurred in Colorado and Ohio in our outlook. 
It is important to note that our 2016 outlook does not include any additional benefits or transaction costs associated with the pending acquisition of Cigna beyond those incurred in the first half of 2016, nor does it include any benefit from lower pharmaceutical pricing, which we continue -- we believe we are entitled to under our current contract with ESI. 
With that, operator, please open the queue for questions."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","[Operator Instructions] Your first question comes from the line of A.J. Rice from UBS.",14,"[Operator Instructions] Your first question comes from the line of A.J. Rice from UBS."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First, just to maybe -- I'm trying to clarify a little bit more on the outlook for the year and particularly what you're assuming for the back half. If my numbers are right, you're allowing for about a 300 to 400 basis point deterioration further from wha",123,"First, just to maybe -- I'm trying to clarify a little bit more on the outlook for the year and particularly what you're assuming for the back half. If my numbers are right, you're allowing for about a 300 to 400 basis point deterioration further from what we saw first half's MLR to back half MLR, and you're getting obviously, as you say, the SG&A leverage. Two parts to this: Is that a normal seasonal pattern? Are you allowing for any other contingencies on the MLR assumption in the back half? And as -- would you characterize what you're doing on the SG&A side as something that's sustainable? Or are these sort of extraordinary measures in light of the MLR pressure you've experienced?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","A.J., this is John. Thank you for the question. Yes, so a couple of questions in there in terms of MLR and G&A. But first of all, on MLR, yes, your math is certainly appropriate from the first half to the last half. And really, what we've seen is that we'",374,"A.J., this is John. Thank you for the question. Yes, so a couple of questions in there in terms of MLR and G&A. But first of all, on MLR, yes, your math is certainly appropriate from the first half to the last half. And really, what we've seen is that we've got an elevated amount of utilization specifically in the ACA individual-compliant plans as well as in Medicaid and most significantly there in Iowa. And we're, at least, for purposes of our outlook, assuming that, that elevated level is going to continue throughout the rest of the year. So while, certainly, if there's any mitigation factors or medical management initiatives end up being more successful than we're planning, there could be upside. But it's really -- it has to do with taking the elevated levels of utilization we've seen and just essentially run rating them for the rest of the year. In terms of the G&A, I'd say the bulk of the G&A is sustainable. What we've really done is done an outstanding job of fixed-cost leveraging. We're increasing membership here this year between 1 million and 1.2 million members and maintaining our cost structure relatively constant. But we are growing. Our headcount increased in the second quarter, but it increased at a far, far slower rate than our membership increased. Revenue's going up about $2.5 billion -- $2 billion to $2.5 billion for the change in guidance from the beginning of the year until -- to today. Yet, the raw SG&A number is only going up very slightly. And so there's really -- it's really has as much to do with an excellent job of fixed-cost leveraging. Clearly, we are looking at some inefficiency and waste in terms of our processes and continue to look at those very closely on a regular basis and try to eliminate those things. And at the end of the day, the last piece of it really is that we're a pay-for-performance company. And as a pay-for-performance company, in order to get our bonus payments, we have to hit our targets. And to the extent that we don't hit our targets, we'll reduce our bonus structure. So that's something that we're looking at very closely as well."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. If I could do just a quick follow-up. Joe, thanks for the comments about the Cigna transaction. I might just ask, do you have any updated assessment of the time line from here? And then I think the merger agreement goes through the end of this year.",73,"Okay. If I could do just a quick follow-up. Joe, thanks for the comments about the Cigna transaction. I might just ask, do you have any updated assessment of the time line from here? And then I think the merger agreement goes through the end of this year. Can you just mention to us what happens after the end of the year if we're still in the court dealing with the proposed transaction?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Thanks, A.J. First of all, when you referenced the end of the year, actually, we have the option on our side, our call, to extend it to the end of April, which obviously, we intend to do so. So I just want to make that record clear that we will continue -",125,"Thanks, A.J. First of all, when you referenced the end of the year, actually, we have the option on our side, our call, to extend it to the end of April, which obviously, we intend to do so. So I just want to make that record clear that we will continue -- and obviously, we're going to run out the litigation as long as it takes, working toward the end of April. Our expectation is, I guess, under normal or usual circumstances for claims like this, I will -- we're expecting the trial to begin somewhere around October. And at the outside, we're looking at 4 months. We believe it'll be about 4 months. Obviously, it could run a little longer, but that's our expectation."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Josh Raskin from Barclays.",12,"Your next question comes from the line of Josh Raskin from Barclays."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I think I'm going to ask very similar questions to A.J., but just, I guess, a different perspective. So on the MLR, forgetting about sort of the first half versus second half, just on a year-over-year basis, the first half is up 188 basis points, and that",179,"I think I'm going to ask very similar questions to A.J., but just, I guess, a different perspective. So on the MLR, forgetting about sort of the first half versus second half, just on a year-over-year basis, the first half is up 188 basis points, and that's only 3 months of Iowa, and you get some ACA benefit. But the second half looks more like an increase of 140 basis points. So the way I'm looking at it, year-over-year, you're actually expecting some noticeable improvement in the second half. So my MLR question is, what's causing that improvement on a relative basis? And then, John, on the G&A side, I think you mentioned that growth is going up a lot less than the revenue growth. But the way I look at it is, second quarter, you added $1.5 billion to revenues but took $600 million of G&A out. So it looks like there are noticeable savings and, I guess, I'm just curious. Is that deferred investment? Or is that some other sort of savings on the G&A side?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Sure, Josh. Great question. So yes, first half -- we'll be clear on the MLR, the first half of the year had the benefit of 3Rs in it. The run rate of claims outside of 3Rs is worse. And so that's obviously being baked into our outlook and our thought proc",108,"Sure, Josh. Great question. So yes, first half -- we'll be clear on the MLR, the first half of the year had the benefit of 3Rs in it. The run rate of claims outside of 3Rs is worse. And so that's obviously being baked into our outlook and our thought process. On the admin side, quite honestly, the single-largest driver of that year-over-year is the bonus program that I referenced at the end of A.J.'s question in terms of being a pay-for-performance company. We adjusted our bonus payable appropriately based on ensuring that we're going to hit our $10.80, and so that's certainly a part of the reconciliation."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And John, what was the 3R benefit? And I don't know, is there a way to size Iowa's impact on 2Q as well?",23,"And John, what was the 3R benefit? And I don't know, is there a way to size Iowa's impact on 2Q as well?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, the 3R benefit in and of itself, we don't provide the level of specificity that you're probably asking for. In terms of Iowa, I'll just say that Iowa is a brand new market. And we expected it to be dilutive in 2016 as we implemented our various medic",219,"Yes, the 3R benefit in and of itself, we don't provide the level of specificity that you're probably asking for. In terms of Iowa, I'll just say that Iowa is a brand new market. And we expected it to be dilutive in 2016 as we implemented our various medical management and revenue optimization processes. We ended up with about 25,000 more members in Iowa than we originally expected when we did our plan at the beginning of the year. And quite honestly, the MLR in Iowa is 25 to 30 basis points higher than we expected when we did our plan as well, so you had the additional members and it's more dilutive simultaneously with the elevated claims level. The really good news to that is that we do believe that our plan -- when we look at what we've done here historically, what the team has done historically in terms of new markets and implementing the managed care-type processes and procedures and the fact that the first year markets have historically been dilutive, and that we've got the target margins within a 18- to 24-month period of time. There's no reason to believe that that's not going to occur again here in Iowa, even though the starting points may be a little bit bumpier than we had hoped."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And these are 25 to 30 basis points or points higher?",11,"And these are 25 to 30 basis points or points higher?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Josh, 25 to 30 points higher, not basis points.",9,"Josh, 25 to 30 points higher, not basis points."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Points. Okay, so it's a huge number. Yes, okay, that makes sense.",12,"Points. Okay, so it's a huge number. Yes, okay, that makes sense."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Dave Windley from Jefferies.",12,"Your next question comes from the line of Dave Windley from Jefferies."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","It's Dave Styblo in for Windley. Just want to come back to -- maybe, if you guys could help us bridge sort of the puts and takes? And obviously the overall guidance remains the same on -- in terms of EPS. But I think, by the math that you guys presented o",121,"It's Dave Styblo in for Windley. Just want to come back to -- maybe, if you guys could help us bridge sort of the puts and takes? And obviously the overall guidance remains the same on -- in terms of EPS. But I think, by the math that you guys presented on the individual book being on a mid-single-digit loss, it sounds like that's about a $0.40 change relative to sort of what you were thinking before. And then on top of that, you've the Medicaid challenges that you highlighted. Is that sort of the right way to think about it? And then the offset being largely just the SG&A improvement on top of that to offset those 2 negatives."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, the other part of that is the top line growth is very clearly a good guy as part of all that. But yes, those are the most significant pieces. I think the good news is, and just to sort of maybe answer your follow-up question before you ask it, is tha",126,"Yes, the other part of that is the top line growth is very clearly a good guy as part of all that. But yes, those are the most significant pieces. I think the good news is, and just to sort of maybe answer your follow-up question before you ask it, is that if we look at 2016 versus 2017, let's be very clear. As I said in the prepared comments, when we did our pricing for 2017, we already had taken this elevated level of claims and utilization into account and baked it into our 2017 outlook. So we believe this is more of a 1-year type of issue. And that we're very committed to returning the ACA block of business back to profitability in 2017."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So you did address my question earlier on the follow-up. So is it -- I guess though, it seems like you priced for these things to happen. And in some ways, it still seems like it's worse than expected. So if you are filing rates and benefit changes earlie",96,"So you did address my question earlier on the follow-up. So is it -- I guess though, it seems like you priced for these things to happen. And in some ways, it still seems like it's worse than expected. So if you are filing rates and benefit changes earlier in the year, maybe if you can just give us more comfort about specifically how you caught these things earlier on when we're starting see more the development come in with higher utilization on the dialysis and COPD and the other elements that you talked about?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure. Well, the rates were developed in the April-May time frame. And so if you look back at our -- when we closed the books in March and the information we had available to us at that point in time, we had seen some of the spikes and the elevations,",190,"Yes, sure. Well, the rates were developed in the April-May time frame. And so if you look back at our -- when we closed the books in March and the information we had available to us at that point in time, we had seen some of the spikes and the elevations, just not to the same -- we weren't crystal clear then it was going to continue for the rest of the year or not. However, we wanted to be conservative. We wanted to be prudent. And so we believe -- we had hoped that it was not a trend. However, when we did our pricing, we felt it was best to assume it was a trend. Here we are 90 days later. I believe our conservatism turned out to be prudent, and that something that we weren't sure if that was going to be a trend or not, probably is. There's still the opportunity that seasonality could be in our favor and that things could get a little bit better in the second half of the year. We just decided not to assume that at this point in time."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then if I could just ask on Medicaid. I know obviously, you highlighted Iowa, and then you mentioned that broadly, there was just higher trends. Is it predominantly just Iowa being the drag in Medicaid? Or are there some specific other states? A",79,"Okay. And then if I could just ask on Medicaid. I know obviously, you highlighted Iowa, and then you mentioned that broadly, there was just higher trends. Is it predominantly just Iowa being the drag in Medicaid? Or are there some specific other states? And maybe, if you could sort of share a percentage of the weighting of the 75% Iowa, 25% other states and highlight what those other states might be and the issues that you're seeing there?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","In terms of -- it is both Iowa as well as other states. And we really don't get into specifics state by state. We're just calling out Iowa as a marker because it's brand new and it is a significant driver in and of itself. I will say that the primary driv",97,"In terms of -- it is both Iowa as well as other states. And we really don't get into specifics state by state. We're just calling out Iowa as a marker because it's brand new and it is a significant driver in and of itself. I will say that the primary drivers of the elevated trends, they're pharmacy, nursing facilities, ER and outpatient surgery. Those 4 items are really the most significant part of our trend issue in the other states. So -- but we are seeing elevated trends in several states, and we're addressing those accordingly."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. But fair to say well above 50% is attributable to Iowa, though.",13,"Okay. But fair to say well above 50% is attributable to Iowa, though."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","We really don't get into that level of detail on a state-by-state basis for competitive reasons.",17,"We really don't get into that level of detail on a state-by-state basis for competitive reasons."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Andy Schenker from Morgan Stanley.",13,"Your next question comes from the line of Andy Schenker from Morgan Stanley."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So just going back to the exchange business here. Just thinking about it, big picture, right? In 2014, you guys were actually profitable. Last year, you were close to breakeven. This year, you're now losing money here. So what has really changed over that",118,"So just going back to the exchange business here. Just thinking about it, big picture, right? In 2014, you guys were actually profitable. Last year, you were close to breakeven. This year, you're now losing money here. So what has really changed over that time frame? Is it just the risk pool has continued to get worse? And therefore, is this something you can actually rectify with pricing? Or are there structural issues to the exchanges? Or are there other more meaningful benefit changes, i.e. networks or other design changes, that you've also incorporated for next year that are going to be necessary to offset what's been a steady deterioration of the profitability of this book every year?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure. No, great question. And in terms of will pricing by itself, rectify it? No. Because there's no one single bullet that actually solves the entire problem. The administration is extremely focused on having a sustainable marketplace. And we think",260,"Yes, sure. No, great question. And in terms of will pricing by itself, rectify it? No. Because there's no one single bullet that actually solves the entire problem. The administration is extremely focused on having a sustainable marketplace. And we think that we've been a very active participant in the exchanges and been a great partner with CMS in trying to help with the stability of the marketplace. They've made changes over the years of tightening the supplemental enrollment a bit and various other requirements. The penalty continues to increase. We think all those things obviously have to be done. Other things that would certainly help the acceleration of stabilization would be to eliminate the health insurer tax in beyond 2017. The risk adjuster model, it's -- it does a lot of what it's intended to do. But quite honestly, there's a bit of an imbalance that the -- that it overcharges for healthy and over-reimburses for certain moderately unhealthy disease states. We think, as I said, the supplemental enrollment period, we really do need a better upfront verification process and that there should not be any restriction on our efforts to innovate product designs to meet consumer needs. And then modifying the grace periods for nonpayment of premiums would be something else. So those are just -- in addition to the pricing, things that we've been working with the administration on and believe should occur. We do believe that with the medical management and various other issues, that we can help get this back to profitability here in 2017."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, this is Joe. Let me just weigh in to add to what John just shared with you. Just reiterate, we've been a very active participant in the exchanges from the beginning and recognize the markets have taken longer than expected to stabilize. And we've sta",363,"Yes, this is Joe. Let me just weigh in to add to what John just shared with you. Just reiterate, we've been a very active participant in the exchanges from the beginning and recognize the markets have taken longer than expected to stabilize. And we've stated that repeatedly. And I think we've been working very closely with the administration and conducting our own modeling to best judge how we're going to continually engage year-over-year in as profitable a context as possible. It's interesting, reflect back to the end of first quarter, we told you that, end of June 30, we'd probably have greater insight into the membership we've captured, recognizing that we had a substantial uptick in membership. Deteriorated a little bit at the end of Q2 to around 925,000 or so members. But what we've observed in terms of the intensity of illness is that, as John pointed out in his earlier remarks, we're dealing with some chronic illnesses like cardiac, diabetes, COPD. We've had a, what we think, is a material uptick in dialysis cost that have hit us. So we're going through an appraisal of all that in terms how to better medically manage those members as well as begin pricing it into '17. That's the trick. I think John has stated it, and I'll restate it. We believe we're well positioned for pricing in '17, given what we now know about the membership we captured. And so I guess, when you put all that together, what we're waiting for now is rate approvals by state. And I can assure you that we're going to be extremely prudent in our continuing engagement. I think we're in something like 138 or so rating regions. And we're going through an appraisal of every one of those regions. And we'll make prudent business decisions in terms of flexing our engagement in appropriate ways going into '17. And so I just -- I want to assure that, notwithstanding we've been active participants, we're also very -- I'll use the word prudent, very thoughtful, in terms of executing a good business practice, in terms of how we continue to stay engaged in the public marketplace."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Great. That was very helpful. Thinking maybe a little bit more broadly. You kind of reiterated your small group -- or Local Group, rather, trend assumptions here. But you did kind of call out timing and medical cost experience for Local Group. Maybe, if y",75,"Great. That was very helpful. Thinking maybe a little bit more broadly. You kind of reiterated your small group -- or Local Group, rather, trend assumptions here. But you did kind of call out timing and medical cost experience for Local Group. Maybe, if you could just talk more about what you're seeing around trend, if there's any pockets you're seeing in patients, et cetera, as it relates to that -- how you define it?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure. So in terms of trend on the Local Group side, that's actually going very well. And we reaffirm the 7% to 7.5% outlook for that and feel very comfortable with that, given the results for the first half of the year. In terms of the timing, that r",158,"Yes, sure. So in terms of trend on the Local Group side, that's actually going very well. And we reaffirm the 7% to 7.5% outlook for that and feel very comfortable with that, given the results for the first half of the year. In terms of the timing, that relates to just a couple, really, accounting and calendar quirks. The first quarter of 2016 had an extra workday in it, driven by leap year. The second quarter of 2016 had an extra workday in it, driven by how the weekends fell. The fourth quarter of 2016 has 1 less workday in it, and so that's significant enough to change the timing pattern on a quarter-over-quarter basis. Then you take that and the fact that our overall product mix in the group side is slightly richer than the overall product mix in the group side a year ago, that changes the timing as well given how the deductibles work."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Gary Taylor from JPMorgan.",12,"Your next question comes from the line of Gary Taylor from JPMorgan."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just a couple of questions. Did you give us the total exchange enrollment as of the end of 2Q? Did I miss that?",23,"Just a couple of questions. Did you give us the total exchange enrollment as of the end of 2Q? Did I miss that?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. It's 923,000.",3,"Yes. It's 923,000."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","And the total -- when you talk about the ACA-compliant book now being mid-single-digit losses, what is the total ACA-compliant enrollment that you're speaking to? So presumably, that's some off exchange and some -- and small group ACA-compliant as well.",40,"And the total -- when you talk about the ACA-compliant book now being mid-single-digit losses, what is the total ACA-compliant enrollment that you're speaking to? So presumably, that's some off exchange and some -- and small group ACA-compliant as well."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","A little more than half of the remainder is ACA-compliant.",11,"A little more than half of the remainder is ACA-compliant."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And I just want to come back to the risk adjustment, because it seems like potentially, it was quite material in the quarter. I know you guys only disclosed that you had a payable at year-end. We calculate that payable by the $105 million and the sw",95,"Okay. And I just want to come back to the risk adjustment, because it seems like potentially, it was quite material in the quarter. I know you guys only disclosed that you had a payable at year-end. We calculate that payable by the $105 million and the swing factor to $190 million payment that CMS was citing for '15 is about $0.60. You say that you booked some valuation allowances against that because of co-op situations. But I mean, should we assume that a material portion of that $0.60 was trued up in this quarter?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","I -- there was a lot of things that went against it, and I'm not going to really comment on your estimate of the payable. But in terms of valuation allowance, it's clearly part of it. Certainly, medical loss ratio rebates were part of it. After all the du",141,"I -- there was a lot of things that went against it, and I'm not going to really comment on your estimate of the payable. But in terms of valuation allowance, it's clearly part of it. Certainly, medical loss ratio rebates were part of it. After all the dust settled, we're going to pay over $100 million in MLR rebates in 2016 related to the 2015 calendar year. And so that's part of it. And you've got the small group versus the individual component is clearly a piece of it. Risk corridor true-ups, reinsure, I mean, there's so many moving parts, it's hard to, on the call here, pin that down exactly. And then quite honestly, whatever benefits existed after all the other offsets have now been baked into our trend outlook and our guidance for the rest of the year."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay, if I could just -- 2 quick clarifications. I think Josh was asking about the G&A run rate and sustainability of that. The guidance for the second half certainly implies this reduced G&A is fairly sustainable. But as you head into '17, do you feel li",77,"Okay, if I could just -- 2 quick clarifications. I think Josh was asking about the G&A run rate and sustainability of that. The guidance for the second half certainly implies this reduced G&A is fairly sustainable. But as you head into '17, do you feel like there's going to be a deferred level that has to rebound? Or is this sort of G&A ratio a number that makes sense as a jumping-off point heading into '17?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","The most significant driver of the G&A benefits here compared to our guidance or our outlook is the top line revenue growth and the fixed-cost leveraging associated with that. And so that clearly is run rate and sustainable. In terms of -- certainly, as a",117,"The most significant driver of the G&A benefits here compared to our guidance or our outlook is the top line revenue growth and the fixed-cost leveraging associated with that. And so that clearly is run rate and sustainable. In terms of -- certainly, as an employee of the company, I'm fully supportive of getting back to the bonus structure, back to target levels. But there's a natural hedge associated with that. So as results warrant it, we then record the expense. If they don't warrant it, we don't record the expense. So what the impact that might be on an exact ratio is to be seen, but the bottom line has a natural hedge built in."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So my last one. When we think about the year, ACA-compliant business, worse than you had anticipated; Iowa and Medicaid overall, worse than anticipated. Yet, you maintained the guidance. So the 2 components that were better that allowed you to maintain co",55,"So my last one. When we think about the year, ACA-compliant business, worse than you had anticipated; Iowa and Medicaid overall, worse than anticipated. Yet, you maintained the guidance. So the 2 components that were better that allowed you to maintain compliance was risk adjustment and some of the additional enrollment growth. Is that fair?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, certainly, admin, risk adjustment, enrollment growth. We're doing extremely well in the national and large local ASO in terms of enrollment. Our Medicare Advantage and our senior business are growing very, very well and exceeding expectations for th",113,"Well, certainly, admin, risk adjustment, enrollment growth. We're doing extremely well in the national and large local ASO in terms of enrollment. Our Medicare Advantage and our senior business are growing very, very well and exceeding expectations for the year. And quite honestly, we had a bit of an initial conservative posture at the beginning of the year as well. So it's a lot of things. Our specialty product line is beating expectations. So I would hate to just point to 1 or 2 items because there are far more positives than there are negatives. It's just that the 2 negatives have really caused our conservative posture to be a more prudent posture."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Justin Lake from Wolfe Research.",13,"Your next question comes from the line of Justin Lake from Wolfe Research."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","First, just a follow-up on the SG&A number for that bonus program. I understand that, as you said, it's a hedge and other things have to improve to offset it. But can you give us a ballpark number there in terms of how much cost comes back into SG&A if yo",57,"First, just a follow-up on the SG&A number for that bonus program. I understand that, as you said, it's a hedge and other things have to improve to offset it. But can you give us a ballpark number there in terms of how much cost comes back into SG&A if you fully accrue that for next year?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, in terms of exactly how much that is, the bonus program target is certainly a significant number in and of itself but, Justin, that's just not a number that we're comfortable giving out.",34,"Well, in terms of exactly how much that is, the bonus program target is certainly a significant number in and of itself but, Justin, that's just not a number that we're comfortable giving out."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. Is there any way to proportion it? For instance, you're losing, you said, mid-single digits on the individual side. I mean, can you remind us what's the ACA-compliant premium number for this year, ballpark?",35,"Okay. Is there any way to proportion it? For instance, you're losing, you said, mid-single digits on the individual side. I mean, can you remind us what's the ACA-compliant premium number for this year, ballpark?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's a bit north of $6 billion, close to -- maybe closer to $7 billion.",16,"It's a bit north of $6 billion, close to -- maybe closer to $7 billion."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So you're talking about $300 million plus in potential -- just getting back to breakeven, right, in the Individual business, right, is how we should think about the earnings power of the business? I assume you're not expecting to run losses for -- e",59,"Okay. So you're talking about $300 million plus in potential -- just getting back to breakeven, right, in the Individual business, right, is how we should think about the earnings power of the business? I assume you're not expecting to run losses for -- even in the intermediate term here as you talked about. So would -- if we..."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","I'm not going to argue with your math.",9,"I'm not going to argue with your math."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. So if Individual comes back to breakeven or better, does this SG&A basically offset that? Or is it larger or smaller than Individual coming back to breakeven?",28,"Okay. So if Individual comes back to breakeven or better, does this SG&A basically offset that? Or is it larger or smaller than Individual coming back to breakeven?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, there's certainly -- it's a natural hedge built in. But to answer your question would be to answer the question that you asked the first time. So good luck. It's a big number, but we're not going to size it specifically.",42,"Well, there's certainly -- it's a natural hedge built in. But to answer your question would be to answer the question that you asked the first time. So good luck. It's a big number, but we're not going to size it specifically."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. But you wouldn't call me crazy if I said it was in the same ballpark as getting back to breakeven in Individual?",23,"Okay. But you wouldn't call me crazy if I said it was in the same ballpark as getting back to breakeven in Individual?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","I would never call you crazy.",6,"I would never call you crazy."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","All right. Last question, just on the government side. So you've laid out the issues here. And you were very clear coming into 2016 saying, for instance, Medicaid, the margins were unsustainable. They were going to come down, plus you were going to have t",123,"All right. Last question, just on the government side. So you've laid out the issues here. And you were very clear coming into 2016 saying, for instance, Medicaid, the margins were unsustainable. They were going to come down, plus you were going to have the Medicaid pressure in Iowa. I guess, my -- what I'm trying to think about here is, these margins are down meaningfully for 2016 in the government overall, and you're saying Medicare is actually improving, so Medicaid, the full brunt. My question is, is Medicaid now at a target margin for 2016 when you think about it overall? Or does the Medicaid margin actually improve going forward from here, given how tough it's been and the worse-than-expected costs overall?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","It's a -- the Medicaid margins are within our target range. Obviously, we're hopeful that we can improve it to the high end of the range. But even with all these headwinds and the negative comments that we had earlier in the year, we're still within the r",49,"It's a -- the Medicaid margins are within our target range. Obviously, we're hopeful that we can improve it to the high end of the range. But even with all these headwinds and the negative comments that we had earlier in the year, we're still within the range."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","So for the full year, you're within the range, but closer to the midpoint, to the low end, and potentially can improve it towards the higher end again, where you've typically been.",32,"So for the full year, you're within the range, but closer to the midpoint, to the low end, and potentially can improve it towards the higher end again, where you've typically been."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","That's a reasonable way of thinking about it, yes.",10,"That's a reasonable way of thinking about it, yes."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Your next question comes from the line of Kevin Fischbeck from Bank of America.",14,"Your next question comes from the line of Kevin Fischbeck from Bank of America."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. Got a couple of questions. I guess, first, on the exchanges. I guess, obviously, you guys believe that you've caught everything as far as pricing for next year and you expect margins to improve next year. But I guess, we've seen now, I don't know, 5",104,"Okay. Got a couple of questions. I guess, first, on the exchanges. I guess, obviously, you guys believe that you've caught everything as far as pricing for next year and you expect margins to improve next year. But I guess, we've seen now, I don't know, 5 or 6 quarters in a row where it kind of seems like the cost continue to rise, I mean, for you, but really, for a lot of the players out there. I mean, can you give a sense as to why you feel confident saying that, given the experience of most companies over the last 1.5 years?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, why we believe that we've caught everything?",8,"Well, why we believe that we've caught everything?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Yes, exactly.",2,"Yes, exactly."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","I think -- well, a lot of it, obviously, has to do with our data analytics and how we track things. And as you look at the rate increases that we put in, approaching 20% range on a weighted-average basis across our 14 states, very significant. And as we -",245,"I think -- well, a lot of it, obviously, has to do with our data analytics and how we track things. And as you look at the rate increases that we put in, approaching 20% range on a weighted-average basis across our 14 states, very significant. And as we -- yes, we also believe that we have some of the best-in-class risk adjuster capabilities of really understanding what drives risk adjuster and things like that. And I think the results that we saw from the CMS true-up really helped verify that. So the other piece that gives us a little bit of comfort in terms of having caught everything is that our 2016 risk adjuster that we're assuming into '17 really is based on 2015 experience. So we think that, that gives us a natural cushion associated with how that's being approached. But at the end of the day, the question is, ""How do we know we've gotten everything?"" Well, we've got 6 months of information. Obviously, there's a lot of new members associated with this block of business, and we can't provide absolute certainty. But we think we have very, very good line of sight. What we saw at the end of the first quarter, we further predicted from a pricing standpoint, and what we saw at the end of the second quarter was exactly consistent with that pricing prediction. So we feel good that we've got a good line of sight on that."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","I guess, is there anything different about you heading into Q3 this year versus you heading into Q3 last year as far as what you're doing from a data analytics perspective? Or anything there that gives you more confidence or visibility this year than what",55,"I guess, is there anything different about you heading into Q3 this year versus you heading into Q3 last year as far as what you're doing from a data analytics perspective? Or anything there that gives you more confidence or visibility this year than what you had heading into the back half of last year?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, this is Joe. I certainly believe that we're always improving year-over-year, and especially in this space, given we've got more and more data. We certainly recognize that this is a company that's had a long-standing engagement of high-risk pools. An",148,"Well, this is Joe. I certainly believe that we're always improving year-over-year, and especially in this space, given we've got more and more data. We certainly recognize that this is a company that's had a long-standing engagement of high-risk pools. And we have a lot of data that has backed us up for a long period of time. And I think that we just -- as I said a moment ago, always expect to continue of improving the space. However, I'll reiterate what I said earlier. We're going to be very surgical with respect to our analytics in and around rating regions. We're going to be very mindful of what price increases are awarded to us by state. And so we'll be making various, I call it, accurate business decisions going into '17 and beyond regarding our continued engagement on a broad scale in the public exchange space."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, and then the other comment that I'll just add to that, I think maybe address here, what would be different going into the third quarter is, 2016, we actually had more members come on board on January 1 than we did in 2015 or 2014. 2014, in particular",115,"Yes, and then the other comment that I'll just add to that, I think maybe address here, what would be different going into the third quarter is, 2016, we actually had more members come on board on January 1 than we did in 2015 or 2014. 2014, in particular, if you recall, we had a vast majority of the members come on board early second quarter. And in 2015, with the extension of the open enrollment period, a lot of members came on later in the first quarter. 2016, a lot more January 1. We actually do have a full 6 months of information this year, and we had not had that in prior years."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay then, just last question. Last quarter, you said that -- when you expected the exchanges to be pretty much breakeven this year, you said next year was probably going to be below your target, 3% to 5%. But by 2018, you'd be in your target margin. Do y",85,"Okay then, just last question. Last quarter, you said that -- when you expected the exchanges to be pretty much breakeven this year, you said next year was probably going to be below your target, 3% to 5%. But by 2018, you'd be in your target margin. Do you still feel like you still have that same ramp over the next couple of years? Or does this set back -- kind of push back when you're going to get to your target margins on exchanges?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","The pricing increases that we've put in really do keep us on that same ramp. And it's very important that we do receive the pricing increases that we've filed for in terms of that. Obviously, we expect the market to continue to harden and pricing to be mo",92,"The pricing increases that we've put in really do keep us on that same ramp. And it's very important that we do receive the pricing increases that we've filed for in terms of that. Obviously, we expect the market to continue to harden and pricing to be more reasonable. I mean, clearly, there's a reason that so many co-ops have gone insolvent in terms of their pricing methodologies. So as more and more of those folks exit the market, it should provide a more sustainable stable marketplace in 2018 and beyond."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","And your final question today comes from the line of Chris Rigg.",12,"And your final question today comes from the line of Chris Rigg."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Just with regard to the ACA-compliant membership, do you have a sense, at this point, how many of the individuals were new members to Anthem? And is there -- if you have that information, is there a pronounced difference in utilization trends among those",64,"Just with regard to the ACA-compliant membership, do you have a sense, at this point, how many of the individuals were new members to Anthem? And is there -- if you have that information, is there a pronounced difference in utilization trends among those that are -- who are new to Anthem versus those that had been enrolled for a year or 2?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Very quick response to the question. A little less than half of the membership was new to us in '16.",21,"Yes. Very quick response to the question. A little less than half of the membership was new to us in '16."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Analysts","Okay. And then just one quick follow-up here. Of the individual that's non-ACA-compliant at this point, will most of them become -- roll into ACA-compliant plans in 2017 because of the grandmothering dynamic? Or will they still stay outside the complaint",42,"Okay. And then just one quick follow-up here. Of the individual that's non-ACA-compliant at this point, will most of them become -- roll into ACA-compliant plans in 2017 because of the grandmothering dynamic? Or will they still stay outside the complaint side?"
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Yes -- no, a great question. We do expect some attrition in that area, as you pointed out. Whether they enroll remains to be seen. But historically, we haven't seen the uptake in ACA-compliant plans that maybe was estimated by the CBO when the law was pas",56,"Yes -- no, a great question. We do expect some attrition in that area, as you pointed out. Whether they enroll remains to be seen. But historically, we haven't seen the uptake in ACA-compliant plans that maybe was estimated by the CBO when the law was passed. But yes, that's certainly a watch area for us."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","And now I would now like to turn the conference back to the company's management for closing comments.",19,"And now I would now like to turn the conference back to the company's management for closing comments."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Executives","Well, as usual, thanks for your questions. They're all very insightful. As a company, we remain committed to tackling our health care system's challenges head on and deliver greater value to consumers by expanding access to high-quality, affordable health",100,"Well, as usual, thanks for your questions. They're all very insightful. As a company, we remain committed to tackling our health care system's challenges head on and deliver greater value to consumers by expanding access to high-quality, affordable health care. That's why we're committed to challenging the DOJ's recent decision to block our acquisition of Cigna in court. We also want to thank all of our associates for their continued commitment to serving our 39.8 million members every day. 
Thanks for your interest in Anthem, and we look forward to speaking with you very soon. Again, thank you very much."
160077,308029078,1014416,"Anthem, Inc., Q2 2016 Earnings Call, Jul 27, 2016",2016-07-27,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, this conference will be available for replay after 11:00 a.m. Eastern Time today through August 10. You may access the AT&T Teleconference Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378817. Int",68,"Ladies and gentlemen, this conference will be available for replay after 11:00 a.m. Eastern Time today through August 10. You may access the AT&T Teleconference Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378817. International participants, dial (320) 365-3844. That does conclude your conference for today. Thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Anthem Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management.",39,"Ladies and gentlemen, thank you for standing by, and welcome to the Anthem Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded. 
I would now like to turn the conference over to the company's management."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Good morning, and welcome to Anthem's Third Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish; Chairman, President and CEO; and John Gallina, our CFO. Joe will offer an overview of",197,"Good morning, and welcome to Anthem's Third Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish; Chairman, President and CEO; and John Gallina, our CFO. Joe will offer an overview of our third quarter 2016 results and our updated 2016 full year outlook. Then John will walk through the financial details and provide some incremental commentary on 2017 before Joe closes with some longer-term strategic commentary. We will then be available for Q&A. 
During the call, we will reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website at antheminc.com. 
We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Anthem. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in today's press release and in our quarterly and annual filings with the SEC. 
I will now turn the call over to Joe."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Doug, and good morning. This morning, we announced third quarter 2016 GAAP earnings per share of $2.30. Adjusted earnings per share was $2.45, consistent with our previous expectations. Within membership, we continued to post strong fully ins",1650,"Thank you, Doug, and good morning. This morning, we announced third quarter 2016 GAAP earnings per share of $2.30. Adjusted earnings per share was $2.45, consistent with our previous expectations. 
Within membership, we continued to post strong fully insured and self-funded enrollment results, as we ended the third quarter with over 39.9 million members. We grew an additional 160,000 lives during the quarter, bringing our year-to-date enrollment growth to 1.3 million lives or 3.4%. Specifically, insured enrollment increased by 39,000 lives during the quarter, as our Medicaid business grew by 81,000 lives to over 6.4 million members. Since closing the Amerigroup transaction in 2012, we've grown Medicaid enrollment by nearly 1.9 million lives or 41%, including growth of approximately 800,000 lives from Medicaid expansion. 
Within Commercial, our insured enrollment came in slightly ahead of expectations, as Local Group fully insured membership tracked well, particularly in the large group marketplace. Our public exchange enrollment declined by a less-than-expected 34,000 during the quarter to 889,000 lives. Our self-funded business increased by 121,000 during the quarter, reflecting the impact of enrollment growth from existing accounts and recently awarded contracts. 
Our solid membership results during the year translated into better-than-expected operating revenue of $21.1 billion during the quarter, an increase of $1.4 billion or 6.8% versus third quarter of 2015. The increase reflects the strong enrollment growth in the government business and additional premium revenue to cover overall cost trends. Additionally, administrative fee revenue grew by 6.4% versus the prior year quarter as a result of our strong self-funded membership trends. These increases were partially offset by fully insured membership losses in our Commercial business. 
The third quarter 2016 benefit expense ratio was in line with our previous expectations at 85.5%, an increase of 190 basis points versus the prior year. The year-over-year increase was primarily driven by the Medicaid business, as higher-than-expected medical cost experience, notably in Iowa, has exceeded the net impact of annual premium rate adjustments made over the last 12 months. In addition, it reflects the impact of growth in membership, as the Medicaid business carries a higher benefit expense ratio than the consolidated company average. Further, the benefit expense ratio reflects the impact of higher medical cost experience in the individual business. These increases were partially offset by the timing of lower medical cost experience in the Local Group business. 
Our SG&A expense ratio was also in line with expectations at 14.8% in the third quarter, a decrease of 80 basis points from the third quarter of 2015. The decrease was driven by an intentional focus on administrative expense control coupled with better-than-expected enrollment trends, as well as the changing mix of our membership towards the government business, which carries a lower than the consolidated average SG&A ratio. 
Turning to discuss the third quarter financial performance of our business units. In the government business, we added 92,000 members during the quarter and grew year-over-year revenue by 10.9% to nearly $11.5 billion. As a reminder, our third quarter results include the impact of the addition of the Iowa contract which was implemented on April 1. Operating margins for the government business were 4.2% during third quarter, a decline of 190 basis points versus the prior year quarter, driven by lower gross margins in the Medicaid business. 
As we communicated previously, we've been expecting Medicaid margins to compress from 2015 levels due to rate actions. In addition, we've been experiencing higher-than-expected claims across the Medicaid business in the current year, including materially higher-than-expected costs in the recently implemented Iowa contract. As expected, there was a rebalancing of funding based on risk pool during the quarter. In addition, we've been informed of a retroactive rate increase which extends through June 2017, when rates will again be adjusted. 
Unfortunately, the recent rate increase is still inadequate, given the claims experienced to date. We remain confident we can make a meaningful impact by improving the cost and quality of care in Iowa as we've done for our other state partners. However, we will remain disciplined and only participating in markets where we receive rates that are actuarially sound. 
Within Medicare, we're pleased with the progress the team continues to make, and our year-to-date margins reflect continued improvement. During the quarter, CMS announced we earned Medicare STAR quality ratings for 2017, consistent with our long-term strategy. In the most recent ratings released by CMS, 51% of Anthem's Medicare Advantage members will be enrolled in plans that achieve 4 stars or higher. This accomplishment represents significant growth from the 22% of MA members in 4-star plans last year. The improvement is the direct result of investments made in the Medicare program over the past 3 years. 
Our 2016 outlook continues to expect margins to improve as the year progresses towards our expected long-range sustainable level. As we stated since our MA restructuring began, we have positioned our portfolio to grow MA in 2017. 
The pipeline of opportunity for our Medicaid business remains substantial with an updated estimate of $81 billion in contracts to be awarded between now and 2021 in markets that we will consider targeting. Approximately 3/4 of this opportunity is in new and specialized services with the remainder in traditional Medicaid services. We continue to believe our experience, targeted investments in critical capabilities and geographic footprint positions us very well to continue our growth as we help states address the challenges of rising health care cost and improving quality for their residents. 
Switching to our Commercial business. Our enrollment increased by 68,000 lives during the quarter, which was slightly better than our previous expectations. Specifically, we experienced growth of 171,000 lives in our Local Group business, partially offset by declines of 48,000 and 54,000 lives in our national and individual businesses, respectively. These results translated into better than previously expected operating revenue of $9.7 billion, representing growth of 2.4%. 
Our third quarter operating margin of 6.6% was flat versus third quarter of 2015. Commercial operating margins during the quarter reflected a lower SG&A ratio due to lower administrative cost resulting from expense efficiency initiatives taken by the company, as well as fixed cost leverage on a growing membership base. In addition, our Commercial business experienced the favorable timing impact of lower medical cost experience in the Local Group business. These increases were offset by higher medical cost experience in our individual ACA-compliant products. 
Within our individual ACA-compliant plans, costs during the third quarter were marginally better than recent expectations, which is reassuring. We continue to experience higher than initially expected costs for members with chronic conditions, as we have discussed with you previously. Overall, the financial performance in individual ACA-compliant products has been disappointing, as membership has been short of our original expectations since its inception and operating margins have been lower than expected beginning in 2015. 
We believe we've taken the appropriate actions across our served market to return to slight profitability in 2017. Clearly, 2017 is a critical year as we continue to assess the long-term viability of our exchange footprint. We will continue to closely monitor this business, and if we do not see clear evidence of an improving environment and a path towards sustainability in the marketplace, we will likely modify our strategy in 2018. We believe both the pricing and regulatory environment need to be improved to drive toward a sustainable and affordable marketplace over the long term. 
Relating to National Accounts, which typically encompass the most sophisticated purchasers of coverage, we're pleased that the team continues to secure wins contributing to the track record of membership growth in 2017. We have added 602,000 lives so far in 2016, building on the growth of over 900,000 lives during the previous 2 years. 
And now turning to our 2016 financial outlook. Our third quarter results were largely in line with the expectations we laid out during our last quarter call. We expect our full year 2016 GAAP earnings per share to be approximately $9.28, including approximately $1.52 of negative adjustment items. On an adjusted basis, we expect earnings per share to be approximately $10.80. 
We now expect our 2016 operating revenue to be approximately $83.5 billion, which is at the high end of our previously guided range, reflecting the impact of slightly better enrollment trends during the quarter. 
Fully insured membership is expected to be in the range of 15 million to 15.1 million members or 50,000 higher than our previous outlook, which reflects stronger than previously expected results in the Commercial business. Self-funded membership is expected to be 24.7 million, members which is at the midpoint of our range, unchanged from our previous outlook. Taken together, we're now projecting total membership growth of just over 1.1 million lives at the midpoint of our range versus where we ended in 2015. 
Consistent with our expectations last quarter, we expect our medical loss ratio to be in the range of 84.9%, plus or minus 30 basis points; the SG&A ratio to be 14.5%, plus or minus 30 basis points; and operating cash flow to be approximately $3 billion. We continue to expect 2016 Local Group medical cost trends to be in the range of 7% to 7.5%. 
Our 2016 outlook continues to not include any benefit from the impact of share repurchase activity for the remainder of the year. As a reminder, we did not repurchase any shares through the first 9 months of 2016. 
It is important to note that our 2016 outlook does not include any additional benefits or transaction costs associated with the pending acquisition of Cigna beyond those incurred in the first 9 months of 2016, nor does it include any benefit from lower pharmaceutical pricing, which we continue to believe we are entitled to under our current contract with ESI. 
I will now turn the call over to John to discuss some key financial metrics and our initial thoughts on headwinds and tailwinds for 2017. John?"
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Joe, and good morning. As Joe stated, our third quarter results were very consistent with the expectations we laid out last quarter. In order to provide you a bit more clarity on our performance, I will highlight some of our key financial metri",656,"Thank you, Joe, and good morning. As Joe stated, our third quarter results were very consistent with the expectations we laid out last quarter. In order to provide you a bit more clarity on our performance, I will highlight some of our key financial metrics. 
First, I'd like to discuss the balance sheet. Consistent with our past practice, we have included a rollforward of our medical claims payable balance in this morning's press release. 
For the 9 months ended September 30, 2016, we experienced favorable prior year reserve development of $773 million, which was moderately better than our expectations. We continue to be at the upper end of our range of mid to high single-digit margins for adverse deviation and believe our reserve balances remained consistent and strong as of September 30, 2016. Our Days in Claims Payable was 40.6 days as of September 30, unchanged from the 40.6 days we reported last quarter. As previously discussed and consistent with our expectations, this metric has trended down over the past year, and we expect Days in Claims Payable to be around 40 days over time. 
Our debt to cap ratio was 38.7% as of September 30, down 40 basis points from the 39.1% at the end of the second quarter, which reflects the impact of an increase in shareholder equity, as we did not repurchase any stock during the quarter. 
We ended the third quarter with approximately $2.1 billion of cash and investments at the parent company, and our investment portfolio was in an unrealized gain position of approximately $983 million as of the end of the quarter. 
For the 3Rs, we continue to book reinsurance as appropriate and continue to reflect a net receivable position for risk adjusters. We also continue our conservative posture of recording a 100% valuation allowance against any unpaid receivables for the 2014, the 2015 and the 2016 benefit years for risk corridors. 
Moving on to cash flow. We reported operating cash flow of approximately $2.9 billion or 1.4x net income during the first 9 months of 2016. During the quarter, we reported operating cash flow of $964 million, which was 1.6x net income. These results include the receipt of a CMS Medicare prepayment of approximately $650 million during the third quarter. Through the full year of 2016, we continue to expect operating cash flows to be approximately $3 billion. We used $171 million during the quarter for our cash dividend. And yesterday, the Audit Committee declared our fourth quarter 2016 dividend of $0.65 per share to shareholders. 
Now turning to 2017. We are currently working through our planning process and analyzing the impact of various expected headwinds and tailwinds. Our current view of the tailwinds include: Number one, enrollment gains across Medicaid, Medicare and National and Large Group self-funded businesses; two, margin improvement due to improving results in our individual ACA-compliant plans, the Iowa Medicaid contract and the impact of the 1-year health insurer fee moratorium in 2017; and three, we expect to resume capital deployment activity in 2017, however, the timing and magnitude is dependent on the timing of the pending Cigna acquisition. 
Potential headwinds include: The return of a 2017 onetime administrative expense cuts that we made in 2016; the impact of lower Local Group enrollment and gross margin pressures as a result of the migration towards ACA-compliant product offerings; and finally, we expect to experience continued pressure in the Medicaid business, primarily driven by rate actions within the Medicaid expansion population over the next year. 
Taken together, these items are expected to represent modest earnings growth from 2016. 
As part of our planning process, we will continue to be focused on identifying steps to maximize our opportunities to drive improved earnings growth over time. We expect to provide more details around our 2017 outlook on our fourth quarter conference call. 
With that, I'm going to turn the call back over to Joe to discuss our longer-term outlook."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, John. 3 years ago, we laid out our plan for growth, which reflected our strategy to capitalize on the substantial opportunities in the government business while recognizing the changing nature of the commercial marketplace as a result of the im",731,"Thank you, John. 3 years ago, we laid out our plan for growth, which reflected our strategy to capitalize on the substantial opportunities in the government business while recognizing the changing nature of the commercial marketplace as a result of the implementation of the Affordable Care Act. Our plan was to establish a leadership position in the Medicaid market, stabilize our Medicare Advantage platform and grow individual ACA-compliant and ASO enrollment to mitigate the expected pressure in the Local Group fully insured segment. 
Since that time we've been pleased with the growth in our Medicaid business, where enrollment has grown 47% since 2013. And we're well positioned to capitalize on the $81 billion pipeline of opportunity between now and 2021 that I mentioned earlier. In addition, we have reconfigured and upgraded our Medicare platform, as evidenced by the improvement in our margin profile and STAR rating performance. We expect to leverage our upgraded Medicare platform to grow MA enrollment in 2017 and beyond. 
Overall, the government business segment has grown nicely and now represents 54% of our consolidated company revenue, up from 44% in 2013. And we remain very optimistic about continued growth potential in this business. 
Switching to individual. As we've discussed previously, the earnings contribution from the individual ACA-compliant business represents a meaningful headwind to our original targets. The volume shortfall from our previous expectation remains substantial. 
For your reference, we laid out a plan to grow individual ACA-compliant enrollment to 3 million members by 2018 using the assumption that the overall individual marketplace would be approximately 25 million members, in line with CBO estimates. In 2016, the overall marketplace is about half of the expected size and has only grown to roughly 10 million to 11 million members. And subsequently, we have grown our individual ACA-compliant enrollment to approximately 1.4 million members as of the third quarter of 2016. We're closely monitoring the progress of our actions to improve the margin profile of this business toward our low to mid-single-digit margin targets of 2018. 
In our self-funded business, we've added 4.4 million members since 2013, as our value proposition has resonated with large employers who are focused on quality and affordability. This ASO growth has helped mitigate some of the pressure from higher-than-expected declines in our Local Group insured enrollment. 
Across our Commercial segment overall, we are generally pleased with our aggregate enrollment growth, but the mix of enrollment has skewed more than expected to self-funded than fully insured, pressuring revenue and earnings growth. Looking ahead, we still have meaningful opportunity to improve the per-member EBITDA contribution from ASO by increasing the penetration of our specialty and other product offerings to help further offset the pressures in Local Group. 
I want to spend a few moments on the pending acquisition of Cigna. We're committed to this combination which will further Anthem's vision to be America's valued health partner. This is truly a compelling opportunity to positively impact the health and well-being of our members and advance our commitment to expand access to high-quality, affordable health care for consumers. It will also save consumers more than $2 billion of medical cost annually, directly benefiting the most vulnerable populations in the country. 
I also would like to briefly address the upcoming trial with the Department of Justice, which will begin on November 21. We continue to believe the DOJ's action to sue to block the acquisition is based on a flawed analysis and a misunderstanding of the dynamic competitive and heavily regulated health care landscape, and we're fully committed to challenging the DOJ's decision in court. 
In terms of the court proceeding, the judge has decided to bifurcate the issues and will first hear evidence on the National Accounts issue. If the judge decides in our favor on the National Account issue, we will then move forward and try the other 2 remaining issues, with the decision on those issues being rendered before the end of January. 
To summarize, we are in the process of updating our long-term growth plan and expect target improved core earning growth rates beyond 2017. The individual ACA-compliant headwinds in our enrollment mix discussed previously represent a meaningful challenge to achieving our $14 earnings target in 2018. And we expect to provide additional clarity around our long-term growth prospects after the Cigna transaction process is complete. 
With that, operator, please open the queue for questions."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","[Operator Instructions] And our first question will come from the line of Ana Gupte from Leerink Partners.",17,"[Operator Instructions] And our first question will come from the line of Ana Gupte from Leerink Partners."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","My question was about the individual book. You said that there were losses this year and they continued into the quarter. Sequentially speaking, what were the losses in -- that you estimated in second quarter? And have they gone up since then? And why are",68,"My question was about the individual book. You said that there were losses this year and they continued into the quarter. Sequentially speaking, what were the losses in -- that you estimated in second quarter? And have they gone up since then? And why are you expecting that will improve next year, when the reinsurance rate case [ph] is out. Are you getting any pricing to do that?"
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Ana, this is John. So thank you for the question. Associated with our individual exchange business, we certainly did, in the second quarter, indicate losses, and we expect that our operating margins are going to be on the mid-single-digit loss for the yea",215,"Ana, this is John. So thank you for the question. Associated with our individual exchange business, we certainly did, in the second quarter, indicate losses, and we expect that our operating margins are going to be on the mid-single-digit loss for the year. Now during the third quarter, the reserve development was okay. The trend has been moderated a bit. And we still expect there's losses in the same general range of what we said, maybe just a little bit better than we had indicated. In terms of 2017, reinsurance is obviously a very important factor, but it's only one aspect of pricing and one aspect of the overall structure of the program. We've got rate increases that average in excess of 20% across the country. I think there's been studies that have been published that have stated that our rate increases are a little bit higher than the average rate increases. We've made adjustments to product offerings. We've changed networks. We've enhanced product designs. We've done many, many things to improve affordability of the specific product mix. So we feel very good about the previous guidance that we provided, that we're really targeting a small profit margin in 2017 and then returning to more -- closely related to target margins in 2018 and beyond."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question is from Christine Arnold from Cowen.",10,"And our next question is from Christine Arnold from Cowen."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","A couple of things. On Iowa, your language there suggests that you got a rate increase, but it may not be adequate; and that you're disciplined, you're going to be in markets that are actuarially sound. Is there an out to get out of that if, in fact, we c",88,"A couple of things. On Iowa, your language there suggests that you got a rate increase, but it may not be adequate; and that you're disciplined, you're going to be in markets that are actuarially sound. Is there an out to get out of that if, in fact, we can't get to actuarially sound rates? And then with respect to individual, what do you think you need to see in order to feel that there's sustainability into '18? What legislatively or administratively do you want to see there?"
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Christine, this is Joe Swedish. Yes, first question regarding, I guess, the out possibilities. As you know, the contract went live earlier this year, and obviously, we're very concerned because it has experienced a deterioration that certainly exceeded ou",275,"Christine, this is Joe Swedish. Yes, first question regarding, I guess, the out possibilities. As you know, the contract went live earlier this year, and obviously, we're very concerned because it has experienced a deterioration that certainly exceeded our forecast expectations regarding the medical loss ratio. We are in the process of having deep discussions with the state regarding the possibility of adjustments. I commented in our discussions just a moment ago that we have realized some positive effect from that discussion. And quite frankly, we're hoping for more. Unfortunately, the recent rate increase is still inadequate, and again, we're hoping for a better outcome with respect to more discussion. With respect to the legal construct of the contract, we are examining our position. We quite frankly, are awaiting the state to respond to the inquiries that we've submitted to them. And I think it's a little early for us to maybe put commentary out regarding our legal position, given the fact that there's still administrative considerations that are working their way through the system. And we're hopeful for a very positive outcome at the end of that review. We are concerned about the actuarial soundness of the rates. And that's been expressed by all the MCOs from the get go. We are engaged in an extensive process of meetings, as I mentioned. And we'll continue to be deeply concerned until we get a resolution to this. And then we'll weigh our options with respect to the endpoint of those negotiations with the state. I think the second question dealt with the exchange, Christine. I wonder if you could restate that for me, I'm sorry."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","One moment please.",3,"One moment please."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","[Audio Gap] and then it sounded like your language suggests that if '17 doesn't go well, you could change your strategy for '18. What do you need to see administratively or legislatively in order to fix this and in order for you to feel that this is where",54,"[Audio Gap] and then it sounded like your language suggests that if '17 doesn't go well, you could change your strategy for '18. What do you need to see administratively or legislatively in order to fix this and in order for you to feel that this is where you're going to stay for '18?"
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Great. Well, on or about midyear '17, obviously, we'll maybe coming to a conclusion on our review about how the adjustments have played out that we're expecting. To you point, what we're looking for are a variety of fixes, such as elimination of the healt",266,"Great. Well, on or about midyear '17, obviously, we'll maybe coming to a conclusion on our review about how the adjustments have played out that we're expecting. To you point, what we're looking for are a variety of fixes, such as elimination of the health insurance tax or at least extending the 2017 moratorium. Another one that you probably heard quite a bit about is updating the risk adjustment model substantially to address existing imbalance that we believe deteriorates the overall risk pool. We are also looking at additional adjustments to special enrollment periods, which we believe the -- needs to be continually narrowed with respect to the variety and number of special enrollments. We also believe that we need to have the flexibility to develop innovative products that should go to market to meet our -- the needs of our customers. Modify the grace period is another great example. And finally, we want to work very closely with the states to ensure actuarially justified rates being approved. Now what I just specified for you, let me just put a characterization to it that I think is very, very important. And that is, this is a specific recipe for solutions, and we believe these recipe characteristics represent the form of long-term sustainable and affordable marketplace. So as I said earlier in my commentary, we believe we must see adjustments such that we can easily map to a 2018 situation of sustainability in this marketplace. And quite frankly, given what may or may not happen, we'll be evaluating the regional engagement across our markets moving into 2018."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","And Joe, I'd just like to say, obviously, everything there is very appropriate, but Christine, we will be watching margins trends performance on a state-by-state and region-by-region basis in 2017 as well. So certainly, the decision in '18 could be a piec",49,"And Joe, I'd just like to say, obviously, everything there is very appropriate, but Christine, we will be watching margins trends performance on a state-by-state and region-by-region basis in 2017 as well. So certainly, the decision in '18 could be a piecemeal decision as opposed to an all-together decision."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. I think thus far, we've been very surgical in our approach, and we'll continue that theme. And so again, we have hope that the sustainability that's expected and commented on quite a bit by leadership of administration actually will occur during the",47,"Yes. I think thus far, we've been very surgical in our approach, and we'll continue that theme. And so again, we have hope that the sustainability that's expected and commented on quite a bit by leadership of administration actually will occur during the early stages of 2017."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question is from A.J. Rice from UBS.",11,"And our next question is from A.J. Rice from UBS."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","I just want to follow up. I appreciate the comments on the headwinds and tailwinds and the comment about modest growth. I guess the 3 variables I just want to throw on the table, you're saying you'll go from a mid-single digit loss on the exchanges, or in",146,"I just want to follow up. I appreciate the comments on the headwinds and tailwinds and the comment about modest growth. I guess the 3 variables I just want to throw on the table, you're saying you'll go from a mid-single digit loss on the exchanges, or in the individual book, to a positive. We got, I guess, about -- that would represent, I think, about a $0.70 swing, roughly 6% to 7% growth in and of itself. I just also wondered, are you including anything in your comments about capital deployment when you talk about modest growth? Or anything on the PBM? And what's the latest thinking on that? And then just to make sure the $10.80 is the base line number upon which you're assuming modest growth. Or is it some other number that you would adjust for as the starting point for '16?"
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure, no, A.J. Thank you for the question. And in terms of capital, we do expect to resume capital deployment in 2017. However, that won't be until after the pending Cigna acquisition process is completed. And so the timing and the magnitude of that",135,"Yes, sure, no, A.J. Thank you for the question. And in terms of capital, we do expect to resume capital deployment in 2017. However, that won't be until after the pending Cigna acquisition process is completed. And so the timing and the magnitude of that capital deployment is still somewhat of an unknown. Associated with the starting point, yes, very clearly, $10.80, we believe, is the appropriate starting point. That's our guidance. That's been our expectation now for some time. And that's our 2016 -- approximately $10.80 is our 2016 guidance number. Yes. And then of course, you have the tailwinds that offset that. But in terms of the PBM, we don't have any of the upside baked in. I think, Joe, maybe some comments just about the PBM situation in general might be helpful."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. A.J., thanks for the question on that. As I've repeatedly stated, we're hopeful we can negotiate a settlement to our concerns or dispute. And I don't need to restate what we've said repeatedly about our perspective on our contractual rights, but let",189,"Yes. A.J., thanks for the question on that. As I've repeatedly stated, we're hopeful we can negotiate a settlement to our concerns or dispute. And I don't need to restate what we've said repeatedly about our perspective on our contractual rights, but let me say that we do believe that we're continually focused on improving the pharmacy pricing on behalf of our customers. We expect to issue a new RFP during the year, that's early 2017, to understand the impact of various pharmacy options available to us as we migrate to potential of a new agreement. And I have to underscore that it's critical that we engage with a really trusted partner with aligned interests in advancing cost-effectiveness and quality for our membership. We've -- I guess we've not ruled anyone in or out in this process of securing an RFP. And I think with respect to any other comments made by ESI or others, we prefer not to comment on that. We do believe that a period of negotiations is still possible. And again, I'll underscore I'm hopeful that we can resolve our differences moving into the future."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from the line of Matt Borsch from Goldman Sachs.",13,"Our next question is from the line of Matt Borsch from Goldman Sachs."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Maybe on a slightly different topic. One of your peer companies has talked in considerable length about pressure in the small group ACA-compliant book. I know you've alluded to that some. Can you just give us an update on how you see that business? Maybe",73,"Maybe on a slightly different topic. One of your peer companies has talked in considerable length about pressure in the small group ACA-compliant book. I know you've alluded to that some. Can you just give us an update on how you see that business? Maybe break down in size and break down your small group between what's ACA-compliant? What's grandmothered, grandfathered? And how you see that transition happening, working going into next year?"
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure. Thank you for the question, very good question. And that really is a meaningful headwind and I think I did try to highlight it in the script. But in terms of other specificity of your question, we don't talk about a lot of this information for",140,"Yes, sure. Thank you for the question, very good question. And that really is a meaningful headwind and I think I did try to highlight it in the script. But in terms of other specificity of your question, we don't talk about a lot of this information for competitive reasons, but maybe 2/3 of our block is non-ACA-compliant today. The grandmothering expires here at the end of the year, and we fully expect to be very aggressive in pursuing and renewing that block of business. The margin aspect of it may be slightly different, slightly lower. The ACA-compliant block typically have a slightly lower margin compression, but we'll ensure that we renew it at appropriate prices and happen to be a profitable business on a go-forward basis, but we did want to spike it out as a headwind in 2017."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Kevin Fischbeck with Bank of America.",11,"Our next question is from Kevin Fischbeck with Bank of America."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","I guess 2 questions. First, a clarification, you mentioned that as far as the Cigna lawsuit or I guess the 2 pieces accounts and the National Accounts first, just wondering if you have a time frame of when we will see that. But then specifically, on the M",83,"I guess 2 questions. First, a clarification, you mentioned that as far as the Cigna lawsuit or I guess the 2 pieces accounts and the National Accounts first, just wondering if you have a time frame of when we will see that. But then specifically, on the Medicaid business, it sounds like Iowa should get better next year, Medicaid expansion should get you worse. Are you looking for net margin improvement or margin pressure on the Medicaid business as a whole in 2017?"
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Let me just comment on the Cigna hearings. Beyond the December judicial process, which we're anticipating a decision sometime on or about mid-December, we would expect that moving forward from there, that's possible that a trial would begin shortly therea",61,"Let me just comment on the Cigna hearings. Beyond the December judicial process, which we're anticipating a decision sometime on or about mid-December, we would expect that moving forward from there, that's possible that a trial would begin shortly thereafter, probably early January. And our hope is that, that would be resolved with a judicial decision by the end of January."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","And then on the Medicaid question, just provide a little clarity. So certainly Iowa is going to be a tailwind in the 2017. Yes, we experienced significant upfront losses in Iowa. And even with rebalancing of the portfolio and retroactive rate increases, i",146,"And then on the Medicaid question, just provide a little clarity. So certainly Iowa is going to be a tailwind in the 2017. Yes, we experienced significant upfront losses in Iowa. And even with rebalancing of the portfolio and retroactive rate increases, it's still -- we do not believe this is actuarially sound and the expectation is that there will be improvement in 2017. However, associated with the remainder of the Medicaid block, we are seeing some slight margin pressure. We were phenomenally successful the past couple of years with our margins. And specifically, our expansion margins have been very, very, very good, and then those get repriced throughout the balance of the year. They're going to be repriced at more of a margin target ratio, target profit ratio, I'm sorry, and that will create a bit of headwind or margin pressure for us in '17."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Justin Lake from Wolfe Research.",10,"Our next question is from Justin Lake from Wolfe Research."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","A couple of things. First, I remember back when we were going into the ACA and those concerns around small group, you guys have put out a number of about $400 million headwind for next year or for the coming couple of years in terms of small group margin",165,"A couple of things. First, I remember back when we were going into the ACA and those concerns around small group, you guys have put out a number of about $400 million headwind for next year or for the coming couple of years in terms of small group margin pressure. Is there any way for you to do something similar here, just to give us an idea? As you go through this repricing, is there a number you can point to say, it sounds like small group is going to be a pretty good pressure this year as expected, maybe a little larger than we thought. Is there a way to put a number on that for us? And then on SG&A, it's been shifting around a bit here and wanted to get your thoughts for the fourth quarter and how we should think about this for 2017 when we add in the -- when we add back some of these one-time benefits this year."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Sure, Justin, great questions. In terms of the small group, yes, we're still working through it, and I really am hesitant to provide an answer until our planning process is done and some of the grandmothering associated with the early renewals that exist,",305,"Sure, Justin, great questions. In terms of the small group, yes, we're still working through it, and I really am hesitant to provide an answer until our planning process is done and some of the grandmothering associated with the early renewals that exist, and we actually have several of our many of our small group plans renewed early on December a couple of years ago in order to maintain the non-ACA-compliant plans. And it's probably premature to throw a number out until we've worked through that process. We will update you and provide more clarity on the fourth quarter call. Associated with the general administrative expenses, I think maybe I'll just repeat sort of a commentary from last time. It's down quite substantially in 2016. And a little more than half of it is a good sustainable run rate, a meaningful decrease in SG&A expense that has to do with more efficient processes, better performance in some of the administrative and core areas of the company, and we grew in our membership and we had a really good membership year from both a membership and premium prospective, raising guidance on that and we're able to do that by maintaining our administrative expense levels. Obviously, then the ratio went down. The other half or a little less than the other half were more of one-time items and those are nonsustainable. And the most significant part of those, other less than the other half is our incentive compensation plans. As I stated, we are a pay for performance company, and we have our promises to Wall Street and what we expected earnings to be and we ensure that we deliver those earnings. And unfortunately, we are below our incentive compensation expense as part of that process. So it's a little less than half come back in 2017."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Michael Newshel from Evercore ISI.",10,"Our next question is from Michael Newshel from Evercore ISI."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Does your expectation for slight profitability in the ACA-compliant business next year assume that the national enrollment is going to be stable or growing? And how would you frame the downside risk to margins if enrollment declines and the risk pool dete",90,"Does your expectation for slight profitability in the ACA-compliant business next year assume that the national enrollment is going to be stable or growing? And how would you frame the downside risk to margins if enrollment declines and the risk pool deteriorates? And also, I mean it looks like your relative pricing versus competitors is generally higher in 2017 than it was this year after the price hike and some market exits. We saw health care.gov. Do you think that provides you any buffer against adverse election next year?"
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Well, there's quite a few questions in there that hopefully I can address and resolve them. But maybe the most simple is that we expect that, overall, individual ACA-compliant membership on a national basis will be slightly down next year and that our mem",183,"Well, there's quite a few questions in there that hopefully I can address and resolve them. But maybe the most simple is that we expect that, overall, individual ACA-compliant membership on a national basis will be slightly down next year and that our membership will reflect that. We still have many, many competitors in our markets. I just do want to point out that some of the exits that have been a very widely publicized, very few of them impact our market specifically. So like, for instance, California still has 11 competitors, Virginia still has 8 competitors, just to rattle off a couple of our states. In terms of the risk pool, we believe that we understand the risk pool. We're very good at the individual marketplace. We're the #1 individual market carrier for years and years prior to the ACA. Our products are designed in such a way to really get a good risk pool that allows us to maximize on risk adjusters and then be a risk adjuster collector. So we feel good about our assumption at this point in time."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Let me add that there are a few key points I think we really need to consider to keep in front. Number one, on average, our price point for targeted bronze silver plans in the marketplace is higher than our competitors. We certainly recognize that and ack",246,"Let me add that there are a few key points I think we really need to consider to keep in front. Number one, on average, our price point for targeted bronze silver plans in the marketplace is higher than our competitors. We certainly recognize that and acknowledge it. And while the number of competitors in our markets has declined overall versus 2016, for the most part, those declines are in less populated areas versus the world market, where we have had historically high market share. On the flip side, there's really still substantial competition across all of our markets, those served markets, most notably in these highly dense urban markets. And finally, some of the largest markets do not see any significant reduction in competition. For example, California still has 11 competitors, down 1 from last year. Virginia still has 8. Georgia still has 5. So we know we're in highly competitive markets and we believe we will compete very effectively. But again, I think we very effectively managed price points with respect to the product that we offer in the marketplace. And so we have a fairly good outlook, as John commented earlier in his remarks, about our expected margins. And as I said then follow on to that, we'll be evaluating our situation in those markets, all of our markets, through the beginning of the year to see how well we perform and how well the regulatory adjustments play out leading up to midyear."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Lance from Sanford Bernstein.",9,"Our next question is from Lance from Sanford Bernstein."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Just wanted to follow up on a question with respect to self-insurance margin strategy. Want to understand how the progress was going on especially penetrations looking at 2017 and where your 2018 and beyond strategies were there. How much upside you saw w",66,"Just wanted to follow up on a question with respect to self-insurance margin strategy. Want to understand how the progress was going on especially penetrations looking at 2017 and where your 2018 and beyond strategies were there. How much upside you saw with respect to self-insurance margins? And then in particular right now, with PBM how does that fit into how you're looking at penetrations?"
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Great question, and certainly, that's one of our growth areas for the future as we look out into our long-term outlook. Yes, we believe that the opportunity to enhance the EBITDA associated with our ASO members is meaningful. We are developing -- we have",157,"Great question, and certainly, that's one of our growth areas for the future as we look out into our long-term outlook. Yes, we believe that the opportunity to enhance the EBITDA associated with our ASO members is meaningful. We are developing -- we have ongoing efforts to drive penetration in specialty products, various ancillary type products, other add-ons that we think that we are underpenetrated right now and believe that we have incredible amount of upside. Yes, we've been the #1 company in growing the ASO large group national membership over the last several years, and we've made quite a nice margin percentage on that business but it's very small dollars. And so now the focus is to take the fact that we do have best-in-class discounts and the most sophisticated purchasers of coverage are picking us. And so now it's our opportunity to really penetrate that better and enhance the EBITDA associated with that membership block."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Gary Taylor from JPMorgan.",9,"Our next question is from Gary Taylor from JPMorgan."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Just a couple more questions on the individual business. First, i just wanted to follow up. I know you had just said you're anticipating exchange enrollment to decline heading into 2017. I know you also thought that would be the case sitting in the 2016.",98,"Just a couple more questions on the individual business. First, i just wanted to follow up. I know you had just said you're anticipating exchange enrollment to decline heading into 2017. I know you also thought that would be the case sitting in the 2016. So is this a rate positioning why you still believe that might play out in '17 versus what happened this year? And then just secondly, could you just comment on any PDRs used in the individual business this quarter and your experience with the special enrollment, period enrollment this year versus last year?"
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Gary, great question. And 2016 was interesting because what we ended up seeing was a flight to safety and that's one of the reasons that our 2016 individual exchange membership grew more than expectations. And so if we go backwards a year and then you loo",247,"Gary, great question. And 2016 was interesting because what we ended up seeing was a flight to safety and that's one of the reasons that our 2016 individual exchange membership grew more than expectations. And so if we go backwards a year and then you look at the number of co-ops who are in our markets that fell, there was a significant impact on our membership. And then as those customers then went into the marketplace, they said it was a flight to safety, they went to Blue. I think the real key difference in the expectations in '16 and expectations in '17 is really the amount of exits within our markets of carriers and who the exits were and how much membership those that exited have. So long story short, the co-ops in certain markets had extremely high market share and they went insolvent and their market share was absorbed, where in 2017, while we certainly have some exits of carriers in our markets, they do not have the breadth or the magnitude of the market share that the ones who exited the year ago had. Associated with the premium deficiency reserves, we have none recorded. We have none recorded in 2015. We have none recorded in 2016. It's a very easy question, which means that our results are pure, our results are clean and that we don't have the puts and takes that maybe you have in some of the other companies that you're modeling."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Joshua Raskin from Barclays.",9,"Our next question is from Joshua Raskin from Barclays."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Question, the short term and long term. Short term, I heard the commentary, I think John you said the results were very consistent with your expectations. And just looking at sort of the cadence of earnings, you saw some mid to high single digit growth in",180,"Question, the short term and long term. Short term, I heard the commentary, I think John you said the results were very consistent with your expectations. And just looking at sort of the cadence of earnings, you saw some mid to high single digit growth in the first half, a big decline in double-digit percentage on EPS in 3Q and now an expected increase back in 4Q. And so I guess if that's all very expected, what changed this year from a seasonality perspective? And then on the long term, from a strategic perspective, when you guys announced the Cigna deal and I know we're going back 1.5 years, now you talked about Cigna bringing commercial expertise and exposure in Medicare to strong specialty and then the international segment. And so I'm curious kind of where those priorities sit today. And in the case that the judge disagrees with you guys and the transaction does not move forward, how do you guys think about the reaction? Is there a need for scale? Is there an appetite to do other stuff?"
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure, thank you. I'll take the first question and turn it over to Joe for the second. Yes, I did say that our results were very consistent with expectations. When you're looking at the seasonality of 2015 to 2016, yes, 2016 is a bit challenging. MLR",147,"Yes, sure, thank you. I'll take the first question and turn it over to Joe for the second. Yes, I did say that our results were very consistent with expectations. When you're looking at the seasonality of 2015 to 2016, yes, 2016 is a bit challenging. MLR is a little bit in the fourth quarter than it was last year. There's a lot of variables associated with that, clearly, the Iowa variable, the individual exchange variable. Please note that we do have the G&A offset that allows us to enjoy the growth in EPS year-over-year, but it's not that there's a significant change in seasonality patterns or a huge business flux as much as it was some of the very specific items that we pointed out, these headwinds for 2016, continue to be headwinds throughout the fourth quarter. I think Joe wants to address your Cigna question."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, let me take that for a moment, Josh. First of all, to your point about, call it, pivoting in the event of an adverse decision, we're going to focus very heavily on what we talked about earlier regarding our tailwinds. Obviously, in the MA growth spac",141,"Yes, let me take that for a moment, Josh. First of all, to your point about, call it, pivoting in the event of an adverse decision, we're going to focus very heavily on what we talked about earlier regarding our tailwinds. Obviously, in the MA growth space, very strong focus on our government business across the entire spectrum and a variety of other initiatives that I already mentioned. I think it's really important to underscore that we'll be coming to you at the time of that announcement whenever we will then share with you our outlook in terms of pivoting the company to tackle some of those opportunities, tailwinds as well as, quite frankly, address the headwinds as robustly as we would anyway. But certainly, we believe ameliorating some of that risk will be a great opportunity to us as well."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, I would just add to that, that we believe that we have long-term sustainable growth opportunities regardless if the deal closes or not. Cigna may help accelerate those, but we're very confident about our future under either scenario.",39,"Yes, I would just add to that, that we believe that we have long-term sustainable growth opportunities regardless if the deal closes or not. Cigna may help accelerate those, but we're very confident about our future under either scenario."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from the line of Chris Rigg with Susquehanna Financial Group.",14,"Our next question is from the line of Chris Rigg with Susquehanna Financial Group."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","John, I know you commented earlier about the dynamic of compliant versus noncompliant in the small group book. But it looks like in the individual side, you still have about 27% of your membership that's noncompliant. Are most of those -- the plans for th",86,"John, I know you commented earlier about the dynamic of compliant versus noncompliant in the small group book. But it looks like in the individual side, you still have about 27% of your membership that's noncompliant. Are most of those -- the plans for the noncompliant individuals going to be enforced through or until December 2017? And then more of a macro question, do you guys have a sense for how many grandmothered -- how many people have grandmothered plans in your markets at this point?"
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, great question. First of all, in the compliance versus noncompliant, yes, the majority of those will not be noncompliant through '17 so that the headwind, tailwind that I talked about with that, that would include both the small group and the individ",122,"Yes, great question. First of all, in the compliance versus noncompliant, yes, the majority of those will not be noncompliant through '17 so that the headwind, tailwind that I talked about with that, that would include both the small group and the individual commentary. In terms of how many grandmothering in our markets including what our competitors have, we actually do not have the specificity of that. But obviously, all the dynamics that we're experiencing and the changes and the loss they're experiencing, is really not -- your question is there an opportunity to get someone else's grandmothered business, the answer is really no. It would have to be -- we would have to give it as part of an ACA-compliant product."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from the line of Ralph Giacobbe from Citi.",12,"Our next question is from the line of Ralph Giacobbe from Citi."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","First, just wanted to clarify a comment on the exchange, again. Joe, you mentioned 2017 as a critical year. And if there was no clear evidence that you'd sort of modify your strategy in 2018, I mean does that mean market exit or willingness to exit if you",118,"First, just wanted to clarify a comment on the exchange, again. Joe, you mentioned 2017 as a critical year. And if there was no clear evidence that you'd sort of modify your strategy in 2018, I mean does that mean market exit or willingness to exit if you're unprofitable again in 2017? And then also separately, I was hoping you could parse out the pressure from Iowa. I know when your peers took a PDR in that book while you're absorbing the losses through the P&L. So just hoping to get a sense of margin may be magnitude of loss this year and what the improvement would be next year even in sort of the inadequate rate bump."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, I will give it the second part of the question to John so we can get to some of the technical aspects of it. But with respect to the first question, let me just underscore that, as I said a moment ago, we're going to be very surgical defined market.",123,"Yes, I will give it the second part of the question to John so we can get to some of the technical aspects of it. But with respect to the first question, let me just underscore that, as I said a moment ago, we're going to be very surgical defined market. Those that define market to be state, but I want to be very clear that we deal with significant array of regions. So we will look at both regional impact as well as state impact and then make determinations with respect to what I call the surgical assessments and decisions and execution that are necessary in order to -- prudent engagement in the marketplace. I believe that probably covers what you're asking."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. And then in terms of Iowa and the headwind for '16 which becomes a tailwind for '17 with the Medicaid block there, we did get a retroactive rate increase. Unfortunately, we think it's still not actuarially justified. We really are not providing an ex",134,"Yes. And then in terms of Iowa and the headwind for '16 which becomes a tailwind for '17 with the Medicaid block there, we did get a retroactive rate increase. Unfortunately, we think it's still not actuarially justified. We really are not providing an exact number at this point as we continue to work with the state and don't want to get out ahead of the state and negotiate this publicly. But just as Joe said, consistent with the individual exchange business, we need to partner with the states that want to be partners. And we believe that we need actuarially justified rates and we will continue to negotiate it. We feel really good about that fact, but if we don't get it, then we'll have a decision to make in Iowa as well."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","And our last question this morning will come from the line of Peter Costa, Wells Fargo.",16,"And our last question this morning will come from the line of Peter Costa, Wells Fargo."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Just a couple of clarifications on things you said. You said you put out an RFP for your PBM in early 2017. So presumably, that means we'd see the answer sometime in mid-27. What sort of things have you been looking for besides the $3 billion in savings t",72,"Just a couple of clarifications on things you said. You said you put out an RFP for your PBM in early 2017. So presumably, that means we'd see the answer sometime in mid-27. What sort of things have you been looking for besides the $3 billion in savings that you already talked about? And are you specifically coming off the $100 billion revenue target that you set out in 2014 for 2018?"
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Why don't I do the second one first, Peter while I got the line. In terms of the headwinds, tailwinds for 2018, in Joe's commentary, it's highly unlikely that we would be able to achieve that number at this point in time. Just look at our guidance for 201",166,"Why don't I do the second one first, Peter while I got the line. In terms of the headwinds, tailwinds for 2018, in Joe's commentary, it's highly unlikely that we would be able to achieve that number at this point in time. Just look at our guidance for 2016 and roll that forward and grow our membership forward, it all boils down to the exchanges. And the CBO estimate with 25 million, 26 million lives to be insured to the exchanges. When we did our 2018 plan, we relied on some of the CBO estimates as part of our estimation process. And yes, we're still maintaining our market share. We still believe that we can hit the target margins that we had for those things. But when the entire country has just over 10 million versus that other, that's a significant delta, and that goes straight into our numbers and I think you'll see that the revenue shortfall can be entirely explained with that dynamic."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, let me pick it up now regarding the PBM question. Yes, that RFP goes to market early 2017. I've said repeatedly that our intention is to be able to deliver to you a solution with respect to ongoing analytics, which, obviously, in the current state is",120,"Yes, let me pick it up now regarding the PBM question. Yes, that RFP goes to market early 2017. I've said repeatedly that our intention is to be able to deliver to you a solution with respect to ongoing analytics, which, obviously, in the current state is significantly impacted by discussions of course potential legal proceedings with the ESI. We're hopeful to bring you a meaningful commentary and maybe solution by the end of 2017. We've never diverged from that commitment, and our hope is that we certainly will be able to put all the parts and pieces together to give you clarity and around the decisions. We're going to execute specific to the termination of the contract by 2019."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Please go ahead with any closing remarks.",7,"Please go ahead with any closing remarks."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Well, again, thank you, everybody, for your questions. They're always very, very good. As a company, we do remain committed tackling our health care system challenges head on, as evidenced by the work that we've communicated to you today. And we believe t",143,"Well, again, thank you, everybody, for your questions. They're always very, very good. As a company, we do remain committed tackling our health care system challenges head on, as evidenced by the work that we've communicated to you today. And we believe that we can and will deliver greater value to consumers by expanding access to high-quality affordable health care and we've stood by that repeatedly. This is why we are committed to challenging the DOJ's recent decision to block Anthem's acquisition of Cigna in court. 
Speaking to my associates, I want to also thank all of them for their continued commitment to serving our nearly 40 million members every day. To all of you on the phone, please accept our thanks, for your interest in Anthem, and we look forward to speaking with you soon at upcoming conferences. Have a great day."
160077,324533304,1069668,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","And ladies and gentlemen, this conference will be made available for replay after 11:00 a.m. today through November 16. You may access the AT&T Executive Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378818, and intern",70,"And ladies and gentlemen, this conference will be made available for replay after 11:00 a.m. today through November 16. You may access the AT&T Executive Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378818, and international participants can dial (320) 365-3844.  That does conclude our conference for today. Thank you for your participation and for using AT&T Executive TeleConference. You may now disconnect."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Anthem Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management.",39,"Ladies and gentlemen, thank you for standing by, and welcome to the Anthem Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded. 
I would now like to turn the conference over to the company's management."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Good morning, and welcome to Anthem's Third Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish; Chairman, President and CEO; and John Gallina, our CFO. Joe will offer an overview of",197,"Good morning, and welcome to Anthem's Third Quarter 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish; Chairman, President and CEO; and John Gallina, our CFO. Joe will offer an overview of our third quarter 2016 results and our updated 2016 full year outlook. Then John will walk through the financial details and provide some incremental commentary on 2017 before Joe closes with some longer-term strategic commentary. We will then be available for Q&A. 
During the call, we will reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website at antheminc.com. 
We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Anthem. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in today's press release and in our quarterly and annual filings with the SEC. 
I will now turn the call over to Joe."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Doug, and good morning. This morning, we announced third quarter 2016 GAAP earnings per share of $2.30. Adjusted earnings per share was $2.45, consistent with our previous expectations. Within membership, we continued to post strong fully ins",1650,"Thank you, Doug, and good morning. This morning, we announced third quarter 2016 GAAP earnings per share of $2.30. Adjusted earnings per share was $2.45, consistent with our previous expectations. 
Within membership, we continued to post strong fully insured and self-funded enrollment results, as we ended the third quarter with over 39.9 million members. We grew an additional 160,000 lives during the quarter, bringing our year-to-date enrollment growth to 1.3 million lives or 3.4%. Specifically, insured enrollment increased by 39,000 lives during the quarter, as our Medicaid business grew by 81,000 lives to over 6.4 million members. Since closing the Amerigroup transaction in 2012, we've grown Medicaid enrollment by nearly 1.9 million lives or 41%, including growth of approximately 800,000 lives from Medicaid expansion. 
Within Commercial, our insured enrollment came in slightly ahead of expectations, as Local Group fully insured membership tracked well, particularly in the large group marketplace. Our public exchange enrollment declined by a less-than-expected 34,000 during the quarter to 889,000 lives. Our self-funded business increased by 121,000 during the quarter, reflecting the impact of enrollment growth from existing accounts and recently awarded contracts. 
Our solid membership results during the year translated into better-than-expected operating revenue of $21.1 billion during the quarter, an increase of $1.4 billion or 6.8% versus third quarter of 2015. The increase reflects the strong enrollment growth in the government business and additional premium revenue to cover overall cost trends. Additionally, administrative fee revenue grew by 6.4% versus the prior year quarter as a result of our strong self-funded membership trends. These increases were partially offset by fully insured membership losses in our Commercial business. 
The third quarter 2016 benefit expense ratio was in line with our previous expectations at 85.5%, an increase of 190 basis points versus the prior year. The year-over-year increase was primarily driven by the Medicaid business, as higher-than-expected medical cost experience, notably in Iowa, has exceeded the net impact of annual premium rate adjustments made over the last 12 months. In addition, it reflects the impact of growth in membership, as the Medicaid business carries a higher benefit expense ratio than the consolidated company average. Further, the benefit expense ratio reflects the impact of higher medical cost experience in the individual business. These increases were partially offset by the timing of lower medical cost experience in the Local Group business. 
Our SG&A expense ratio was also in line with expectations at 14.8% in the third quarter, a decrease of 80 basis points from the third quarter of 2015. The decrease was driven by an intentional focus on administrative expense control coupled with better-than-expected enrollment trends, as well as the changing mix of our membership towards the government business, which carries a lower than the consolidated average SG&A ratio. 
Turning to discuss the third quarter financial performance of our business units. In the government business, we added 92,000 members during the quarter and grew year-over-year revenue by 10.9% to nearly $11.5 billion. As a reminder, our third quarter results include the impact of the addition of the Iowa contract which was implemented on April 1. Operating margins for the government business were 4.2% during third quarter, a decline of 190 basis points versus the prior year quarter, driven by lower gross margins in the Medicaid business. 
As we communicated previously, we've been expecting Medicaid margins to compress from 2015 levels due to rate actions. In addition, we've been experiencing higher-than-expected claims across the Medicaid business in the current year, including materially higher-than-expected costs in the recently implemented Iowa contract. As expected, there was a rebalancing of funding based on risk pool during the quarter. In addition, we've been informed of a retroactive rate increase which extends through June 2017, when rates will again be adjusted. 
Unfortunately, the recent rate increase is still inadequate, given the claims experienced to date. We remain confident we can make a meaningful impact by improving the cost and quality of care in Iowa as we've done for our other state partners. However, we will remain disciplined and only participating in markets where we receive rates that are actuarially sound. 
Within Medicare, we're pleased with the progress the team continues to make, and our year-to-date margins reflect continued improvement. During the quarter, CMS announced we earned Medicare STAR quality ratings for 2017, consistent with our long-term strategy. In the most recent ratings released by CMS, 51% of Anthem's Medicare Advantage members will be enrolled in plans that achieve 4 stars or higher. This accomplishment represents significant growth from the 22% of MA members in 4-star plans last year. The improvement is the direct result of investments made in the Medicare program over the past 3 years. 
Our 2016 outlook continues to expect margins to improve as the year progresses towards our expected long-range sustainable level. As we stated since our MA restructuring began, we have positioned our portfolio to grow MA in 2017. 
The pipeline of opportunity for our Medicaid business remains substantial with an updated estimate of $81 billion in contracts to be awarded between now and 2021 in markets that we will consider targeting. Approximately 3/4 of this opportunity is in new and specialized services with the remainder in traditional Medicaid services. We continue to believe our experience, targeted investments in critical capabilities and geographic footprint positions us very well to continue our growth as we help states address the challenges of rising health care cost and improving quality for their residents. 
Switching to our Commercial business. Our enrollment increased by 68,000 lives during the quarter, which was slightly better than our previous expectations. Specifically, we experienced growth of 171,000 lives in our Local Group business, partially offset by declines of 48,000 and 54,000 lives in our national and individual businesses, respectively. These results translated into better than previously expected operating revenue of $9.7 billion, representing growth of 2.4%. 
Our third quarter operating margin of 6.6% was flat versus third quarter of 2015. Commercial operating margins during the quarter reflected a lower SG&A ratio due to lower administrative cost resulting from expense efficiency initiatives taken by the company, as well as fixed cost leverage on a growing membership base. In addition, our Commercial business experienced the favorable timing impact of lower medical cost experience in the Local Group business. These increases were offset by higher medical cost experience in our individual ACA-compliant products. 
Within our individual ACA-compliant plans, costs during the third quarter were marginally better than recent expectations, which is reassuring. We continue to experience higher than initially expected costs for members with chronic conditions, as we have discussed with you previously. Overall, the financial performance in individual ACA-compliant products has been disappointing, as membership has been short of our original expectations since its inception and operating margins have been lower than expected beginning in 2015. 
We believe we've taken the appropriate actions across our served market to return to slight profitability in 2017. Clearly, 2017 is a critical year as we continue to assess the long-term viability of our exchange footprint. We will continue to closely monitor this business, and if we do not see clear evidence of an improving environment and a path towards sustainability in the marketplace, we will likely modify our strategy in 2018. We believe both the pricing and regulatory environment need to be improved to drive toward a sustainable and affordable marketplace over the long term. 
Relating to National Accounts, which typically encompass the most sophisticated purchasers of coverage, we're pleased that the team continues to secure wins contributing to the track record of membership growth in 2017. We have added 602,000 lives so far in 2016, building on the growth of over 900,000 lives during the previous 2 years. 
And now turning to our 2016 financial outlook. Our third quarter results were largely in line with the expectations we laid out during our last quarter call. We expect our full year 2016 GAAP earnings per share to be approximately $9.28, including approximately $1.52 of negative adjustment items. On an adjusted basis, we expect earnings per share to be approximately $10.80. 
We now expect our 2016 operating revenue to be approximately $83.5 billion, which is at the high end of our previously guided range, reflecting the impact of slightly better enrollment trends during the quarter. 
Fully insured membership is expected to be in the range of 15 million to 15.1 million members or 50,000 higher than our previous outlook, which reflects stronger than previously expected results in the Commercial business. Self-funded membership is expected to be 24.7 million, members which is at the midpoint of our range, unchanged from our previous outlook. Taken together, we're now projecting total membership growth of just over 1.1 million lives at the midpoint of our range versus where we ended in 2015. 
Consistent with our expectations last quarter, we expect our medical loss ratio to be in the range of 84.9%, plus or minus 30 basis points; the SG&A ratio to be 14.5%, plus or minus 30 basis points; and operating cash flow to be approximately $3 billion. We continue to expect 2016 Local Group medical cost trends to be in the range of 7% to 7.5%. 
Our 2016 outlook continues to not include any benefit from the impact of share repurchase activity for the remainder of the year. As a reminder, we did not repurchase any shares through the first 9 months of 2016. 
It is important to note that our 2016 outlook does not include any additional benefits or transaction costs associated with the pending acquisition of Cigna beyond those incurred in the first 9 months of 2016, nor does it include any benefit from lower pharmaceutical pricing, which we continue to believe we are entitled to under our current contract with ESI. 
I will now turn the call over to John to discuss some key financial metrics and our initial thoughts on headwinds and tailwinds for 2017. John?"
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Joe, and good morning. As Joe stated, our third quarter results were very consistent with the expectations we laid out last quarter. In order to provide you a bit more clarity on our performance, I will highlight some of our key financial metri",656,"Thank you, Joe, and good morning. As Joe stated, our third quarter results were very consistent with the expectations we laid out last quarter. In order to provide you a bit more clarity on our performance, I will highlight some of our key financial metrics. 
First, I'd like to discuss the balance sheet. Consistent with our past practice, we have included a roll-forward of our medical claims payable balance in this morning's press release. 
For the 9 months ended September 30, 2016, we experienced favorable prior year reserve development of $773 million, which was moderately better than our expectations. We continue to be at the upper end of our range of mid to high single-digit margins for adverse deviation and believe our reserve balances remained consistent and strong as of September 30, 2016. Our Days in Claims Payable was 40.6 days as of September 30, unchanged from the 40.6 days we reported last quarter. As previously discussed and consistent with our expectations, this metric has trended down over the past year, and we expect Days in Claims Payable to be around 40 days over time. 
Our debt to cap ratio was 38.7% as of September 30, down 40 basis points from the 39.1% at the end of the second quarter, which reflects the impact of an increase in shareholder equity, as we did not repurchase any stock during the quarter. 
We ended the third quarter with approximately $2.1 billion of cash and investments at the parent company, and our investment portfolio was in an unrealized gain position of approximately $983 million as of the end of the quarter. 
For the 3Rs, we continue to book reinsurance as appropriate and continue to reflect a net receivable position for risk adjusters. We also continue our conservative posture of recording a 100% valuation allowance against any unpaid receivables for the 2014, the 2015 and the 2016 benefit years for risk corridors. 
Moving on to cash flow. We reported operating cash flow of approximately $2.9 billion or 1.4x net income during the first 9 months of 2016. During the quarter, we reported operating cash flow of $964 million, which was 1.6x net income. These results include the receipt of a CMS Medicare prepayment of approximately $650 million during the third quarter. Through the full year of 2016, we continue to expect operating cash flows to be approximately $3 billion. We used $171 million during the quarter for our cash dividend. And yesterday, the Audit Committee declared our fourth quarter 2016 dividend of $0.65 per share to shareholders. 
Now turning to 2017. We are currently working through our planning process and analyzing the impact of various expected headwinds and tailwinds. Our current view of the tailwinds include: Number one, enrollment gains across Medicaid, Medicare and National and Large Group self-funded businesses; two, margin improvement due to improving results in our individual ACA-compliant plans, the Iowa Medicaid contract and the impact of the 1-year health insurer fee moratorium in 2017; and three, we expect to resume capital deployment activity in 2017, however, the timing and magnitude is dependent on the timing of the pending Cigna acquisition. 
Potential headwinds include: The return of a 2017 onetime administrative expense cuts that we made in 2016; the impact of lower Local Group enrollment and gross margin pressures as a result of the migration towards ACA-compliant product offerings; and finally, we expect to experience continued pressure in the Medicaid business, primarily driven by rate actions within the Medicaid expansion population over the next year. 
Taken together, these items are expected to represent modest earnings growth from 2016. 
As part of our planning process, we will continue to be focused on identifying steps to maximize our opportunities to drive improved earnings growth over time. We expect to provide more details around our 2017 outlook on our fourth quarter conference call. 
With that, I'm going to turn the call back over to Joe to discuss our longer-term outlook."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, John. 3 years ago, we laid out our plan for growth, which reflected our strategy to capitalize on the substantial opportunities in the government business while recognizing the changing nature of the commercial marketplace as a result of the im",731,"Thank you, John. 3 years ago, we laid out our plan for growth, which reflected our strategy to capitalize on the substantial opportunities in the government business while recognizing the changing nature of the commercial marketplace as a result of the implementation of the Affordable Care Act. Our plan was to establish a leadership position in the Medicaid market, stabilize our Medicare Advantage platform and grow individual ACA-compliant and ASO enrollment to mitigate the expected pressure in the Local Group fully insured segment. 
Since that time we've been pleased with the growth in our Medicaid business, where enrollment has grown 47% since 2013. And we're well positioned to capitalize on the $81 billion pipeline of opportunity between now and 2021 that I mentioned earlier. In addition, we have reconfigured and upgraded our Medicare platform, as evidenced by the improvement in our margin profile and STAR rating performance. We expect to leverage our upgraded Medicare platform to grow MA enrollment in 2017 and beyond. 
Overall, the government business segment has grown nicely and now represents 54% of our consolidated company revenue, up from 44% in 2013. And we remain very optimistic about continued growth potential in this business. 
Switching to individual. As we've discussed previously, the earnings contribution from the individual ACA-compliant business represents a meaningful headwind to our original targets. The volume shortfall from our previous expectation remains substantial. 
For your reference, we laid out a plan to grow individual ACA-compliant enrollment to 3 million members by 2018 using the assumption that the overall individual marketplace would be approximately 25 million members, in line with CBO estimates. In 2016, the overall marketplace is about half of the expected size and has only grown to roughly 10 million to 11 million members. And subsequently, we have grown our individual ACA-compliant enrollment to approximately 1.4 million members as of the third quarter of 2016. We're closely monitoring the progress of our actions to improve the margin profile of this business toward our low to mid-single-digit margin targets of 2018. 
In our self-funded business, we've added 4.4 million members since 2013, as our value proposition has resonated with large employers who are focused on quality and affordability. This ASO growth has helped mitigate some of the pressure from higher-than-expected declines in our Local Group insured enrollment. 
Across our Commercial segment overall, we are generally pleased with our aggregate enrollment growth, but the mix of enrollment has skewed more than expected to self-funded than fully insured, pressuring revenue and earnings growth. Looking ahead, we still have meaningful opportunity to improve the per-member EBITDA contribution from ASO by increasing the penetration of our specialty and other product offerings to help further offset the pressures in Local Group. 
I want to spend a few moments on the pending acquisition of Cigna. We're committed to this combination which will further Anthem's vision to be America's valued health partner. This is truly a compelling opportunity to positively impact the health and well-being of our members and advance our commitment to expand access to high-quality, affordable health care for consumers. It will also save consumers more than $2 billion of medical cost annually, directly benefiting the most vulnerable populations in the country. 
I also would like to briefly address the upcoming trial with the Department of Justice, which will begin on November 21. We continue to believe the DOJ's action to sue to block the acquisition is based on a flawed analysis and a misunderstanding of the dynamic competitive and heavily regulated health care landscape, and we're fully committed to challenging the DOJ's decision in court. 
In terms of the court proceeding, the judge has decided to bifurcate the issues and will first hear evidence on the National Accounts issue. If the judge decides in our favor on the National Account issue, we will then move forward and try the other 2 remaining issues, with the decision on those issues being rendered before the end of January. 
To summarize, we are in the process of updating our long-term growth plan and expect target improved core earning growth rates beyond 2017. The individual ACA-compliant headwinds in our enrollment mix discussed previously represent a meaningful challenge to achieving our $14 earnings target in 2018. And we expect to provide additional clarity around our long-term growth prospects after the Cigna transaction process is complete. 
With that, operator, please open the queue for questions."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","[Operator Instructions] And our first question will come from the line of Ana Gupte from Leerink Partners.",17,"[Operator Instructions] And our first question will come from the line of Ana Gupte from Leerink Partners."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","My question was about the individual book. You said that there were losses this year and they continued into the quarter. Sequentially speaking, what were the losses in -- that you estimated in second quarter? And have they gone up since then? And why are",68,"My question was about the individual book. You said that there were losses this year and they continued into the quarter. Sequentially speaking, what were the losses in -- that you estimated in second quarter? And have they gone up since then? And why are you expecting that will improve next year, when the reinsurance rate case [ph] is out. Are you getting any pricing to do that?"
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Ana, this is John. So thank you for the question. Associated with our individual exchange business, we certainly did, in the second quarter, indicate losses, and we expect that our operating margins are going to be on the mid-single-digit loss for the yea",215,"Ana, this is John. So thank you for the question. Associated with our individual exchange business, we certainly did, in the second quarter, indicate losses, and we expect that our operating margins are going to be on the mid-single-digit loss for the year. Now during the third quarter, the reserve development was okay. The trend has been moderated a bit. And we still expect there's losses in the same general range of what we said, maybe just a little bit better than we had indicated. In terms of 2017, reinsurance is obviously a very important factor, but it's only one aspect of pricing and one aspect of the overall structure of the program. We've got rate increases that average in excess of 20% across the country. I think there's been studies that have been published that have stated that our rate increases are a little bit higher than the average rate increases. We've made adjustments to product offerings. We've changed networks. We've enhanced product designs. We've done many, many things to improve affordability of the specific product mix. So we feel very good about the previous guidance that we provided, that we're really targeting a small profit margin in 2017 and then returning to more -- closely related to target margins in 2018 and beyond."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question is from Christine Arnold from Cowen.",10,"And our next question is from Christine Arnold from Cowen."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","A couple of things. On Iowa, your language there suggests that you got a rate increase, but it may not be adequate; and that you're disciplined, you're going to be in markets that are actuarially sound. Is there an out to get out of that if, in fact, we c",88,"A couple of things. On Iowa, your language there suggests that you got a rate increase, but it may not be adequate; and that you're disciplined, you're going to be in markets that are actuarially sound. Is there an out to get out of that if, in fact, we can't get to actuarially sound rates? And then with respect to individual, what do you think you need to see in order to feel that there's sustainability into '18? What legislatively or administratively do you want to see there?"
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Christine, this is Joe Swedish. Yes, first question regarding, I guess, the out possibilities. As you know, the contract went live earlier this year, and obviously, we're very concerned because it has experienced a deterioration that certainly exceeded ou",275,"Christine, this is Joe Swedish. Yes, first question regarding, I guess, the out possibilities. As you know, the contract went live earlier this year, and obviously, we're very concerned because it has experienced a deterioration that certainly exceeded our forecast expectations regarding the medical loss ratio. We are in the process of having deep discussions with the state regarding the possibility of adjustments. I commented in our discussions just a moment ago that we have realized some positive effect from that discussion. And quite frankly, we're hoping for more. Unfortunately, the recent rate increase is still inadequate, and again, we're hoping for a better outcome with respect to more discussion. With respect to the legal construct of the contract, we are examining our position. We quite frankly, are awaiting the state to respond to the inquiries that we've submitted to them. And I think it's a little early for us to maybe put commentary out regarding our legal position, given the fact that there's still administrative considerations that are working their way through the system. And we're hopeful for a very positive outcome at the end of that review. We are concerned about the actuarial soundness of the rates. And that's been expressed by all the MCOs from the get go. We are engaged in an extensive process of meetings, as I mentioned. And we'll continue to be deeply concerned until we get a resolution to this. And then we'll weigh our options with respect to the endpoint of those negotiations with the state. I think the second question dealt with the exchange, Christine. I wonder if you could restate that for me, I'm sorry."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","One moment please.",3,"One moment please."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","[Audio Gap] and then it sounded like your language suggests that if '17 doesn't go well, you could change your strategy for '18. What do you need to see administratively or legislatively in order to fix this and in order for you to feel that this is where",54,"[Audio Gap] and then it sounded like your language suggests that if '17 doesn't go well, you could change your strategy for '18. What do you need to see administratively or legislatively in order to fix this and in order for you to feel that this is where you're going to stay for '18?"
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Great. Well, on or about midyear '17, obviously, we'll maybe coming to a conclusion on our review about how the adjustments have played out that we're expecting. To you point, what we're looking for are a variety of fixes, such as elimination of the healt",266,"Great. Well, on or about midyear '17, obviously, we'll maybe coming to a conclusion on our review about how the adjustments have played out that we're expecting. To you point, what we're looking for are a variety of fixes, such as elimination of the health insurance tax or at least extending the 2017 moratorium. Another one that you probably heard quite a bit about is updating the risk adjustment model substantially to address existing imbalance that we believe deteriorates the overall risk pool. We are also looking at additional adjustments to special enrollment periods, which we believe the -- needs to be continually narrowed with respect to the variety and number of special enrollments. We also believe that we need to have the flexibility to develop innovative products that should go to market to meet our -- the needs of our customers. Modify the grace period is another great example. And finally, we want to work very closely with the states to ensure actuarially justified rates being approved. Now what I just specified for you, let me just put a characterization to it that I think is very, very important. And that is, this is a specific recipe for solutions, and we believe these recipe characteristics represent the form of long-term sustainable and affordable marketplace. So as I said earlier in my commentary, we believe we must see adjustments such that we can easily map to a 2018 situation of sustainability in this marketplace. And quite frankly, given what may or may not happen, we'll be evaluating the regional engagement across our markets moving into 2018."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","And Joe, I'd just like to say, obviously, everything there is very appropriate, but Christine, we will be watching margins trends performance on a state-by-state and region-by-region basis in 2017 as well. So certainly, the decision in '18 could be a piec",49,"And Joe, I'd just like to say, obviously, everything there is very appropriate, but Christine, we will be watching margins trends performance on a state-by-state and region-by-region basis in 2017 as well. So certainly, the decision in '18 could be a piecemeal decision as opposed to an all-together decision."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. I think thus far, we've been very surgical in our approach, and we'll continue that theme. And so again, we have hope that the sustainability that's expected and commented on quite a bit by leadership of administration actually will occur during the",47,"Yes. I think thus far, we've been very surgical in our approach, and we'll continue that theme. And so again, we have hope that the sustainability that's expected and commented on quite a bit by leadership of administration actually will occur during the early stages of 2017."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question is from A.J. Rice from UBS.",11,"And our next question is from A.J. Rice from UBS."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","I just want to follow up. I appreciate the comments on the headwinds and tailwinds and the comment about modest growth. I guess the 3 variables I just want to throw on the table, you're saying you'll go from a mid-single digit loss on the exchanges, or in",146,"I just want to follow up. I appreciate the comments on the headwinds and tailwinds and the comment about modest growth. I guess the 3 variables I just want to throw on the table, you're saying you'll go from a mid-single digit loss on the exchanges, or in the individual book, to a positive. We got, I guess, about -- that would represent, I think, about a $0.70 swing, roughly 6% to 7% growth in and of itself. I just also wondered, are you including anything in your comments about capital deployment when you talk about modest growth? Or anything on the PBM? And what's the latest thinking on that? And then just to make sure the $10.80 is the base line number upon which you're assuming modest growth. Or is it some other number that you would adjust for as the starting point for '16?"
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure, no, A.J. Thank you for the question. And in terms of capital, we do expect to resume capital deployment in 2017. However, that won't be until after the pending Cigna acquisition process is completed. And so the timing and the magnitude of that",135,"Yes, sure, no, A.J. Thank you for the question. And in terms of capital, we do expect to resume capital deployment in 2017. However, that won't be until after the pending Cigna acquisition process is completed. And so the timing and the magnitude of that capital deployment is still somewhat of an unknown. Associated with the starting point, yes, very clearly, $10.80, we believe, is the appropriate starting point. That's our guidance. That's been our expectation now for some time. And that's our 2016 -- approximately $10.80 is our 2016 guidance number. Yes. And then of course, you have the tailwinds that offset that. But in terms of the PBM, we don't have any of the upside baked in. I think, Joe, maybe some comments just about the PBM situation in general might be helpful."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. A.J., thanks for the question on that. As I've repeatedly stated, we're hopeful we can negotiate a settlement to our concerns or dispute. And I don't need to restate what we've said repeatedly about our perspective on our contractual rights, but let",189,"Yes. A.J., thanks for the question on that. As I've repeatedly stated, we're hopeful we can negotiate a settlement to our concerns or dispute. And I don't need to restate what we've said repeatedly about our perspective on our contractual rights, but let me say that we do believe that we're continually focused on improving the pharmacy pricing on behalf of our customers. We expect to issue a new RFP during the year, that's early 2017, to understand the impact of various pharmacy options available to us as we migrate to potential of a new agreement. And I have to underscore that it's critical that we engage with a really trusted partner with aligned interests in advancing cost-effectiveness and quality for our membership. We've -- I guess we've not ruled anyone in or out in this process of securing an RFP. And I think with respect to any other comments made by ESI or others, we prefer not to comment on that. We do believe that a period of negotiations is still possible. And again, I'll underscore I'm hopeful that we can resolve our differences moving into the future."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from the line of Matt Borsch from Goldman Sachs.",13,"Our next question is from the line of Matt Borsch from Goldman Sachs."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Maybe on a slightly different topic. One of your peer companies has talked in considerable length about pressure in the small group ACA-compliant book. I know you've alluded to that some. Can you just give us an update on how you see that business? Maybe",73,"Maybe on a slightly different topic. One of your peer companies has talked in considerable length about pressure in the small group ACA-compliant book. I know you've alluded to that some. Can you just give us an update on how you see that business? Maybe break down in size and break down your small group between what's ACA-compliant? What's grandmothered, grandfathered? And how you see that transition happening, working going into next year?"
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure. Thank you for the question, very good question. And that really is a meaningful headwind and I think I did try to highlight it in the script. But in terms of other specificity of your question, we don't talk about a lot of this information for",142,"Yes, sure. Thank you for the question, very good question. And that really is a meaningful headwind and I think I did try to highlight it in the script. But in terms of other specificity of your question, we don't talk about a lot of this information for competitive reasons, but maybe 2/3 of our block is non-ACA-compliant today. The grandmothering expires here at the end of the year, and we fully expect to be very aggressive in pursuing and renewing that block of business. The margin aspect of it may be slightly different, slightly lower, as the ACA-compliant blocks typically have a slightly lower margin compression. But we'll ensure that we renew it at appropriate prices and have it to be a profitable business on a go-forward basis, but we did want to spike it out as a headwind in 2017."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Kevin Fischbeck with Bank of America.",11,"Our next question is from Kevin Fischbeck with Bank of America."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","I guess 2 questions. First, a clarification, you mentioned that as far as the Cigna lawsuit [indiscernible] 2 pieces, and that they're going to get National Accounts first. Just wondering if you have a time frame of when we'd hear that. But then specifica",81,"I guess 2 questions. First, a clarification, you mentioned that as far as the Cigna lawsuit [indiscernible] 2 pieces, and that they're going to get National Accounts first. Just wondering if you have a time frame of when we'd hear that. But then specifically, on the Medicaid business, it sounds like Iowa should get better next year, Medicaid expansion should get worse. Are you looking for net margin improvement or margin pressure on the Medicaid business as a whole in 2017?"
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. Let me just comment on the Cigna hearings. Beyond the December judicial process, which we're anticipating a decision sometime on or about mid-December, we would expect that moving forward from there, that's possible then a trial would begin shortly t",62,"Yes. Let me just comment on the Cigna hearings. Beyond the December judicial process, which we're anticipating a decision sometime on or about mid-December, we would expect that moving forward from there, that's possible then a trial would begin shortly thereafter, probably early January. And our hope is that, that would be resolved with a judicial decision by the end of January."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","And then on the Medicaid question, just provide a little clarity. So certainly, Iowa is going to be a tailwind in the 2017. Yes, we experienced significant upfront losses in Iowa. And even with rebalancing of the portfolio and retroactive rate increase, i",148,"And then on the Medicaid question, just provide a little clarity. So certainly, Iowa is going to be a tailwind in the 2017. Yes, we experienced significant upfront losses in Iowa. And even with rebalancing of the portfolio and retroactive rate increase, it's still -- we do not believe is actuarially sound. And the expectation is, is that there will be improvement in 2017. However, associated with the remainder of the Medicaid block, we are seeing some slight margin pressure. We were phenomenally successful the past couple of years with our margins. And specifically, our expansion margins have been very, very, very good. And then as those get repriced throughout the balance of the year, they're going to be repriced at more of a margin target ratio -- target profit ratio, I'm sorry. And that will create a bit of headwind or margin pressure for us in '17."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Justin Lake from Wolfe Research.",10,"Our next question is from Justin Lake from Wolfe Research."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","A couple of things. First, I remember back when we were going into the ACA and there was concerns around small group, you guys have put out a number of about a $400 million headwind for next year -- or for the coming couple of years in terms of small grou",173,"A couple of things. First, I remember back when we were going into the ACA and there was concerns around small group, you guys have put out a number of about a $400 million headwind for next year -- or for the coming couple of years in terms of small group margin pressure. Is there any way for you to do something similar here, just to give us an idea, that as you go through this repricing, is there a number you can point to, to say, here's -- it sounds like small group's going to be a pretty good pressure this year as expected, maybe a little larger than we thought. The -- is there a way to put a number on that for us? And then on SG&A, it's been shifting around a bit here. And wanted to get your thoughts for the fourth quarter and how we should think about this for 2017 when we add in the -- when we add back some of these onetime benefits this year."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Sure, Justin, great questions. The -- in terms of the small group, we're still working through it, and I really am hesitant to provide an answer until our planning process is done. And some of the grandmothering associated with the early renewals that exi",303,"Sure, Justin, great questions. The -- in terms of the small group, we're still working through it, and I really am hesitant to provide an answer until our planning process is done. And some of the grandmothering associated with the early renewals that exist, we actually have several of our -- many of our small group plans renewed early on December a couple of years ago in order to maintain the non-ACA-compliant plans. And could probably be premature to throw a number out until we've worked through that process. So we will update that and provide more clarity on our fourth quarter call. Associated with the general administrative expenses, I think maybe I'll just repeat sort of the commentary from last time. It's down quite substantially in 2016. And a little more than half of it is a good, sustainable run rate, meaningful decrease in SG&A expense. Has to do with more efficient processes, better performance in some of the administrative and core areas of the company. And we grew in our membership. We had a really good membership year from both a membership and premium prospective, raising guidance on that, and we're able to do that by maintaining our administrative expense levels. Obviously then, the ratio went down. The other half -- or a little less than the other half were more of onetime items, and those are nonsustainable. And the most significant part of those, other less than the other half is our incentive compensation plans. As we've stated, we're a pay-for-performance company, and we had our promises to Wall Street and what we expected earnings to be and we ensured that we delivered those earnings. And unfortunately, we had to lower our incentive compensation expense as part of that process. So a little less than half come back in 2017."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Michael Newshel from Evercore ISI.",10,"Our next question is from Michael Newshel from Evercore ISI."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Does your expectation for slight profitability in the ACA-compliant business next year assume that the national enrollment is going to be stable or growing? And how would you frame the downside risk to margins if enrollment declines and the risk pool dete",93,"Does your expectation for slight profitability in the ACA-compliant business next year assume that the national enrollment is going to be stable or growing? And how would you frame the downside risk to margins if enrollment declines and the risk pool deteriorates? And also, I mean, it looks like your relative pricing versus competitors is generally higher in 2017 than it was -- than it is this year after the price hikes and market exits, at least on HealthCare.gov. Do you think that provides you any buffer against adverse selection next year?"
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Well, there's quite a few questions in there. Hopefully, I can address and all of them. But maybe the most simple is that we expect that, overall, individual ACA-compliant membership on a national basis will be slightly down next year and that our members",183,"Well, there's quite a few questions in there. Hopefully, I can address and all of them. But maybe the most simple is that we expect that, overall, individual ACA-compliant membership on a national basis will be slightly down next year and that our membership will reflect that. We still have many, many competitors in our markets. I just do want to point out that some of the exits that have been a very widely publicized, very few of them impact our market specifically. So like, for instance, California still has 11 competitors, Virginia still has 8 competitors, just to rattle off a couple of our states. In terms of the risk pool, we believe that we understand the risk pool. We're very good at the individual marketplace. We're been #1 individual market carrier for years and years prior to the ACA. Our products are designed in such a way to really get a good risk pool that allows us to maximize on risk adjusters and then be a risk adjuster collector. So we feel good about our assumptions at this point in time."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Let me add that there are a few key points I think we really need to consider to keep in front. Number one, on average, our price point for targeted bronze, silver plans in the marketplace is higher than our competitors. We certainly recognize that and ac",250,"Let me add that there are a few key points I think we really need to consider to keep in front. Number one, on average, our price point for targeted bronze, silver plans in the marketplace is higher than our competitors. We certainly recognize that and acknowledge it. And while the number of competitors in our markets has declined overall versus 2016, for the most part, those declines are in less populated areas, such as the rural market, where we have had historically high market share. There's -- On the flip side, there's really still substantial competition across all of our markets, those served markets, most notably in these highly dense urban markets. And finally, some of the largest markets do not see any significant reduction in competition. For example, California still has 11 competitors, down 1 from last year. Virginia still has 8. Georgia still has 5. So we know we're in highly competitive markets and we believe we will compete very effectively. But again, I think we very effectively managed the price points with respect to the product that we've offered in the marketplace. And so we have a fairly good outlook, as John commented earlier in his remarks, about our expected margins. And as I said then follow on to that, we'll be evaluating our situation in those markets, all of our markets, through the beginning of the year to see how well we performed and how well the regulatory adjustments play out leading up to midyear."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Lance Wilkes from Sanford Bernstein.",10,"Our next question is from Lance Wilkes from Sanford Bernstein."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Just wanted to follow up on a question with respect to self-insurance margin strategy. Want to understand how the progress was going on, especially penetrations looking at 2017, and where your 2018 and beyond strategies were there. How much upside you saw",66,"Just wanted to follow up on a question with respect to self-insurance margin strategy. Want to understand how the progress was going on, especially penetrations looking at 2017, and where your 2018 and beyond strategies were there. How much upside you saw with respect to self-insurance margins. And then in particular right now with PBM, how does that fit into how you're looking at penetrations?"
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Great question. And certainly, that's one of our growth areas for the future as we look out into our long-term outlook. We believe that the opportunity to enhance the EBITDA associated with our ASO members is meaningful. We are developing -- we have ongoi",156,"Great question. And certainly, that's one of our growth areas for the future as we look out into our long-term outlook. We believe that the opportunity to enhance the EBITDA associated with our ASO members is meaningful. We are developing -- we have ongoing efforts to drive penetration in specialty products, various ancillary type products, other add-ons, that we think that we are underpenetrated right now and believe that we have an incredible amount of upside. We've been the #1 company in growing the ASO large group national membership over the last several years, and we've made quite a nice margin percentage on that business, but it's very small dollars. And so now the focus is to take the fact that we do have best-in-class discounts and the most sophisticated purchasers of coverage are picking us. And so now it's our opportunity to really penetrate that better and enhance the EBITDA associated with that membership block."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Gary Taylor from JPMorgan.",9,"Our next question is from Gary Taylor from JPMorgan."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Just a couple more questions on the individual business. First, I just wanted to follow up. I know you had just said you're anticipating exchange enrollment to decline heading into 2017. I know you also thought that would be the case heading into 2016. So",97,"Just a couple more questions on the individual business. First, I just wanted to follow up. I know you had just said you're anticipating exchange enrollment to decline heading into 2017. I know you also thought that would be the case heading into 2016. So is this a rate positioning, why you still believe that might play out in '17 versus what happened this year? And then just secondly, could you just comment on any PDRs used in the individual business this quarter and your experience with the special enrollment, period enrollment, this year versus last year?"
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Gary, great question. And 2016 was interesting because what we ended up seeing was a flight to safety, and that was one of the reasons that our 2016 individual exchange membership grew more than expectations. And so if we go backwards a year and then you",255,"Gary, great question. And 2016 was interesting because what we ended up seeing was a flight to safety, and that was one of the reasons that our 2016 individual exchange membership grew more than expectations. And so if we go backwards a year and then you look at the number of co-ops who are in our markets that failed, it was a significant impact on our membership. And then as those customers then went into the marketplace, they -- as I said, it was a flight to safety, they went for Blue. I think the real key difference in the expectations in '16 and the expectations in '17 is, really, the amount of exits within our markets of carriers and who the exits were and how much membership those that exited had. So long story short, the co-ops in certain markets were -- had extremely high market share and they went insolvent and their market share then was absorbed. Where in 2017, while we certainly have some exits of carriers in our markets, they do not have the breadth or the magnitude of the market share that the ones who exited a year ago had. Associated with the premium deficiency reserves, we have none recorded. We had none recorded in 2015. We have none recorded in 2016. It's a very easy question. Which means that our results are pure, our results are clean and that we don't have the puts and takes that maybe you have in some of the other companies that you're modeling."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Josh Raskin from Barclays.",9,"Our next question is from Josh Raskin from Barclays."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Question on the short term and long term. Short term, I heard the commentary, I think John, you said the results were very consistent with your expectations. And just looking at sort of the cadence of earnings, you saw some mid to high single digit growth",181,"Question on the short term and long term. Short term, I heard the commentary, I think John, you said the results were very consistent with your expectations. And just looking at sort of the cadence of earnings, you saw some mid to high single digit growth in the first half, a big decline in double-digit percentage on EPS in 3Q and now an expected increase back in 4Q. And so I guess, if that's all very expected, what changed this year from a seasonality perspective? And then on the long term, from a strategic perspective, when you guys announced the Cigna deal, and I know we're going back 1.5 years now, you talked about Cigna bringing commercial expertise and exposure to Medicare, the strong specialty and then the international segment. And so I'm curious kind of where those priorities sit today. And in the case that the judge disagrees with you guys and the transaction does not move forward, how do you guys think about the reaction? Is there a need for scale? Is there an appetite to do other stuff?"
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure, thank you. I'll take the first question and turn it over to Joe for the second. Yes, I did say that our results were very consistent with expectations. When you're looking at the seasonality of 2015 to 2016, yes, 2016 is a bit challenged. The M",153,"Yes, sure, thank you. I'll take the first question and turn it over to Joe for the second. Yes, I did say that our results were very consistent with expectations. When you're looking at the seasonality of 2015 to 2016, yes, 2016 is a bit challenged. The MLR is a little bit in the fourth quarter than it was last year. There's a lot of variables associated with that, clearly, the Iowa variable, the individual exchange variable. Please note that we do have the G&A offset that allows us to enjoy the growth in EPS year-over-year. But it's not that there is a significant change in seasonality patterns or a huge business flux as much as it was some of the very specific items that we pointed out to as headwinds for 2016 continue to be headwinds throughout the fourth quarter. On the -- I think Joe wants to address your Cigna question."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, let me take that for a moment, Josh. First of all, to your point about, call it, pivoting in the event of an adverse decision, we're going to focus very heavily on what we talked about earlier regarding our tailwinds, obviously, in the MA growth spac",141,"Yes, let me take that for a moment, Josh. First of all, to your point about, call it, pivoting in the event of an adverse decision, we're going to focus very heavily on what we talked about earlier regarding our tailwinds, obviously, in the MA growth space, very strong focus on our government business across the entire spectrum and a variety of other initiatives that I already mentioned. I think it's really important to underscore that we'll be coming to you at the time of that announcement, whatever, we will then share with you our outlook in terms of pivoting the company to tackle some of those opportunities, tailwinds, as well as, quite frankly, address the headwinds as robustly as we would anyway. But certainly, we believe ameliorating some of that risk would be a great opportunity to us as well."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, I would just add to that, that we believe that we have long-term sustainable growth opportunities regardless if the deal closes or not. Cigna may help accelerate those, but we're very confident about our future under either scenario.",39,"Yes, I would just add to that, that we believe that we have long-term sustainable growth opportunities regardless if the deal closes or not. Cigna may help accelerate those, but we're very confident about our future under either scenario."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from the line of Chris Rigg with Susquehanna Financial Group.",14,"Our next question is from the line of Chris Rigg with Susquehanna Financial Group."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","John, I know you commented earlier about the dynamic of compliant versus noncompliant in the small group book. But it looks like in the individual side, you still have about 27% of your membership that's noncompliant. Are most of those -- the plans for th",87,"John, I know you commented earlier about the dynamic of compliant versus noncompliant in the small group book. But it looks like in the individual side, you still have about 27% of your membership that's noncompliant. Are most of those -- the plans for the noncompliant individuals going to be in-force through -- or until December 2017? And then more of a macro question, do you guys have a sense for how many grandmothered -- how many people have grandmothered plans in your markets at this point?"
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, great question. First of all, in the compliant versus noncompliant, the majority of those will not be noncompliant through '17. So that the headwind, tailwind that I talked about with that, that would include both the small group and the individual c",125,"Yes, great question. First of all, in the compliant versus noncompliant, the majority of those will not be noncompliant through '17. So that the headwind, tailwind that I talked about with that, that would include both the small group and the individual commentary. In terms of how many grandmothering are in our markets, including what our competitors have, we actually do not have the specificity of that. But obviously, all the dynamics that we're experiencing and the changes in the laws, they're experiencing. So there's really not -- if your question is, is there an opportunity to get someone else's grandmothered business? The answer is really no. It would have to be -- we would have to give it as part of an ACA-compliant product."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from the line of Ralph Giacobbe from Citi.",12,"Our next question is from the line of Ralph Giacobbe from Citi."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","First, just wanted to clarify the comments on the exchange again. Joe, you mentioned 2017 as a critical year. And if there was no clear evidence, that you'd sort of modify your strategy in 2018. I mean, does that mean market exit or willingness to exit if",118,"First, just wanted to clarify the comments on the exchange again. Joe, you mentioned 2017 as a critical year. And if there was no clear evidence, that you'd sort of modify your strategy in 2018. I mean, does that mean market exit or willingness to exit if you're unprofitable again in 2017? And then also separately, I was hoping you could parse out the pressure from Iowa. I know one of your peers took a PDR in that book while you're absorbing the losses through the P&L. So just hoping to get a sense of margins, maybe magnitude of loss this year, and what the improvement would be next year, even on sort of the inadequate rate bump."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Great. Thanks. I will pivot the second part of the question to John so he can get into some of the technical aspects of it. But with respect to the first question, let me just underscore that, as I said a moment ago, we're going to be very surgical. Let m",130,"Great. Thanks. I will pivot the second part of the question to John so he can get into some of the technical aspects of it. But with respect to the first question, let me just underscore that, as I said a moment ago, we're going to be very surgical. Let me define market. There are those that define market to be state, but I want to be very clear that we deal with a significant array of regions. So we will look at both regional impact as well as state impact, and then make determinations with respect to what I call the surgical assessments and then decisions and execution that are necessary in order -- for prudent engagement in the marketplace. I believe that probably covers what you were asking."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Okay, yes. And then in terms of Iowa and the headwind for '16 which becomes a tailwind for '17 with the Medicaid block there. We did get a retroactive rate increase, unfortunately, we think it's still not actuarially justified. We really are not providing",136,"Okay, yes. And then in terms of Iowa and the headwind for '16 which becomes a tailwind for '17 with the Medicaid block there. We did get a retroactive rate increase, unfortunately, we think it's still not actuarially justified. We really are not providing an exact number at this point as we continue to work with the state and don't want to get out ahead of the state and negotiate this publicly. But just as Joe said, consistent with the individual exchange business, we need to partner with states that want to be partners. And we believe that we need actuarially justified rates. And if -- we will continue to negotiate it. We feel really good about that fact, but if we don't get it, then we'll have a decision to make in Iowa as well."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","And our last question this morning will come from the line of Peter Costa of please go ahead.",18,"And our last question this morning will come from the line of Peter Costa of please go ahead."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Just a couple of clarifications on things you said. You said you put out an RFP for your PBM in early 2017. So presumably, that means we'd see the answer some time in mid-2017. What sort of things have you going to be looking for besides the $3 billion in",76,"Just a couple of clarifications on things you said. You said you put out an RFP for your PBM in early 2017. So presumably, that means we'd see the answer some time in mid-2017. What sort of things have you going to be looking for besides the $3 billion in savings that you already talked about? And then are you specifically coming off the $100 billion revenue target that you set out in 2014 for 2018?"
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Why don't I do the second one first, Peter, while I've got the line. In terms of the headwinds, tailwinds for 2018 in Joe's commentary, it's highly unlikely that we would be able to achieve that number at this point in time. Just look at our guidance for",166,"Why don't I do the second one first, Peter, while I've got the line. In terms of the headwinds, tailwinds for 2018 in Joe's commentary, it's highly unlikely that we would be able to achieve that number at this point in time. Just look at our guidance for 2016 and roll that forward and roll our membership forward, it all boils down to the exchanges. And the CBO had estimated, what, 25 million, 26 million lives to be insured through the exchanges. When we did our 2018 plan, we relied on some of the CBO estimates as part of our estimation process. And we're still maintaining our market share. We still believe that we can hit the target margins that we had for those things. But when the entire country has just over 10 million versus that other, that's a significant delta, and that goes straight into our numbers. And I think you'll see that the revenue shortfall can be entirely explained with that dynamic."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, let me pick it up now regarding the PBM question. Yes, that RFP goes to market early 2017. I've said repeatedly that our intention is to be able to deliver to you a solution with respect to ongoing analytics, which obviously, in the current state, is",122,"Yes, let me pick it up now regarding the PBM question. Yes, that RFP goes to market early 2017. I've said repeatedly that our intention is to be able to deliver to you a solution with respect to ongoing analytics, which obviously, in the current state, is significantly impacted by our discussions, and then of course potential legal proceedings with ESI. We're hopeful to bring you a meaningful commentary and maybe solution by the end of 2017. We've never diverged from that commitment, and our hope is that we certainly will be able to put all the parts and pieces together to give you clarity and around the decisions we're going to execute specific to the termination of the contract by 2019."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Thank you, and please go ahead with any closing remarks.",10,"Thank you, and please go ahead with any closing remarks."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Well, again, thank you, everybody, for your questions. They're always very, very good. As a company, we do remain committed to tackling our health care system challenges head on, as evidenced by the work that we've communicated to you today. And we beli",146,"Well, again, thank you, everybody, for your questions. They're always very, very good. 
As a company, we do remain committed to tackling our health care system challenges head on, as evidenced by the work that we've communicated to you today. And we believe that we can and will deliver greater value to consumers by expanding access to high-quality affordable health care, and we've stood that -- by that repeatedly. This is why we are committed to challenging the DOJ's recent decision to block Anthem's acquisition of Cigna in court. 
Speaking to my associates, I want to also thank all of them for their continued commitment to serving our nearly 40 million members every day. 
To all of you on the phone, please accept our thanks for your interest in Anthem, and we look forward to speaking with you soon at upcoming conferences. Have a great day."
160077,324533304,1069778,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Thank you. And ladies and gentlemen, this conference will be made available for replay after 11:00 a.m. today through November 16. You may access the AT&T Executive Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378818.",71,"Thank you. And ladies and gentlemen, this conference will be made available for replay after 11:00 a.m. today through November 16. You may access the AT&T Executive Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378818. International participants can dial (320) 365-3844. 
That does conclude our conference for today. Thank you for your participation and for using AT&T Executive TeleConference. You may now disconnect."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Anthem Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management.",39,"Ladies and gentlemen, thank you for standing by, and welcome to the Anthem Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded. 
I would now like to turn the conference over to the company's management."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Good morning, and welcome to Anthem's Third Quarter of 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish; Chairman, President and CEO; and John Gallina, our CFO. Joe will offer an overview",198,"Good morning, and welcome to Anthem's Third Quarter of 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish; Chairman, President and CEO; and John Gallina, our CFO. Joe will offer an overview of our third quarter 2016 results and our updated 2016 full year outlook. Then John will walk through the financial details and provide some incremental commentary on 2017 before Joe closes with some longer-term strategic commentary. We will then be available for Q&A. 
During the call, we will reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website at antheminc.com. 
We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Anthem. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in today's press release and in our quarterly and annual filings with the SEC. 
I will now turn the call over to Joe."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Doug, and good morning. This morning, we announced third quarter 2016 GAAP earnings per share of $2.30. Adjusted earnings per share was $2.45, consistent with our previous expectations. Within membership, we continue to post strong fully insu",1656,"Thank you, Doug, and good morning. This morning, we announced third quarter 2016 GAAP earnings per share of $2.30. Adjusted earnings per share was $2.45, consistent with our previous expectations. 
Within membership, we continue to post strong fully insured and self-funded enrollment results, as we ended the third quarter with over 39.9 million members. We grew an additional 160,000 lives during the quarter, bringing our year-to-date enrollment growth to 1.3 million lives or 3.4%. Specifically, insured enrollment increased by 39,000 lives during the quarter, as our Medicaid business grew by 81,000 lives to over 6.4 million members. Since closing the Amerigroup transaction in 2012, we've grown Medicaid enrollment by nearly 1.9 million lives, or 41%, including growth of approximately 800,000 lives from Medicaid expansion. 
Within Commercial, our insured enrollment came in slightly ahead of expectations, as Local Group fully insured membership tracked well, particularly in the large group marketplace. Our public exchange enrollment declined by a less-than-expected 34,000 during the quarter to 889,000 lives. Our self-funded business increased by 121,000 during the quarter, reflecting the impact of enrollment growth from existing accounts and recently awarded contracts. 
Our solid membership results during the year translated into better than expected operating revenue of $21.1 billion during the quarter, an increase of $1.4 billion or 6.8% versus third quarter of 2015. The increase reflects the strong enrollment growth in the government business and additional premium revenue to cover overall cost trends. Additionally, administrative fee revenue grew by 6.4% versus the prior year quarter as a result of our strong self-funded membership trends. These increases were partially offset by fully insured membership losses in our Commercial business. 
The third quarter 2016 benefit expense ratio was in line with our previous expectations at 85.5%, an increase of 190 basis points versus the prior year. The year-over-year increase was primarily driven by the Medicaid business, as higher-than-expected medical cost experience, notably in Iowa, has exceeded the net impact of annual premium rate adjustments made over the last 12 months. In addition, it reflects the impact of growth in membership, as the Medicaid business carries a higher benefit expense ratio than the consolidated company average. Further, the benefit expense ratio reflects the impact of higher medical cost experience in the Individual business. These increases were partially offset by the timing of lower medical cost experience in the Local Group business. 
Our SG&A expense ratio was also in line with expectations at 14.8% in the third quarter, a decrease of 80 basis points from the third quarter of 2015. The decrease was driven by an intentional focus on administrative expense control coupled with better than expected enrollment trends, as well as the changing mix of our membership towards the government business, which carries a lower than the consolidated average SG&A ratio. 
Turning to discuss the third quarter financial performance of our business units. In the government business, we added 92,000 members during the quarter and grew year-over-year revenue by 10.9% to nearly $11.5 billion. As a reminder, our third quarter results include the impact of the addition of the Iowa contract, which was implemented on April 1. Operating margins for the government business were 4.2% during the third quarter, a decline of 190 basis points versus the prior year quarter, driven by lower gross margins in the Medicaid business. 
As we communicated previously, we've been expecting Medicaid margins to compress from 2015 levels due to rate actions. In addition, we've been experiencing higher-than-expected claims across the Medicaid business in the current year, including materially higher-than-expected costs in the recently implemented Iowa contract. As expected, there was a rebalancing of funding based on risk pool during the quarter. In addition, we've been informed of a retroactive rate increase which extends through June 2017, when rates will again be adjusted. 
Unfortunately, the recent rate increase is still inadequate, given the claims experience to date. We remain confident we can make a meaningful impact by improving the cost and quality of care in Iowa as we've done for our other state partners. However, we will remain disciplined and only participating in markets where we receive rates that are actuarially sound. 
Within Medicare, we're pleased with the progress the team continues to make, and our year-to-date margins reflect continued improvement. During the quarter, CMS announced we earned Medicare STAR quality ratings for 2017 consistent with our long-term strategy. In the most recent ratings released by CMS, 51% of Anthem's Medicare Advantage members will be enrolled in plans that achieve 4 stars or higher. This accomplishment represents significant growth from the 22% of MA members in 4-star plans last year. The improvement is the direct result of investments made in the Medicare program over the past 3 years. 
Our 2016 outlook continues to expect margins to improve as the year progresses towards our expected long-range sustainable level. As we've stated since our MA restructuring began, we have positioned our portfolio to grow MA in 2017. 
The pipeline of opportunity for our Medicaid business remains substantial, with an updated estimate of $81 billion in contracts to be awarded between now and 2021 in markets that we will consider targeting. Approximately 3/4 of this opportunity is in new and specialized services with the remainder in traditional Medicaid services. We continue to believe our experience, targeted investments and critical capabilities and geographic footprint positions us very well to continue our growth as we help states address the challenges of rising health care costs and improving quality for their residents. 
Switching to our Commercial business. Our enrollment increased by 68,000 lives during the quarter, which was slightly better than our previous expectations. Specifically, we experienced growth of 171,000 lives in our Local Group business, partially offset by declines of 48,000 and 54,000 lives in our national and Individual businesses, respectively. These results translated into better than previously expected operating revenue of $9.7 billion, representing growth of 2.4%. 
Our third quarter operating margin of 6.6% was flat versus the third quarter of 2015. Commercial operating margins during the quarter reflected a lower SG&A ratio due to lower administrative costs resulting from expense efficiency initiatives taken by the company, as well as fixed cost leverage on a growing membership base. In addition, our Commercial business experienced the favorable timing impact of lower medical cost experience in the Local Group business. These increases were offset by higher medical cost experience in our Individual ACA-compliant products. 
Within our Individual ACA-compliant plans, costs during the third quarter were marginally better than recent expectations, which is reassuring. We continue to experience higher than initially expected costs for members with chronic conditions, as we have discussed with you previously. Overall, the financial performance in Individual ACA-compliant products has been disappointing, as membership has been short of our original expectations since its inception and operating margins have been lower than expected beginning in 2015. 
We believe we've taken the appropriate actions across our served markets to return to slight profitability in 2017. Clearly, 2017 is a critical year as we continue to assess the long-term viability of our exchange footprint. We will continue to closely monitor this business, and if we do not see clear evidence of an improving environment and a path towards sustainability in the marketplace, we will likely modify our strategy in 2018. We believe both the pricing and regulatory environment need to be improved to drive toward a sustainable and affordable marketplace over the long term. 
Relating to National Accounts, which typically encompass the most sophisticated purchasers of coverage, we're pleased that the team continues to secure wins contributing to the track record of membership growth in 2017. We have added 602,000 lives so far in 2016, building on the growth of over 900,000 lives during the previous 2 years. 
And now turning to our 2016 financial outlook. Our third quarter results were largely in line with the expectations we laid out during our last quarter call. We expect our full year 2016 GAAP earnings per share to be approximately $9.28, including approximately $1.52 of negative adjustment items. On an adjusted basis, we expect earnings per share to be approximately $10.80. 
We now expect our 2016 operating revenue to be approximately $83.5 billion, which is at the high end of our previously guided range, reflecting the impact of slightly better enrollment trends during the quarter. 
Fully insured membership is expected to be in the range of 15 million to 15.1 million members, or 50,000 higher than our previous outlook, which reflects stronger than previously expected results in the Commercial business. Self-funded membership is expected to be 24.7 million members, which is at the midpoint of our range, unchanged from our previous outlook. Taken together, we're now projecting total membership growth of just over 1.1 million lives, at the midpoint of our range versus where we ended in 2015. 
Consistent with our expectations last quarter, we expect our medical loss ratio to be in the range of 84.9%, plus or minus 30 basis points; the SG&A ratio to be 14.5%, plus or minus 30 basis points; and operating cash flow to be approximately $3 billion. We continue to expect 2016 Local Group medical cost trends to be in the range of 7% to 7.5%. 
Our 2016 outlook continues to not include any benefit from the impact of share repurchase activity for the remainder of the year. As a reminder, we did not repurchase any shares through the first 9 months of 2016. 
It is important to note that our 2016 outlook does not include any additional benefits or transaction costs associated with the pending acquisition of Cigna beyond those incurred in the first 9 months of 2016, nor does it include any benefit from lower pharmaceutical pricing, which we continue to believe we are entitled to under our current contract with ESI. 
I will now turn the call over to John to discuss some key financial metrics and our initial thoughts on headwinds and tailwinds for 2017. John?"
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Joe, and good morning. As Joe stated, our third quarter results were very consistent with the expectations we laid out last quarter. In order to provide you a bit more clarity on our performance, I will highlight some of our key financial metri",656,"Thank you, Joe, and good morning. As Joe stated, our third quarter results were very consistent with the expectations we laid out last quarter. In order to provide you a bit more clarity on our performance, I will highlight some of our key financial metrics. 
First, I'd like to discuss the balance sheet. Consistent with our past practice, we have included a roll-forward of our medical claims payable balance in this morning's press release. 
For the 9 months ended September 30, 2016, we experienced a favorable prior year reserve development of $773 million, which was moderately better than our expectations. We continue to be at the upper end of our range of mid to high single-digit margins for adverse deviation and believe our reserve balances remained consistent and strong as of September 30, 2016. Our Days in Claims Payable was 40.6 days as of September 30, unchanged from the 40.6 days we reported last quarter. As previously discussed and consistent with our expectations, this metric has trended down over the past year, and we expect Days in Claims Payable to be around 40 days over time. 
Our debt-to-cap ratio was 38.7% as of September 30, down 40 basis points from the 39.1% at the end of the second quarter, which reflects the impact of an increase in shareholder equity, as we did not repurchase any stock during the quarter. 
We ended the third quarter with approximately $2.1 billion of cash and investments at the parent company, and our investment portfolio was in an unrealized gain position of approximately $983 million as of the end of the quarter. 
For the 3Rs, we continue to book reinsurance as appropriate and continue to reflect a net receivable position for risk adjusters. We also continue our conservative posture of recording a 100% valuation allowance against any unpaid receivables for the 2014, the 2015 and the 2016 benefit years for risk corridors. 
Moving on to cash flow. We reported operating cash flow of approximately $2.9 billion, or 1.4x net income, during the first 9 months of 2016. During the quarter, we reported operating cash flow of $964 million, which was 1.6x net income. These results include the receipt of a CMS Medicare prepayment of approximately $650 million during the third quarter. For the full year of 2016, we continue to expect operating cash flows to be approximately $3 billion. We used $171 million during the quarter for our cash dividend, and yesterday, the Audit Committee declared our fourth quarter 2016 dividend of $0.65 per share to shareholders. 
Now turning to 2017. We are currently working through our planning process and analyzing the impact of various expected headwinds and tailwinds. Our current view of the tailwinds include: Number one, enrollment gains across Medicaid, Medicare and National and Large Group self-funded businesses; two, margin improvement due to improving results in our Individual ACA-compliant plans, the Iowa Medicaid contract and the impact of the 1-year health insurer fee moratorium in 2017; and three, we expect to resume capital deployment activity in 2017, however, the timing and magnitude is dependent on the timing of the pending Cigna acquisition. 
Potential headwinds include: The return of the 2017 onetime administrative expense cuts that we made in 2016; the impact of lower Local Group enrollment and gross margin pressures as a result of the migration towards ACA-compliant product offerings; and finally, we expect to experience continued budgeting pressure in the Medicaid business, primarily driven by rate actions within the Medicaid expansion population over the next year. 
Taken together, these items are expected to represent modest earnings growth from 2016. 
As part of our planning process, we will continue to be focused on identifying steps that maximize our opportunities to drive improved earnings growth over time. We expect to provide more details around our 2017 outlook on our fourth quarter conference call. 
With that, I'm going to turn the call back over to Joe to discuss our longer-term outlook."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, John. Three years ago, we laid out our plan for growth, which reflected our strategy to capitalize on the substantial opportunities in the government business while recognizing the changing nature of the commercial marketplace as a result of th",735,"Thank you, John. Three years ago, we laid out our plan for growth, which reflected our strategy to capitalize on the substantial opportunities in the government business while recognizing the changing nature of the commercial marketplace as a result of the implementation of the Affordable Care Act. Our plan was to establish a leadership position in the Medicaid market, stabilize our Medicare Advantage platform and grow Individual ACA-compliant and ASO enrollment to mitigate the expected pressure in the Local Group fully insured segment. 
Since that time, we've been pleased with the growth in our Medicaid business, where enrollment has grown 47% since 2013. And we are well positioned to capitalize on the $81 billion pipeline of opportunity between now and 2021 that I mentioned earlier. In addition, we have reconfigured and upgraded our Medicare platform, as evidenced by the improvement in our margin profile and STAR rating performance. We expect to leverage our upgraded Medicare platform to grow MA enrollment in 2017 and beyond. 
Overall, the government business segment has grown nicely and now represents 54% of our consolidated company revenue, up from 44% in 2013. And we remain very optimistic about continued growth potential in this business. 
Switching to Individual. As we've discussed previously, the earnings contribution from the Individual ACA-compliant business represents a meaningful headwind to our original targets. The volume shortfall from our previous expectation remains substantial. 
For your reference, we laid out a plan to grow Individual ACA-compliant enrollment to 3 million members by 2018 using the assumption that the overall Individual marketplace would be approximately 25 million members, in line with CBO estimates. In 2016, the overall marketplace was about half of the expected size and has only grown to roughly 10 million to 11 million members. And subsequently, we have grown our Individual ACA-compliant enrollment to approximately 1.4 million members as of the third quarter of 2016. We are closely monitoring the progress of our actions to improve the margin profile of this business toward our low to mid-single-digit margin targets of 2018. 
In our self-funded business, we've added 4.4 million members since 2013 as our value proposition has resonated with large employers who are focused on quality and affordability. This ASO growth has helped mitigate some of the pressure from higher-than-expected declines in our Local Group insured enrollment. 
Across our Commercial segment overall, we are generally pleased with our aggregate enrollment growth, but the mix of enrollment has skewed more than expected to self-funded than fully insured, pressuring revenue and earnings growth. Looking ahead, we still have meaningful opportunity to improve the per-member EBITDA contribution from ASO by increasing the penetration of our Specialty and other product offerings to help further offset the pressures in Local Group. 
I want to spend a few moments on the pending acquisition of Cigna. We are committed to this combination which will further Anthem's vision to be America's valued health partner. This is truly a compelling opportunity to positively impact the health and well-being of our members and advance our commitment to expand access to high-quality, affordable health care for consumers. It will also save consumers more than $2 billion of medical costs annually, directly benefiting the most vulnerable populations in the country. 
I also would like to briefly address the upcoming trial with the Department of Justice, which will begin on November 21. We continue to believe the DOJ's action to sue to block the acquisition is based on a flawed analysis and a misunderstanding of the dynamic competitive and heavily regulated health care landscape, and we're fully committed to challenging the DOJ's decision in court. 
In terms of the court proceeding, the judge has decided to bifurcate the issues and will first hear evidence on the National Accounts issue. If the judge decides in our favor on the National Account issue, we will then move forward and try the other 2 remaining issues, with a decision on those issues being rendered before the end of January. 
To summarize, we are in the process of updating our long-term growth plan and expect to target improved core earnings growth rates beyond 2017. The Individual ACA-compliant headwinds in our enrollment mix discussed previously represent a meaningful challenge to achieving our $14 earnings target in 2018. And we expect to provide additional clarity around our long-term growth prospects after the Cigna transaction process is complete. 
With that, operator, please open the queue for questions."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","[Operator Instructions] And our first question will come from the line of Ana Gupte from Leerink Partners.",17,"[Operator Instructions] And our first question will come from the line of Ana Gupte from Leerink Partners."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","My question was about the Individual book. You said that there were losses this year and they continued into the quarter. Sequentially speaking, what were the losses in -- that you estimated in the second quarter? And have they gone up since then? And why",67,"My question was about the Individual book. You said that there were losses this year and they continued into the quarter. Sequentially speaking, what were the losses in -- that you estimated in the second quarter? And have they gone up since then? And why are you expecting that will improve next year, when the reinsurance all phases out. Are you getting adequate pricing to do that?"
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Ana, this is John. So thank you for the question. Associated with our Individual exchange business, we certainly did, in the second quarter, indicate losses and that we expect that our operating margins are going to be on the mid-single-digit loss for the",215,"Ana, this is John. So thank you for the question. Associated with our Individual exchange business, we certainly did, in the second quarter, indicate losses and that we expect that our operating margins are going to be on the mid-single-digit loss for the year. Now during the third quarter, the reserve development was okay. The trend has been moderated a bit. And we still expect those losses in the same general range of what we said, maybe just a little bit better than we had indicated. In terms of 2017, reinsurance is obviously a very important factor, but it's only one aspect of pricing and one aspect of the overall structure of the program. We've got rate increases that average in excess of 20% across the country. I think there's been studies that have been published that have stated that our rate increases are a little bit higher than the average rate increases. We've made adjustments to product offerings. We've changed networks. We've enhanced product designs. We've done many, many things to improve affordability of the specific product mix. So we feel very good about the previous guidance that we provided, that we're really targeting a small profit margin in 2017 and then returning to more closely related to target margins in 2018 and beyond."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question is from Christine Arnold from Cowen.",10,"And our next question is from Christine Arnold from Cowen."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","A couple of things. On Iowa, your language there suggests that you got a rate increase, but it may not be adequate and that you're disciplined and you're only going to be in markets that are actuarially sound. Is there an out to get out of that if, in fac",90,"A couple of things. On Iowa, your language there suggests that you got a rate increase, but it may not be adequate and that you're disciplined and you're only going to be in markets that are actuarially sound. Is there an out to get out of that if, in fact, we can't get to actuarially sound rates? And then with respect to Individual, what do you think you need to see in order to feel that there's sustainability into '18? What legislatively or administratively do you want to see there?"
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Christine, this is Joe Swedish. Yes, first question regarding, I guess, the out possibilities. As you know, the contract went live earlier this year, and obviously, we're very concerned because it has experienced a deterioration that certainly exceeded ou",276,"Christine, this is Joe Swedish. Yes, first question regarding, I guess, the out possibilities. As you know, the contract went live earlier this year, and obviously, we're very concerned because it has experienced a deterioration that certainly exceeded our forecast expectations regarding the medical loss ratio. We are in the process of having deep discussions with the state regarding the possibility of adjustments. I commented in our discussions just a moment ago that we have realized some positive effect from that discussion. And quite frankly, we're hoping for more. Unfortunately, the recent rate increase is still inadequate, and again, we're hoping for a better outcome with respect to more discussion. With respect to the legal construct of the contract, we are examining our position. We, quite frankly, are awaiting the state to respond to the inquiries that we've submitted to them. And I think it's a little early for us to maybe put commentary out regarding our legal position, given the fact that there's still administrative considerations that are working their way through the system. And we're hopeful for a very positive outcome at the end of that review. We are concerned about the actuarial soundness of the rates. And that's been expressed by all of the MCOs from the get go. We are engaged in an extensive process of meetings, as I mentioned. And we'll continue to be deeply concerned until we get a resolution to this. And then we'll weigh our options with respect to the endpoint of those negotiations with the state. I think the second question dealt with the exchange, Christine. I wonder if you could restate that for me, I'm sorry."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","One moment please.",3,"One moment please."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","[Audio Gap] And then it sounded like your language suggests that if '17 doesn't go well, you could change your strategy for '18. What do you need to see administratively or legislatively in order to fix this and in order for you to feel that this is whe",54,"[Audio Gap] 
And then it sounded like your language suggests that if '17 doesn't go well, you could change your strategy for '18. What do you need to see administratively or legislatively in order to fix this and in order for you to feel that this is where you're going to stay for '18?"
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Great. Well, on or about midyear '17, obviously, we'll maybe coming to a conclusion on our review about how the adjustments have played out that we are expecting. To your point, what we're looking for are a variety of fixes such as elimination of the heal",271,"Great. Well, on or about midyear '17, obviously, we'll maybe coming to a conclusion on our review about how the adjustments have played out that we are expecting. To your point, what we're looking for are a variety of fixes such as elimination of the health insurance tax or at least extending the 2017 moratorium. Another one that you've probably heard quite a bit about is updating the risk adjustment model substantially to address the existing imbalance that we believe deteriorates the overall risk pool. We are also looking at additional adjustments to the special enrollment periods, which we believe the -- needs to be continually narrowed with respect to the variety and number of special enrollments. We also believe that we need to have the flexibility to develop innovative products that should go to market to meet our -- the needs of our customers. Modify the grace period is another great example. And finally, we want to work very closely with the states to ensure actuarially justified rates being approved. Now what I just specified for you, and let me just put a characterization to it that I think is very, very important, and that is this is a specific recipe for solutions, and we believe these recipe characteristics represent the form of a long-term, sustainable and affordable marketplace. So as I said earlier in my commentary, we believe we must see adjustments such that we can easily map to a 2018 situation of sustainability in this marketplace. And, quite frankly, given what may or may not happen, we'll be evaluating the regional engagement across our markets moving into 2018."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","And Joe, I'd just like to say, obviously, everything there is very appropriate, but Christine, we will be watching margins trends performance on a state-by-state and region-by-region basis in 2017 as well. So certainly, the decision in '18 could be a piec",49,"And Joe, I'd just like to say, obviously, everything there is very appropriate, but Christine, we will be watching margins trends performance on a state-by-state and region-by-region basis in 2017 as well. So certainly, the decision in '18 could be a piecemeal decision as opposed to an altogether decision."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. I think thus far, we've been very surgical in our approach, and we'll continue that theme. And so again, we have a hope that the sustainability that's expected and commented on quite a bit by leadership of the administration actually will occur durin",49,"Yes. I think thus far, we've been very surgical in our approach, and we'll continue that theme. And so again, we have a hope that the sustainability that's expected and commented on quite a bit by leadership of the administration actually will occur during the early stages of 2017."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question is from A.J. Rice from UBS.",11,"And our next question is from A.J. Rice from UBS."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","I just want to follow up. I appreciate the comments on the headwinds and tailwinds and the comment about modest growth. I guess there are 3 variables I just want to throw on the table. You're saying you'll go from a mid-single digit loss on the exchanges,",147,"I just want to follow up. I appreciate the comments on the headwinds and tailwinds and the comment about modest growth. I guess there are 3 variables I just want to throw on the table. You're saying you'll go from a mid-single digit loss on the exchanges, or in the Individual book, to a positive. We got, I guess, about a -- that would represent, I think, about a $0.70 swing, roughly 6% to 7% growth in and of itself. I just also wondered, are you including anything in your comments about capital deployment when you talk about modest growth? Or anything on the PBM? And what's the latest thinking on that? And then just to make sure the $10.80 is the baseline number upon which you're assuming modest growth. Or is it some other number that you would adjust for as the starting point for '16?"
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure, no, A.J. Thank you for the question. And in terms of capital, we do expect to resume capital deployment in 2017. However, that won't be until after the pending Cigna acquisition process is completed. And so the timing and the magnitude of that",134,"Yes, sure, no, A.J. Thank you for the question. And in terms of capital, we do expect to resume capital deployment in 2017. However, that won't be until after the pending Cigna acquisition process is completed. And so the timing and the magnitude of that capital deployment is still somewhat of an unknown. Associated with the starting point, yes, very clearly, $10.80, we believe is the appropriate starting point. That's our guidance. That's been our expectations now for some time. And that's our 2016 -- approximately $10.80 is our 2016 guidance number. And then, of course, you have the tailwinds that offset that. But in terms of the PBM, we don't have any of the upside baked in. I think, Joe, maybe some comments just about the PBM situation in general might be helpful."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. A.J., thanks for the question on that. As I've repeatedly stated, we're hopeful we can negotiate a settlement to our concerns, our dispute. And I don't need to restate what we've said repeatedly about our perspective on our contractual rights, but le",193,"Yes. A.J., thanks for the question on that. As I've repeatedly stated, we're hopeful we can negotiate a settlement to our concerns, our dispute. And I don't need to restate what we've said repeatedly about our perspective on our contractual rights, but let me say that we do believe that we are continually focused on improving the pharmacy pricing on behalf of our customers. We expect to issue a new RFP during the year, that's early 2017, to understand the impact of various pharmacy options available to us as we migrate to the potential of a new agreement. And I have to underscore that it's critical that we engage with a really trusted partner with aligned interests in advancing the cost effectiveness and quality for our membership. We've -- I guess we've not ruled anyone in or out in this process of securing an RFP. And I think with respect to any other comments made by ESI or others, we prefer not to comment on that. We do believe that a period of negotiations is still possible. And again, I'll underscore I'm hopeful that we can resolve our differences moving into the future."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from the line of Matt Borsch from Goldman Sachs.",13,"Our next question is from the line of Matt Borsch from Goldman Sachs."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Maybe on a slightly different topic. One of your peer companies has talked in considerable length about pressure in the small group ACA-compliant book. I know you've alluded to that some. Can you just give us an update on how you see that business? Maybe",74,"Maybe on a slightly different topic. One of your peer companies has talked in considerable length about pressure in the small group ACA-compliant book. I know you've alluded to that some. Can you just give us an update on how you see that business? Maybe break down in size and break down your small group between what's ACA-compliant and what's grandmothered, grandfathered? And how you see that transition happening, working going into next year?"
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure. Thank you for the question, very good question. And that really is a meaningful headwind. And I think I did try to highlight it in the script. But in terms of the specificity of the question, we don't talk about a lot of this information for co",142,"Yes, sure. Thank you for the question, very good question. And that really is a meaningful headwind. And I think I did try to highlight it in the script. But in terms of the specificity of the question, we don't talk about a lot of this information for competitive reasons, but maybe 2/3 of our block is non-ACA-compliant today. The grandmothering expires here at the end of the year, and we fully expect to be very aggressive in pursuing and renewing that block of business. The margin aspect of it may be slightly different, slightly lower, as the ACA-compliant blocks typically have a slightly lower margin compression. But we'll ensure that we renew it at appropriate prices and have it to be a profitable business on a go-forward basis, but we did want to spike it out as a headwind in 2017."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Kevin Fischbeck with Bank of America.",11,"Our next question is from Kevin Fischbeck with Bank of America."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","I guess 2 questions. First, a clarification, you mentioned that as far as the Cigna lawsuit, they're going to break it up into 2 pieces, and that they're going to hear National Accounts first. I'm just wondering if you had a time frame for when we'd hear",88,"I guess 2 questions. First, a clarification, you mentioned that as far as the Cigna lawsuit, they're going to break it up into 2 pieces, and that they're going to hear National Accounts first. I'm just wondering if you had a time frame for when we'd hear that. But then specifically, on the Medicaid business, it sounds like Iowa should get better next year, Medicaid expansion should get worse. Are you looking for net margin improvement or margin pressure on the Medicaid business as a whole in 2017?"
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, let me just comment on the Cigna hearings. Beyond the December judicial process, which we're anticipating a decision sometime on or about mid-December, we would expect that moving forward from there, that it's possible then a trial would begin shortl",63,"Yes, let me just comment on the Cigna hearings. Beyond the December judicial process, which we're anticipating a decision sometime on or about mid-December, we would expect that moving forward from there, that it's possible then a trial would begin shortly thereafter, probably early January. And our hope is that, that would be resolved with a judicial decision by the end of January."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","And then on the Medicaid question, just to provide a little clarity. So certainly, Iowa is going to be a tailwind into 2017. We experienced significant upfront losses in Iowa. And even with rebalancing of the portfolio and the retroactive rate increase, i",147,"And then on the Medicaid question, just to provide a little clarity. So certainly, Iowa is going to be a tailwind into 2017. We experienced significant upfront losses in Iowa. And even with rebalancing of the portfolio and the retroactive rate increase, it's still -- we do not believe it's actuarially sound. And the expectation is that there will be improvement in 2017. However, associated with the remainder of the Medicaid block, we are seeing some slight margin pressure. We were phenomenally successful the past couple of years with our margins. And specifically, our expansion margins have been very, very, very good. And then as those get repriced throughout the balance of the year, they're going to be repriced at more of a target margin ratio -- target profit ratio, I'm sorry. And that will create a bit of headwind or margin pressure for us in '17."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Justin Lake from Wolfe Research.",10,"Our next question is from Justin Lake from Wolfe Research."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","A couple of things. First, I remember back when we were going into the ACA and there was concerns around small group. You guys had put out a number of about a $400 million headwind for next year -- or for the coming couple of years in terms of small group",177,"A couple of things. First, I remember back when we were going into the ACA and there was concerns around small group. You guys had put out a number of about a $400 million headwind for next year -- or for the coming couple of years in terms of small group margin pressure. Is there any way for you to do something similar here, just to give us an idea of as you go through this repricing, is there a number you can point to, to say, here's -- it sounds like small group's going to be a pretty good pressure next year, as expected. It maybe a little larger than we thought. The -- is there a way to put a number on that for us? And then on SG&A, it's been shifting around a bit here. And wanted to get your thoughts for the fourth quarter and how we should think about this for 2017 when we add in the -- when we add back some of these onetime benefits that you had this year."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Sure, Justin, great questions. The -- in terms of the small group, we're still working through it, and I really am hesitant to provide an answer until our planning process is done. And some of the grandmothering associated with the early renewals that exi",306,"Sure, Justin, great questions. The -- in terms of the small group, we're still working through it, and I really am hesitant to provide an answer until our planning process is done. And some of the grandmothering associated with the early renewals that exist, we actually have several of our -- many of our small group plans renewed early on December a couple of years ago in order to maintain their non-ACA-compliant plans. And I think it'd probably be premature to throw a number out until we've worked through that process. So we will update that and provide more clarity on our fourth quarter call. Associated with the general and administrative expenses, I think maybe I'll just repeat sort of the commentary from last time. It's down quite substantially in 2016. And a little more than half of it is a good, sustainable run rate, meaningful decrease in SG&A expense. That has to do with more efficient processes, better performance in some of the administrative and core areas of the company. And we grew into our membership. We had a really good membership year from both a membership and premium prospective, raising guidance on that. And we're able to do that by maintaining our administrative expense levels. Obviously, then the ratio went down. The other half, or a little less than the other half, were more onetime items, and those are nonsustainable. And the most significant part of those other, less than the other half is our incentive compensation plans. As we've stated, we're a pay-for-performance company, and we had our promises to Wall Street in what we expected earnings to be, and we ensured that we delivered those earnings. And unfortunately, we had to lower our incentive compensation expense as part of that process. So a little less than half will come back in 2017."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Michael Newshel from Evercore ISI.",10,"Our next question is from Michael Newshel from Evercore ISI."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Does your expectation for slight profitability in the ACA-compliant business next year assume that the national enrollment is going to be stable or growing? And how would you frame the downside risk to margins if enrollment declines and the risk pool dete",93,"Does your expectation for slight profitability in the ACA-compliant business next year assume that the national enrollment is going to be stable or growing? And how would you frame the downside risk to margins if enrollment declines and the risk pool deteriorates? And also, I mean, it looks like your relative pricing versus competitors is generally higher in 2017 than it was -- than it is this year after the price hikes and market exits, at least on HealthCare.gov. Do you think that provides you any buffer against adverse selection next year?"
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Well, there's quite a few questions in there. Hopefully, I can address all of them. But I think maybe the most simple is that we expect that overall Individual ACA-compliant membership on a national basis will be slightly down next year and that our membe",184,"Well, there's quite a few questions in there. Hopefully, I can address all of them. But I think maybe the most simple is that we expect that overall Individual ACA-compliant membership on a national basis will be slightly down next year and that our membership will reflect that. We still have many, many competitors in our markets. I just do want to point out that some of the exits that have been very widely publicized, very few of them impact our market specifically. So like, for instance, California still has 11 competitors, Virginia still has 8 competitors, just to rattle off a couple of our states. In terms of the risk pool, we believe that we understand the risk pool. We're very good at the Individual marketplace. We've been the #1 Individual market carrier for years and years prior to the ACA. Our products are designed in such a way to really get a good risk pool that allows us to maximize on risk adjusters and then be a risk adjuster collector. So we feel good about our assumptions at this point in time."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Let me add that there are a few key points I think we really need to consider and keep in front. Number one, on average, our price point for targeted bronze and silver plans in the marketplace is higher than our competitors. We certainly recognize that an",252,"Let me add that there are a few key points I think we really need to consider and keep in front. Number one, on average, our price point for targeted bronze and silver plans in the marketplace is higher than our competitors. We certainly recognize that and acknowledge it. And while the number of competitors in our markets has declined overall versus 2016, for the most part, those declines are in less populated areas, such as the rural market, where we have had historically high market shares. There's -- on the flip side, there's really still substantial competition across all of our markets, those served markets, most notably in these highly dense urban markets. And finally, some of the largest markets did not see any significant reduction in competition. For example, California still has 11 competitors, down one from last year. Virginia still has 8. Georgia still has 5. So we know we're in highly competitive markets, and we believe we will compete very effectively. But again, I think we've very effectively managed the price points with respect to the products that we've offered in the marketplace. And so we have a fairly good outlook, as John commented earlier in his remarks, about our expected margins. And as I said then to follow on to that, we'll be evaluating our situation in those markets, all of our markets, through the beginning of the year to see how well we perform and how well the regulatory adjustments play out leading up to midyear."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Lance Wilkes from Sanford Bernstein.",10,"Our next question is from Lance Wilkes from Sanford Bernstein."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","I just wanted to follow up on a question with respect to self-insurance margin strategy. I wanted to understand how the progress was going on Specialty penetrations looking at 2017, and what your 2018 and beyond strategies were there. How much upside you",68,"I just wanted to follow up on a question with respect to self-insurance margin strategy. I wanted to understand how the progress was going on Specialty penetrations looking at 2017, and what your 2018 and beyond strategies were there. How much upside you saw with respect to self-insurance margins. And then in particular right now with PBM, how does that fit into how you're looking at penetrations?"
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Great question, and certainly, that's one of our growth areas for the future as we look out into our long-term outlook. We believe that the opportunity to enhance the EBITDA associated with our ASO members is meaningful. We are developing -- we have ongoi",157,"Great question, and certainly, that's one of our growth areas for the future as we look out into our long-term outlook. We believe that the opportunity to enhance the EBITDA associated with our ASO members is meaningful. We are developing -- we have ongoing efforts to drive penetration in Specialty products, various ancillary type products, other add-ons, that -- we think that we are underpenetrated right now and believe that we have an incredible amount of upside. We've been the #1 company in growing the ASO large group national membership over the last several years, and we've made quite a nice margin percentage on that business, but it's very small dollars. And so now the focus is to take the fact that we do have best-in-class discounts and the most sophisticated purchasers of coverage are picking us. And so now it's our opportunity to really penetrate that better and enhance the EBITDA associated with that membership block."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Gary Taylor from JPMorgan.",9,"Our next question is from Gary Taylor from JPMorgan."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Just a couple more questions on the Individual business. First, I just wanted to follow up, I know you had just said you're anticipating exchange enrollment to decline heading into 2017. I know you also thought that would be the case heading into 2016. So",97,"Just a couple more questions on the Individual business. First, I just wanted to follow up, I know you had just said you're anticipating exchange enrollment to decline heading into 2017. I know you also thought that would be the case heading into 2016. So is just your rate positioning why you still believe that might play out in '17 versus what happened this year? And then just secondly, could you just comment on any PDRs used in the Individual business this quarter in your experience with the special enrollment period enrollment this year versus last year?"
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Gary, great question. And 2016 was interesting because what we ended up seeing was a flight to safety, and that was one of the reasons that our 2016 Individual exchange membership grew more than expectations. And so if you go backwards a year and then you",255,"Gary, great question. And 2016 was interesting because what we ended up seeing was a flight to safety, and that was one of the reasons that our 2016 Individual exchange membership grew more than expectations. And so if you go backwards a year and then you look at the number of co-ops who are in our markets that failed, it was a significant impact on our membership. And then as those customers then went into the marketplace, they -- as I said, it was a flight to safety, they went for Blue. I think the real key difference in the expectations in '16 and the expectations in '17 is, really, the amount of exits within our markets of carriers and who the exits were and how much membership those that exited had. So long story short, the co-ops in certain markets were -- had extremely high market share, and they went insolvent and their market share then was absorbed. Where in 2017, while we certainly have some exits of carriers in our markets, they do not have the breadth or the magnitude of the market share that the ones who exited a year ago had. Associated with the premium deficiency reserves, we have none recorded. We had none recorded in 2015. We have none recorded in 2016. It's a very easy question. Which means that our results are pure, our results are clean and that we don't have the puts and takes that maybe you have in some of the other companies that you're modeling."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Josh Raskin from Barclays.",9,"Our next question is from Josh Raskin from Barclays."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","A question -- a short term and a long term. Short term, I heard the commentary. I think, John, you said the results were very consistent with your expectations. And just looking at sort of the cadence of earnings, you saw some mid- to high single-digit gr",182,"A question -- a short term and a long term. Short term, I heard the commentary. I think, John, you said the results were very consistent with your expectations. And just looking at sort of the cadence of earnings, you saw some mid- to high single-digit growth in the first half, a big decline of double-digit percentage on EPS in 3Q and now an expected increase back in 4Q. And so I guess, if that's all very expected, what changed this year from a seasonality perspective? And then on the long term, from a strategic perspective, when you guys announced the Cigna deal, and I know we're going back 1.5 years now, you talked about Cigna bringing commercial expertise and exposure to Medicare, the strong Specialty and then the international segment. And so I'm curious kind of where those priorities sit today. And in the case that the judge disagrees with you guys and the transaction does not move forward, how do you guys think about the reaction? Is there a need for scale? Is there an appetite to do other stuff?"
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure, thank you. I'll take the first question and turn it over to Joe for the second. Yes, I did say that our results were very consistent with expectations. When you're looking at the seasonality of 2015 to 2016, yes, 2016 is a bit challenged. The M",153,"Yes, sure, thank you. I'll take the first question and turn it over to Joe for the second. Yes, I did say that our results were very consistent with expectations. When you're looking at the seasonality of 2015 to 2016, yes, 2016 is a bit challenged. The MLR is a little bit in the fourth quarter than it was last year. There's a lot of variables associated with that. Clearly, the Iowa variable, the Individual exchange variable. Please note that we do have the G&A offset that allows us to enjoy the growth in EPS year-over-year. But it's not that there was a significant change in seasonality patterns or a huge business flux as much as it was some of the very specific items that we pointed out to as headwinds for 2016 continue to be headwinds throughout the fourth quarter. On the -- I think Joe wants to address your Cigna question."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, let me take that for a moment, Josh. First of all, to your point about, call it, pivoting in the event of an adverse decision, we're going to focus very heavily on what we talked about earlier regarding our tailwinds. Obviously, in the MA growth spac",142,"Yes, let me take that for a moment, Josh. First of all, to your point about, call it, pivoting in the event of an adverse decision, we're going to focus very heavily on what we talked about earlier regarding our tailwinds. Obviously, in the MA growth space, a very strong focus on our government business across the entire spectrum and a variety of other initiatives that I already mentioned. I think it's really important to underscore that we'll be coming to you at the time of that announcement, whatever. We will then share with you our outlook in terms of pivoting the company to tackle some of those opportunities, tailwinds, as well as, quite frankly, address the headwinds as robustly as we would anyway, but certainly we believe ameliorating some of that risk would be a great opportunity to us as well."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, I would just add to that, that we believe that we have long-term sustainable growth opportunities regardless if the deal closes or not. Cigna may help accelerate those, but we're very confident about our future under either scenario.",39,"Yes, I would just add to that, that we believe that we have long-term sustainable growth opportunities regardless if the deal closes or not. Cigna may help accelerate those, but we're very confident about our future under either scenario."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from the line of Chris Rigg with Susquehanna Financial Group.",14,"Our next question is from the line of Chris Rigg with Susquehanna Financial Group."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","John, I know you commented earlier about the dynamic of compliant versus noncompliant in the small group book. But it looks like in the Individual side, you still have about 27% of your membership that's noncompliant. Are most of those -- the plans for th",87,"John, I know you commented earlier about the dynamic of compliant versus noncompliant in the small group book. But it looks like in the Individual side, you still have about 27% of your membership that's noncompliant. Are most of those -- the plans for the noncompliant individuals going to remain in-force through -- or until December 2017? And then more of a macro question, do you guys have a sense for how many grandmothered -- how many people have grandmothered plans in your markets at this point?"
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, great question. First of all, in the compliant versus noncompliant, the majority of those will not be noncompliant through '17. So that the headwind, tailwind that I talked about with that, that would include both the small group and the Individual c",126,"Yes, great question. First of all, in the compliant versus noncompliant, the majority of those will not be noncompliant through '17. So that the headwind, tailwind that I talked about with that, that would include both the small group and the Individual commentary. In terms of how many grandmothering are in our markets, including what our competitors have, we actually do not have the specificity of that. But obviously, all the dynamics that we're experiencing and the changes in the laws, they're experiencing. So there's really not an -- if your question is, is there an opportunity to get someone else's grandmothered business? The answer is really no. It would have to be -- we would have to get it as part of an ACA-compliant product."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from the line of Ralph Giacobbe from Citi.",12,"Our next question is from the line of Ralph Giacobbe from Citi."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","First, just wanted to clarify the comments on the exchange again. Joe, you mentioned 2017 as a critical year. And if there was no clear evidence, that you'd sort of modify your strategy in 2018. I mean, does that mean market exit or willingness to exit if",119,"First, just wanted to clarify the comments on the exchange again. Joe, you mentioned 2017 as a critical year. And if there was no clear evidence, that you'd sort of modify your strategy in 2018. I mean, does that mean market exit or willingness to exit if you're unprofitable again in 2017? And then also separately, I was hoping you could parse out the pressure from Iowa. I know one of your peers took a PDR in that book, while you're absorbing the losses through the P&L. So just hoping to get a sense of margins and maybe magnitude of loss this year, and what the improvement would be next year, even on sort of the inadequate rate bump."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Great. Thanks. I will pivot the second part of the question to John so he can get into some of the technical aspects of it. But with respect to the first question, let me just underscore that, as I said a moment ago, we're going to be very surgical. And l",130,"Great. Thanks. I will pivot the second part of the question to John so he can get into some of the technical aspects of it. But with respect to the first question, let me just underscore that, as I said a moment ago, we're going to be very surgical. And let me define market. There are those that define market to be state, but I want to be very clear that we deal with a significant array of regions. So we will look at both regional impact as well as state impact and then make determinations with respect to what I call the surgical assessments and then decisions and execution that are necessary in order for prudent engagement in that marketplace. I believe that probably covers what you were asking."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Okay, yes. And then in terms of Iowa and the headwind for '16, which becomes a tailwind for '17 with the Medicaid block there. We did get a retroactive rate increase. Unfortunately, we think it's still not actuarially justified. We really are not providin",136,"Okay, yes. And then in terms of Iowa and the headwind for '16, which becomes a tailwind for '17 with the Medicaid block there. We did get a retroactive rate increase. Unfortunately, we think it's still not actuarially justified. We really are not providing an exact number at this point as we continue to work with the state and don't want to get out ahead of the state and negotiate this publicly. But just as Joe said, consistent with the Individual exchange business, we need to partner with states that want to be partners. And we believe that we need actuarially justified rates. And if -- we will continue to negotiate it. We feel really good about that fact, but if we don't get it, then we'll have a decision to make in Iowa as well."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","And our last question this morning will come from the line of Peter Costa.",14,"And our last question this morning will come from the line of Peter Costa."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Just a couple of clarifications on things you said. You said you put out an RFP for your PBM in early 2017. So presumably, that means we'd see an answer sometime in mid-2017. What sort of things have you going to be looking for besides the $3 billion in s",75,"Just a couple of clarifications on things you said. You said you put out an RFP for your PBM in early 2017. So presumably, that means we'd see an answer sometime in mid-2017. What sort of things have you going to be looking for besides the $3 billion in savings that you already talked about? And then are you specifically coming off the $100 billion revenue target that you set out in 2014 for 2018?"
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Why don't I do the second one first, Peter, while I've got the line. In terms of the headwinds, tailwinds for 2018 in Joe's commentary, it's highly unlikely that we would be able to achieve that number at this point in time. Just look at our guidance for",166,"Why don't I do the second one first, Peter, while I've got the line. In terms of the headwinds, tailwinds for 2018 in Joe's commentary, it's highly unlikely that we would be able to achieve that number at this point in time. Just look at our guidance for 2016 and roll that forward and roll our membership forward, it all boils down to the exchanges. And the CBO had estimated, what, 25 million, 26 million lives to be insured through the exchanges. When we did our 2018 plan, we relied on some of the CBO estimates as part of our estimation process. And we're still maintaining our market share. We still believe that we can hit the target margins that we had for those things. But when the entire country has just over 10 million versus that other, that's a significant delta, and that goes straight into our numbers. And I think you'll see that the revenue shortfall can be entirely explained with that dynamic."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, and let me pick it up now regarding the PBM question. Yes, that RFP goes to market early 2017. I've said repeatedly that our intention is to be able to deliver to you a solution with respect to our ongoing analytics, which obviously, in the current s",126,"Yes, and let me pick it up now regarding the PBM question. Yes, that RFP goes to market early 2017. I've said repeatedly that our intention is to be able to deliver to you a solution with respect to our ongoing analytics, which obviously, in the current state, isn't significantly impacted by our discussions and, of course, the potential legal proceedings with ESI. We were hopeful to bring you a meaningful commentary and maybe solution by the end of 2017. We've never diverged from that commitment, and our hope is that we certainly will be able to put all the parts and pieces together to give you clarity in and around the decisions we're going to execute specific to the termination of the contract by 2019."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Thank you, and please go ahead with any closing remarks.",10,"Thank you, and please go ahead with any closing remarks."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Well, again, thank you, everybody, for your questions. They're always very, very good. As a company, we do remain committed to tackling our health care system challenges head on, as evidenced by the work that we've communicated to you today. And we beli",146,"Well, again, thank you, everybody, for your questions. They're always very, very good. 
As a company, we do remain committed to tackling our health care system challenges head on, as evidenced by the work that we've communicated to you today. And we believe that we can and will deliver greater value to consumers by expanding access to high-quality affordable health care. And we've stood that -- by that repeatedly. This is why we are committed to challenging the DOJ's recent decision to block Anthem's acquisition of Cigna in court. 
Speaking to my associates, I want to also thank all of them for their continued commitment to serving our nearly 40 million members every day. 
To all of you on the phone, please accept our thanks for your interest in Anthem, and we look forward to speaking with you soon at upcoming conferences. Have a great day."
160077,324533304,1070293,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Thank you. And ladies and gentlemen, this conference will be made available for replay after 11:00 a.m. today through November 16. You may access the AT&T Executive Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378818.",71,"Thank you. And ladies and gentlemen, this conference will be made available for replay after 11:00 a.m. today through November 16. You may access the AT&T Executive Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378818. International participants can dial (320) 365-3844. 
That does conclude our conference for today. Thank you for your participation and for using AT&T Executive TeleConference. You may now disconnect."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Anthem Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded. I would now like to turn the conference over to the company's management.",39,"Ladies and gentlemen, thank you for standing by, and welcome to the Anthem Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded. 
I would now like to turn the conference over to the company's management."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Good morning, and welcome to Anthem's Third Quarter of 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish; Chairman, President and CEO; and John Gallina, our CFO. Joe will offer an overview",198,"Good morning, and welcome to Anthem's Third Quarter of 2016 Earnings Call. This is Doug Simpson, Vice President of Investor Relations. With us this morning are Joe Swedish; Chairman, President and CEO; and John Gallina, our CFO. Joe will offer an overview of our third quarter 2016 results and our updated 2016 full year outlook. Then John will walk through the financial details and provide some incremental commentary on 2017 before Joe closes with some longer-term strategic commentary. We will then be available for Q&A. 
During the call, we will reference certain non-GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are available on our website at antheminc.com. 
We will also be making some forward-looking statements on this call. Listeners are cautioned that these statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Anthem. These risks and uncertainties can cause actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in today's press release and in our quarterly and annual filings with the SEC. 
I will now turn the call over to Joe."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Doug, and good morning. This morning, we announced third quarter 2016 GAAP earnings per share of $2.30. Adjusted earnings per share was $2.45, consistent with our previous expectations. Within membership, we continue to post strong fully insu",1656,"Thank you, Doug, and good morning. This morning, we announced third quarter 2016 GAAP earnings per share of $2.30. Adjusted earnings per share was $2.45, consistent with our previous expectations. 
Within membership, we continue to post strong fully insured and self-funded enrollment results, as we ended the third quarter with over 39.9 million members. We grew an additional 160,000 lives during the quarter, bringing our year-to-date enrollment growth to 1.3 million lives or 3.4%. Specifically, insured enrollment increased by 39,000 lives during the quarter, as our Medicaid business grew by 81,000 lives to over 6.4 million members. Since closing the Amerigroup transaction in 2012, we've grown Medicaid enrollment by nearly 1.9 million lives, or 41%, including growth of approximately 800,000 lives from Medicaid expansion. 
Within Commercial, our insured enrollment came in slightly ahead of expectations, as Local Group fully insured membership tracked well, particularly in the large group marketplace. Our public exchange enrollment declined by a less-than-expected 34,000 during the quarter to 889,000 lives. Our self-funded business increased by 121,000 during the quarter, reflecting the impact of enrollment growth from existing accounts and recently awarded contracts. 
Our solid membership results during the year translated into better than expected operating revenue of $21.1 billion during the quarter, an increase of $1.4 billion or 6.8% versus third quarter of 2015. The increase reflects the strong enrollment growth in the government business and additional premium revenue to cover overall cost trends. Additionally, administrative fee revenue grew by 6.4% versus the prior year quarter as a result of our strong self-funded membership trends. These increases were partially offset by fully insured membership losses in our Commercial business. 
The third quarter 2016 benefit expense ratio was in line with our previous expectations at 85.5%, an increase of 190 basis points versus the prior year. The year-over-year increase was primarily driven by the Medicaid business, as higher-than-expected medical cost experience, notably in Iowa, has exceeded the net impact of annual premium rate adjustments made over the last 12 months. In addition, it reflects the impact of growth in membership, as the Medicaid business carries a higher benefit expense ratio than the consolidated company average. Further, the benefit expense ratio reflects the impact of higher medical cost experience in the Individual business. These increases were partially offset by the timing of lower medical cost experience in the Local Group business. 
Our SG&A expense ratio was also in line with expectations at 14.8% in the third quarter, a decrease of 80 basis points from the third quarter of 2015. The decrease was driven by an intentional focus on administrative expense control coupled with better than expected enrollment trends, as well as the changing mix of our membership towards the government business, which carries a lower than the consolidated average SG&A ratio. 
Turning to discuss the third quarter financial performance of our business units. In the government business, we added 92,000 members during the quarter and grew year-over-year revenue by 10.9% to nearly $11.5 billion. As a reminder, our third quarter results include the impact of the addition of the Iowa contract, which was implemented on April 1. Operating margins for the government business were 4.2% during the third quarter, a decline of 190 basis points versus the prior year quarter, driven by lower gross margins in the Medicaid business. 
As we communicated previously, we've been expecting Medicaid margins to compress from 2015 levels due to rate actions. In addition, we've been experiencing higher-than-expected claims across the Medicaid business in the current year, including materially higher-than-expected costs in the recently implemented Iowa contract. As expected, there was a rebalancing of funding based on risk pool during the quarter. In addition, we've been informed of a retroactive rate increase which extends through June 2017, when rates will again be adjusted. 
Unfortunately, the recent rate increase is still inadequate, given the claims experience to date. We remain confident we can make a meaningful impact by improving the cost and quality of care in Iowa as we've done for our other state partners. However, we will remain disciplined and only participating in markets where we receive rates that are actuarially sound. 
Within Medicare, we're pleased with the progress the team continues to make, and our year-to-date margins reflect continued improvement. During the quarter, CMS announced we earned Medicare STAR quality ratings for 2017 consistent with our long-term strategy. In the most recent ratings released by CMS, 51% of Anthem's Medicare Advantage members will be enrolled in plans that achieve 4 stars or higher. This accomplishment represents significant growth from the 22% of MA members in 4-star plans last year. The improvement is the direct result of investments made in the Medicare program over the past 3 years. 
Our 2016 outlook continues to expect margins to improve as the year progresses towards our expected long-range sustainable level. As we've stated since our MA restructuring began, we have positioned our portfolio to grow MA in 2017. 
The pipeline of opportunity for our Medicaid business remains substantial, with an updated estimate of $81 billion in contracts to be awarded between now and 2021 in markets that we will consider targeting. Approximately 3/4 of this opportunity is in new and specialized services with the remainder in traditional Medicaid services. We continue to believe our experience, targeted investments and critical capabilities and geographic footprint positions us very well to continue our growth as we help states address the challenges of rising health care costs and improving quality for their residents. 
Switching to our Commercial business. Our enrollment increased by 68,000 lives during the quarter, which was slightly better than our previous expectations. Specifically, we experienced growth of 171,000 lives in our Local Group business, partially offset by declines of 48,000 and 54,000 lives in our national and Individual businesses, respectively. These results translated into better than previously expected operating revenue of $9.7 billion, representing growth of 2.4%. 
Our third quarter operating margin of 6.6% was flat versus the third quarter of 2015. Commercial operating margins during the quarter reflected a lower SG&A ratio due to lower administrative costs resulting from expense efficiency initiatives taken by the company, as well as fixed cost leverage on a growing membership base. In addition, our Commercial business experienced the favorable timing impact of lower medical cost experience in the Local Group business. These increases were offset by higher medical cost experience in our Individual ACA-compliant products. 
Within our Individual ACA-compliant plans, costs during the third quarter were marginally better than recent expectations, which is reassuring. We continue to experience higher than initially expected costs for members with chronic conditions, as we have discussed with you previously. Overall, the financial performance in Individual ACA-compliant products has been disappointing, as membership has been short of our original expectations since its inception and operating margins have been lower than expected beginning in 2015. 
We believe we've taken the appropriate actions across our served markets to return to slight profitability in 2017. Clearly, 2017 is a critical year as we continue to assess the long-term viability of our exchange footprint. We will continue to closely monitor this business, and if we do not see clear evidence of an improving environment and a path towards sustainability in the marketplace, we will likely modify our strategy in 2018. We believe both the pricing and regulatory environment need to be improved to drive toward a sustainable and affordable marketplace over the long term. 
Relating to National Accounts, which typically encompass the most sophisticated purchasers of coverage, we're pleased that the team continues to secure wins contributing to the track record of membership growth in 2017. We have added 602,000 lives so far in 2016, building on the growth of over 900,000 lives during the previous 2 years. 
And now turning to our 2016 financial outlook. Our third quarter results were largely in line with the expectations we laid out during our last quarter call. We expect our full year 2016 GAAP earnings per share to be approximately $9.28, including approximately $1.52 of negative adjustment items. On an adjusted basis, we expect earnings per share to be approximately $10.80. 
We now expect our 2016 operating revenue to be approximately $83.5 billion, which is at the high end of our previously guided range, reflecting the impact of slightly better enrollment trends during the quarter. 
Fully insured membership is expected to be in the range of 15 million to 15.1 million members, or 50,000 higher than our previous outlook, which reflects stronger than previously expected results in the Commercial business. Self-funded membership is expected to be 24.7 million members, which is at the midpoint of our range, unchanged from our previous outlook. Taken together, we're now projecting total membership growth of just over 1.1 million lives, at the midpoint of our range versus where we ended in 2015. 
Consistent with our expectations last quarter, we expect our medical loss ratio to be in the range of 84.9%, plus or minus 30 basis points; the SG&A ratio to be 14.5%, plus or minus 30 basis points; and operating cash flow to be approximately $3 billion. We continue to expect 2016 Local Group medical cost trends to be in the range of 7% to 7.5%. 
Our 2016 outlook continues to not include any benefit from the impact of share repurchase activity for the remainder of the year. As a reminder, we did not repurchase any shares through the first 9 months of 2016. 
It is important to note that our 2016 outlook does not include any additional benefits or transaction costs associated with the pending acquisition of Cigna beyond those incurred in the first 9 months of 2016, nor does it include any benefit from lower pharmaceutical pricing, which we continue to believe we are entitled to under our current contract with ESI. 
I will now turn the call over to John to discuss some key financial metrics and our initial thoughts on headwinds and tailwinds for 2017. John?"
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, Joe, and good morning. As Joe stated, our third quarter results were very consistent with the expectations we laid out last quarter. In order to provide you a bit more clarity on our performance, I will highlight some of our key financial metri",656,"Thank you, Joe, and good morning. As Joe stated, our third quarter results were very consistent with the expectations we laid out last quarter. In order to provide you a bit more clarity on our performance, I will highlight some of our key financial metrics. 
First, I'd like to discuss the balance sheet. Consistent with our past practice, we have included a roll-forward of our medical claims payable balance in this morning's press release. 
For the 9 months ended September 30, 2016, we experienced a favorable prior year reserve development of $773 million, which was moderately better than our expectations. We continue to be at the upper end of our range of mid to high single-digit margins for adverse deviation and believe our reserve balances remained consistent and strong as of September 30, 2016. Our Days in Claims Payable was 40.6 days as of September 30, unchanged from the 40.6 days we reported last quarter. As previously discussed and consistent with our expectations, this metric has trended down over the past year, and we expect Days in Claims Payable to be around 40 days over time. 
Our debt-to-cap ratio was 38.7% as of September 30, down 40 basis points from the 39.1% at the end of the second quarter, which reflects the impact of an increase in shareholder equity, as we did not repurchase any stock during the quarter. 
We ended the third quarter with approximately $2.1 billion of cash and investments at the parent company, and our investment portfolio was in an unrealized gain position of approximately $983 million as of the end of the quarter. 
For the 3Rs, we continue to book reinsurance as appropriate and continue to reflect a net receivable position for risk adjusters. We also continue our conservative posture of recording a 100% valuation allowance against any unpaid receivables for the 2014, the 2015 and the 2016 benefit years for risk corridors. 
Moving on to cash flow. We reported operating cash flow of approximately $2.9 billion, or 1.4x net income, during the first 9 months of 2016. During the quarter, we reported operating cash flow of $964 million, which was 1.6x net income. These results include the receipt of a CMS Medicare prepayment of approximately $650 million during the third quarter. For the full year of 2016, we continue to expect operating cash flows to be approximately $3 billion. We used $171 million during the quarter for our cash dividend, and yesterday, the Audit Committee declared our fourth quarter 2016 dividend of $0.65 per share to shareholders. 
Now turning to 2017. We are currently working through our planning process and analyzing the impact of various expected headwinds and tailwinds. Our current view of the tailwinds include: Number one, enrollment gains across Medicaid, Medicare and National and Large Group self-funded businesses; two, margin improvement due to improving results in our Individual ACA-compliant plans, the Iowa Medicaid contract and the impact of the 1-year health insurer fee moratorium in 2017; and three, we expect to resume capital deployment activity in 2017, however, the timing and magnitude is dependent on the timing of the pending Cigna acquisition. 
Potential headwinds include: The return of the 2017 onetime administrative expense cuts that we made in 2016; the impact of lower Local Group enrollment and gross margin pressures as a result of the migration towards ACA-compliant product offerings; and finally, we expect to experience continued budgeting pressure in the Medicaid business, primarily driven by rate actions within the Medicaid expansion population over the next year. 
Taken together, these items are expected to represent modest earnings growth from 2016. 
As part of our planning process, we will continue to be focused on identifying steps that maximize our opportunities to drive improved earnings growth over time. We expect to provide more details around our 2017 outlook on our fourth quarter conference call. 
With that, I'm going to turn the call back over to Joe to discuss our longer-term outlook."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Thank you, John. 3 years ago, we laid out our plan for growth, which reflected our strategy to capitalize on the substantial opportunities in the government business while recognizing the changing nature of the commercial marketplace as a result of the im",735,"Thank you, John. 3 years ago, we laid out our plan for growth, which reflected our strategy to capitalize on the substantial opportunities in the government business while recognizing the changing nature of the commercial marketplace as a result of the implementation of the Affordable Care Act. Our plan was to establish a leadership position in the Medicaid market, stabilize our Medicare Advantage platform and grow Individual ACA-compliant and ASO enrollment to mitigate the expected pressure in the Local Group fully insured segment. 
Since that time, we've been pleased with the growth in our Medicaid business, where enrollment has grown 47% since 2013. And we are well positioned to capitalize on the $81 billion pipeline of opportunity between now and 2021 that I mentioned earlier. In addition, we have reconfigured and upgraded our Medicare platform, as evidenced by the improvement in our margin profile and STAR rating performance. We expect to leverage our upgraded Medicare platform to grow MA enrollment in 2017 and beyond. 
Overall, the government business segment has grown nicely and now represents 54% of our consolidated company revenue, up from 44% in 2013. And we remain very optimistic about continued growth potential in this business. 
Switching to Individual. As we've discussed previously, the earnings contribution from the Individual ACA-compliant business represents a meaningful headwind to our original targets. The volume shortfall from our previous expectation remains substantial. 
For your reference, we laid out a plan to grow Individual ACA-compliant enrollment to 3 million members by 2018 using the assumption that the overall Individual marketplace would be approximately 25 million members, in line with CBO estimates. In 2016, the overall marketplace was about half of the expected size and has only grown to roughly 10 million to 11 million members. And subsequently, we have grown our Individual ACA-compliant enrollment to approximately 1.4 million members as of the third quarter of 2016. We are closely monitoring the progress of our actions to improve the margin profile of this business toward our low to mid-single-digit margin targets of 2018. 
In our self-funded business, we've added 4.4 million members since 2013 as our value proposition has resonated with large employers who are focused on quality and affordability. This ASO growth has helped mitigate some of the pressure from higher-than-expected declines in our Local Group insured enrollment. 
Across our Commercial segment overall, we are generally pleased with our aggregate enrollment growth, but the mix of enrollment has skewed more than expected to self-funded than fully insured, pressuring revenue and earnings growth. Looking ahead, we still have meaningful opportunity to improve the per-member EBITDA contribution from ASO by increasing the penetration of our Specialty and other product offerings to help further offset the pressures in Local Group. 
I want to spend a few moments on the pending acquisition of Cigna. We are committed to this combination which will further Anthem's vision to be America's valued health partner. This is truly a compelling opportunity to positively impact the health and well-being of our members and advance our commitment to expand access to high-quality, affordable health care for consumers. It will also save consumers more than $2 billion of medical costs annually, directly benefiting the most vulnerable populations in the country. 
I also would like to briefly address the upcoming trial with the Department of Justice, which will begin on November 21. We continue to believe the DOJ's action to sue to block the acquisition is based on a flawed analysis and a misunderstanding of the dynamic competitive and heavily regulated health care landscape, and we're fully committed to challenging the DOJ's decision in court. 
In terms of the court proceeding, the judge has decided to bifurcate the issues and will first hear evidence on the National Accounts issue. If the judge decides in our favor on the National Account issue, we will then move forward and try the other 2 remaining issues, with a decision on those issues being rendered before the end of January. 
To summarize, we are in the process of updating our long-term growth plan and expect to target improved core earnings growth rates beyond 2017. The Individual ACA-compliant headwinds in our enrollment mix discussed previously represent a meaningful challenge to achieving our $14 earnings target in 2018. And we expect to provide additional clarity around our long-term growth prospects after the Cigna transaction process is complete. 
With that, operator, please open the queue for questions."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","[Operator Instructions] And our first question will come from the line of Ana Gupte from Leerink Partners.",17,"[Operator Instructions] And our first question will come from the line of Ana Gupte from Leerink Partners."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","My question was about the Individual book. You said that there were losses this year and they continued into the quarter. Sequentially speaking, what were the losses in -- that you estimated in the second quarter? And have they gone up since then? And why",67,"My question was about the Individual book. You said that there were losses this year and they continued into the quarter. Sequentially speaking, what were the losses in -- that you estimated in the second quarter? And have they gone up since then? And why are you expecting that will improve next year, when the reinsurance all phases out. Are you getting adequate pricing to do that?"
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Ana, this is John. So thank you for the question. Associated with our Individual exchange business, we certainly did, in the second quarter, indicate losses and that we expect that our operating margins are going to be on the mid-single-digit loss for the",215,"Ana, this is John. So thank you for the question. Associated with our Individual exchange business, we certainly did, in the second quarter, indicate losses and that we expect that our operating margins are going to be on the mid-single-digit loss for the year. Now during the third quarter, the reserve development was okay. The trend has been moderated a bit. And we still expect those losses in the same general range of what we said, maybe just a little bit better than we had indicated. In terms of 2017, reinsurance is obviously a very important factor, but it's only one aspect of pricing and one aspect of the overall structure of the program. We've got rate increases that average in excess of 20% across the country. I think there's been studies that have been published that have stated that our rate increases are a little bit higher than the average rate increases. We've made adjustments to product offerings. We've changed networks. We've enhanced product designs. We've done many, many things to improve affordability of the specific product mix. So we feel very good about the previous guidance that we provided, that we're really targeting a small profit margin in 2017 and then returning to more closely related to target margins in 2018 and beyond."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question is from Christine Arnold from Cowen.",10,"And our next question is from Christine Arnold from Cowen."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","A couple of things. On Iowa, your language there suggests that you got a rate increase, but it may not be adequate and that you're disciplined and you're only going to be in markets that are actuarially sound. Is there an out to get out of that if, in fac",90,"A couple of things. On Iowa, your language there suggests that you got a rate increase, but it may not be adequate and that you're disciplined and you're only going to be in markets that are actuarially sound. Is there an out to get out of that if, in fact, we can't get to actuarially sound rates? And then with respect to Individual, what do you think you need to see in order to feel that there's sustainability into '18? What legislatively or administratively do you want to see there?"
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Christine, this is Joe Swedish. Yes, first question regarding, I guess, the out possibilities. As you know, the contract went live earlier this year, and obviously, we're very concerned because it has experienced a deterioration that certainly exceeded ou",276,"Christine, this is Joe Swedish. Yes, first question regarding, I guess, the out possibilities. As you know, the contract went live earlier this year, and obviously, we're very concerned because it has experienced a deterioration that certainly exceeded our forecast expectations regarding the medical loss ratio. We are in the process of having deep discussions with the state regarding the possibility of adjustments. I commented in our discussions just a moment ago that we have realized some positive effect from that discussion. And quite frankly, we're hoping for more. Unfortunately, the recent rate increase is still inadequate, and again, we're hoping for a better outcome with respect to more discussion. With respect to the legal construct of the contract, we are examining our position. We, quite frankly, are awaiting the state to respond to the inquiries that we've submitted to them. And I think it's a little early for us to maybe put commentary out regarding our legal position, given the fact that there's still administrative considerations that are working their way through the system. And we're hopeful for a very positive outcome at the end of that review. We are concerned about the actuarial soundness of the rates. And that's been expressed by all of the MCOs from the get go. We are engaged in an extensive process of meetings, as I mentioned. And we'll continue to be deeply concerned until we get a resolution to this. And then we'll weigh our options with respect to the endpoint of those negotiations with the state. I think the second question dealt with the exchange, Christine. I wonder if you could restate that for me, I'm sorry."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","One moment please.",3,"One moment please."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","[Audio Gap] And then it sounded like your language suggests that if '17 doesn't go well, you could change your strategy for '18. What do you need to see administratively or legislatively in order to fix this and in order for you to feel that this is whe",54,"[Audio Gap] 
And then it sounded like your language suggests that if '17 doesn't go well, you could change your strategy for '18. What do you need to see administratively or legislatively in order to fix this and in order for you to feel that this is where you're going to stay for '18?"
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Great. Well, on or about midyear '17, obviously, we'll maybe coming to a conclusion on our review about how the adjustments have played out that we are expecting. To your point, what we're looking for are a variety of fixes such as elimination of the heal",271,"Great. Well, on or about midyear '17, obviously, we'll maybe coming to a conclusion on our review about how the adjustments have played out that we are expecting. To your point, what we're looking for are a variety of fixes such as elimination of the health insurance tax or at least extending the 2017 moratorium. Another one that you've probably heard quite a bit about is updating the risk adjustment model substantially to address the existing imbalance that we believe deteriorates the overall risk pool. We are also looking at additional adjustments to the special enrollment periods, which we believe the -- needs to be continually narrowed with respect to the variety and number of special enrollments. We also believe that we need to have the flexibility to develop innovative products that should go to market to meet our -- the needs of our customers. Modify the grace period is another great example. And finally, we want to work very closely with the states to ensure actuarially justified rates being approved. Now what I just specified for you, and let me just put a characterization to it that I think is very, very important, and that is this is a specific recipe for solutions, and we believe these recipe characteristics represent the form of a long-term, sustainable and affordable marketplace. So as I said earlier in my commentary, we believe we must see adjustments such that we can easily map to a 2018 situation of sustainability in this marketplace. And, quite frankly, given what may or may not happen, we'll be evaluating the regional engagement across our markets moving into 2018."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","And Joe, I'd just like to say, obviously, everything there is very appropriate, but Christine, we will be watching margins trends performance on a state-by-state and region-by-region basis in 2017 as well. So certainly, the decision in '18 could be a piec",49,"And Joe, I'd just like to say, obviously, everything there is very appropriate, but Christine, we will be watching margins trends performance on a state-by-state and region-by-region basis in 2017 as well. So certainly, the decision in '18 could be a piecemeal decision as opposed to an altogether decision."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. I think thus far, we've been very surgical in our approach, and we'll continue that theme. And so again, we have a hope that the sustainability that's expected and commented on quite a bit by leadership of the administration actually will occur durin",49,"Yes. I think thus far, we've been very surgical in our approach, and we'll continue that theme. And so again, we have a hope that the sustainability that's expected and commented on quite a bit by leadership of the administration actually will occur during the early stages of 2017."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","And our next question is from A.J. Rice from UBS.",11,"And our next question is from A.J. Rice from UBS."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","I just want to follow up. I appreciate the comments on the headwinds and tailwinds and the comment about modest growth. I guess there are 3 variables I just want to throw on the table. You're saying you'll go from a mid-single digit loss on the exchanges,",147,"I just want to follow up. I appreciate the comments on the headwinds and tailwinds and the comment about modest growth. I guess there are 3 variables I just want to throw on the table. You're saying you'll go from a mid-single digit loss on the exchanges, or in the Individual book, to a positive. We got, I guess, about a -- that would represent, I think, about a $0.70 swing, roughly 6% to 7% growth in and of itself. I just also wondered, are you including anything in your comments about capital deployment when you talk about modest growth? Or anything on the PBM? And what's the latest thinking on that? And then just to make sure the $10.80 is the baseline number upon which you're assuming modest growth. Or is it some other number that you would adjust for as the starting point for '16?"
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure, no, A.J. Thank you for the question. And in terms of capital, we do expect to resume capital deployment in 2017. However, that won't be until after the pending Cigna acquisition process is completed. And so the timing and the magnitude of that",134,"Yes, sure, no, A.J. Thank you for the question. And in terms of capital, we do expect to resume capital deployment in 2017. However, that won't be until after the pending Cigna acquisition process is completed. And so the timing and the magnitude of that capital deployment is still somewhat of an unknown. Associated with the starting point, yes, very clearly, $10.80, we believe is the appropriate starting point. That's our guidance. That's been our expectations now for some time. And that's our 2016 -- approximately $10.80 is our 2016 guidance number. And then, of course, you have the tailwinds that offset that. But in terms of the PBM, we don't have any of the upside baked in. I think, Joe, maybe some comments just about the PBM situation in general might be helpful."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes. A.J., thanks for the question on that. As I've repeatedly stated, we're hopeful we can negotiate a settlement to our concerns, our dispute. And I don't need to restate what we've said repeatedly about our perspective on our contractual rights, but le",193,"Yes. A.J., thanks for the question on that. As I've repeatedly stated, we're hopeful we can negotiate a settlement to our concerns, our dispute. And I don't need to restate what we've said repeatedly about our perspective on our contractual rights, but let me say that we do believe that we are continually focused on improving the pharmacy pricing on behalf of our customers. We expect to issue a new RFP during the year, that's early 2017, to understand the impact of various pharmacy options available to us as we migrate to the potential of a new agreement. And I have to underscore that it's critical that we engage with a really trusted partner with aligned interests in advancing the cost effectiveness and quality for our membership. We've -- I guess we've not ruled anyone in or out in this process of securing an RFP. And I think with respect to any other comments made by ESI or others, we prefer not to comment on that. We do believe that a period of negotiations is still possible. And again, I'll underscore I'm hopeful that we can resolve our differences moving into the future."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from the line of Matt Borsch from Goldman Sachs.",13,"Our next question is from the line of Matt Borsch from Goldman Sachs."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Maybe on a slightly different topic. One of your peer companies has talked in considerable length about pressure in the small group ACA-compliant book. I know you've alluded to that some. Can you just give us an update on how you see that business? Maybe",74,"Maybe on a slightly different topic. One of your peer companies has talked in considerable length about pressure in the small group ACA-compliant book. I know you've alluded to that some. Can you just give us an update on how you see that business? Maybe break down in size and break down your small group between what's ACA-compliant and what's grandmothered, grandfathered? And how you see that transition happening, working going into next year?"
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure. Thank you for the question, very good question. And that really is a meaningful headwind. And I think I did try to highlight it in the script. But in terms of the specificity of the question, we don't talk about a lot of this information for co",142,"Yes, sure. Thank you for the question, very good question. And that really is a meaningful headwind. And I think I did try to highlight it in the script. But in terms of the specificity of the question, we don't talk about a lot of this information for competitive reasons, but maybe 2/3 of our block is non-ACA-compliant today. The grandmothering expires here at the end of the year, and we fully expect to be very aggressive in pursuing and renewing that block of business. The margin aspect of it may be slightly different, slightly lower, as the ACA-compliant blocks typically have a slightly lower margin compression. But we'll ensure that we renew it at appropriate prices and have it to be a profitable business on a go-forward basis, but we did want to spike it out as a headwind in 2017."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Kevin Fischbeck with Bank of America.",11,"Our next question is from Kevin Fischbeck with Bank of America."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","I guess 2 questions. First, a clarification, you mentioned that as far as the Cigna lawsuit, they're going to break it up into 2 pieces, and that they're going to hear National Accounts first. I'm just wondering if you had a time frame for when we'd hear",88,"I guess 2 questions. First, a clarification, you mentioned that as far as the Cigna lawsuit, they're going to break it up into 2 pieces, and that they're going to hear National Accounts first. I'm just wondering if you had a time frame for when we'd hear that. But then specifically, on the Medicaid business, it sounds like Iowa should get better next year, Medicaid expansion should get worse. Are you looking for net margin improvement or margin pressure on the Medicaid business as a whole in 2017?"
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, let me just comment on the Cigna hearings. Beyond the December judicial process, which we're anticipating a decision sometime on or about mid-December, we would expect that moving forward from there, that it's possible then a trial would begin shortl",63,"Yes, let me just comment on the Cigna hearings. Beyond the December judicial process, which we're anticipating a decision sometime on or about mid-December, we would expect that moving forward from there, that it's possible then a trial would begin shortly thereafter, probably early January. And our hope is that, that would be resolved with a judicial decision by the end of January."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","And then on the Medicaid question, just to provide a little clarity. So certainly, Iowa is going to be a tailwind into 2017. We experienced significant upfront losses in Iowa. And even with rebalancing of the portfolio and the retroactive rate increase, i",147,"And then on the Medicaid question, just to provide a little clarity. So certainly, Iowa is going to be a tailwind into 2017. We experienced significant upfront losses in Iowa. And even with rebalancing of the portfolio and the retroactive rate increase, it's still -- we do not believe it's actuarially sound. And the expectation is that there will be improvement in 2017. However, associated with the remainder of the Medicaid block, we are seeing some slight margin pressure. We were phenomenally successful the past couple of years with our margins. And specifically, our expansion margins have been very, very, very good. And then as those get repriced throughout the balance of the year, they're going to be repriced at more of a target margin ratio -- target profit ratio, I'm sorry. And that will create a bit of headwind or margin pressure for us in '17."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Justin Lake from Wolfe Research.",10,"Our next question is from Justin Lake from Wolfe Research."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","A couple of things. First, I remember back when we were going into the ACA and there was concerns around small group. You guys had put out a number of about a $400 million headwind for next year -- or for the coming couple of years in terms of small group",177,"A couple of things. First, I remember back when we were going into the ACA and there was concerns around small group. You guys had put out a number of about a $400 million headwind for next year -- or for the coming couple of years in terms of small group margin pressure. Is there any way for you to do something similar here, just to give us an idea of as you go through this repricing, is there a number you can point to, to say, here's -- it sounds like small group's going to be a pretty good pressure next year, as expected. It maybe a little larger than we thought. The -- is there a way to put a number on that for us? And then on SG&A, it's been shifting around a bit here. And wanted to get your thoughts for the fourth quarter and how we should think about this for 2017 when we add in the -- when we add back some of these onetime benefits that you had this year."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Sure, Justin, great questions. The -- in terms of the small group, we're still working through it, and I really am hesitant to provide an answer until our planning process is done. And some of the grandmothering associated with the early renewals that exi",306,"Sure, Justin, great questions. The -- in terms of the small group, we're still working through it, and I really am hesitant to provide an answer until our planning process is done. And some of the grandmothering associated with the early renewals that exist, we actually have several of our -- many of our small group plans renewed early on December a couple of years ago in order to maintain their non-ACA-compliant plans. And I think it'd probably be premature to throw a number out until we've worked through that process. So we will update that and provide more clarity on our fourth quarter call. Associated with the general and administrative expenses, I think maybe I'll just repeat sort of the commentary from last time. It's down quite substantially in 2016. And a little more than half of it is a good, sustainable run rate, meaningful decrease in SG&A expense. That has to do with more efficient processes, better performance in some of the administrative and core areas of the company. And we grew into our membership. We had a really good membership year from both a membership and premium prospective, raising guidance on that. And we're able to do that by maintaining our administrative expense levels. Obviously, then the ratio went down. The other half, or a little less than the other half, were more onetime items, and those are nonsustainable. And the most significant part of those other, less than the other half is our incentive compensation plans. As we've stated, we're a pay-for-performance company, and we had our promises to Wall Street in what we expected earnings to be, and we ensured that we delivered those earnings. And unfortunately, we had to lower our incentive compensation expense as part of that process. So a little less than half will come back in 2017."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Michael Newshel from Evercore ISI.",10,"Our next question is from Michael Newshel from Evercore ISI."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Does your expectation for slight profitability in the ACA-compliant business next year assume that the national enrollment is going to be stable or growing? And how would you frame the downside risk to margins if enrollment declines and the risk pool dete",93,"Does your expectation for slight profitability in the ACA-compliant business next year assume that the national enrollment is going to be stable or growing? And how would you frame the downside risk to margins if enrollment declines and the risk pool deteriorates? And also, I mean, it looks like your relative pricing versus competitors is generally higher in 2017 than it was -- than it is this year after the price hikes and market exits, at least on HealthCare.gov. Do you think that provides you any buffer against adverse selection next year?"
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Well, there's quite a few questions in there. Hopefully, I can address all of them. But I think maybe the most simple is that we expect that overall Individual ACA-compliant membership on a national basis will be slightly down next year and that our membe",184,"Well, there's quite a few questions in there. Hopefully, I can address all of them. But I think maybe the most simple is that we expect that overall Individual ACA-compliant membership on a national basis will be slightly down next year and that our membership will reflect that. We still have many, many competitors in our markets. I just do want to point out that some of the exits that have been very widely publicized, very few of them impact our market specifically. So like, for instance, California still has 11 competitors, Virginia still has 8 competitors, just to rattle off a couple of our states. In terms of the risk pool, we believe that we understand the risk pool. We're very good at the Individual marketplace. We've been the #1 Individual market carrier for years and years prior to the ACA. Our products are designed in such a way to really get a good risk pool that allows us to maximize on risk adjusters and then be a risk adjuster collector. So we feel good about our assumptions at this point in time."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Let me add that there are a few key points I think we really need to consider and keep in front. Number one, on average, our price point for targeted bronze and silver plans in the marketplace is higher than our competitors. We certainly recognize that an",252,"Let me add that there are a few key points I think we really need to consider and keep in front. Number one, on average, our price point for targeted bronze and silver plans in the marketplace is higher than our competitors. We certainly recognize that and acknowledge it. And while the number of competitors in our markets has declined overall versus 2016, for the most part, those declines are in less populated areas, such as the rural market, where we have had historically high market shares. There's -- on the flip side, there's really still substantial competition across all of our markets, those served markets, most notably in these highly dense urban markets. And finally, some of the largest markets did not see any significant reduction in competition. For example, California still has 11 competitors, down 1 from last year. Virginia still has 8. Georgia still has 5. So we know we're in highly competitive markets, and we believe we will compete very effectively. But again, I think we've very effectively managed the price points with respect to the products that we've offered in the marketplace. And so we have a fairly good outlook, as John commented earlier in his remarks, about our expected margins. And as I said then to follow on to that, we'll be evaluating our situation in those markets, all of our markets, through the beginning of the year to see how well we perform and how well the regulatory adjustments play out leading up to midyear."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Lance Wilkes from Sanford Bernstein.",10,"Our next question is from Lance Wilkes from Sanford Bernstein."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","I just wanted to follow up on a question with respect to self-insurance margin strategy. I wanted to understand how the progress was going on Specialty penetrations looking at 2017, and what your 2018 and beyond strategies were there. How much upside you",68,"I just wanted to follow up on a question with respect to self-insurance margin strategy. I wanted to understand how the progress was going on Specialty penetrations looking at 2017, and what your 2018 and beyond strategies were there. How much upside you saw with respect to self-insurance margins. And then in particular right now with PBM, how does that fit into how you're looking at penetrations?"
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Great question, and certainly, that's one of our growth areas for the future as we look out into our long-term outlook. We believe that the opportunity to enhance the EBITDA associated with our ASO members is meaningful. We are developing -- we have ongoi",157,"Great question, and certainly, that's one of our growth areas for the future as we look out into our long-term outlook. We believe that the opportunity to enhance the EBITDA associated with our ASO members is meaningful. We are developing -- we have ongoing efforts to drive penetration in Specialty products, various ancillary type products, other add-ons, that -- we think that we are underpenetrated right now and believe that we have an incredible amount of upside. We've been the #1 company in growing the ASO large group national membership over the last several years, and we've made quite a nice margin percentage on that business, but it's very small dollars. And so now the focus is to take the fact that we do have best-in-class discounts and the most sophisticated purchasers of coverage are picking us. And so now it's our opportunity to really penetrate that better and enhance the EBITDA associated with that membership block."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Gary Taylor from JPMorgan.",9,"Our next question is from Gary Taylor from JPMorgan."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Just a couple more questions on the Individual business. First, I just wanted to follow up, I know you had just said you're anticipating exchange enrollment to decline heading into 2017. I know you also thought that would be the case heading into 2016. So",97,"Just a couple more questions on the Individual business. First, I just wanted to follow up, I know you had just said you're anticipating exchange enrollment to decline heading into 2017. I know you also thought that would be the case heading into 2016. So is just your rate positioning why you still believe that might play out in '17 versus what happened this year? And then just secondly, could you just comment on any PDRs used in the Individual business this quarter in your experience with the special enrollment period enrollment this year versus last year?"
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Gary, great question. And 2016 was interesting because what we ended up seeing was a flight to safety, and that was one of the reasons that our 2016 Individual exchange membership grew more than expectations. And so if you go backwards a year and then you",255,"Gary, great question. And 2016 was interesting because what we ended up seeing was a flight to safety, and that was one of the reasons that our 2016 Individual exchange membership grew more than expectations. And so if you go backwards a year and then you look at the number of co-ops who are in our markets that failed, it was a significant impact on our membership. And then as those customers then went into the marketplace, they -- as I said, it was a flight to safety, they went for Blue. I think the real key difference in the expectations in '16 and the expectations in '17 is, really, the amount of exits within our markets of carriers and who the exits were and how much membership those that exited had. So long story short, the co-ops in certain markets were -- had extremely high market share, and they went insolvent and their market share then was absorbed. Where in 2017, while we certainly have some exits of carriers in our markets, they do not have the breadth or the magnitude of the market share that the ones who exited a year ago had. Associated with the premium deficiency reserves, we have none recorded. We had none recorded in 2015. We have none recorded in 2016. It's a very easy question. Which means that our results are pure, our results are clean and that we don't have the puts and takes that maybe you have in some of the other companies that you're modeling."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from Josh Raskin from Barclays.",9,"Our next question is from Josh Raskin from Barclays."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","A question -- a short term and a long term. Short term, I heard the commentary. I think, John, you said the results were very consistent with your expectations. And just looking at sort of the cadence of earnings, you saw some mid- to high single-digit gr",182,"A question -- a short term and a long term. Short term, I heard the commentary. I think, John, you said the results were very consistent with your expectations. And just looking at sort of the cadence of earnings, you saw some mid- to high single-digit growth in the first half, a big decline of double-digit percentage on EPS in 3Q and now an expected increase back in 4Q. And so I guess, if that's all very expected, what changed this year from a seasonality perspective? And then on the long term, from a strategic perspective, when you guys announced the Cigna deal, and I know we're going back 1.5 years now, you talked about Cigna bringing commercial expertise and exposure to Medicare, the strong Specialty and then the international segment. And so I'm curious kind of where those priorities sit today. And in the case that the judge disagrees with you guys and the transaction does not move forward, how do you guys think about the reaction? Is there a need for scale? Is there an appetite to do other stuff?"
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, sure, thank you. I'll take the first question and turn it over to Joe for the second. Yes, I did say that our results were very consistent with expectations. When you're looking at the seasonality of 2015 to 2016, yes, 2016 is a bit challenged. The M",153,"Yes, sure, thank you. I'll take the first question and turn it over to Joe for the second. Yes, I did say that our results were very consistent with expectations. When you're looking at the seasonality of 2015 to 2016, yes, 2016 is a bit challenged. The MLR is a little bit in the fourth quarter than it was last year. There's a lot of variables associated with that. Clearly, the Iowa variable, the Individual exchange variable. Please note that we do have the G&A offset that allows us to enjoy the growth in EPS year-over-year. But it's not that there was a significant change in seasonality patterns or a huge business flux as much as it was some of the very specific items that we pointed out to as headwinds for 2016 continue to be headwinds throughout the fourth quarter. On the -- I think Joe wants to address your Cigna question."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, let me take that for a moment, Josh. First of all, to your point about, call it, pivoting in the event of an adverse decision, we're going to focus very heavily on what we talked about earlier regarding our tailwinds. Obviously, in the MA growth spac",142,"Yes, let me take that for a moment, Josh. First of all, to your point about, call it, pivoting in the event of an adverse decision, we're going to focus very heavily on what we talked about earlier regarding our tailwinds. Obviously, in the MA growth space, a very strong focus on our government business across the entire spectrum and a variety of other initiatives that I already mentioned. I think it's really important to underscore that we'll be coming to you at the time of that announcement, whatever. We will then share with you our outlook in terms of pivoting the company to tackle some of those opportunities, tailwinds, as well as, quite frankly, address the headwinds as robustly as we would anyway, but certainly we believe ameliorating some of that risk would be a great opportunity to us as well."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, I would just add to that, that we believe that we have long-term sustainable growth opportunities regardless if the deal closes or not. Cigna may help accelerate those, but we're very confident about our future under either scenario.",39,"Yes, I would just add to that, that we believe that we have long-term sustainable growth opportunities regardless if the deal closes or not. Cigna may help accelerate those, but we're very confident about our future under either scenario."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from the line of Chris Rigg with Susquehanna Financial Group.",14,"Our next question is from the line of Chris Rigg with Susquehanna Financial Group."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","John, I know you commented earlier about the dynamic of compliant versus noncompliant in the small group book. But it looks like in the Individual side, you still have about 27% of your membership that's noncompliant. Are most of those -- the plans for th",87,"John, I know you commented earlier about the dynamic of compliant versus noncompliant in the small group book. But it looks like in the Individual side, you still have about 27% of your membership that's noncompliant. Are most of those -- the plans for the noncompliant individuals going to remain in-force through -- or until December 2017? And then more of a macro question, do you guys have a sense for how many grandmothered -- how many people have grandmothered plans in your markets at this point?"
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, great question. First of all, in the compliant versus noncompliant, the majority of those will not be noncompliant through '17. So that the headwind, tailwind that I talked about with that, that would include both the small group and the Individual c",126,"Yes, great question. First of all, in the compliant versus noncompliant, the majority of those will not be noncompliant through '17. So that the headwind, tailwind that I talked about with that, that would include both the small group and the Individual commentary. In terms of how many grandmothering are in our markets, including what our competitors have, we actually do not have the specificity of that. But obviously, all the dynamics that we're experiencing and the changes in the laws, they're experiencing. So there's really not an -- if your question is, is there an opportunity to get someone else's grandmothered business? The answer is really no. It would have to be -- we would have to get it as part of an ACA-compliant product."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Our next question is from the line of Ralph Giacobbe from Citi.",12,"Our next question is from the line of Ralph Giacobbe from Citi."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","First, just wanted to clarify the comments on the exchange again. Joe, you mentioned 2017 as a critical year. And if there was no clear evidence, that you'd sort of modify your strategy in 2018. I mean, does that mean market exit or willingness to exit if",119,"First, just wanted to clarify the comments on the exchange again. Joe, you mentioned 2017 as a critical year. And if there was no clear evidence, that you'd sort of modify your strategy in 2018. I mean, does that mean market exit or willingness to exit if you're unprofitable again in 2017? And then also separately, I was hoping you could parse out the pressure from Iowa. I know one of your peers took a PDR in that book, while you're absorbing the losses through the P&L. So just hoping to get a sense of margins and maybe magnitude of loss this year, and what the improvement would be next year, even on sort of the inadequate rate bump."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Great. Thanks. I will pivot the second part of the question to John so he can get into some of the technical aspects of it. But with respect to the first question, let me just underscore that, as I said a moment ago, we're going to be very surgical. And l",130,"Great. Thanks. I will pivot the second part of the question to John so he can get into some of the technical aspects of it. But with respect to the first question, let me just underscore that, as I said a moment ago, we're going to be very surgical. And let me define market. There are those that define market to be state, but I want to be very clear that we deal with a significant array of regions. So we will look at both regional impact as well as state impact and then make determinations with respect to what I call the surgical assessments and then decisions and execution that are necessary in order for prudent engagement in that marketplace. I believe that probably covers what you were asking."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Okay, yes. And then in terms of Iowa and the headwind for '16, which becomes a tailwind for '17 with the Medicaid block there. We did get a retroactive rate increase. Unfortunately, we think it's still not actuarially justified. We really are not providin",136,"Okay, yes. And then in terms of Iowa and the headwind for '16, which becomes a tailwind for '17 with the Medicaid block there. We did get a retroactive rate increase. Unfortunately, we think it's still not actuarially justified. We really are not providing an exact number at this point as we continue to work with the state and don't want to get out ahead of the state and negotiate this publicly. But just as Joe said, consistent with the Individual exchange business, we need to partner with states that want to be partners. And we believe that we need actuarially justified rates. And if -- we will continue to negotiate it. We feel really good about that fact, but if we don't get it, then we'll have a decision to make in Iowa as well."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","And our last question this morning will come from the line of Peter Costa.",14,"And our last question this morning will come from the line of Peter Costa."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Analysts","Just a couple of clarifications on things you said. You said you put out an RFP for your PBM in early 2017. So presumably, that means we'd see an answer sometime in mid-2017. What sort of things have you going to be looking for besides the $3 billion in s",75,"Just a couple of clarifications on things you said. You said you put out an RFP for your PBM in early 2017. So presumably, that means we'd see an answer sometime in mid-2017. What sort of things have you going to be looking for besides the $3 billion in savings that you already talked about? And then are you specifically coming off the $100 billion revenue target that you set out in 2014 for 2018?"
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Why don't I do the second one first, Peter, while I've got the line. In terms of the headwinds, tailwinds for 2018 in Joe's commentary, it's highly unlikely that we would be able to achieve that number at this point in time. Just look at our guidance for",166,"Why don't I do the second one first, Peter, while I've got the line. In terms of the headwinds, tailwinds for 2018 in Joe's commentary, it's highly unlikely that we would be able to achieve that number at this point in time. Just look at our guidance for 2016 and roll that forward and roll our membership forward, it all boils down to the exchanges. And the CBO had estimated, what, 25 million, 26 million lives to be insured through the exchanges. When we did our 2018 plan, we relied on some of the CBO estimates as part of our estimation process. And we're still maintaining our market share. We still believe that we can hit the target margins that we had for those things. But when the entire country has just over 10 million versus that other, that's a significant delta, and that goes straight into our numbers. And I think you'll see that the revenue shortfall can be entirely explained with that dynamic."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Yes, and let me pick it up now regarding the PBM question. Yes, that RFP goes to market early 2017. I've said repeatedly that our intention is to be able to deliver to you a solution with respect to our ongoing analytics, which obviously, in the current s",126,"Yes, and let me pick it up now regarding the PBM question. Yes, that RFP goes to market early 2017. I've said repeatedly that our intention is to be able to deliver to you a solution with respect to our ongoing analytics, which obviously, in the current state, isn't significantly impacted by our discussions and, of course, the potential legal proceedings with ESI. We were hopeful to bring you a meaningful commentary and maybe solution by the end of 2017. We've never diverged from that commitment, and our hope is that we certainly will be able to put all the parts and pieces together to give you clarity in and around the decisions we're going to execute specific to the termination of the contract by 2019."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Thank you, and please go ahead with any closing remarks.",10,"Thank you, and please go ahead with any closing remarks."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Executives","Well, again, thank you, everybody, for your questions. They're always very, very good. As a company, we do remain committed to tackling our health care system challenges head on, as evidenced by the work that we've communicated to you today. And we beli",146,"Well, again, thank you, everybody, for your questions. They're always very, very good. 
As a company, we do remain committed to tackling our health care system challenges head on, as evidenced by the work that we've communicated to you today. And we believe that we can and will deliver greater value to consumers by expanding access to high-quality affordable health care. And we've stood that -- by that repeatedly. This is why we are committed to challenging the DOJ's recent decision to block Anthem's acquisition of Cigna in court. 
Speaking to my associates, I want to also thank all of them for their continued commitment to serving our nearly 40 million members every day. 
To all of you on the phone, please accept our thanks for your interest in Anthem, and we look forward to speaking with you soon at upcoming conferences. Have a great day."
160077,324533304,1071347,"Anthem, Inc., Q3 2016 Earnings Call, Nov 02, 2016",2016-11-02,"Earnings Calls","Elevance Health, Inc.","Operator","Thank you. And ladies and gentlemen, this conference will be made available for replay after 11:00 a.m. today through November 16. You may access the AT&T Executive Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378818.",71,"Thank you. And ladies and gentlemen, this conference will be made available for replay after 11:00 a.m. today through November 16. You may access the AT&T Executive Replay System at any time by dialing 1 (800) 475-6701 and entering the access code 378818. International participants can dial (320) 365-3844. 
That does conclude our conference for today. Thank you for your participation and for using AT&T Executive TeleConference. You may now disconnect."
